0001199835-14-000562.txt : 20141114 0001199835-14-000562.hdr.sgml : 20141114 20141114131056 ACCESSION NUMBER: 0001199835-14-000562 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20141114 DATE AS OF CHANGE: 20141114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tongji Healthcare Group, Inc. CENTRAL INDEX KEY: 0001389518 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-140645 FILM NUMBER: 141222414 BUSINESS ADDRESS: STREET 1: NO.5 BEIJI ROAD, NANNING, CHINA CITY: NANNING STATE: F4 ZIP: ----- BUSINESS PHONE: 212-930-9700 MAIL ADDRESS: STREET 1: NO.5 BEIJI ROAD, NANNING, CHINA CITY: NANNING STATE: F4 ZIP: ----- 10-Q 1 tongji_10q-16202.htm TONGJI HEALTHCARE GROUP, INC. 09/30/2014 10-Q tongji_10q-16202.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
 
(Mark One)
 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2014
 
o
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
 
For the transition period from ______________ to _____________
 
Commission file number: 333-140645
 
TONGJI HEALTHCARE GROUP, INC.

(Exact name of registrant as specified in its charter)

Nevada
 
99-0364697
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
     
 
No. 5 Beiji Road
Nanning, Guangxi, People’s Republic of China
 
530011
(Address of principal executive offices)
 
(Zip Code)

011-86-771-2020000
(Registrant’s telephone number, including area code)

 
(Former name, former address and former fiscal year, if changed since last report)
 
Indicate by check mark whether the registrant (1) has filed reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 
Yes x No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
 
Yes x No o
 
 
 
 
1

 
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
o
Accelerated filer
o
       
Non-accelerated filer
o
Smaller reporting company
x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

 
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
 
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13, or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes o No o

 
APPLICABLE ONLY TO CORPORATE ISSUERS
 
Indicate the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:
 
As of November 13,2014, there were 15,812,191 shares of $0.001 par value common stock issued and outstanding.
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
2

 


FORM 10-Q

TONGJI HEALTHCARE GROUP, INC.

 
INDEX


 
     
Page
       
PART I.
Financial Information
 
4
       
 
Item 1. Financial Statements (Unaudited).
 
4
       
 
Condensed Consolidated Balance Sheets as of September 30, 2014 (Unaudited) and December 31, 2013.
 
5
       
 
Condensed Consolidated Statements of Operations and Comprehensive Income (loss) for the Three and Nine Months Ended September 30, 2014 and 2013 (Unaudited).
 
6
       
 
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2014 and 2013 (Unaudited).
 
7
       
 
Notes to Condensed Consolidated Financial Statements as of September 30, 2014 (Unaudited).
 
8
       
 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
 
20
       
 
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
 
25
       
 
Item 4. Controls and Procedures.
 
25
       
PART II.
Other Information
 
27
       
 
Item 1. Legal Proceedings.
 
27
       
 
Item 1A. Risk Factors.
 
27
       
 
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
 
27
       
 
Item 3. Defaults Upon Senior Securities.
 
27
       
 
Item 4. Mine Safety Disclosures.
 
27
       
 
Item 5. Other Information.
 
27
       
 
Item 6. Exhibits.
 
28

 

 



 

 
3

 


PART I. FINANCIAL INFORMATION
 
Item 1. Financial Statements (Unaudited)
 
The unaudited condensed consolidated financial statements of registrant as of September 30, 2014 and December 31, 2013 and for the Three and Nine Months ended September 30, 2014 and 2013 follow. The condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal and recurring nature.

 
 
 



















 
 
 

 
 
4

 

TONGJI HEALTHCARE GROUP, INC.
 
CONDENSED CONSOLIDATED BALANCE SHEETS
 
             
   
September 30, 2014
   
December 31, 2013
 
   
(Unaudited)
       
             
ASSETS
 
             
Current Assets
           
Cash
  $ 5,236     $ 7,793  
Accounts receivable, net
    138,967       351,221  
Due from related parties
    111,754       120,352  
Medical supplies
    70,753       148,286  
Prepaid expenses and other current assets
    -       10,690  
                 
Total Current Assets
    326,710       638,342  
                 
Equipment, net
    1,481,953       1,555,282  
                 
Construction in progress
    15,331,474       13,376,281  
                 
Deposits
    185,739       189,851  
                 
Intangible assets, net
    81,650       90,468  
                 
TOTAL ASSETS
  $ 17,407,526     $ 15,850,224  
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT
 
                 
Current Liabilities
               
Accounts payable and accrued expenses
  $ 735,165     $ 633,061  
Due to related parties
    16,167,143       14,232,773  
Settlement payable
    1,323,801       -  
Other payable
    488,832       612,800  
Current portion of capital lease payable
    426,450       402,138  
                 
Total Current Liabilities
    19,141,391       15,880,772  
                 
Capital lease payable
    362,462       695,689  
                 
Total Liabilities
    19,503,853       16,576,461  
                 
Contingencies
    -       1,267,637  
                 
STOCKHOLDERS' DEFICIT
               
Preferred stock; $0.001 par value, 20,000,000 shares authorized and none issued and outstanding
    -       -  
Common stock; $0.001 par value, 50,000,000 shares authorized and 15,812,191 shares issued and  outstanding as of September 30, 2014 and December 31, 2013 respectively
    15,812       15,812  
Additional paid in capital
    443,349       439,510  
Accumulated deficit
    (2,648,087 )     (2,515,021 )
Accumulated other comprehensive income
    92,599       65,825  
                 
Total Stockholders' Deficit
    (2,096,327 )     (1,993,874 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
  $ 17,407,526     $ 15,850,224  
                 
                 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 

 
5

 
 
TONGJI HEALTHCARE GROUP, INC.
 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
 
(UNAUDITED)
 
                         
   
For the Three Months Ended September 30,
   
For the Nine Months Ended September 30,
 
   
2014
   
2013
   
2014
   
2013
 
                         
OPERATING REVENUE
                       
    In-patient service revenue
  $ 269,207     $ 269,061     $ 847,809     $ 806,988  
    Out-patient service revenue
    380,186       338,177       1,012,297       913,813  
         Total operating revenue
    649,393       607,238       1,860,106       1,720,801  
                                 
OPERATING EXPENSES
                               
    Administrative expenses
    49,376       53,145       147,610       108,397  
    Depreciation and amortization expenses
    22,403       30,692       67,746       76,611  
    Contingency loss
    -       25,500       -       83,955  
    Medicine and supplies
    271,889       266,512       812,421       775,357  
    Other operating expenses
    83,215       122,872       242,777       278,526  
    Salary and fringes
    215,957       184,425       587,540       541,213  
         Total operating expenses
    642,840       683,146       1,858,094       1,864,059  
                                 
INCOME (LOSS) FROM OPERATIONS
    6,553       (75,908 )     2,012       (143,258 )
                                 
OTHER INCOME (EXPENSE)
                               
    Other income
    7,023       4,333       24,948       18,947  
    Interest expense, net
    (64,646 )     (13,045 )     (160,026 )     (88,272 )
        Total Other Expense
    (51,070 )     (8,712 )     (135,078 )     (69,325 )
                                 
LOSS BEFORE INCOME TAXES
    (51,070 )     (84,620 )     (133,066 )     (212,583 )
                                 
Provision for income taxes
    -       -       -       -  
                                 
NET LOSS
    (51,070 )     (84,620 )     (133,066 )     (212,583 )
                                 
OTHER COMPREHENSIVE LOSS
                               
Foreign currency translation gain (loss)
    (21,855 )     (7,939 )     26,774       (37,366 )
                                 
NET COMPREHENSIVE LOSS
  $ (72,925 )   $ (92,559 )   $ (106,292 )   $ (249,949 )
                                 
Net loss per common stock-Basic and Diluted
  $ (0.007 )   $ (0.006 )   $ (0.007 )   $ (0.016 )
                                 
                                 
Weighted average common stock outstanding
                               
Basic and Diluted
    15,812,191       15,812,191       15,812,191       15,812,191  
                                 
                                 
                                 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
 
 
 
6

 
 
TONJI HEALTHCARE GROUP, INC.
 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 
FOR THE NINE MONTH PERIODS ENDED SEPTEMBER 30,
 
(UNAUDITED)
 
             
   
2014
   
2013
 
Operating activities:
           
Net loss
  $ (133,066 )   $ (212,583 )
Adjustments to reconcile net loss to
               
Net cash provided by (used in) operating activities:
               
Depreciation expense
    67,747       76,612  
Stock option expense
    3,839       3,839  
Increase/(decrease) in operating assets and liabilities:
         
Accounts receivable
    206,459       77,836  
Medical supplies
    75,143       3,210  
Prepaid expense and other current assets
    10,492       (970 )
Deposit
    1,499       -  
Accounts payable and accrued expenses
    110,280       162,616  
Other payables
    (115,011 )     (168,937 )
Settlement (contingent liability)
    73,229       98,270  
                 
Net Cash Provided by Operating Activities
    300,611       39,893  
                 
Investing activities:
               
Acquisitions of fixed assets
    (8,481 )     (20,353 )
Acquisitions of intangible assets
    -       (100,541 )
Construction in progress
    (2,128,894 )     (1,195,636 )
Due from related parties
    6,912       52,973  
                 
Net Cash Used in Investing Activities
    (2,130,463 )     (1,263,557 )
                 
Financing activities:
               
Payments of capital lease
    (292,462 )     (265,517 )
Due to related parties
    2,119,877       1,414,749  
                 
Net Cash Provided by Financing Activities
    1,827,415       1,149,232  
                 
Effects of foreign currency translation
    (120 )     1,830  
                 
Net decrease in Cash
    (2,557 )     (72,602 )
                 
Cash-Beginning of Period
    7,793       81,135  
                 
Cash-Ending of Period
  $ 5,236     $ 8,533  
                 
Cash Paid During the Year for:
               
Income taxes
  $ -     $ -  
Interest paid
  $ 69,158     $ 65,300  
                 
                 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 


 
7

TONGJI HEALTHCARE GROUP, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(UNAUDITED)
 
NOTE 1- ORGANIZATION
 
Nanning Tongji Hospital, Inc. ("NTH") was established in Nanning in the province of Guangxi of the People’s Republic of China ("PRC" or “China”) by Nanning Tongji Medical Co. Ltd. and an individual on October 30, 2003.  
 
NTH is a designated hospital for medical insurance in the city of Nanning and Guangxi province. NTH specializes in the areas of internal medicine, surgery, gynecology, pediatrics, emergency medicine, ophthalmology, medical cosmetology, rehabilitation, dermatology, otolaryngology, traditional Chinese medicine, medical imaging, anesthesia, acupuncture, physical therapy, health examination, and prevention.  
 
On December 19, 2006, NTH filed the Articles of Incorporation in the State of Nevada to establish Tongji Healthcare Group, Inc. (the "Company"). On the same day, Tongji, Inc., a wholly owned subsidiary of the Company, was incorporated in the State of Colorado. Tongji Inc. was later dissolved on March 25, 2011.  
 
On December 27, 2006, Tongji Inc. acquired 100% of the equity in NTH pursuant to an Agreement and Plan of Merger, pursuant to which NTH became a wholly owned subsidiary of Tongji Inc. Pursuant to the Agreement and Plan of Merger, the Company issued 15,652,557 shares of common stock to the stockholders of NTH in exchange for 100% of the issued and outstanding shares of common stock of NTH. Thereafter and for purposes of these consolidated financial statements the "Company" and "NTH" are used to refer to the operations of NTH. The acquisition of NTH was accounted for as a reverse acquisition under the purchase method of accounting since the stockholders of NTH obtained control of the consolidated entity. Accordingly, the reorganization of the two companies was recorded as a recapitalization of NTH, with NTH being treated as the continuing operating entity.
 
The Company is authorized to issue 50,000,000 shares of common stock, par value $0.001 per share and 20,000,000 shares of preferred stock, par value $0.001 per share.
 
According to the PRC Regulation of Healthcare Institutions, hospitals are subject to registration with the health department of the local government to obtain business license for hospital services. We received our renewed business license from Nanning municipal government in November 2007, and this license is valid until November, 2020. Other existing regulations having material effects on our business include regulations dealing with physician's licensing, usage of medicine and injection, and public security in health and medical advertising.  
 
NTH must register with and maintain an operating license from the local health department, due to the fact that NTH currently maintains a facility with over 100 beds. NTH is subject to review by the local health department at least once every three years. If NTH fails to meet their standards, NTH’s business license may be revoked. NTH is also obligated to provide free services or dispatch our physicians or other employees in the event of a need for public assistance. NTH dedicates a very small percentage of its resources to providing free public services.  
 
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements include all of the adjustments, which, in the opinion of management, are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. The condensed consolidated balance sheet information as of December 31, 2013 was derived from the audited consolidated financial statements included in the Form 10-K. These condensed consolidated financial statements should be read in conjunction with the audited financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended on December 31, 2013 (“Form 10-K”), filed with the Commission on March 31, 2014.
 
 
 
8

TONGJI HEALTHCARE GROUP, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(UNAUDITED)
 
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
 
This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the condensed consolidated financial statements and the Form 10-K.
 
BASIS OF PRESENTATION AND CONSOLIDATION
 
These financial statements present the Company’s results of operations, financial position and cash flows on a consolidated basis. The consolidated financial statements include the Company and its wholly owned subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. Our policy is to consolidate all subsidiaries in which a greater than 50% voting interest is owned. The Company operates in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”.
  
CASH AND CASH EQUIVALENTS
 
For purposes of the statements of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. A substantial amount of the Company’s cash is held in bank accounts in the PRC and is not protected by Federal Deposit Insurance Corporation (FDIC) insurance or any other similar insurance. Cash held in China amounted to $5,236 as of September 30, 2014. Given the current economic environment and the financial condition of the banking industry, there is a risk that the deposits may not be readily available or covered by such insurance. The Company has had no loss of cash in domestic or foreign banks in past years.
 
USE OF ESTIMATES
 
The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of net revenues and expenses during the reporting period. Actual results may differ from those estimates and such differences may be material. The more significant estimates and assumptions by management include, among others, useful lives and residual values of fixed assets, valuation of inventories, accounts receivable, stock based compensation, and allowance for bad debt. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.
 
TRANSLATION ADJUSTMENT
 
The Company's functional currency is the Chinese Renminbi (RMB). The reporting currency is that of the US Dollar. Capital accounts of the consolidated financial statements are translated into United States dollars from RMB at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rates as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the year. The RMB is not freely convertible into foreign currency and all foreign currency exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US dollar at the rates used in translation.  
 
 
 
9

TONGJI HEALTHCARE GROUP, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(UNAUDITED)
 
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
 
The exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements were as follows:
 
September 30, 2014
 
Balance sheet
RMB 6.14 to US $1.00
   
Statement of income and other comprehensive income
RMB 6.17 to US $1.00
   
December 31, 2013
 
Balance sheet
RMB 6.05 to US $1.00
   
Statement of income and other comprehensive income
RMB 6.15 to US $1.00
 
September 30, 2013
 
Statement of income and other comprehensive income
RMB 6.17 to US $1.00
 
RECLASSIFICATIONS 
 
Certain items previously reported under specific financial statement captions have been reclassified to conform to the current year presentation.  
 
REVENUE RECOGNITION 
 
The Company's revenue recognition policies are in compliance with Staff Accounting Bulletin 104 (ASC 605). Service revenue is recognized on the dates services were rendered. When a formal arrangement exists, the price is fixed or determinable. When the service is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.  
 
The Company generates revenue from individual patients as well as third-party payers, including PRC government programs and insurance providers, under which the hospital is paid based upon government established charges. Revenues for pharmaceutical drug sales are recognized upon the drug being administered to a patient.  
 
Patient revenues are recorded based on pre-established rates set by the local government. The Company bills for services provided to Medicare patients through a medical card (the US equivalent of an insurance card). There have not been significant differences between the amounts the Company has billed the government Medicare funds and the amounts collected from the Medicare funds.  
 
ACCOUNTS RECEIVABLE 
 
Accounts receivable are recorded at the estimated net realizable amounts from government fund, insurance companies and patients. Collections have not been considered an area that exposes the Company to additional risk. Hospital staff verifies patient coverage prior to examinations and/or procedures.  
 
For any Medicare patient who visits the hospital and is qualified for acceptance, the hospital will only include the portion that the social insurance organization will pay in the accounts receivable and collects the self-pay portion in cash at the time of service. Management continues to estimate the likelihood of bad debt on an ongoing basis.  
 
The Company has estimated a bad debt allowance of approximately $31,000 as of September 30, 2014 and $44,000 as of December 31, 2013.  
 
FAIR VALUE OF FINANCIAL INSTRUMENTS 
 
The Company applies the provisions of FASB ASC Topic 825, which requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of September 30, 2014 and December 31, 2013 the fair value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, notes payable and other payables approximated the carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates except for related party debt or receivables for which it is not practicable to estimate fair value.
 
 
 
10

TONGJI HEALTHCARE GROUP, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(UNAUDITED)
 
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
 
FAIR VALUE MEASUREMENTS 
 
FASB ASC Topic 820, “Fair Value Measurements and Disclosures”, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements.  
 
Various inputs are considered when determining the fair value of the Company’s investments, and long-term debt. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below.  
 
 
Level 1 – observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets.
 
Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.).
 
Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments).
 
The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or non-recurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. The Company had no financial assets and liabilities carried at fair value on a recurring basis.  
 
The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment.  
 
CONCENTRATIONS, RISKS, AND UNCERTAINTIES 
 
All of the Company’s operations are located in the PRC. There can be no assurance that the Company will be able to successfully continue to operate and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. In addition, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. These contingencies include general economic conditions, the price of medicine, competition, governmental and political conditions, and changes in regulations. Because the Company is dependent on the domestic market of the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company’s operations will be subject to risk of restrictions on the transfer of funds, domestic policy changes, changing taxation policies, foreign exchange restrictions, and political and governmental regulations.
 
CONTINGENCIES 
 
Certain conditions may exist as of the date the consolidated financial statements are issued. These conditions may result in a future loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.  
 
 
 
11

TONGJI HEALTHCARE GROUP, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(UNAUDITED)
 
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
 
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.  
 
MEDICAL SUPPLIES 
 
Medical supplies include both western and traditional Chinese medicine, are valued on the lower of weighted average cost or market basis. Inventory includes product cost and inbound freight. Management compares the cost of medical supplies with the market value and allowance is made for writing down their inventories to market value, if such value is lower.  
 
EQUIPMENT 
 
Equipment is recorded at cost. Depreciation is computed over the estimated useful lives of the related asset type using the straight-line method. Maintenance and repairs are expensed as incurred and the costs of additions and betterments that increase the useful lives of the assets are capitalized. When equipment is disposed, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in other income or expenses.  
 
CONSTRUCTION-IN-PROGRESS 
 
A hospital facility currently under development is accounted for as construction-in-progress. Construction-in-progress is recorded at acquisition cost, including land rights cost, development expenditure, and professional fees capitalized during the course of construction for the purpose of financing the project. Upon completion of the project, the cost of construction-in-progress will be transferred to fixed assets, at which time depreciation will commence.
 
CAPITALIZATION OF INTEREST 
 
Interest cost is capitalized for qualifying assets when the portion of the interest cost incurred during the assets' acquisition periods could have been avoided if expenditures for the assets had not been made. The amount capitalized in an accounting period is determined by applying the capitalization rate to the average amount of accumulated expenditures for the asset during the period. The capitalization rates used in an accounting period is based on the rates applicable to borrowings outstanding during the period (also see Note 4).  
 
Capitalization period covers the duration of the activities required to get the asset ready for its intended use, provided that expenditures for the asset have been made and interest cost is being incurred. Interest capitalization continues as long as those activities and the incurrence of interest cost continue.  
  
IMPAIRMENT OF LONG-LIVED ASSETS 
 
The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of FASB Topic ASC 360, “Property, Plant, and Equipment”, and FASB ASC Topic 205 “Presentation of Financial Statements”. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value.  
 
The Company tests long-lived assets for recoverability at least annually or more frequently upon the occurrence of an event or when circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. The Company considers historical performance and future estimated results in its evaluation of potential impairment and then compares the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, the Company measures the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows at the rate the Company utilizes to evaluate potential investments. The Company estimates fair value based on the information available in making whatever estimates, judgments and projections are considered necessary. There was no impairment of long-lived assets for the Three and Nine Months ended September 30, 2014 and 2013.  
 
 
 
12

TONGJI HEALTHCARE GROUP, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(UNAUDITED)
 
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
 
BASIC AND DILUTED EARNINGS PER SHARE 
 
Earnings per share (EPS) is calculated in accordance with the FASB ASC Topic 260, “Earnings Per Share.” Basic net income (loss) per share is based upon the weighted average number of common shares outstanding. Diluted net income (loss) per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Potentially dilutive securities to purchase 100,000 shares of common stock were not included in the calculation of the diluted earnings per share as their effect would be anti-dilutive for the Three and Nine Months ended September 30, 2014. During the three and nine month period ended September 30, 2014, the average market price of the common stock was less than the exercise price of the stock options and the Company was in net loss position. Accordingly, the stock options were anti-dilutive and have not been included in the calculation of diluted earnings per share.
 
INCOME TAXES 
 
FASB ASC Topic 740, "Income Taxes” requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.  
 
In accordance with ASC Topic 740-10, “Accounting for Uncertainty in Income Taxes — An Interpretation of FASB ASC Topic 740” , which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.  
 
The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.
 
The Company has made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by ASC 740-10 and has not recognized any material uncertain tax positions.  
 
In addition, companies in the PRC are required to pay business taxes consisting of 5% of income they derive from providing medical treatment, as well as city construction taxes and educational taxes which are 7% and 3%, respectively, of the business taxes. In April 2010, the Company was granted an exemption from these taxes until further notice from the tax bureau.  
 
The Company had accrued approximately $40,000 for failure to file US tax returns and Form 5472 between the years 2006 to 2009. The Company is current with its required filings. In addition, the Company does not accrue United States income taxes on unremitted earnings from foreign operations, as it is the Company’s intention to invest these earnings in the foreign operations indefinitely.  
 
 
 
13

TONGJI HEALTHCARE GROUP, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(UNAUDITED)
 
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
 
STATEMENT OF CASH FLOWS 
 
In accordance with FASB ASC Topic 230, "Statement of Cash Flows," cash flows from the Company's operations are calculated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet.  
 
EMPLOYEE BENEFIT COSTS 
 
The Company contributes to a defined contribution retirement plan organized by the municipal government in the province in which the Company’s subsidiary is registered. The Company makes contributes for qualified employees that are eligible to participate in the plan. Contributions to the plan are calculated at 30% of the employees’ salaries above a fixed threshold amount; employees contribute 8% and the Company’s subsidiary contributes the balance of 22%. The Chinese government is responsible for the benefit liability to retired employees. The Company has no other material obligation for the payment of retirement beyond the annual contribution.  
 
STOCK-BASED COMPENSATION 
 
For purposes of determining the variables used in the calculation of stock compensation expense under the provisions of FASB ASC Topic 505, “Equity” and FASB ASC Topic 718, “Compensation — Stock Compensation,” we perform an analysis of current market data and historical Company data to calculate an estimate of implied volatility, the expected term of the option and the expected forfeiture rate. With the exception of the expected forfeiture rate, which is not an input, we use these estimates as variables in the Black Scholes model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. In addition, any differences between estimated forfeitures and actual forfeitures could also have a material impact on our financial statements.  
 
Stock-based compensation costs that have been included in operating expenses amounted to $3,839 for the nine month periods ended September 30, 2014 and 2013.  
 
COMPREHENSIVE INCOME 
 
The Company reports comprehensive income in accordance with FASB ASC Topic 220 “Comprehensive Income," which established standards for reporting and displaying comprehensive income and its components in a financial statement that is displayed with the same prominence as other financial statements.  
 
Total comprehensive income is defined as all changes in stockholders' equity during a period, other than those resulting from investments by and distributions to stockholders (i.e., issuance of equity securities and dividends). Generally, for the Company, total comprehensive income (loss) equals net income (loss) plus or minus adjustments for currency translation. Total comprehensive income (loss) represents the activity for a period net of related tax and was a loss of $72,925 and $92,559 for the three month periods ended September 30, 2014 and 2013, respectively.  Total comprehensive income (loss) represents the activity for a period net of related tax and was a loss of $106,292 and $249,949 for the nine month periods ended September 30, 2014 and 2013, respectively.  
 
While total comprehensive income is the activity in a period and is largely driven by net earnings in that period, accumulated other comprehensive income or loss (“AOCI”) represents the cumulative balance of other comprehensive income as of the balance sheet date. For the Company, AOCI is primarily the cumulative balance related to the currency adjustments and increased overall equity by $92,559 and $65,825 as of September 30, 2014 and December 31, 2013, respectively.  
 
 
 
14

TONGJI HEALTHCARE GROUP, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(UNAUDITED)
 
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
 
RECENT ACCOUNTING PRONOUNCEMENTS 
 
Recent accounting pronouncements issued by the FASB, the AICPA and the SEC  did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.   
 
GOING CONCERN 
 
The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has negative working capital of $18,814,681, an accumulated deficit of $2,648,087, and a stockholders’ deficit of $2,096,327 as of September 30, 2014. The Company’s ability to continue as a going concern ultimately is dependent on the management’s ability to obtain equity or debt financing, attain further operating efficiencies, and achieve profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company not be able to continue as a going concern.  
 
Management has taken certain restructuring steps to provide the necessary capital to continue its operations. These steps included: 1) plan to convert existed related parties’ loans into equity, 2) to complete construction of the new hospital and begin generating revenue by the end of the next year, 3) plan to increase sales revenue with additional medical equipments. No assurances can be given that the steps taken will provide necessary capital for the Company to continue its operations.  
 
NOTE 3- EQUIPMENT 
 
Equipment as of September 30, 2014 and December 31, 2013 comprised the following:
 
 
Estimated Useful Lives (Years)
 
June 30,
2014
   
December 31,
2013
 
Office equipment
5-10
 
$
87,763
   
$
88,985
 
Medical equipment
5
   
2,801,508
     
2,831,882
 
Fixtures
10
   
115,433
     
117,040
 
Vehicles
5
   
45,364
     
45,995
 
Total equipments
     
3,050,068
     
3,083,902
 
                   
Less accumulated depreciation
     
(1,568,115
)
   
(1,528,620
)
                   
Property and equipment, net
   
$
1,481,953
   
$
1,555,282
 

Depreciation expense charged to operations was $22,403 and $30,692 for the three months periods ended September 30, 2014 and 2013. Depreciation expense charged to operations was $67,746 and $76,611 for the nine months periods ended September 30, 2014 and 2013.  
 
NOTE 4- CONSTRUCTION IN PROGRESS 
 
The Company is constructing a new hospital building on leased land. Costs capitalized primarily consists of payments for construction costs, acquisition cost, land rights cost, development expenditure, professional fees, and capitalized interest. The Company is required to make payments for construction costs of approximately $7,870,000 and any excess construction cost payments incurred during the construction phase. As of September 30, 2014, the Company had paid approximately $15,300,000 for the construction of the hospital building. The Company estimates the additional costs to complete the project to be $35,000,000. The land lease term will start upon completion of the new hospital building, which is expected to be in the middle of 2015.  
 
The Company will amortize the cost of the hospital building over the life of the land lease of twenty years. Capitalized interest was approximately $548,000 as of September 30, 2014.  
 
 
 
15

TONGJI HEALTHCARE GROUP, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(UNAUDITED)
 
NOTE 5- LAWSUIT
 
In September 2009, Guangxi Nanning Tingyouyuxiang Commercial Co., Ltd. (“Tingyouyuxiang”) filed a civil suit against Nanning Tongji in the People’s Court. In the complaint, Tingyouyuxiang asserted a breach of contract claim against Nanting Tongji, alleging that Nanning Tongji had failed to make timely and total payment of RMB 5,050,000 (approximately $800,000) under certain Supplement Agreement by and among Nanning Tongji, Tingyouyuxiang and the Eighth Group of Langdong Village Committee, Nanhu Community Office, Qingxiu District, Nanning City (the “Village Committee”). On December 30, 2009, the People’s Court ruled that Nanning Tongji shall pay to Tingyouyuxiang damages of RMB 5,050,000 (approximately $800,000) plus interest and the court hearing fee of approximately $320,000. On March 9, 2012, Nanning Tongji appealed to the Intermediate Court, alleging, among other things, that Nanning Tongji was never served. On June 6, 2012, the Intermediate Court remanded the case to the People’s Court. On April 16, 2014, the Intermediate Court dismissed Tingyouyuxiang’s appeal and affirmed the decision of the People’s Court. Upon settlement of the lawsuit, the Company had accrued approximately $1,324,000 in settlement payable as of September 30, 2014.  
 
NOTE 6- MAJOR SUPPLIERS AND CUSTOMERS 
 
The Company had two major suppliers for the nine month period ended September 30, 2014: Guangxi Sunshine Pharmaceutical Co., Ltd. and Guangxi Tongji Medicine Co. Ltd., a related party with common major stockholders. Medicine purchased from Guangxi Sunshine Pharmaceutical Co., Ltd. and Guangxi Tongji Medicine Co. Ltd. accounted for 31% and 14% of all medicine purchases for nine month period ended September 30, 2014. As of September 30, 2014, total amount due to Guangxi Sunshine Pharmaceutical Co., Ltd., and Guangxi Tongji Medicine Co. Ltd were $152,449 and $996,999, respectively. The Company had two major suppliers for the nine month period ended September 30, 2013: Guangxi East Dragon Century Pharmaceutical Co., Ltd. and Guangxi Tongji Medicine Co. Ltd., which accounted for 20% and 45%, respectively, of all medicine purchases for the nine month period ended September 30, 2013. As of September 30, 2013, amount due to Guangxi East Dragon Century Pharmaceutical Co., Ltd. and Guangxi Tongji Medicine Co. Ltd were approximately $185,000 and $1,000,000, respectively.
 
The Company had one major customer, Nanning Social Insurance Center for the nine month period ended September 30, 2014 and 2013. Nanning Social Insurance Center accounted for 9% and 10% of revenue for the nine month periods ended September 30, 2014 and 2013. As of September 30, 2014 and 2013, accounts receivable due from Nanning Social Insurance Center was approximately $207,000, and $405,000 respectively.  
 
NOTE 7- CAPITAL LEASE OBLIGATIONS 
 
Sale and Lease Back 
 
On March 25, 2011, the Company completed a financing arrangement with an independent third party to sell and leaseback certain machinery and equipment. The net carrying value of the machinery and equipment sold was $262,683. The machinery and equipment was sold for $371,517, of which $334,365 was received in cash and $37,152 was held as refundable deposit. The transaction has been accounted for as a financing arrangement, wherein the property remains on the Company’s books and will continue to be depreciated. A financing obligation in the amount of $371,517, representing the proceeds, has been recorded under “Capital Lease Payable” in the Company’s Balance Sheet, and is being reduced based on payments under the lease. Capital lease payable was $148,701 as of September 30, 2014. The lease does not contain an option to renew. There is also no contingent rent or concessions, or any leasehold improvement incentives.
 
The lease has a term of 5 years and requires minimum annual rental payments including principal and interest as follows:
 
Year Ending December 31
 
Amount
 
2014
 
$
25,588
 
2015
   
102,353
 
2016
   
34,118
 
Total minimum lease payments
   
162,059
 
Less: interest payments
   
13,358
 
PV of minimum capital lease payments
   
148,701
 
Less: current obligations under capital lease
   
91,032
 
Long term capital lease obligation
 
$
57,669
 
 
 
 
16

TONGJI HEALTHCARE GROUP, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(UNAUDITED)
 
NOTE 7- CAPITAL LEASE OBLIGATIONS - continued
 
In October 2011, the Company entered into an agreement to lease certain machinery and equipment that are classified as capital leases. The cost of equipment under capital leases of approximately $1,430,000 is included in the Balance Sheet as property, plant, and equipment at September 30, 2014. Those equipments are to be placed in service upon usage approval from the Chinese government and hiring qualified personnel. As of September 30, 2014, the Company still has not received the approval. Accumulated depreciation and impairment loss of the leased equipment at September 30, 2014 was approximately $565,000.  Capital Lease Payable was approximately $640,000 as of September 30, 2014.
 
The lease has a term of 5 years and requires minimum annual rental payments including principal and interest as follows:
 
Year Ending December 31
 
Amount
 
2014
 
$
95,463
 
2015
   
381,857
 
2016
   
227,750
 
Total minimum lease payments
   
700,070
 
Less: interest payments
   
59,859
 
PV of minimum capital lease payments
   
640,211
 
Less: current obligations under capital lease
   
335,418
 
Long term capital lease obligation
 
 $
304,793
 
 
NOTE 8- OTHER PAYABLE 
 
Other payable as of September 30, 2014 and December 31, 2013 consists of the following:
 
   
September 30, 2014
   
December 31,
2013
 
Advance from customers
 
$
(30,924)
   
$
5,160
 
Welfare payable
   
13,392
     
31,343
 
Capital lease deposits paid by third party
   
354,294
     
359,227
 
Other payables
   
152,070
     
217,070
 
Total
 
$
488,832
   
$
612,800
 

NOTE 9- STOCKHOLDERS' EQUITY 
 
Preferred Stock 
 
As of September 30, 2014 and December 31, 2013, the Company has 20,000,000 shares of preferred stock authorized with a par value of $0.001. There are no shares of preferred stock issued and outstanding as of September 30, 2014.  
 
Common Stock 
 
As of September 30, 2014 and December 31, 2013, the Company has 50,000,000 shares of common stock authorized with a par value of $0.001.  There are 15,812,191 shares issued and outstanding as of September 30, 2014.
  
 
 
17

TONGJI HEALTHCARE GROUP, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(UNAUDITED)
 
NOTE 9- STOCKHOLDERS' EQUITY - continued
 
Statutory Reserves 
 
As stipulated by the Company Law of the PRC, net income after taxation can only be distributed as dividends after appropriation has been made for the following:  
 
i.
Making up cumulative prior years’ losses, if any;
 
ii.
Allocations to the “Statutory surplus reserve” of at least 10% of income after tax, as determined under PRC accounting rules and regulations, until the fund amounts to 50% of the Company’s registered capital;
   
iii.
Allocations to the discretionary surplus reserve, if approved in the stockholders’ general meeting.
 
As of September 30, 2014, the Company had accumulated deficits of $2,648,087. Therefore, the Company did not appropriate any fund for the statutory surplus reserve for the three month period ended September 30, 2014.  
 
Stock Option 
 
Stock-based compensation amounted to $3,839 for the nine month periods ended September 30, 2014 and 2013.  
 
On March 3, 2011, an option to purchase 100,000 shares of common stock was granted to the Company’s CFO. The option vests in two equal installments of 33,333 shares each, with the last installment being 33,334 shares, starting on the first anniversary of grant and subsequent anniversaries thereafter, at an exercise price equivalent to the closing price per share of common stock on the date of grant.
 
The fair value of the option award is estimated on the date of grant using the Black Scholes model to be $15,400. The valuation was based on the assumptions noted in the following table.
 
Expected volatility
 
105
%
Expected dividends
 
0
%
Stock price
 
0.24
 
Expected term (in years)
 
3 years
Risk-free rate
 
1.32
%

The risk-free interest rate is based on the U.S. Treasury yield curve in effect for the expected term of the option at the time of grant. The dividend yield on our common stock is assumed to be zero since we do not pay dividends and have no current plans to pay them in the future. The market price volatility of our common stock was based on historical volatility since May 13, 2010. The expected life of the options is based upon our anticipated expectations of exercise behavior since no options have been exercised in the past to provide relevant historical data.  
 
The fair value of the option granted will be expensed according to following schedule:  
 
Year
 
Expense
 
2011
 
$
4,262
 
2012
   
5,147
 
2013
   
5,133
 
2014
   
858
 
Thereafter
   
-
 
Total
 
$
15,400
 
 
 
 
18

TONGJI HEALTHCARE GROUP, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(UNAUDITED)
 
NOTE 9- STOCKHOLDERS' EQUITY - continued
 
The following table summarizes stock option activity in the Company's stock-based compensation plans for the three month period ended September 30, 2014
 
 
Number of
Shares
   
Weighted
Average
Exercise
Price
   
Aggregate
Intrinsic Value
(in thousands)
   
Number of
Shares
Exercisable
 
Outstanding at January 1, 2014
   
100,000
   
$
0.24
   
$
-
     
-
 
Granted
   
-
     
-
     
-
     
-
 
Exercised
   
-
     
-
     
-
     
-
 
Cancelled/expired
   
-
     
-
     
-
     
-
 
                                 
Outstanding at September 30, 2014
   
100,000
   
$
0.24
   
$
-
     
-
 
 
There were no options granted, exercised or cancelled/expired during the nine month period ended September 30, 2014.  
 
NOTE 10- RELATED PARTY TRANSACTIONS AND COMMITMENTS 
 
Due from/to Related Parties 
 
The Company has entered into agreements with Nanning Tongji Chain Pharmacy Co. Ltd., Guangxi Tongji Medicine Co. Ltd., and Nanning Switch Factory whereby the Company from time to time will advance funds to assist them with their operations. The three companies have common major stockholders. The advanced amounts accrue interest at a rate of 1.5% per annum. The amount receivable as of September 30, 2014 and December 31, 2013 was $45,067 and $45,695, respectively. Interest income for the three month periods ended September 30, 2014 and 2013 was approximately $169 and $168, respectively. Interest income for the nine month periods ended September 30, 2014 and 2013 was approximately $505 and $502, respectively.  
 
The Company has entered into an agreement with the Chairman and a stockholder of the Company, Nanning Tongji Chain Pharmacy Co. Ltd., Guangxi Tongji Medicine Co. Ltd., and Nanning Tongji Electric Coating Factory, whereby the Company from time to time will be advanced funds to for its operations. The advanced amounts accrue interest at a rate of 1.5% per annum. As of September 30, 2014 and December 31, 2013, $13,416,581 and $11,421,363 were payable to these related parties, respectively. Interest expense for the three month periods ended September 30, 2014 and 2013 was $79,036 and $43,396 respectively. Interest expense for the nine month periods ended September 30, 2014 and 2013 was $170,742 and $118,075 respectively.    
 
Rental Commitments 
 
The Company has entered into a lease agreement for their hospital with Guangxi Tongji Medicine Co. Ltd that expires in December 2014. The monthly lease payment is approximately $2,500. The Company is also in the process of building a new 600-bed hospital in Nanning, China and expects the new hospital to be completed by the middle of 2015. The hospital is being constructed by Guangxi Construction Engineering Corporation Langdong 8th Group and, when completed, the land will be leased by the Company for a twenty-year term. The annual lease payments will gradually increase each year. Based on the exchange rate at September 30, 2014, minimum future lease payments are as follows:  
 
   
Related Party
   
Non-Related Party
   
Total
 
1-5 years
 
$
8,035
   
$
2,786,603
   
$
2,794,637
 
6-10 years
   
-
     
3,193,901
     
3,193,901
 
11-15 years
   
-
     
3,589,660
     
3,589,660
 
16-20 years
   
-
     
1,482,568
     
1,482,568
 
Total
 
$
8,035
   
$
11,052,732
   
$
11,060,766
 

 

 
19

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 
 
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our condensed consolidated financial statements and the related condensed notes included elsewhere in this report. Our financial statements have been prepared in accordance with U.S. GAAP. The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements. 
 
Overview 
 
Nanning Tongji Hospital, Inc. ("NTH" or “Tongji Hospital”) was established in Nanning city, Guangxi province of the Peoples’ Republic of China ("PRC") by the Guangxi Tongji Medical Co. Ltd. and an individual on October 30, 2003.  
 
NTH is a designated hospital for medical insurance in city of Nanning and Guangxi province. NTH specializes in the areas of internal medicine, surgery, gynecology, pediatrics, emergency medicine, ophthalmology, medical cosmetology, rehabilitation, dermatology, otolaryngology, traditional Chinese medicine, medical imaging, anesthesia, acupuncture, physical therapy, health examination, and prevention.  
 
On December 27, 2006, we, through our wholly-owned subsidiary, Tongji, Inc., a Colorado company, acquired 100% of the equity in NTH pursuant to an Agreement and Plan of Merger. We issued 15,652,557 shares of common stock to the shareholders of NTH in exchange for 100% of the issued and outstanding shares of NTH. Accordingly, NTH became a wholly owned subsidiary of Tongji, Inc. We have been in the business of operating hospitals and providing healthcare services in Nanning, Guangxi province of the PRC.  
 
The acquisition of NTH was accounted for as a reverse acquisition under the purchase method of accounting since the shareholders of NTH obtained control of the consolidated entity. Accordingly, the reorganization of the two companies was recorded as a recapitalization of NTH. We treated NTH as the continuing operating entity. We have two sources of operating revenues: in-patient service revenues and out-patient service revenues. In addition to provide services to our patients, we also sell pharmaceutical drugs to our patients. Revenues from such sales are included in either our in-patient service revenues or our out-patient service revenues. Our revenues come from individuals as well as third-party payers, including PRC government programs and insurance providers, under which the hospital is paid based upon local government established charges. Revenues are recorded at estimated net amounts due from patients or third-party payers. Revenues from pharmaceutical drug sales are recognized upon the drug being administered to a patient or at the time a prescription by a registered physician is filled.  
 
Patient revenues are recorded based on pre-established rates set by the local government. The Company bills for services provided to Medicare patients through a medical card (the US equivalent of an insurance card). Historically, there have been no significant differences between the amounts the Company has billed the government Medicare funds and the amounts collected from the Medicare funds.    
 
We had one major customer for the nine month period ended September 30, 2014 and 2013 which accounted for 9% and 10% of revenue for the nine month periods ended September 30, 2014 and 2013.
 
During the nine month period ended September 30, 2014, about 14% of the drugs and medications we used in the hospital and sell to our patients are purchased from Guangxi Tongji Medicine Co., Ltd., a related company controlled by our Chief Executive Officer, Yunhui Yu, at prevailing market prices. The rest comes from other suppliers. One of these other suppliers is responsible for 31% of our total purchases.  
 
Difference in the Medical System between the U.S. and China 
 
In the United States most hospitals have contracts with health insurance companies that provide reduced rates for healthcare services for patients with health insurance. Medicare and Medicaid patients, also, receive reduced rates. Functionally, the patient is billed for health services at the higher rate normally charged to patients without insurance. The amount billed is then reduced by the charges paid by the insurance carrier and by the difference (sometimes known as the "contractual allowance") between the normal rate for the services and the reduced rate that the hospital estimates it will receive from Medicare, Medicaid and insurance companies.  
 

 
20

 
 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued
 
For financial reporting purposes, hospitals in the United States record revenues based upon established billing rates less adjustment for contractual allowances. Revenues are recorded based upon the amounts due from the patients and third-party payers, including federal and state agencies (under the Medicare and Medicaid programs) managed care health plans, health insurance companies, and employers. Estimates of contractual allowances under third-party payer arrangements are based upon the payment terms specified in the related contractual agreements. Third-party payer contractual payment terms are generally based upon predetermined rates per diagnosis, per diem rates, or discounted fee-for-service rates.  
 
Due to the complexities involved in determining amounts ultimately due under reimbursement arrangements with a large number of third-party payers, which are often subject to interpretation, the reimbursement actually received by U.S. hospitals for health care services is sometimes different from their estimates.  

The medical system in the PRC is different from that in the United States. Private medical insurance is not generally available to the PRC’s population and as a result services and medications provided by our hospital are usually paid by cash or by the Medicare agencies of the Nanning municipal government and the Guangxi provincial government. Our billing system automatically calculates the reimbursements that we are entitled to base upon regulations promulgated by theses government agencies. We bill the Medicare agencies directly for services provided to patients covered by these Medicare programs. In addition, due to the fact that rates are established by the government, there is no difference between rates for patients covered by Medicare and patients who pay cash.  
 
Since we only deal with the Nanning municipal and the Guangxi provincial Medicare agencies, we are familiar with their regulations pertaining to reimbursements. As a result, there is normally no material difference between the amounts we bill and the amounts we receive for services provided to Medicare patients.  
 
Results of Operation - Three Months Ended September 30, 2014 and 2013 
 
Material changes of items in our Statement of Operations for the three months ended September 30, 2014, as compared to the three months ended September 30, 2013, are discussed below.  
 
Operating Revenues – Operating revenue for the three month period ended September 30, 2014, which resulted primarily from in-patient service and out-patient service, was $649,393, an increase of $42,155 or 7%, as compared with the operating revenue of $607,238 for the same period of 2013. Our in-patient service revenue was $269,207 for the three month period ended September 30, 2014, as compared to $269,061 for the same period in 2013, a slight increase of $146. Our out-patient service revenue was $380,186 for the three month period ended September 30, 2014, an increase of $42,009 or 12% as compared to $338,177 for the same period in 2013. The increase in the in-patient and out-patient service revenue was primarily a result of our marketing effort and extended service hours offered in some of our out-patient service department. 
 
Operating Expenses – Operating expenses were $642,840 for the three month period ended September 30, 2014, a decrease of 6% as compared to $683,146 for the same period of 2013. The decrease was primarily due to a decrease of approximately $40,000 in other operating expense and a decrease of $25,500 in contingency loss, offset by an increase of approximately of $32,000 in salary and fringes expenses and an increase of approximately $5,000 in medicine and supplies resulting from the increase in in-patient and out-patient service revenue.

Income from Operations - Operating income was $6,553 for the three month period ended September 30, 2014, an increase of $82,461 or 109% as compared to an operating loss of $75,908 for the same period of 2013. The primary reason for the decrease is the aforementioned changes.  
 
Interest Expense – Interest expense for the three month period ended September 30, 2014 was $64,646 as compared to $13,045 for the three month period ended September 30, 2013, an increase of $52,000 or 396%.   The increase was primarily due to the increase in related party borrowings to fund the new hospital construction.
 
Net Loss - As a result of the forgoing, the Company had a net loss of $51,070 during the quarter ended September 30, 2014, compared to a net loss of $84,620 for the comparative period in 2013, a decrease of $33,550 or 40%.
 

 
21

 
 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued
 
Results of Operation - Nine Months Ended September 30, 2014 and 2013 
 
Material changes of items in our Statement of Operations for the Nine Months ended September 30, 2014, as compared to the nine months ended September 30, 2013, are discussed below.  
 
Operating Revenues – Operating revenue for the nine month period ended September 30, 2014, which resulted primarily from in-patient service and out-patient service, was $1,860,106, an increase of $139,305 or 8%, as compared with the operating revenue of $1,720,801 for the same period of 2013. Our in-patient service revenue was $847,809 for the nine month period ended September 30, 2014, as compared to $806,988 for the same period in 2013, an increase of $40,821 or 5%. Our out-patient service revenue was $1,012,297 for the nine month period ended September 30, 2014, an increase of $98,484 or 11% as compared to $913,813 for the same period in 2013. The increase in the in-patient and out-patient service revenue was primarily a result of our marketing effort and extended service hours offered in some of our out-patient service department. 
 
Operating Expenses – Operating expenses were $1,858,094 for the nine month period ended September 30, 2014, a slight decrease of $5,965 as compared to $1,864,059 for the same period of 2013. The decrease was primarily due to a decrease of approximately $84,000 in contingency loss, offset by an increase of approximately of $37,000 in medicine and supplies purchase, and an increase of approximately $46,000 in salary and fringes resulting from the increase in in-patient and out-patient service revenue.
 
Income/Loss from Operations - Operating income was $2,012 for the nine month period ended September 30, 2014, an increase of $145,270 or 101% as compared to an operating loss of $143,258 for the same period of 2013. The primary reason for the increase is the aforementioned changes.  
 
Interest Expense – Interest expense for the nine month period ended September 30, 2014 was $160,026 as compared to $88,272 for the nine month period ended September 30, 2013, an increase of $72,000 or 80%.   The increase was primarily due to the increase in related party borrowings to fund the new hospital construction.
 
Net Loss - As a result of the forgoing, the Company had a net loss of $133,066 during the nine month period ended September 30, 2014, compared to a net loss of $212,583 for the comparative period in 2013, a decrease of $79,517or 37%.
 
Trends, Events and Uncertainties 
 
The China Ministry of Health, as well as other related agencies, has proposed changes to the price limit we can charge for medical services, drugs and medications. We cannot predict the impact of these proposed changes since the changes are not fully defined and we do not know whether those proposed changes will be implemented or when they may take effect.  
 
We are in the process of building a new 600-bed hospital building in Nanning city on leased land. We expect the new hospital building to be completed by the middle of 2015. The hospital building is being constructed by Guangxi Construction Engineering Corporation Langdong 8th Group (“Langdong 8th Group”). The lease payments for the land will start after the construction is completed. Annual lease payments for the land will increase every year. Our agreement with Langdong 8th Group obligates us to pay approximately $7,870,000 for construction related costs. In addition, we are responsible for any additional costs necessary to complete the project. As of September 30, 2014, we had paid approximately $15,300,000 for the construction of the hospital. We borrowed most of the funds from our related company Guangxi Tongji Medicine Co., Ltd. We estimate the additional costs to complete the project to be $35,000,000. We expect to obtain the additional funding through borrowing from bank and sales of some company owned properties. We will continue to operate in our existing hospital buildings after the completion of the new hospital building.  We plan to acquire other hospitals and companies involved in the healthcare industry in the PRC using cash and shares of our common stock. Substantial capital may be needed for these acquisitions and we may need to raise additional funds through the sale of our common stock, debt financing or other arrangements. We do not have any commitments or arrangements from any person to provide us with any additional capital. Additional capital may not be available to us, or if available, on acceptable terms, in which case we would not be able to acquire other hospitals or businesses in the healthcare industry.  
 
 
 
 
22

 
 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued
 
Other than the factors listed above we do not know of any trends, events or uncertainties that have had or are reasonably expected to have a material impact on our net sales or revenues or income from continuing operations. Our business is not seasonal in nature.  
 
Accounting Estimates 
 
In the United States most hospitals have contracts with health insurance companies that provide reduced rates for healthcare services for patients with health insurance. Medicare and Medicaid patients also receive reduced rates. Functionally, the patient is billed for health services at the higher rate normally charged to patients without insurance. The amount billed is then reduced by the charges paid by the insurance carrier and by the difference (sometimes known as the "contractual allowance") between the normal rate for the services and the reduced rate that the hospital estimates it will receive from Medicare, Medicaid and insurance companies.  
 
For financial reporting purposes, hospitals in the United States record revenues based upon established billing rates less adjustment for contractual allowances. Revenues are recorded based upon the amounts due from the patients and third-party payers, including federal and state agencies (under the Medicare and Medicaid programs) managed care health plans, health insurance companies, and employers. Estimates of contractual allowances under third-party payer arrangements are based upon the payment terms specified in the related contractual agreements. Third-party payer contractual payment terms are generally based upon predetermined rates per diagnosis, per diem rates, or discounted fee-for-service rates.
 
Due to the complexities involved in determining amounts ultimately due under reimbursement arrangements with a large number of third-party payers, which are often subject to interpretation, the reimbursement actually received by U.S. hospitals for health care services is sometimes different from their estimates.  
 
The medical system in the PRC is different from that in the United States. Private medical insurance is not generally available to the PRC’s population and as a result services and medications provided by our hospital are usually paid for in cash or by the Medicare agencies of the Nanning municipal government and the Guangxi provincial government. Our billing system automatically calculates the reimbursements that we are entitled to based upon regulations promulgated by theses government agencies. We bill the Medicare agencies directly for services provided to patients covered by theses Medicare programs. In addition, due to the fact that rates are established by the government, there is no difference between rates for patients covered by Medicare and patients who only use cash.  
 
Since we only deal with the Nanning municipal and the Guangxi provincial Medicare agencies we are familiar with their regulations pertaining to reimbursements. As a result, there is normally no material difference between the amounts we bill and the amounts we receive for services provided to Medicare patients.   

Liquidity and Capital Resources 
 
We generally finance our operations through our operating profits and borrowings from related parties. As of the date of this report, we have not experienced any difficulty in raising funds from related parties, and we have not experienced any liquidity problems in settling our payables in our ordinary course of business. We believe that we have adequate funds and capital with respect to conducting its business over the next twelve months.  
 
The following shows our material sources and uses of cash during the nine month periods ended September 30, 2014 and 2013:  
 
   
September 30, 2014
   
September 30, 2013
 
Cash provided by (used in) operating activities
 
$
300,611
   
$
39,893
 
                 
Cash (used in) investing activities
 
$
(2,130,463
)
 
$
(1,263,557
)
                 
Cash provided by financing activities
 
$
1,827,415
   
$
1,149,232
 
 
 
23

 
 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued
 
The Company carefully monitors and controls the amount of cash used to fund operating activities. However, substantial funds are required to fund the construction costs on the new hospital building and a lawsuit settlement (see Note 5 to the Financial Statements accompanying this Report). Financing of operations has come primarily from advances from related parties. We are dependent on related parties to provide working capital and pay our management team until such time as our operations are profitable. There can be no assurances that related parties will continue to provide additional capital. Without additional capital, we may be forced to cease operations and liquidate.  
 
Operating Activities 
 
Net cash used in operating activities primarily consists of net loss, as adjusted by depreciation, stock option, and changes in operating assets and liabilities such as accounts receivable, medical supplies, capital lease deposits, prepaid expense and other current assets, accounts payables and accrued liabilities , and other payables.  
 
Net cash provided by operating activities was $300,611 for the nine months ended September 30, 2014, an increase of $260,718 or 654%, as compared with the net cash provided by operating activities of $39,893 for the same period in 2013. The increase in net cash provided by operating activities was primarily due to an increase in account receivable collection of approximately $129,000, a decrease of approximately $72,000 in medical supply purchases, and a decrease of $80,000 in net operating loss, offset by a decrease of approximately $25,000 in contingent liability pay-out for the nine month period ended September 30, 2014.
 
Investing Activities 
 
Net cash used in investing activities primarily consists of acquisition of equipment and purchases of construction in progress.  
 
Net cash used in investing activities was $2,130,463 for the nine months ended September 30, 2014, an increase of $866,906 or 69%, as compared with the net cash used in investing activities of $1,263,557 for the same period in 2013. The increase in net cash used in investing activities was primarily due to an increase of approximately $930,000 in construction in progress offset by a decrease of approximately $100,000 in intangible assets acquisitions.  
 
Financing Activities 
 
Net cash provided by financing activities primarily consists of proceeds from related party loans.  
 
Net cash provided by financing activities was $1,827,415 for the nine months ended September 30, 2014, an increase of $678,183 or 59%, as compared with the net cash provided by financing activities of $1,149,232 for the same period in 2013. The increase was primarily attributable to increase in fund advanced by related parties for the construction of the new hospital building.  
 
Working Capital 
 
Our working capital was negative $18,814,681 as of September 30, 2014, as compared with negative $15,242,430 as of December 31, 2013, an increase of $3,572,251, which is primarily attributable to the reclassification of lawsuit payable of approximately $1,300,000 from contingency liabilities and the related party loan of approximately $2,000,000 to fund the construction of the new hospital.  
 
Rental Commitments 
 
The Company has entered into a lease agreement for their hospital building with Guangxi Tongji Medicine Co. Ltd that expires in December 2014. The monthly lease payment is approximately $2,500. The Company is also in the process of building a new 600-bed hospital building in Nanning, China and expects the new hospital building to be completed by the middle of 2015. The hospital building is being constructed by Langdong 8th Group and, when completed, the land will be leased by the Company for a twenty-year term. The annual lease payments will gradually increase each year. Based on the exchange rate at September 30, 2014, minimum future lease payments are as follows: 
 
 
 
24

 
 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued
 
   
Related Party
   
Non-Related Party
   
Total
 
1-5 years
 
$
8,035
   
$
2,786,603
   
$
2,794,637
 
6-10 years
   
-
     
3,193,901
     
3,193,901
 
11-15 years
   
-
     
3,589,660
     
3,589,660
 
16-20 years
   
-
     
1,482,568
     
1,482,568
 
Total
 
$
8,035
   
$
11,052,732
   
$
11,060,766
 

Going Concern 
 
The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has negative working capital of $18,814,681, an accumulated deficit of $2,648,087, and a stockholders’ deficit of $2,096,327 as of September 30, 2014. The Company’s ability to continue as a going concern ultimately is dependent on the management’s ability to obtain equity or debt financing, attain further operating efficiencies, and achieve profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company not be able to continue as a going concern.  
 
Management has taken certain restructuring steps to provide the necessary capital to continue its operations. These steps included: 1) plan to convert existed related parties’ loans into equity, 2) to complete construction of the new hospital and begin generating revenue by the end of the next year, 3) plan to increase sales revenue with additional medical equipment. No assurances can be given that the steps taken will provide necessary capital for the Company to continue its operations.  
 
Off-Balance Sheet Arrangements 
 
We do not have any off-balance sheet items reasonably likely to have a material effect on our financial condition.  
 
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
 
Not applicable.
 
Item 4. Controls and Procedures. 
 
Evaluation of Disclosure Controls 
 
Our management maintains disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to provide reasonable assurance that the material information required to be disclosed by us in our periodic reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.  
 
 
 
25

 
 
Item 4. Controls and Procedures - continued
 
As of September 30, 2014, our management, under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as required by Rules 13a-15(b) and 15d-15(b) under the Exchange Act. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of September 30, 2014 as a result of the material weaknesses identified in our internal control over financial reporting, which are discussed below. Our management considers our internal control over financial reporting to be an integral part of our disclosure controls and procedures.  
 
Specifically, our management identified certain matters involving internal control and our operations that it considered to be material weaknesses. As defined in the Exchange Act, a material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the registrant's annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses identified by our management as of September 30, 2014, are described below:  
 
 
We did not design, implement, or maintain effective entity-level controls related to our control environment, resulting in the following significant control deficiencies:
 
 
o
The Code of Business Conduct and Ethics, which was specifically designed for public company applicability, has yet to be formally acknowledged by members of management and the finance department.
 
 
o
There is an absence of independence and financial expertise on the Board of Directors, and we do not have an Audit Committee or a formalized internal audit function, limiting its ability to provide effective oversight of our management.
 
 
o
The full implementation of, and related training for, our newly-formalized IT policies and procedures were still in process at year-end. Accordingly, we lacked sufficiently-trained personnel to provide for adequate segregation of duties within the accounting system and effective oversight of controls over access, change, data, and security management.
 
Our management believes that the pervasive nature of these control deficiencies, when aggregated, impact all significant accounts and disclosures and rise to the level of material weakness.  
  
Our management will continue to monitor and evaluate the effectiveness of its disclosure controls and procedures, as well as its internal control over financial reporting, on an ongoing basis, and is committed to taking further action and implementing additional improvements, as necessary and as funds allow. However, our management cannot guarantee that the measures taken or any future measures will remediate the material weaknesses identified or that any additional material weaknesses or significant deficiencies will not arise in the future due to a failure to implement and maintain adequate internal control over financial reporting.  
 
Notwithstanding the material weaknesses described above, our management believes that there are no material inaccuracies or omissions of material fact and, to the best of its knowledge, believes that the consolidated financial statements included in this annual report present fairly, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States.  
 
Changes in Internal Control over Financial Reporting 
 
No changes in the Company's internal control over financial reporting has come to management's attention during the Company's last fiscal quarter that have materially affected, or are likely to materially affect, the Company's internal control over financial reporting.
 
 
26

 
 
PART II - OTHER INFORMATION 
 
Item 1. Legal Proceedings.
 
In September 2009, Guangxi Nanning Tingyouyuxiang Commercial Co., Ltd. (“Tingyouyuxiang”) filed a civil suit against NTH in the People’s Court. In the complaint, Tingyouyuxiang asserted a breach of contract claim against NTH, alleging that NTH had failed to make timely and total payment of RMB 5,050,000 (approximately $800,000) under certain Supplement Agreement by and among NTH, Tingyouyuxiang and Langdong 8th Group. On December 30, 2009, the People’s Court ruled that NTH shall pay to Tingyouyuxiang damages of RMB 5,050,000 (approximately $800,000) plus interest and the court hearing fee of approximately $320,000. On March 9, 2012, NTH appealed to the Intermediate People’s Court in Nanning City, People’s Republic of China (“Intermediate Court”), alleging, among other things, that NTH was never served. On June 6, 2012, the Intermediate Court remanded the case to the People’s Court. On June 20, 2013, the People’s Court dismissed the action. On October 21, 2013, Tingyouyuxiang appealed the dismissal to the Intermediate Court and the Intermediate Court accepted the appeal on October 21, 2013. On April 16, 2014, the Intermediate Court dismissed Tingyouyuxiang’s appeal and affirmed the decision of the People’s Court.  The Company had accrued approximately $1,324,000 as of September 30, 2014.  
 
Item 1A. Risk Factors.
 
Not Applicable.  
 
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
 
None.  
 
Item 3. Defaults Upon Senior Securities.
 
None.  
 
Item 4. Mine Safety Disclosures.
 
Not applicable.
 
Item 5. Other Information.
 
None.  
 
 
 
 
 
 
 
 
 
 
27

 
 
Item 6. Exhibits.
 
Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.  
 
Exhibit No.
Title of Document
3.1
Articles of Incorporation (1)
3.2
Bylaws (1)
10.1
Agreement with Eric Zhang, dated July 30, 2014 (3)
10.2
Guangxi Medical Insurance and Designated Medical Institution Agreement (2)
101.INS
XBRL Instance Document*
101.SCH
XBRL Taxonomy Extension Schema Document*
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document*
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document*
101.LAB
XBRL Taxonomy Extension Label Linkbase Document*
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document*
 
* Filed herewith.
** Furnished herewith.
(1) Incorporated by reference to the same exhibit filed with our registration statement on Form SB-2 (File No. 333-140645).
(2) Incorporated by reference to the same exhibit filed with our quarterly report on Form 10-Q filed on May 15, 2014.
(3) Incorporated by reference to the same exhibit filed with our quarterly report on Form 10-Q filed on August 4, 2014.
 
 
 
 
 
 
 
 
 
 
 
 
28

 
 
SIGNATURES
 
Pursuant to the requirements of the securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
TONGJI HEALTHCARE GROUP, INC.
   
Date: November 14, 2014
By:
/s/ Yunhui Yu
 
Yunhui Yu
President and Chief Executive Officer
(Principal Executive Officer)

 
Date: November 14, 2014
By:
/s/ Eric Zhang
 
Eric Zhang
Chief Financial Officer
(Principal Financial Officer)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29
EX-31.1 2 exhibit_31-1.htm CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 exhibit_31-1.htm

EXHIBIT 31.1
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002

I, Yunhui Yu, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Tongji Healthcare Group, Inc.
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b) designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
 
a) all significant deficiencies and material weakness in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data; and
 
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
       
Date : November 14, 2014
By:
/s/ Yunhui Yu
 
   
Yunhui Yu
 
   
President and Chief Executive Officer
(Principal Executive Officer)
 
EX-31.2 3 exhibit_31-2.htm CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 exhibit_31-2.htm

EXHIBIT 31.2
 
CERTIFICATION OF VICE PRESIDENT OF CORPORATE FINANCE PURSUANT TO
SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002

I, Eric Zhang, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Tongji Healthcare Group, Inc.
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b) designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
 
a) all significant deficiencies and material weakness in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data; and
 
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 

 
     
       
Date: November 14, 2014
By:
/s/ Eric Zhang
 
   
Eric Zhang
 
   
Chief Financial Officer
(Principal Financial Officer)
 

EX-32.1 4 exhibit_32-1.htm CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 exhibit_32-1.htm

EXHIBIT 32.1
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, the President and Chief Executive Officer of Tongji Healthcare Group, Inc. (the "Company"), does hereby certify under the standards set forth and solely for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2014 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in that Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated: November 14, 2014
     
/s/ Yunhui Yu
       
Yunhui Yu
President and Chief Executive Officer
(Principal Executive Officer)

EX-32.2 5 exhibit_32-2.htm CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 exhibit_32-2.htm

EXHIBIT 32.2
 
CERTIFICATION OF VICE PRESIDENT OF CORPORATE FINANCE
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, the Chief Financial Officer of Tongji Healthcare Group, Inc. (the "Company"), does hereby certify under the standards set forth and solely for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2014 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in that Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated: November 14, 2014
     
/s/ Eric Zhang
       
Eric Zhang
Chief Financial Officer
(Principal Financial Officer)


EX-101.INS 6 tonj-20140930.xml XBRL INSTANCE DOCUMENT 0001389518 2014-01-01 2014-09-30 0001389518 2013-01-01 2013-09-30 0001389518 2013-12-31 0001389518 2014-09-30 0001389518 TONJ:BalanceSheetMember TONJ:RMBMember 2014-09-30 0001389518 TONJ:BalanceSheetMember TONJ:USDollarMember 2014-09-30 0001389518 TONJ:StatementOfOperationsAndOtherComprehensiveLossMember TONJ:RMBMember 2014-09-30 0001389518 TONJ:StatementOfOperationsAndOtherComprehensiveLossMember TONJ:USDollarMember 2014-09-30 0001389518 TONJ:StatementOfOperationsAndOtherComprehensiveLossMember TONJ:RMBMember 2013-09-30 0001389518 TONJ:StatementOfOperationsAndOtherComprehensiveLossMember TONJ:USDollarMember 2013-09-30 0001389518 TONJ:RelatedPartyMember 2014-09-30 0001389518 TONJ:NonRelatedPartyMember 2014-09-30 0001389518 2012-12-31 0001389518 TONJ:NanningSocialInsuranceCenterMember 2014-09-30 0001389518 TONJ:NanningSocialInsuranceCenterMember 2013-09-30 0001389518 TONJ:BalanceSheetMember TONJ:RMBMember 2013-12-31 0001389518 TONJ:BalanceSheetMember TONJ:USDollarMember 2013-12-31 0001389518 TONJ:StatementOfOperationsAndOtherComprehensiveLossMember TONJ:RMBMember 2013-12-31 0001389518 TONJ:StatementOfOperationsAndOtherComprehensiveLossMember TONJ:USDollarMember 2013-12-31 0001389518 2013-09-30 0001389518 TONJ:MajorCustomerMember 2014-01-01 2014-09-30 0001389518 TONJ:MajorCustomerMember 2013-01-01 2013-09-30 0001389518 TONJ:GuangxiTongjiMedicineCoLtdMember 2014-01-01 2014-09-30 0001389518 TONJ:GuangxiTongjiMedicineCoLtdMember 2013-01-01 2013-09-30 0001389518 2014-07-01 2014-09-30 0001389518 2013-07-01 2013-09-30 0001389518 us-gaap:OfficeEquipmentMember 2014-01-01 2014-09-30 0001389518 us-gaap:EquipmentMember 2014-01-01 2014-09-30 0001389518 us-gaap:FurnitureAndFixturesMember 2014-01-01 2014-09-30 0001389518 us-gaap:VehiclesMember 2014-01-01 2014-09-30 0001389518 TONJ:GuangxiSunshinePharmaceuticalCoLtd.Member 2014-01-01 2014-09-30 0001389518 TONJ:GuangxiSunshinePharmaceuticalCoLtd.Member 2014-09-30 0001389518 TONJ:GuangxiTongjiMedicineCoLtdMember 2014-09-30 0001389518 TONJ:GuangxiEastDragonCenturyPharmaceuticalCoLtdMember 2013-01-01 2013-09-30 0001389518 TONJ:GuangxiEastDragonCenturyPharmaceuticalCoLtdMember 2013-09-30 0001389518 TONJ:GuangxiTongjiMedicineCoLtdMember 2013-09-30 0001389518 2014-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Tongji Healthcare Group, Inc. 0001389518 10-Q 2014-09-30 false --12-31 No No Yes Smaller Reporting Company Q3 2014 15850224 17407526 439510 443349 15812 15812 0 0 1267637 14232773 16167143 633061 735165 15850224 17407526 90468 81650 189851 185739 13376281 15331474 638342 326710 10690 0 148286 70753 120352 111754 351221 138967 15812191 15812191 15812191 15812191 6.14 1 6.17 1 6.17 1 6.05 1.00 6.15 1.00 5160 -30924 31343 13392 359227 354294 217070 152070 612800 488832 20000000 20000000 0.001 .001 0 0 0 0 50000000 50000000 0.001 0.001 -2515021 -2648087 45695 45067 11421363 13416581 1555282 1481953 1323801 44000 31000 88985 87763 2831882 2801508 117040 115433 45995 45364 3083902 3050068 -1528620 -1568115 15812191 7793 5236 81135 8533 402138 426450 15880772 19141391 695689 362462 16576461 19503853 65825 92599 -1993874 -2096327 -0.007 -0.016 -0.007 -0.006 -106292 -249949 -72925 -92559 26774 -37366 -21855 -7939 -133066 -212583 -51070 -84620 0 0 0 0 -133066 -212583 -51070 -84620 -135078 -69325 -51070 -8712 -160026 -88272 -64646 -13045 24948 18947 7023 4333 2012 -143258 6553 -75908 1858094 1864059 642840 683146 587540 541213 215957 184425 242777 278526 83215 122872 812421 775357 271889 266512 0 83955 0 25500 67746 76611 22403 30692 147610 108397 49376 53145 1860106 1720801 649393 607238 1012297 913813 380186 338177 847809 806988 269207 269061 15812191 15812191 15812191 15812191 67747 76612 3839 3839 -206459 -77836 -75143 -3210 -10492 970 1499 0 110280 162616 -115011 -168937 73229 98270 300611 39893 8481 20353 0 100541 2128894 1195636 -6912 -52973 -2130463 -1263557 292462 265517 2119877 1414749 1827415 1149232 -120 1830 -2557 -72602 0 0 69158 65300 <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Nanning Tongji Hospital, Inc. (&#34;NTH&#34;) was established in Nanning in the province of Guangxi of the People&#146;s Republic of China (&#34;PRC&#34; or &#147;China&#148;) by Nanning Tongji Medical Co. Ltd. and an individual on October 30, 2003. &#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">NTH is a designated hospital for medical insurance in the city of Nanning and Guangxi province. NTH specializes in the areas of internal medicine, surgery, gynecology, pediatrics, emergency medicine, ophthalmology, medical cosmetology, rehabilitation, dermatology, otolaryngology, traditional Chinese medicine, medical imaging, anesthesia, acupuncture, physical therapy, health examination, and prevention. &#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">On December 19, 2006, NTH filed the Articles of Incorporation in the State of Nevada to establish Tongji Healthcare Group, Inc. (the &#34;Company&#34;). On the same day, Tongji, Inc., a wholly owned subsidiary of the Company, was incorporated in the State of Colorado. Tongji Inc. was later dissolved on March 25, 2011. &#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">On December 27, 2006, Tongji Inc. acquired 100% of the equity in NTH pursuant to an Agreement and Plan of Merger, pursuant to which NTH became a wholly owned subsidiary of Tongji Inc. Pursuant to the Agreement and Plan of Merger, the Company issued 15,652,557 shares of common stock to the stockholders of NTH in exchange for 100% of the issued and outstanding shares of common stock of NTH. Thereafter and for purposes of these consolidated financial statements the &#34;Company&#34; and &#34;NTH&#34; are used to refer to the operations of NTH. The acquisition of NTH was accounted for as a reverse acquisition under the purchase method of accounting since the stockholders of NTH obtained control of the consolidated entity. Accordingly, the reorganization of the two companies was recorded as a recapitalization of NTH, with NTH being treated as the continuing operating entity.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company is authorized to issue 50,000,000 shares of common stock, par value $0.001 per share and 20,000,000 shares of preferred stock, par value $0.001 per share.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">According to the PRC Regulation of Healthcare Institutions, hospitals are subject to registration with the health department of the local government to obtain business license for hospital services. We received our renewed business license from Nanning municipal government in November 2007, and this license is valid until November, 2020. Other existing regulations having material effects on our business include regulations dealing with physician's licensing, usage of medicine and injection, and public security in health and medical advertising. &#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">NTH must register with and maintain an operating license from the local health department, due to the fact that NTH currently maintains a facility with over 100 beds. NTH is subject to review by the local health department at least once every three years. If NTH fails to meet their standards, NTH&#146;s business license may be revoked. NTH is also obligated to provide free services or dispatch our physicians or other employees in the event of a need for public assistance. NTH dedicates a very small percentage of its resources to providing free public services.&#160;<b>&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements include all of the adjustments, which, in the opinion of management, are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. The condensed consolidated balance sheet information as of December 31, 2013 was derived from the audited consolidated financial statements included in the Form 10-K. These condensed consolidated financial statements should be read in conjunction with the audited financial statements in the Company&#146;s Annual Report on Form 10-K for the fiscal year ended on December 31, 2013 (&#147;Form 10-K&#148;), filed with the Commission on March 31, 2014.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This summary of significant accounting policies of the Company is presented to assist in understanding the Company&#146;s consolidated financial statements. The consolidated financial statements and notes are representations of the Company&#146;s management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the condensed consolidated financial statements and the Form 10-K.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>BASIS OF PRESENTATION AND CONSOLIDATION</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements present the Company&#146;s results of operations, financial position and cash flows on a consolidated basis. The consolidated financial statements include the Company and its wholly owned subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. Our policy is to consolidate all subsidiaries in which a greater than 50% voting interest is owned. The Company operates in one segment in accordance with the accounting guidance FASB ASC topic 280, &#147;Segment Reporting&#148;.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>CASH AND CASH EQUIVALENTS</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">For purposes of the statements of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. A substantial amount of the Company&#146;s cash is held in bank accounts in the PRC and is not protected by Federal Deposit Insurance Corporation (FDIC) insurance or any other similar insurance. Cash held in China amounted to $5,236 as of September 30, 2014. Given the current economic environment and the financial condition of the banking industry, there is a risk that the deposits may not be readily available or covered by such insurance. The Company has had no loss of cash in domestic or foreign banks in past years.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>USE OF ESTIMATES</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of net revenues and expenses during the reporting period. Actual results may differ from those estimates and such differences may be material. The more significant estimates and assumptions by management include, among others, useful lives and residual values of fixed assets, valuation of inventories, accounts receivable, stock based compensation, and allowance for bad debt. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>TRANSLATION ADJUSTMENT</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company's functional currency is the Chinese Renminbi (RMB). The reporting currency is that of the US Dollar. Capital accounts of the consolidated financial statements are translated into United States dollars from RMB at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rates as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the year. The RMB is not freely convertible into foreign currency and all foreign currency exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US dollar at the rates used in translation.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements were as follows:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 69%; border-bottom: black 1.5pt solid"><font style="font-size: 8pt">September 30, 2014</font></td> <td style="width: 31%; border-bottom: black 1.5pt solid">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Balance sheet</font></td> <td><font style="font-size: 8pt">RMB 6.14 to US $1.00</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Statement of income and other comprehensive income</font></td> <td><font style="font-size: 8pt">RMB 6.17 to US $1.00</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: white"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 8pt">December 31, 2013</font></td> <td style="border-bottom: black 1.5pt solid">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Balance sheet</font></td> <td><font style="font-size: 8pt">RMB 6.05 to US $1.00</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Statement of income and other comprehensive income</font></td> <td><font style="font-size: 8pt">RMB 6.15 to US $1.00</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 69%; border-bottom: black 1.5pt solid"><font style="font-size: 8pt">September 30, 2013</font></td> <td style="width: 31%; border-bottom: black 1.5pt solid">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Statement of income and other comprehensive income</font></td> <td><font style="font-size: 8pt">RMB 6.17 to US $1.00</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>RECLASSIFICATIONS&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Certain items previously reported under specific financial statement captions have been reclassified to conform to the current year presentation.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>REVENUE RECOGNITION&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company's revenue recognition policies are in compliance with Staff Accounting Bulletin 104 (ASC 605). Service revenue is recognized on the dates services were rendered. When a formal arrangement exists, the price is fixed or determinable. When the service is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company generates revenue from individual patients as well as third-party payers, including PRC government programs and insurance providers, under which the hospital is paid based upon government established charges. Revenues for pharmaceutical drug sales are recognized upon the drug being administered to a patient.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Patient revenues are recorded based on pre-established rates set by the local government. The Company bills for services provided to Medicare patients through a medical card (the US equivalent of an insurance card). There have not been significant differences between the amounts the Company has billed the government Medicare funds and the amounts collected from the Medicare funds.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>ACCOUNTS RECEIVABLE&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Accounts receivable are recorded at the estimated net realizable amounts from government fund, insurance companies and patients. Collections have not been considered an area that exposes the Company to additional risk. Hospital staff verifies patient coverage prior to examinations and/or procedures.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">For any Medicare patient who visits the hospital and is qualified for acceptance, the hospital will only include the portion that the social insurance organization will pay in the accounts receivable and collects the self-pay portion in cash at the time of service. Management continues to estimate the likelihood of bad debt on an ongoing basis.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company has estimated a bad debt allowance of approximately $31,000 as of September 30, 2014 and $44,000 as of December 31, 2013.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>FAIR VALUE OF FINANCIAL INSTRUMENTS&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company applies the provisions of FASB ASC Topic 825, which requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of September 30, 2014 and December 31, 2013 the fair value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, notes payable and other payables approximated the carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates except for related party debt or receivables for which it is not practicable to estimate fair value.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>FAIR VALUE MEASUREMENTS&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">FASB ASC Topic 820, &#147;Fair Value Measurements and Disclosures&#148;, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Various inputs are considered when determining the fair value of the Company&#146;s investments, and long-term debt. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%">&#160;</td> <td style="width: 3%"><font style="font-size: 8pt">&#9679;</font></td> <td style="width: 94%"><font style="font-size: 8pt">Level 1 &#150; observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 8pt">&#9679;</font></td> <td><font style="font-size: 8pt">Level 2 &#150; other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.).</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 8pt">&#9679;</font></td> <td><font style="font-size: 8pt">Level 3 &#150; significant unobservable inputs (including the Company&#146;s own assumptions in determining the fair value of investments).</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or non-recurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. The Company had no financial assets and liabilities carried at fair value on a recurring basis.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>CONCENTRATIONS, RISKS, AND UNCERTAINTIES&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">All of the Company&#146;s operations are located in the PRC. There can be no assurance that the Company will be able to successfully continue to operate and failure to do so would have a material adverse effect on the Company&#146;s financial position, results of operations and cash flows. In addition, the success of the Company&#146;s operations is subject to numerous contingencies, some of which are beyond management&#146;s control. These contingencies include general economic conditions, the price of medicine, competition, governmental and political conditions, and changes in regulations. Because the Company is dependent on the domestic market of the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company&#146;s operations will be subject to risk of restrictions on the transfer of funds, domestic policy changes, changing taxation policies, foreign exchange restrictions, and political and governmental regulations.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>CONTINGENCIES&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Certain conditions may exist as of the date the consolidated financial statements are issued. These conditions may result in a future loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company&#146;s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company&#146;s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>MEDICAL SUPPLIES&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Medical supplies include both western and traditional Chinese medicine, are valued on the lower of weighted average cost or market basis. Inventory includes product cost and inbound freight. Management compares the cost of medical supplies with the market value and allowance is made for writing down their inventories to market value, if such value is lower.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>EQUIPMENT&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Equipment is recorded at cost. Depreciation is computed over the estimated useful lives of the related asset type using the straight-line method. Maintenance and repairs are expensed as incurred and the costs of additions and betterments that increase the useful lives of the assets are capitalized. When equipment is disposed, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in other income or expenses.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>CONSTRUCTION-IN-PROGRESS&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">A hospital facility currently under development is accounted for as construction-in-progress. Construction-in-progress is recorded at acquisition cost, including land rights cost, development expenditure, and professional fees capitalized during the course of construction for the purpose of financing the project. Upon completion of the project, the cost of construction-in-progress will be transferred to fixed assets, at which time depreciation will commence.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>CAPITALIZATION OF INTEREST&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Interest cost is capitalized for qualifying assets when the portion of the interest cost incurred during the assets' acquisition periods could have been avoided if expenditures for the assets had not been made. The amount capitalized in an accounting period is determined by applying the capitalization rate to the average amount of accumulated expenditures for the asset during the period. The capitalization rates used in an accounting period is based on the rates applicable to borrowings outstanding during the period (also see Note 4).&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Capitalization period covers the duration of the activities required to get the asset ready for its intended use, provided that expenditures for the asset have been made and interest cost is being incurred. Interest capitalization continues as long as those activities and the incurrence of interest cost continue.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>IMPAIRMENT OF LONG-LIVED ASSETS&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company&#146;s long-lived assets are reviewed for impairment in accordance with the guidance of FASB Topic ASC 360, &#147;Property, Plant, and Equipment&#148;, and FASB ASC Topic 205 &#147;Presentation of Financial Statements&#148;. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company tests long-lived assets for recoverability at least annually or more frequently upon the occurrence of an event or when circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. The Company considers historical performance and future estimated results in its evaluation of potential impairment and then compares the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, the Company measures the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows at the rate the Company utilizes to evaluate potential investments. The Company estimates fair value based on the information available in making whatever estimates, judgments and projections are considered necessary. There was no impairment of long-lived assets for the Three and Nine Months ended September 30, 2014 and 2013.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>BASIC AND DILUTED EARNINGS PER SHARE&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Earnings per share (EPS) is calculated in accordance with the FASB ASC Topic 260, &#147;Earnings Per Share.&#148; Basic net income (loss) per share is based upon the weighted average number of common shares outstanding. Diluted net income (loss) per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Potentially dilutive securities to purchase 100,000 shares of common stock were not included in the calculation of the diluted earnings per share as their effect would be anti-dilutive for the Three and Nine Months ended September 30, 2014. During the three and nine month period ended September 30, 2014, the average market price of the common stock was less than the exercise price of the stock options and the Company was in net loss position. Accordingly, the stock options were anti-dilutive and have not been included in the calculation of diluted earnings per share.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>INCOME TAXES&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">FASB ASC Topic 740, &#34;Income Taxes&#148; requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">In accordance with ASC Topic 740-10, &#147;Accounting for Uncertainty in Income Taxes &#151; An Interpretation of FASB ASC Topic 740&#148;&#160;<i>,&#160;</i>which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company has made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by ASC 740-10 and has not recognized any material uncertain tax positions.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">In addition, companies in the PRC are required to pay business taxes consisting of 5% of income they derive from providing medical treatment, as well as city construction taxes and educational taxes which are 7% and 3%, respectively, of the business taxes. In April 2010, the Company was granted an exemption from these taxes until further notice from the tax bureau.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company had accrued approximately $40,000 for failure to file US tax returns and Form 5472 between the years 2006 to 2009. The Company is current with its required filings. In addition, the Company does not accrue United States income taxes on unremitted earnings from foreign operations, as it is the Company&#146;s intention to invest these earnings in the foreign operations indefinitely.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;<b><u>STATEMENT OF CASH FLOWS&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">In accordance with FASB ASC Topic 230, &#34;Statement of Cash Flows,&#34; cash flows from the Company's operations are calculated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>EMPLOYEE BENEFIT COSTS&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company contributes to a defined contribution retirement plan organized by the municipal government in the province in which the Company&#146;s subsidiary is registered. The Company makes contributes for qualified employees that are eligible to participate in the plan. Contributions to the plan are calculated at 30% of the employees&#146; salaries above a fixed threshold amount; employees contribute 8% and the Company&#146;s subsidiary contributes the balance of 22%. The Chinese government is responsible for the benefit liability to retired employees. The Company has no other material obligation for the payment of retirement beyond the annual contribution.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>STOCK-BASED COMPENSATION&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">For purposes of determining the variables used in the calculation of stock compensation expense under the provisions of FASB ASC Topic 505, &#147;Equity&#148; and FASB ASC Topic 718, &#147;Compensation&#160;<i>&#151; Stock Compensation,&#148;&#160;</i>we perform an analysis of current market data and historical Company data to calculate an estimate of implied volatility, the expected term of the option and the expected forfeiture rate. With the exception of the expected forfeiture rate, which is not an input, we use these estimates as variables in the Black Scholes model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. In addition, any differences between estimated forfeitures and actual forfeitures could also have a material impact on our financial statements.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Stock-based compensation costs that have been included in operating expenses amounted to $3,839 for the nine month periods ended September 30, 2014 and 2013.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>COMPREHENSIVE INCOME&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company reports comprehensive income in accordance with FASB ASC Topic 220 &#147;Comprehensive Income,&#34; which established standards for reporting and displaying comprehensive income and its components in a financial statement that is displayed with the same prominence as other financial statements.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Total comprehensive income is defined as all changes in stockholders' equity during a period, other than those resulting from investments by and distributions to stockholders (i.e., issuance of equity securities and dividends). Generally, for the Company, total comprehensive income (loss) equals net income (loss) plus or minus adjustments for currency translation. Total comprehensive income (loss) represents the activity for a period net of related tax and was a loss of $72,925 and $92,559 for the three month periods ended September 30, 2014 and 2013, respectively.&#160;&#160;Total comprehensive income (loss) represents the activity for a period net of related tax and was a loss of $106,292 and $249,949 for the nine month periods ended September 30, 2014 and 2013, respectively.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">While total comprehensive income is the activity in a period and is largely driven by net earnings in that period, accumulated other comprehensive income or loss (&#147;AOCI&#148;) represents the cumulative balance of other comprehensive income as of the balance sheet date. For the Company, AOCI is primarily the cumulative balance related to the currency adjustments and increased overall equity by $92,559 and $65,825 as of September 30, 2014 and December 31, 2013, respectively.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>RECENT ACCOUNTING PRONOUNCEMENTS&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recent accounting pronouncements issued by the FASB, the AICPA and the SEC&#160;&#160;did not, or are not believed by management to, have a material effect on the Company&#146;s present or future consolidated financial statements.&#160;&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>GOING CONCERN&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has negative working capital of $18,814,681, an accumulated deficit of $2,648,087, and a stockholders&#146; deficit of $2,096,327 as of September 30, 2014. The Company&#146;s ability to continue as a going concern ultimately is dependent on the management&#146;s ability to obtain equity or debt financing, attain further operating efficiencies, and achieve profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company not be able to continue as a going concern.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Management has taken certain restructuring steps to provide the necessary capital to continue its operations. These steps included: 1) plan to convert existed related parties&#146; loans into equity, 2) to complete construction of the new hospital and begin generating revenue by the end of the next year, 3) plan to increase sales revenue with additional medical equipments. No assurances can be given that the steps taken will provide necessary capital for the Company to continue its operations.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Equipment as of September 30, 2014 and December 31, 2013 comprised the following:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Estimated Useful Lives (Years)</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">June 30,</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">2014</p></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">December 31,</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">2013</p></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 46%"><font style="font-size: 8pt">Office equipment</font></td> <td style="vertical-align: bottom; width: 16%; text-align: center"><font style="font-size: 8pt">5-10</font></td> <td style="vertical-align: top; width: 1%">&#160;</td> <td style="vertical-align: top; width: 1%"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; width: 16%; text-align: right"><font style="font-size: 8pt">87,763</font></td> <td style="vertical-align: top; width: 1%; text-align: right">&#160;</td> <td style="vertical-align: top; width: 1%; text-align: right">&#160;</td> <td style="vertical-align: top; width: 1%; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; width: 16%; text-align: right"><font style="font-size: 8pt">88,985</font></td> <td style="vertical-align: top; width: 1%">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">Medical equipment</font></td> <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">5</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">2,801,508</font></td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">2,831,882</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><font style="font-size: 8pt">Fixtures</font></td> <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">10</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">115,433</font></td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">117,040</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">Vehicles</font></td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><font style="font-size: 8pt">5</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">45,364</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">45,995</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><font style="font-size: 8pt">Total equipments</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">3,050,068</font></td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">3,083,902</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">Less accumulated depreciation</font></td> <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">(1,568,115</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">(1,528,620</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 3pt"><font style="font-size: 8pt">Property and equipment, net</font></td> <td style="vertical-align: bottom; padding-bottom: 3pt">&#160;</td> <td style="vertical-align: top; padding-bottom: 3pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">1,481,953</font></td> <td style="vertical-align: top; padding-bottom: 3pt; text-align: right">&#160;</td> <td style="vertical-align: top; padding-bottom: 3pt; text-align: right">&#160;</td> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">1,555,282</font></td> <td style="vertical-align: top; padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Depreciation expense charged to operations was $22,403 and $30,692 for the three months periods ended September 30, 2014 and 2013. Depreciation expense charged to operations was $67,746 and $76,611 for the nine months periods ended September 30, 2014 and 2013.&#160;<b>&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company is constructing a new hospital building on leased land. Costs capitalized primarily consists of payments for construction costs, acquisition cost, land rights cost, development expenditure, professional fees, and capitalized interest. The Company is required to make payments for construction costs of approximately $7,870,000 and any excess construction cost payments incurred during the construction phase. As of September 30, 2014, the Company had paid approximately $15,300,000 for the construction of the hospital building. The Company estimates the additional costs to complete the project to be $35,000,000. The land lease term will start upon completion of the new hospital building, which&#160;is expected to be in the middle of 2015.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company will amortize the cost of the hospital building over the life of the land lease of twenty years. Capitalized interest was approximately $548,000 as of September 30, 2014.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">In September 2009, Guangxi Nanning Tingyouyuxiang Commercial Co., Ltd. (&#147;Tingyouyuxiang&#148;) filed a civil suit against Nanning Tongji in the People&#146;s Court. In the complaint, Tingyouyuxiang asserted a breach of contract claim against Nanting Tongji, alleging that Nanning Tongji had failed to make timely and total payment of RMB 5,050,000 (approximately $800,000) under certain Supplement Agreement by and among Nanning Tongji, Tingyouyuxiang and the Eighth Group of Langdong Village Committee, Nanhu Community Office, Qingxiu District, Nanning City (the &#147;Village Committee&#148;). On December 30, 2009, the People&#146;s Court ruled that Nanning Tongji shall pay to Tingyouyuxiang damages of RMB 5,050,000 (approximately $800,000) plus interest and the court hearing fee of approximately $320,000. On March 9, 2012, Nanning Tongji appealed to the Intermediate Court, alleging, among other things, that Nanning Tongji was never served. On June 6, 2012, the Intermediate Court remanded the case to the People&#146;s Court. On April 16, 2014, the Intermediate Court dismissed Tingyouyuxiang&#146;s appeal and affirmed the decision of the People&#146;s Court. Upon settlement of the lawsuit, the Company had accrued approximately $1,324,000 in settlement payable&#160;as of September 30, 2014.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company had two major suppliers for the nine month period ended September 30, 2014: Guangxi Sunshine Pharmaceutical Co., Ltd. and Guangxi Tongji Medicine Co. Ltd., a related party with common major stockholders. Medicine purchased from Guangxi Sunshine Pharmaceutical Co., Ltd. and Guangxi Tongji Medicine Co. Ltd. accounted for 31% and 14% of all medicine purchases for nine month period ended September 30, 2014. As of September 30, 2014, total amount due to Guangxi Sunshine Pharmaceutical Co., Ltd., and Guangxi Tongji Medicine Co. Ltd were $152,449 and $996,999, respectively. The Company had two major suppliers for the nine month period ended September 30, 2013: Guangxi East Dragon Century Pharmaceutical Co., Ltd. and Guangxi Tongji Medicine Co. Ltd., which accounted for 20% and 45%, respectively, of all medicine purchases for the nine month period ended September 30, 2013. As of September 30, 2013, amount due to Guangxi East Dragon Century Pharmaceutical Co., Ltd. and Guangxi Tongji Medicine Co. Ltd were approximately $185,000 and $1,000.000, respectively.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company had one major customer, Nanning Social Insurance Center for the nine month period ended September 30, 2014 and 2013. Nanning Social Insurance Center accounted for 9% and 10% of revenue for the nine month periods ended September 30, 2014 and 2013. As of September 30, 2014 and 2013, accounts receivable due from Nanning Social Insurance Center was approximately $207,000, and $405,000 respectively.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Sale and Lease Back&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">On March 25, 2011, the Company completed a financing arrangement with an independent third party to sell and leaseback certain machinery and equipment. The net carrying value of the machinery and equipment sold was $262,683. The machinery and equipment was sold for $371,517, of which $334,365 was received in cash and $37,152 was held as refundable deposit. The transaction has been accounted for as a financing arrangement, wherein the property remains on the Company&#146;s books and will continue to be depreciated. A financing obligation in the amount of $371,517, representing the proceeds, has been recorded under &#147;Capital Lease Payable&#148; in the Company&#146;s Balance Sheet, and is being reduced based on payments under the lease. Capital lease payable was $148,701 as of September 30, 2014. The lease does not contain an option to renew. There is also no contingent rent or concessions, or any leasehold improvement incentives.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The lease has a term of 5 years and requires minimum annual rental payments including principal and interest as follows:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><font style="font-size: 8pt">Year Ending December 31</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Amount</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 69%"><font style="font-size: 8pt">2014</font></td> <td style="vertical-align: top; width: 1%">&#160;</td> <td style="vertical-align: top; width: 1%"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; width: 28%; text-align: right"><font style="font-size: 8pt">25,588</font></td> <td style="vertical-align: top; width: 1%">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">2015</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">102,353</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">2016</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">34,118</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">Total minimum lease payments</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">162,059</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">Less: interest payments</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">13,358</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">PV of minimum capital lease payments</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">148,701</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">Less: current obligations under capital lease</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">91,032</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-bottom: 3pt"><font style="font-size: 8pt">Long term capital lease obligation</font></td> <td style="vertical-align: top; padding-bottom: 3pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">57,669</font></td> <td style="vertical-align: top; padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2011, the Company entered into an agreement to lease certain machinery and equipment that are classified as capital leases. The cost of equipment under capital leases of approximately $1,430,000 is included in the Balance Sheet as property, plant, and equipment at September 30, 2014. Those equipments are to be placed in service upon usage approval from the Chinese government and hiring qualified personnel. As of September 30, 2014, the Company still has not received the approval. Accumulated depreciation and impairment loss of the leased equipment at September 30, 2014 was approximately $565,000.&#160;&#160;Capital Lease Payable was approximately $640,000 as of September 30, 2014.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The lease has a term of 5 years and requires minimum annual rental payments including principal and interest as follows:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><font style="font-size: 8pt">Year Ending December 31</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Amount</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 69%"><font style="font-size: 8pt">2014</font></td> <td style="vertical-align: top; width: 1%">&#160;</td> <td style="vertical-align: top; width: 1%"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; width: 28%; text-align: right"><font style="font-size: 8pt">95,463</font></td> <td style="vertical-align: top; width: 1%">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">2015</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">381,857</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">2016</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">227,750</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">Total minimum lease payments</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">700,070</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">Less: interest payments</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">59,859</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">PV of minimum capital lease payments</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">640,211</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">Less: current obligations under capital lease</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">335,418</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-bottom: 3pt"><font style="font-size: 8pt">Long term capital lease obligation</font></td> <td style="vertical-align: top; padding-bottom: 3pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 2.25pt double"><font style="font-size: 8pt">&#160;$</font></td> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">304,793</font></td> <td style="vertical-align: top; padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Other payable as of September 30, 2014 and December 31, 2013 consists of the following:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">September 30, 2014</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">December 31,</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">2013</p></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%"><font style="font-size: 8pt">Advance from customers</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 8pt">(30,924)</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 8pt">5,160</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">Welfare payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">13,392</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">31,343</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Capital lease deposits paid by third party</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">354,294</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">359,227</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">Other payables</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">152,070</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">217,070</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 3pt"><font style="font-size: 8pt">Total</font></td> <td style="padding-bottom: 3pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">488,832</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">612,800</font></td> <td style="padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Preferred Stock&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">As of September 30, 2014 and December 31, 2013, the Company has 20,000,000 shares of preferred stock authorized with a par value of $0.001. There are no shares of preferred stock issued and outstanding as of September 30, 2014. </p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Common Stock&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; color: #222222"><font style="background-color: white">As of September 30, 2014 and December 31, 2013, the Company has 50,000,000 shares of common stock authorized with a par value of $0.001. There are 15,812,191 shares issued and outstanding as of September 30, 2014.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;<b>Statutory Reserves&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">As stipulated by the Company Law of the PRC, net income after taxation can only be distributed as dividends after appropriation has been made for the following:&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 5%; font: 8pt Times New Roman, Times, Serif"><font style="font-size: 8pt">i.</font></td> <td style="width: 95%; font: 8pt Times New Roman, Times, Serif"><font style="font-size: 8pt">Making up cumulative prior years&#146; losses, if any;</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 5%"><font style="font-size: 8pt">ii.</font></td> <td style="width: 95%"><font style="font-size: 8pt">Allocations to the &#147;Statutory surplus reserve&#148; of at least 10% of income after tax, as determined under PRC accounting rules and regulations, until the fund amounts to 50% of the Company&#146;s registered capital;</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 8pt">iii.</font></td> <td><font style="font-size: 8pt">Allocations to the discretionary surplus reserve, if approved in the stockholders&#146; general meeting.</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">As of September 30, 2014, the Company had accumulated deficits of $2,648,087. Therefore, the Company did not appropriate any fund for the statutory surplus reserve for the three month period ended September 30, 2014.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><u>Stock Option&#160;</u></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Stock-based compensation amounted to $3,839 for the nine month periods ended September 30, 2014 and 2013.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 3, 2011, an option to purchase 100,000 shares of common stock was granted to the Company&#146;s CFO. The option vests in two equal installments of 33,333 shares each, with the last installment being 33,334 shares, starting on the first anniversary of grant and subsequent anniversaries thereafter, at an exercise price equivalent to the closing price per share of common stock on the date of grant.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The fair value of the option award is estimated on the date of grant using the Black Scholes model to be $15,400. The valuation was based on the assumptions noted in the following table.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%"><font style="font-size: 8pt">Expected volatility</font></td> <td style="width: 4%">&#160;</td> <td style="width: 12%; text-align: right"><font style="font-size: 8pt">105</font></td> <td style="width: 4%"><font style="font-size: 8pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">Expected dividends</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">0</font></td> <td><font style="font-size: 8pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Stock price</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">0.24</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">Expected term (in years)</font></td> <td>&#160;</td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">3 years</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Risk-free rate</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.32</font></td> <td><font style="font-size: 8pt">%</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk-free interest rate is based on the U.S. Treasury yield curve in effect for the expected term of the option at the time of grant. The dividend yield on our common stock is assumed to be zero since we do not pay dividends and have no current plans to pay them in the future. The market price volatility of our common stock was based on historical volatility since May 13, 2010. The expected life of the options is based upon our anticipated expectations of exercise behavior since no options have been exercised in the past to provide relevant historical data.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The fair value of the option granted will be expensed according to following schedule:&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 8pt">Year</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Expense</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%"><font style="font-size: 8pt">2011</font></td> <td style="width: 2%">&#160;</td> <td style="width: 2%"><font style="font-size: 8pt">$</font></td> <td style="width: 24%; text-align: right"><font style="font-size: 8pt">4,262</font></td> <td style="width: 2%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">2012</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">5,147</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">2013</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">5,133</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">2014</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">858</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">Thereafter</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 3pt"><font style="font-size: 8pt">Total</font></td> <td style="padding-bottom: 3pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">15,400</font></td> <td style="padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes stock option activity in the Company's stock-based compensation plans for the three month period ended September 30, 2014</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="3" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shares</b></p></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Price</b></p></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Intrinsic Value</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(in thousands)</b></p></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shares</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercisable</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%"><font style="font-size: 8pt">Outstanding at January 1, 2014</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 12%; text-align: right"><font style="font-size: 8pt">100,000</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 8pt">0.24</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 12%; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="width: 1%; text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">Granted</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Exercised</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">Cancelled/expired</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 3pt"><font style="font-size: 8pt">Outstanding at September 30, 2014</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">100,000</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">0.24</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">There were no options granted, exercised or cancelled/expired during the nine month period ended September 30, 2014.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Due from/to Related Parties&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company has entered into agreements with Nanning Tongji Chain Pharmacy Co. Ltd., Guangxi Tongji Medicine Co. Ltd., and Nanning Switch Factory whereby the Company from time to time will advance funds to assist them with their operations. The three companies have common major stockholders. The advanced amounts accrue interest at a rate of 1.5% per annum. The amount receivable as of September 30, 2014 and December 31, 2013 was $45,067 and $45,695, respectively. Interest income for the three month periods ended September 30, 2014 and 2013 was approximately $169 and $168, respectively. Interest income for the nine month periods ended September 30, 2014 and 2013 was approximately $505 and $502, respectively.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company has entered into an agreement with the Chairman and a stockholder of the Company, Nanning Tongji Chain Pharmacy Co. Ltd., Guangxi Tongji Medicine Co. Ltd., and Nanning Tongji Electric Coating Factory, whereby the Company from time to time will be advanced funds to for its operations. The advanced amounts accrue interest at a rate of 1.5% per annum. As of September 30, 2014 and December 31, 2013, $13,416,581 and $11,421,363 were payable to these related parties, respectively. Interest expense for the three month periods ended September 30, 2014 and 2013 was $79,036 and $43,396 respectively. Interest expense for the nine month periods ended September 30, 2014 and 2013 was $170,742 and $118,075 respectively. &#160;&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Rental Commitments&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company has entered into a lease agreement for their hospital with Guangxi Tongji Medicine Co. Ltd that expires in December 2014. The monthly lease payment is approximately $2,500. The Company is also in the process of building a new 600-bed hospital in Nanning, China and expects the new hospital to be completed by the middle of 2015. The hospital is being constructed by Guangxi Construction Engineering Corporation Langdong 8th Group and, when completed, the land will be leased by the Company for a twenty-year term. The annual lease payments will gradually increase each year. Based on the exchange rate at September 30, 2014, minimum future lease payments are as follows:&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Related Party</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Non-Related Party</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Total</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 43%"><font style="font-size: 8pt">1-5 years</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 8pt">8,035</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 8pt">2,786,603</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 8pt">2,794,637</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">6-10 years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">3,193,901</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">3,193,901</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">11-15 years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">3,589,660</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">3,589,660</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">16-20 years</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">1,482,568</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">1,482,568</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 3pt"><font style="font-size: 8pt">Total</font></td> <td style="padding-bottom: 3pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">8,035</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">11,052,732</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">11,060,766</font></td> <td style="padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements present the Company&#146;s results of operations, financial position and cash flows on a consolidated basis. The consolidated financial statements include the Company and its wholly owned subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. Our policy is to consolidate all subsidiaries in which a greater than 50% voting interest is owned. The Company operates in one segment in accordance with the accounting guidance FASB ASC topic 280, &#147;Segment Reporting&#148;.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">For purposes of the statements of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. A substantial amount of the Company&#146;s cash is held in bank accounts in the PRC and is not protected by Federal Deposit Insurance Corporation (FDIC) insurance or any other similar insurance. Cash held in China amounted to $5,236 as of September 30, 2014. Given the current economic environment and the financial condition of the banking industry, there is a risk that the deposits may not be readily available or covered by such insurance. The Company has had no loss of cash in domestic or foreign banks in past years.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of net revenues and expenses during the reporting period. Actual results may differ from those estimates and such differences may be material. The more significant estimates and assumptions by management include, among others, useful lives and residual values of fixed assets, valuation of inventories, accounts receivable, stock based compensation, and allowance for bad debt. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company's functional currency is the Chinese Renminbi (RMB). The reporting currency is that of the US Dollar. Capital accounts of the consolidated financial statements are translated into United States dollars from RMB at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rates as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the year. The RMB is not freely convertible into foreign currency and all foreign currency exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US dollar at the rates used in translation.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements were as follows:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 69%; border-bottom: black 1.5pt solid"><font style="font-size: 8pt">September 30, 2014</font></td> <td style="width: 31%; border-bottom: black 1.5pt solid">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Balance sheet</font></td> <td><font style="font-size: 8pt">RMB 6.14 to US $1.00</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Statement of income and other comprehensive income</font></td> <td><font style="font-size: 8pt">RMB 6.17 to US $1.00</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: white"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 8pt">December 31, 2013</font></td> <td style="border-bottom: black 1.5pt solid">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Balance sheet</font></td> <td><font style="font-size: 8pt">RMB 6.05 to US $1.00</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Statement of income and other comprehensive income</font></td> <td><font style="font-size: 8pt">RMB 6.15 to US $1.00</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 69%; border-bottom: black 1.5pt solid"><font style="font-size: 8pt">September 30, 2013</font></td> <td style="width: 31%; border-bottom: black 1.5pt solid">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Statement of income and other comprehensive income</font></td> <td><font style="font-size: 8pt">RMB 6.17 to US $1.00</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Certain items previously reported under specific financial statement captions have been reclassified to conform to the current year presentation.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company's revenue recognition policies are in compliance with Staff Accounting Bulletin 104 (ASC 605). Service revenue is recognized on the dates services were rendered. When a formal arrangement exists, the price is fixed or determinable. When the service is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company generates revenue from individual patients as well as third-party payers, including PRC government programs and insurance providers, under which the hospital is paid based upon government established charges. Revenues for pharmaceutical drug sales are recognized upon the drug being administered to a patient.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Patient revenues are recorded based on pre-established rates set by the local government. The Company bills for services provided to Medicare patients through a medical card (the US equivalent of an insurance card). There have not been significant differences between the amounts the Company has billed the government Medicare funds and the amounts collected from the Medicare funds.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Accounts receivable are recorded at the estimated net realizable amounts from government fund, insurance companies and patients. Collections have not been considered an area that exposes the Company to additional risk. Hospital staff verifies patient coverage prior to examinations and/or procedures.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">For any Medicare patient who visits the hospital and is qualified for acceptance, the hospital will only include the portion that the social insurance organization will pay in the accounts receivable and collects the self-pay portion in cash at the time of service. Management continues to estimate the likelihood of bad debt on an ongoing basis.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company has estimated a bad debt allowance of approximately $31,000 as of September 30, 2014 and $44,000 as of December 31, 2013.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company applies the provisions of FASB ASC Topic 825, which requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of September 30, 2014 and December 31, 2013 the fair value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, notes payable and other payables approximated the carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates except for related party debt or receivables for which it is not practicable to estimate fair value.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">FASB ASC Topic 820, &#147;Fair Value Measurements and Disclosures&#148;, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Various inputs are considered when determining the fair value of the Company&#146;s investments, and long-term debt. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%">&#160;</td> <td style="width: 3%"><font style="font-size: 8pt">&#9679;</font></td> <td style="width: 94%"><font style="font-size: 8pt">Level 1 &#150; observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 8pt">&#9679;</font></td> <td><font style="font-size: 8pt">Level 2 &#150; other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.).</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 8pt">&#9679;</font></td> <td><font style="font-size: 8pt">Level 3 &#150; significant unobservable inputs (including the Company&#146;s own assumptions in determining the fair value of investments).</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or non-recurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. The Company had no financial assets and liabilities carried at fair value on a recurring basis.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">All of the Company&#146;s operations are located in the PRC. There can be no assurance that the Company will be able to successfully continue to operate and failure to do so would have a material adverse effect on the Company&#146;s financial position, results of operations and cash flows. In addition, the success of the Company&#146;s operations is subject to numerous contingencies, some of which are beyond management&#146;s control. These contingencies include general economic conditions, the price of medicine, competition, governmental and political conditions, and changes in regulations. Because the Company is dependent on the domestic market of the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company&#146;s operations will be subject to risk of restrictions on the transfer of funds, domestic policy changes, changing taxation policies, foreign exchange restrictions, and political and governmental regulations.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Certain conditions may exist as of the date the consolidated financial statements are issued. These conditions may result in a future loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company&#146;s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company&#146;s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Medical supplies include both western and traditional Chinese medicine, are valued on the lower of weighted average cost or market basis. Inventory includes product cost and inbound freight. Management compares the cost of medical supplies with the market value and allowance is made for writing down their inventories to market value, if such value is lower.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Equipment is recorded at cost. Depreciation is computed over the estimated useful lives of the related asset type using the straight-line method. Maintenance and repairs are expensed as incurred and the costs of additions and betterments that increase the useful lives of the assets are capitalized. When equipment is disposed, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in other income or expenses.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">A hospital facility currently under development is accounted for as construction-in-progress. Construction-in-progress is recorded at acquisition cost, including land rights cost, development expenditure, and professional fees capitalized during the course of construction for the purpose of financing the project. Upon completion of the project, the cost of construction-in-progress will be transferred to fixed assets, at which time depreciation will commence.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Interest cost is capitalized for qualifying assets when the portion of the interest cost incurred during the assets' acquisition periods could have been avoided if expenditures for the assets had not been made. The amount capitalized in an accounting period is determined by applying the capitalization rate to the average amount of accumulated expenditures for the asset during the period. The capitalization rates used in an accounting period is based on the rates applicable to borrowings outstanding during the period (also see Note 4).&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Capitalization period covers the duration of the activities required to get the asset ready for its intended use, provided that expenditures for the asset have been made and interest cost is being incurred. Interest capitalization continues as long as those activities and the incurrence of interest cost continue.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company&#146;s long-lived assets are reviewed for impairment in accordance with the guidance of FASB Topic ASC 360, &#147;Property, Plant, and Equipment&#148;, and FASB ASC Topic 205 &#147;Presentation of Financial Statements&#148;. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company tests long-lived assets for recoverability at least annually or more frequently upon the occurrence of an event or when circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. The Company considers historical performance and future estimated results in its evaluation of potential impairment and then compares the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, the Company measures the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows at the rate the Company utilizes to evaluate potential investments. The Company estimates fair value based on the information available in making whatever estimates, judgments and projections are considered necessary. There was no impairment of long-lived assets for the Three and Nine Months ended September 30, 2014 and 2013.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Earnings per share (EPS) is calculated in accordance with the FASB ASC Topic 260, &#147;Earnings Per Share.&#148; Basic net income (loss) per share is based upon the weighted average number of common shares outstanding. Diluted net income (loss) per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Potentially dilutive securities to purchase 100,000 shares of common stock were not included in the calculation of the diluted earnings per share as their effect would be anti-dilutive for the Three and Nine Months ended September 30, 2014. During the three and nine month period ended September 30, 2014, the average market price of the common stock was less than the exercise price of the stock options and the Company was in net loss position. Accordingly, the stock options were anti-dilutive and have not been included in the calculation of diluted earnings per share.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">FASB ASC Topic 740, &#34;Income Taxes&#148; requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">In accordance with ASC Topic 740-10, &#147;Accounting for Uncertainty in Income Taxes &#151; An Interpretation of FASB ASC Topic 740&#148;&#160;<i>,&#160;</i>which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company has made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by ASC 740-10 and has not recognized any material uncertain tax positions.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">In addition, companies in the PRC are required to pay business taxes consisting of 5% of income they derive from providing medical treatment, as well as city construction taxes and educational taxes which are 7% and 3%, respectively, of the business taxes. In April 2010, the Company was granted an exemption from these taxes until further notice from the tax bureau.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company had accrued approximately $40,000 for failure to file US tax returns and Form 5472 between the years 2006 to 2009. The Company is current with its required filings. In addition, the Company does not accrue United States income taxes on unremitted earnings from foreign operations, as it is the Company&#146;s intention to invest these earnings in the foreign operations indefinitely.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">In accordance with FASB ASC Topic 230, &#34;Statement of Cash Flows,&#34; cash flows from the Company's operations are calculated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company contributes to a defined contribution retirement plan organized by the municipal government in the province in which the Company&#146;s subsidiary is registered. The Company makes contributes for qualified employees that are eligible to participate in the plan. Contributions to the plan are calculated at 30% of the employees&#146; salaries above a fixed threshold amount; employees contribute 8% and the Company&#146;s subsidiary contributes the balance of 22%. The Chinese government is responsible for the benefit liability to retired employees. The Company has no other material obligation for the payment of retirement beyond the annual contribution.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">For purposes of determining the variables used in the calculation of stock compensation expense under the provisions of FASB ASC Topic 505, &#147;Equity&#148; and FASB ASC Topic 718, &#147;Compensation&#160;<i>&#151; Stock Compensation,&#148;&#160;</i>we perform an analysis of current market data and historical Company data to calculate an estimate of implied volatility, the expected term of the option and the expected forfeiture rate. With the exception of the expected forfeiture rate, which is not an input, we use these estimates as variables in the Black Scholes model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. In addition, any differences between estimated forfeitures and actual forfeitures could also have a material impact on our financial statements.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Stock-based compensation costs that have been included in operating expenses amounted to $3,839 for the nine month periods ended September 30, 2014 and 2013.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The Company reports comprehensive income in accordance with FASB ASC Topic 220 &#147;Comprehensive Income,&#34; which established standards for reporting and displaying comprehensive income and its components in a financial statement that is displayed with the same prominence as other financial statements.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Total comprehensive income is defined as all changes in stockholders' equity during a period, other than those resulting from investments by and distributions to stockholders (i.e., issuance of equity securities and dividends). Generally, for the Company, total comprehensive income (loss) equals net income (loss) plus or minus adjustments for currency translation. Total comprehensive income (loss) represents the activity for a period net of related tax and was a loss of $72,925 and $92,559 for the three month periods ended September 30, 2014 and 2013, respectively.&#160;&#160;Total comprehensive income (loss) represents the activity for a period net of related tax and was a loss of $106,292 and $249,949 for the nine month periods ended September 30, 2014 and 2013, respectively.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">While total comprehensive income is the activity in a period and is largely driven by net earnings in that period, accumulated other comprehensive income or loss (&#147;AOCI&#148;) represents the cumulative balance of other comprehensive income as of the balance sheet date. For the Company, AOCI is primarily the cumulative balance related to the currency adjustments and increased overall equity by $92,559 and $65,825 as of September 30, 2014 and December 31, 2013, respectively.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recent accounting pronouncements issued by the FASB, the AICPA and the SEC&#160;&#160;did not, or are not believed by management to, have a material effect on the Company&#146;s present or future consolidated financial statements.&#160;&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has negative working capital of $18,814,681, an accumulated deficit of $2,648,087, and a stockholders&#146; deficit of $2,096,327 as of September 30, 2014. The Company&#146;s ability to continue as a going concern ultimately is dependent on the management&#146;s ability to obtain equity or debt financing, attain further operating efficiencies, and achieve profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company not be able to continue as a going concern.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Management has taken certain restructuring steps to provide the necessary capital to continue its operations. These steps included: 1) plan to convert existed related parties&#146; loans into equity, 2) to complete construction of the new hospital and begin generating revenue by the end of the next year, 3) plan to increase sales revenue with additional medical equipments. No assurances can be given that the steps taken will provide necessary capital for the Company to continue its operations.&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 69%; border-bottom: black 1.5pt solid"><font style="font-size: 8pt">September 30, 2014</font></td> <td style="width: 31%; border-bottom: black 1.5pt solid">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Balance sheet</font></td> <td><font style="font-size: 8pt">RMB 6.14 to US $1.00</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Statement of income and other comprehensive income</font></td> <td><font style="font-size: 8pt">RMB 6.17 to US $1.00</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: white"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 8pt">December 31, 2013</font></td> <td style="border-bottom: black 1.5pt solid">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Balance sheet</font></td> <td><font style="font-size: 8pt">RMB 6.05 to US $1.00</font></td></tr> <tr style="vertical-align: top; background-color: white"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Statement of income and other comprehensive income</font></td> <td><font style="font-size: 8pt">RMB 6.15 to US $1.00</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 69%; border-bottom: black 1.5pt solid"><font style="font-size: 8pt">September 30, 2013</font></td> <td style="width: 31%; border-bottom: black 1.5pt solid">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Statement of income and other comprehensive income</font></td> <td><font style="font-size: 8pt">RMB 6.17 to US $1.00</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Estimated Useful Lives (Years)</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">June 30,</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">2014</p></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">December 31,</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">2013</p></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 46%"><font style="font-size: 8pt">Office equipment</font></td> <td style="vertical-align: bottom; width: 16%; text-align: center"><font style="font-size: 8pt">5-10</font></td> <td style="vertical-align: top; width: 1%">&#160;</td> <td style="vertical-align: top; width: 1%"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; width: 16%; text-align: right"><font style="font-size: 8pt">87,763</font></td> <td style="vertical-align: top; width: 1%; text-align: right">&#160;</td> <td style="vertical-align: top; width: 1%; text-align: right">&#160;</td> <td style="vertical-align: top; width: 1%; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; width: 16%; text-align: right"><font style="font-size: 8pt">88,985</font></td> <td style="vertical-align: top; width: 1%">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">Medical equipment</font></td> <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">5</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">2,801,508</font></td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">2,831,882</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><font style="font-size: 8pt">Fixtures</font></td> <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">10</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">115,433</font></td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">117,040</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">Vehicles</font></td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><font style="font-size: 8pt">5</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">45,364</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">45,995</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><font style="font-size: 8pt">Total equipments</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">3,050,068</font></td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">3,083,902</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">Less accumulated depreciation</font></td> <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">(1,568,115</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">(1,528,620</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 3pt"><font style="font-size: 8pt">Property and equipment, net</font></td> <td style="vertical-align: bottom; padding-bottom: 3pt">&#160;</td> <td style="vertical-align: top; padding-bottom: 3pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">1,481,953</font></td> <td style="vertical-align: top; padding-bottom: 3pt; text-align: right">&#160;</td> <td style="vertical-align: top; padding-bottom: 3pt; text-align: right">&#160;</td> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">1,555,282</font></td> <td style="vertical-align: top; padding-bottom: 3pt">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><font style="font-size: 8pt">Year Ending December 31</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Amount</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 69%"><font style="font-size: 8pt">2014</font></td> <td style="vertical-align: top; width: 1%">&#160;</td> <td style="vertical-align: top; width: 1%"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; width: 28%; text-align: right"><font style="font-size: 8pt">25,588</font></td> <td style="vertical-align: top; width: 1%">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">2015</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">102,353</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">2016</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">34,118</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">Total minimum lease payments</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">162,059</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">Less: interest payments</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">13,358</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">PV of minimum capital lease payments</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">148,701</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">Less: current obligations under capital lease</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">91,032</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-bottom: 3pt"><font style="font-size: 8pt">Long term capital lease obligation</font></td> <td style="vertical-align: top; padding-bottom: 3pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">57,669</font></td> <td style="vertical-align: top; padding-bottom: 3pt">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><font style="font-size: 8pt">Year Ending December 31</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Amount</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 69%"><font style="font-size: 8pt">2014</font></td> <td style="vertical-align: top; width: 1%">&#160;</td> <td style="vertical-align: top; width: 1%"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: top; width: 28%; text-align: right"><font style="font-size: 8pt">95,463</font></td> <td style="vertical-align: top; width: 1%">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">2015</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">381,857</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">2016</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">227,750</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">Total minimum lease payments</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">700,070</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">Less: interest payments</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">59,859</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><font style="font-size: 8pt">PV of minimum capital lease payments</font></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">640,211</font></td> <td style="vertical-align: top">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 8pt">Less: current obligations under capital lease</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">335,418</font></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; padding-bottom: 3pt"><font style="font-size: 8pt">Long term capital lease obligation</font></td> <td style="vertical-align: top; padding-bottom: 3pt">&#160;</td> <td style="vertical-align: top; border-bottom: black 2.25pt double"><font style="font-size: 8pt">&#160;$</font></td> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">304,793</font></td> <td style="vertical-align: top; padding-bottom: 3pt">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">September 30, 2014</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">December 31,</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">2013</p></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%"><font style="font-size: 8pt">Advance from customers</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 8pt">(30,924)</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 8pt">5,160</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">Welfare payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">13,392</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">31,343</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Capital lease deposits paid by third party</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">354,294</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">359,227</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">Other payables</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">152,070</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">217,070</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 3pt"><font style="font-size: 8pt">Total</font></td> <td style="padding-bottom: 3pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">488,832</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">612,800</font></td> <td style="padding-bottom: 3pt">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%"><font style="font-size: 8pt">Expected volatility</font></td> <td style="width: 4%">&#160;</td> <td style="width: 12%; text-align: right"><font style="font-size: 8pt">105</font></td> <td style="width: 4%"><font style="font-size: 8pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">Expected dividends</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">0</font></td> <td><font style="font-size: 8pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Stock price</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">0.24</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">Expected term (in years)</font></td> <td>&#160;</td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">3 years</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Risk-free rate</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.32</font></td> <td><font style="font-size: 8pt">%</font></td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 8pt">Year</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Expense</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%"><font style="font-size: 8pt">2011</font></td> <td style="width: 2%">&#160;</td> <td style="width: 2%"><font style="font-size: 8pt">$</font></td> <td style="width: 24%; text-align: right"><font style="font-size: 8pt">4,262</font></td> <td style="width: 2%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">2012</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">5,147</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">2013</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">5,133</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">2014</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">858</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">Thereafter</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 3pt"><font style="font-size: 8pt">Total</font></td> <td style="padding-bottom: 3pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">15,400</font></td> <td style="padding-bottom: 3pt">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="3" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shares</b></p></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Price</b></p></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Intrinsic Value</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(in thousands)</b></p></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shares</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercisable</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%"><font style="font-size: 8pt">Outstanding at January 1, 2014</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 12%; text-align: right"><font style="font-size: 8pt">100,000</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 8pt">0.24</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 12%; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="width: 1%; text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">Granted</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Exercised</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">Cancelled/expired</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 3pt"><font style="font-size: 8pt">Outstanding at September 30, 2014</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">100,000</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">0.24</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 3pt">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Related Party</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Non-Related Party</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Total</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 43%"><font style="font-size: 8pt">1-5 years</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 8pt">8,035</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 8pt">2,786,603</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 8pt">2,794,637</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">6-10 years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">3,193,901</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">3,193,901</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">11-15 years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">3,589,660</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">3,589,660</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">16-20 years</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">1,482,568</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">1,482,568</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 3pt"><font style="font-size: 8pt">Total</font></td> <td style="padding-bottom: 3pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">8,035</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">11,052,732</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">11,060,766</font></td> <td style="padding-bottom: 3pt">&#160;</td></tr> </table> 100000 100000 18814681 P5Y P10Y p5y p10y p5y 67746 76611 22403 30692 15300000 548000 1324000 .14 .31 152449 996999 .09 .10 .45 .20 207000 405000 185000 1000000 57669 91032 148701 13358 162059 34118 102353 25588 304793 335418 640211 59859 700070 227750 381857 95463 1430000 565000 640000 1.05 0 .24 P3Y 0.0132 15400 0 858 5133 5147 4262 100000 100000 0 0 0 .24 .24 0 0 0 0 0 0 0 0 0 0 0 0 0 11060766 8035 11052732 1482568 0 1482568 3589660 0 3589660 3193901 0 3193901 2794637 8035 2786603 505 502 169 168 170742 118075 79036 43396 EX-101.SCH 7 tonj-20140930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - 1. ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 3. EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 4. CONSTRUCTION IN PROGRESS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 5. LAWSUIT link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 6. MAJOR SUPPLIERS AND CUSTOMERS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 7. CAPITAL LEASE OBLIGATIONS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 8. OTHER PAYABLES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 9. STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 10. RELATED PARTY TRANSACTIONS AND COMMITMENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 3. EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 7. CAPITAL LEASE OBLIGATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 8. OTHER PAYABLES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 9. STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 3. EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 3. EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 4. CONSTRUCTION IN PROGRESS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 5. LAWSUIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 6. MAJOR SUPPLIERS AND CUSTOMERS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 7. CAPITAL LEASE OBLIGATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 7. CAPITAL LEASE OBLIGATIONS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 7. CAPITAL LEASE OBLIGATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 8. OTHER PAYABLES (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 9. STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 9. STOCKHOLDERS' EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 9. STOCKHOLDERS' EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 9. STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - 10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - 10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 tonj-20140930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 tonj-20140930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 tonj-20140930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE BalanceSheetMember InformationByFinancialStatementLineItem [Axis] RMBMember Currency [Axis] USDollarMember StatementOfOperationsAndOtherComprehensiveLossMember Nanning Social Insurance Center MajorCustomers [Axis] Guangxi East Dragon Century Pharmaceutical Related Party [Member] RelatedPartyTransactionsByRelatedParty [Axis] Non Related Party [Member] China UMS Co., Ltd. [Member] Guangxi Province Social Insurance Center Nanning Social Insurance Center and China UMS Co., Ltd [Member] Guangxi Tongji Medicine Co. Ltd [Member] Office Equipment Property, Plant and Equipment, Type [Axis] Medical equipment Fixtures Vehicles Guangxi Sunshine Pharmaceutical Co., Ltd. Guangxi East Dragon Century Pharmaceutical Co., Ltd Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Accounts receivable, net Due from related parties Medical supplies Prepaid expenses and other current assets Total Current Assets Equipment, net Construction in progress Deposits Intangible assets, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable and accrued expenses Due to related parties Settlement payable Other payable Current portion of capital lease payable Total Current Liabilities Capital lease payable Total Liabilities Contingencies STOCKHOLDERS' DEFICIT Preferred stock; $0.001 par value, 20,000,000 shares authorized and none issued and outstanding Common stock; $0.001 par value, 50,000,000 shares authorized and 15,812,191 shares issued and outstanding as of September 30, 2014 and December 31, 2013 respectively Additional paid in capital Accumulated deficit Accumulated other comprehensive income Total Stockholders' Deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Stockholders equity: Preferred stock, par value Preferred stock, authorized shares Preferred stock, issued shares Preferred stock, outstanding shares Common stock, par value Common stock, authorized shares Common stock, issued shares Common stock, outstanding shares Income Statement [Abstract] OPERATING REVENUE In-patient service revenue Out-patient service revenue Total operating revenue OPERATING EXPENSES Administrative expenses Depreciation and amortization expenses Contingency loss Medicine and supplies Other operating expenses Salary and fringes Total operating expenses INCOME (LOSS) FROM OPERATIONS OTHER INCOME (EXPENSE) Other income Interest expense, net Total Other Expense LOSS BEFORE INCOME TAXES Provision for income taxes NET LOSS OTHER COMPREHENSIVE LOSS Foreign currency translation gain (loss) NET COMPREHENSIVE LOSS Net loss per common stock-Basic and Diluted Weighted average common stock outstanding Basic and Diluted Statement of Cash Flows [Abstract] Operating activities: Net Loss Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation expense Stock option expense Increase/(decrease) in operating assets and liabilities: Accounts receivable Medical supplies Prepaid expense and other current assets Deposit Accounts payable and accrued expenses Other payables Settlement (contingent liability) Net Cash Provided By Operating Activities Investing activities: Acquisitions of fixed assets Acquisitions of intangible assets Construction in Progress Due from related parties Net Cash Used in Investing Activities Financing activities: Payments of capital lease Due to related parties Net Cash Provided by Financing Activities Effects of foreign currency translation Net decrease in Cash Cash-Beginning of Period Cash-Ending of Period Cash Paid During the Year for: Income taxes Interest paid Organization, Consolidation and Presentation of Financial Statements [Abstract] NOTE 1 - ORGANIZATION Accounting Policies [Abstract] NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] NOTE 3 - EQUIPMENT Notes to Financial Statements NOTE 4 - CONSTRUCTION IN PROGRESS Commitments and Contingencies Disclosure [Abstract] NOTE 5- LAWSUIT NOTE 6 - MAJOR SUPPLIERS AND CUSTOMERS Debt Disclosure [Abstract] NOTE 7 - CAPITAL LEASE OBLIGATIONS Payables and Accruals [Abstract] NOTE 8 - OTHER PAYABLES NOTE 9 - STOCKHOLDERS' EQUITY Related Party Transactions [Abstract] NOTE 10 - RELATED PARTY TRANSACTIONS AND COMMITMENTS BASIS OF PRESENTATION AND CONSOLIDATION CASH AND CASH EQUIVALENTS USE OF ESTIMATES TRANSLATION ADJUSTMENT RECLASSIFICATIONS REVENUE RECOGNITION ACCOUNTS RECEIVABLE FAIR VALUE OF FINANCIAL INSTRUMENTS FAIR VALUE MEASUREMENTS CONCENTRATIONS, RISKS, AND UNCERTAINTIES CONTINGENCIES MEDICAL SUPPLIES EQUIPMENT CONSTRUCTION-IN-PROGRESS CAPITALIZATION OF INTEREST IMPAIRMENT OF LONG-LIVED ASSETS BASIC AND DILUTED EARNINGS PER SHARE INCOME TAXES STATEMENT OF CASH FLOWS EMPLOYEE BENEFIT COSTS STOCK-BASED COMPENSATION COMPREHENSIVE INCOME RECENT ACCOUNTING PRONOUNCEMENTS GOING CONCERN Summary Of Significant Accounting Policies Tables Schedule of Translation Adjustments Equipment Tables Schedule of Equipment Capital Lease Obligations Tables Sales lease back obligation Schedule of Capital Lease Obligations Other Payables Tables Schedule of Other Payables Fair value of the option award Fair value of the option granted Stock option activity Related Party Transactions And Commitments Tables Minimum future lease payments Statement [Table] Statement [Line Items] Information by Financial Statement Line Item [Axis] Exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements Cash and cash equivalents Estimated bad debt allowance Dilutive securities not included in the calculation of the diluted earnings per share Stock-based compensation costs Comprehensive Income Loss Working capital Stockholders deficit Office equipment Medical equipment Fixtures Vehicles Total equipments Less accumulated depreciation Estimated Useful Lives Estimated Useful Lives, minimum Estimated Useful Lives, maximum Depreciation expenses Construction In Progress Details Narrative Construction cost paid Capitalized interest Lawsuit Details Narrative Accrued contingency Customer [Axis] Percentage of medicine purchases Amounts due Percentage of Revenue from major customers Accounts receivable from major cutomers Capital Lease Obligation Details Capital Lease Future Minimum Payment Due 2014 2015 2016 Total minimum lease payments Less: interest payments PV of minimum capital lease payments Less: Current obligations under sales lease back Long term sales lease back obligation Capital Lease Obligations Details 1 2014 2015 2016 Total minimum lease payments Less: interest payments PV of minimum capital lease payments Less: Current obligations under capital lease Long term capital lease obligation Capital Lease Obligation Details Narrative Capital lease payable under sales lease back Cost of equipment under capital leases Accumulated depreciation of leased equipment Capital lease payable Other Payables Details Advance from customers Welfare payable Capital lease deposits paid by third party Lawsuit settlement payable Other payables Total Expected volatility Expected Dividends Stock price Expected term (in years) Risk-free rate 2011 2012 2013 2014 Thereafter Total Number of Shares Outstanding at beginning of period Granted Exercised Cancelled/expired Outstanding at end of the year Weighted Average Exercise Price Outstanding at beginning of period Granted Exercised Cancelled/expired Outstanding at end of the year Aggregate Intrinsic Value Outstanding at beginning of period Granted Exercised Cancelled/expired Outstanding at end of the year Number of Shares Exercisable Outstanding at beginning of period Granted Exercised Cancelled/expired Outstanding at end of the year Stockholders Equity Details Narrative Preferred stock authorized Preferred stock par value Preferred stock shares issued Preferred stock shares outstanding Common Stock shares Authorized Common Stock par value Accumulated deficits Related Party [Axis] 1-5 years 6-10 years 11-15 years 16-20 years Total Related Party Transactions And Commitments Details Narrative Amount receivable Interest income Amount Payable Interest expenses Custom Element. Custom Element. Custom Element. Custom Element 2011 FairValueOfOptionGrantedExpensedInFourYears 2013 2012 Thereafter Total Custom Element. Custom Element. Custom Element. Custom Element. Less: Current obligations under sales lease back Long term sales lease back obligation Custom Element. Custom Element Custom Element. Custom Element. Number of Shares Exercisable Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisedIntrinsicValue ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndExpiredIntrinsicValue ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberCancelledexpired ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberGranted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Assets, Current Assets Liabilities, Current Liabilities Liabilities and Equity Health Care Organization, Revenue Costs and Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income Tax Expense (Benefit) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Intangible Assets Payments for Construction in Process Increase (Decrease) in Due from Related Parties Net Cash Provided by (Used in) Investing Activities Repayments of Debt and Capital Lease Obligations Proceeds from Related Party Debt Net Cash Provided by (Used in) Financing Activities WorkingCapital Machinery and Equipment, Gross Fixtures and Equipment, Gross Vehicles [Default Label] Capital Leases, Future Minimum Payments Due, Next Twelve Months Capital Leases, Future Minimum Payments Due in Two Years Capital Leases, Future Minimum Payments Due in Three Years Capital Leases, Future Minimum Payments Due Capital Leases, Future Minimum Payments, Interest Included in Payments Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments Debt and Capital Lease Obligations Accounts Payable, Other, Current FairValueOfOptionGrantedExpensedInFourYears Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisedIntrinsicValue ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndExpiredIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberGranted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberCancelledexpired Operating Leases, Future Minimum Payments Due EX-101.PRE 11 tonj-20140930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Details Narrative) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Dec. 31, 2013
Related Party Transactions And Commitments Details Narrative          
Amount receivable $ 45,067   $ 45,067   $ 45,695
Interest income 169 168 505 502  
Amount Payable 13,416,581   13,416,581   11,421,363
Interest expenses $ 79,036 $ 43,396 $ 170,742 $ 118,075  
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0"4*VK8[`$``-X8```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F4%/VS`8AN](^P^1KU/C MVAZ,34TY;.P(2+`?X,5?FZB);=D&VG^/DP)"J"NJ5FGO)5$:^WN?^O`?MR2!NLB*']N%0U;%M/==6^N42?F#->]2)L\)9=XYKHE- MZ^/GC,'XSH3AS=\#GO==YZ,)K:'B1H=TI?N,P=<=?W1A]<>Y5;E_R`Y*MUBT M-1E7W_?Y!,KH`VD3&Z+4=^5X+WO=VA?N/?GCXLC'FS@RR/#_QL$'.8#^K+F#8=Q2-7#MNA'R4W M.I"Y32'W[$<'>#M['T=NH6^"\S'W\8$./X67PGW8/?%Y$(74TFOEOJNZ?DW, M7?[A@>^Z]=J>*V?5@^@8B)G:13'&HX<85?= MWFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B] MSCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`:799%/P!``#G M%P``&@`(`7AL+U]R96QS+W=OK,4>MN?!Q"V$HV'F)B"92!_C.>=(OKYYVVV+ M%Q_BIN\J0[.Y*7Q7]\VF6U?FZ?'VSX4I8G)=X[9]YRNS]]'<+'__NK[W6Y?R MGV*[&6*15^EB9=J4ABMK8]WZG8NS?O!=?K+JP\ZE/`QK.[CZV:V]Y?E\8B/3PAF65F8[_!R?70Q;E`.+Q0QN$%PI%+91RY1#A,RCA,"$=*91PI M$4[)4^+$U@7?/*20G2/FA3_4=3*-:,ZGA!DU?009ISYD?HY@)JW,N//W,(Q@ M2%OC!#7..2)4'9#GJ#JL;3D,+:>=N/" MOB7UTL#:L'88,`P#T;8\@9XGVG$@,`_*23TOY=.Q/XKZ,+2'7]@Q9\J^>P9] M1IN&(`YKWQ(8WA)8^Y;`\)8@VD8LV(DG5=-/0@J>($C[!$'P!"':.270=;1C M"J:4]IN"+XJT2T.P-JR=X`P3G+43G&&"B[;G"/0_>VB817EF9A$O=%Y4(6!18ODR",7_KBW+O_<2T*6>['@1\E,>N+ M[RP3[P;?O]WND_3O5+:>.'L7A`N$G/P4A6JW#)QLERMV%Q?@!)6>3G0#]; MA]M,'-RNPH@]'CH2_.W6\C?`^RT2A]U(ZJ7A;?+*1X#-D^^SA4E,+;4Q@'R;[X M*DC[7E4:$-B7EY["(%_#=5F6J\\>6/BRSH\?`KR$\$L%X3[EJQ"7[1T5H>`4 MU>,\S-^I$1_4#Q.PL%#=@,X444AO0GB3&H%2$,L!IBLET$$KG3#+_43`9$+]2IMN$ M4:CM3(AE_"&>85NHA0ZX6ATKDX![4*D[GTZ)LZ#V/76-B67<&R-B>92,1O8< MPV!?KIIWUZC^>V[,IKKEX3/8A>OFF4[IH>?,1P5C:EATYM@31W==#($=Z#4A MNM0D3^[@^[0&5F0H:G73E[ADUSV>A0( MCWX]V.:XZ*%0WUM@]K`5*]<5+G2*3!W=+&=G1AQO03V'6"XIG7`IQNEA'"YU M[?&IA1?'4/EB#B%'U4AV<1"5MB12SW^.X-<`G<6!5+A$MG@*6!@'IU+A8MFT M]001'%+8NXTU=]+=$R@XHBH7T7:3:^;@F*I<3-M=!BTJS6<9"@:C-H73@T(IUGCTMP.A!>.AM,,!3"2RB4"CY]+/UK" M&PO=V]R:W-H965T&ULE)EMCYLX$,??GW3?`?$^ MB6T>;*+-5N6A=Y5ZTNET#Z_9A"2H28B`[;;?_L:8@&>2)FPKM;OXY\'_F;%G M@*WJKZ:[,OBM8!"Z=FY>[;]KQ<+)KUOCCFS;PZ%R<8V5;U,6_AUWJW M:,YUD6^Z27*-A64]Q4:UW9;K(JW6K\?BU!HC=7'(6UA_LR_/ MS<7:<3W%W#&OO[Z>9^OJ>`83+^6A;']T1EWGN%Y^WIVJ.G\Y@.[OW,_7%]O= M+U?FC^6ZKIIJV\[!W,(L]%ISM(@68.GY:5."`NUVIRZV*_!OBI"/P4E5?-?IYHR_!Y,75[$]=!/ZLG4VQ MS5\/[5_5V^]%N=NW$.X`%&EAR\V/M&C6X%$P,Q>!MK2N#K``^-N%\X#R3P.N/-2-.VG4IMTG?5KTU;'_PS$>U/&B.B-P(S>"!=S MH0(>A(^M+,R*.H%IWN;/3W7UYD#6P#V;%M_`I>L>B6\@'D:2"Z(=J,VFEPNC68ZG9!="1P\4 M#;+`6;:LVX&ZK%[#>O67^\;F`M@>Y!`UR34A?;RT]!HA1K)KPC*"Y'COD:-A MB**U>AG@M<4&\2V$$,E#(GU(9/<()`\6,CU:&EZYX+LA.#(D\@RBND048228 MQ$!"`!:2O$IM0/E2L0A;R!#`PDBI`4#28$]-EZ9A(HVL/#9(V$GS%..*:$\0 MX"DNB874!CCC0D2$R&PBXF!CW*A(6_@>;1HFVD:7==L]-HC1%OJ1%XWW[8`$ M`4P*CUA(;0![!@4`.^]0>#Z7T:6+: MXS(,^7A_)(]#<9X>N(XFPLC"XI[QNR.%>#WI!WO90<`(D-Z;G:'9$+)@C#H6 MI)1B@;K43Q=H&@,DD'07,3>,$:@\P4?7FK,2`7#**]J1I8@`=9*6B@P34@5B MS%JL3Y?ZZ?I,8X#TD>7'W#!]`'D06:[M!=H$5[XOB(T4V0B4#'R2O1DF?"Y^ M5NJXKO?3!9KN``D."F0PB1NLY(@0T*[CJ M9&A\QGU/!*,)K$X7_NGJ3)L`&394:ZO!Z]49YEY%YP^1]#&2W46P2%W^IXLT MS0(*X9@;O4C#F!!))JY":(_[GD?&4VZ/"S_RQ_!T-\@0P%7DCTF$I>GZ/UV: MZ19L:1'9^S&W.XI9Z,-?G%T))KC'KKH60H2,62=D+Q#=1BEAG<-8H>X`IBLT M_0)22,I3S.V>8A9P)HD/$DPH23=8B@'N!4Q>11#=)8Q@#PY^1`+%NUJ7CL:M M"^VIXI[I#Y!;`C&A_%`0%Z28X![T;B0/,HP(>&EC]1M8XKL:&7'=R-!'GKAG M;G=G]P;3>X/93P:Q&$BNZ0DI-$WB18I1W#/WXF6L],3->"'B=KP0NH>8 MO.>$Z3CLJA"-N6X.S)ZY5Q4>(^EC)+N+X#B^JW<1U[U+1#9$W#-]E`1T'L0- M"28D/,L/9T+GIQ0!0C\082!#P,R3GK4ML;QW]2WZ52E-T['D]#$TC'E_-),B MLDZTCDAZ*ST!XU93U>M#-N`]!%BA"A$"Q3'R1R]AB:1YF?90*TSW`9MA:&(B M$;X>$:*9TRX1X9G\'F8S4;G8<_H_F+Z!C;= M"/+(Z/(^^';'P@-X[N,1*:P)?&L8&]?;3#J!T=\L[M@Q0LU'"?/._EC4NR(I M#H?&65>O^H.#!X$;K@X?0SX*_2Z;7(_Y$MZP7U]/X>-)=WTQ3(!O%^=\5_R1 MU[ORU#B'8@NW8G,)"5N;KQ_FE[8Z=U\07JH6OEIT/^[A*U4![^[9'.!M5;67 M7_0;^N&[U_/_````__\#`%!+`P04``8`"````"$``V:[';L"``!G!P``&0`` M`'AL+W=OP'3X2 MA51-JFZ55FF:]G'M@`E6`2/;:=I_OV.R'R.-M+@O1[C+TX_O=58H\;5A;L%JV/$,O7*/KU<<4;IGW9\1;NE%(US,"EV@6Z4YP5_:*F#D@8QD'#1(M,P/^NA*=?DUK\DOB&J8>]]U5+IL.(K:B%N:E#T5> MDR_N=ZU4;%M#W<]XQO+7[/[B++X1N9):EL:'N,")GM<\#^8!)*V6A8`*;-L] MQ#%)D'!:MGWYZ?@!SWX[.E*'CXI47P1+8=FPYCL`+92/EKTOK!?P>+@ M;/5=/X"ORBMXR?:U^28/G[G850:F'4%!MJY%\7++=0X-A1B?1#8IES4(P%^O M$79G0$/8<___(`I398C&?I2$%`/N;;DV=\)&(B_?:R.;7P["QR@70HXA%.R/ M]XE/T@A'\;]3`F?4%WC+#%LME3QXL&G@F;IC=@OB!23_N2(HQ;(W%NZ7@*R& M*3RM9C1:!D_0NOS(K,\9,B8VYP0-3T@`7B,7*#!UWN9N$,0?;)C21TXN:8M&_K%0WG9#8&-D,@PO%?>@;%7>YE MX:G7Y+%KQ\2]%Z9T/AWG\#[%=/96UZA?L-&'7O85HO`BOK_A[**IWV1B:\;8N8B$R038#`&"DR$P M,DO^Q\S"8S.23-\#Q[B]-DO3E$Z'.@1B3-+P3=V9N;/2'24=V_$'IG:BU5[- M2YALZ"?0=>5.2G=A9-N%/8M//Y&KWP`` M`/__`P!02P,$%``&``@````A`(H0.%=Q`@``(`8``!D```!X;"]W;W)K&ULE%1=;]HP%'V?M/]@^;UQ$DA*$4E5A-@J;5(U[>/9 M.`ZQB./(-E__?MOU,Y]9CA&2;I$1<*@.;C"EQ1AJ''F8*30Z_` M8T9=0M%P=!^>)%X(`(WG`MX/WX%?-Q[TQGQCCTD/C0=;QN_ M*WJM8-CS>P4>XQ4D:?)/`>FE@/>M._!EX^24J._K(3[R=/B&<7_(_1EHZ9)_ MIWHI&H-J7L(DP^`>E&M_Q/W"JK;;ZPMEX6AVKQ7L]A7<_+KY^--03QM6%^Q5O9\3EZY)K>+CQ]F&ZF>=,.Y\8"AUW/2&#-, M@T"7#>^8]N7`>]BII>J8@:5:!7I0G%4NJ&L#&H99T#'1$V28JDLX9%V+DC_( M76DQ.O*Z9=5+Q5; MMN#[)4I8^<;M%B?TG2B5U+(V/M`%F.BIYTDP"8!I,:L$.+#'[BE>S\E=-+V/ M0A(L9NZ`?@N^T7OOGF[DYI,2U5?1(`,1W&8#J]1G8(,B4>'L9I#M^E^4]8I(]S(@XR`!H M]C-XW[L%SPEUKFD8)4>BN%VX[4F:9/%N_T`2LKILN!CW>.&0@SJ9DE(H^B\ M\.10^+*+;(,.$TCH:`R-(P83B.,TB<:;?E!J&,!76'?H0VF:'7?9%H2W*0Z3 M?#)6!;5Q9.-$&]B*?V-J)7KMM;R&R1#Z.32JPH&-"R,'-[F6TL"@=:\-?%@Y MC+70!W`MI7E;V$_"[E.]^`L``/__`P!02P,$%``&``@````A`&[Q\G3-`@`` M[`<``!D```!X;"]W;W)K&ULE%7;;J,P$'U?:?_! M\GL!<\M%(56KJKN5=J75:B_/#IA@%3"RG:;]^QW;E!#2=I.7`/&9<^;,#,/J M^KFIT1.3BHLVP\0+,&)M+@K>;C/\^]?]U1PCI6E;T%JT+,,O3.'K]>=/J[V0 MCZIB3"-@:%6&*ZV[I>^KO&(-59[H6`LGI9`-U?`HM[[J)*.%#6IJ/PR"U&\H M;[%C6,IS.$19\IS=B7S7L%8[$LEJJB%_5?%.O;(U^3ET#96/N^XJ%TT'%!M> M<_UB23%J\N7#MA62;FKP_4QBFK]RVX<3^H;G4BA1:@_H?)?HJ>>%O_"!:;TJ M.#@P94>2E1F^(,J@V],ET8"/$HX$^ M%.8O"/9/HN]M!WY(5+"2[FK]4^R_,KZM-+0[`4?&V+)XN6,JAXH"C1\T%6&H]1+9D%$`(XV3.E[;B@QRG=*B^:O`Y&>RI&$ M/0E<>Q(2>N$\(4GZ?Q;?960-WE%-URLI]@BF!C151\T,DB4P&V<1U.=M9V#) MQ-R8(!L*:`7M>%K'8;SRGZ"$>8^Y/<6$`\('\2$#4+T\`Q,$F6(TRB`9^&V6 MMPX3CS`'Q%$&0#/.X&/O!ISAT+H.`S*U[8[G[CA)YO,AJ2-)R.I\20,>21Y< M.)_N.+62)`BC)'I;$T;M?$T#'FFF`Z73=,=.,XH)><=F>HFD`1O)0T_#]#`S M3M=A>J]I&"2+(;&C^LXN$3;@J?"AAD[887KA*$K>,6PV_NAU^GB4#'BJ.YTG MA^EUX_DL(&\;7AP+G_<>FZ#C!.)PVFF'<0DL2!`=.G)4<%B_%SBWZ*GR;'#F M2MZ#W+N4S-)TVFNWK]TZZ^B6?:=RRUN%:E;"6@B\&4RI=-O:/6C1V;6U$1JV MK+VMX*O*8*<%'H!+(?3K@_D>#-_I]3\```#__P,`4$L#!!0`!@`(````(0"2 MERAUV0,``#H.```9````>&PO=V]R:W-H965T8_?']Z=/"]>1*BFS).)8G2I4#$4H9NR>EJI7OR_1$BT1ZO*(E7#EP420*#L71 MEY6@258O*G(_#(*97R2L=#'"2HR)P0\'EM)'GIX+6BH,(FB>*."7)U;):[0B M'1.N2,3SN?J4\J*"$'N6,_56!W6=(EU]/99<)/L<\GXE49)>8]<'=^$+E@HN M^4%Y$,Y'T/N!+"3X\[*)2+3V7Z"F M::/9WFN(J=A=%=H*P&L9(?,N8W_5KRA:K%&T"YIMBR<@=LL66O>]5\QO\`8) M5*A+HJLU@6X:)M*+8A=NT@)$9&HB;%$3=3268C>D,!@A2)=QF$V+;;:9Q8:: M>5#[&G@3VS:\#I]M?C=V@PQZ?3R9%MMD9,MR!6FR#VCZC9E;[O%S.EDO;9Q2,0%N::.-\UHML1(M@BYI^`O09%6VU MHW=^)`2>)]WJC4.L5UF,86#U8B,:@FPD6&J"[=!&,4PF^FG=<7DD)S[CC8=A M:#7:M@X=NX.<&*=?8G+JI_O_Y\298'`2VW."HGX(-+V1M*[?1H\)^:'!0GHF MR[WI0X.C@41)8_IB"K:_XSFD^H%:ZE5V;]X*43-L"8H&:SDD,41-.6I.:$@Y-DL;I(8G)9TV; MD27L&3OW'8DB'-MA,.^V6X/9541!3T/B5AUWL@451[JC>2Z=E)_U-CR$2=&> M;5\1'D*]*;3.;_6K@S[OMQ=@YUXE1_HM$4=62B>G!P@9>',P5N#>'P\4K^K] M\YXKV+/77T_PCD9ATQEX(#YPKJX'^@;M6]_F-P```/__`P!02P,$%``&``@` M```A`(VM2(TA`@``E@0``!D```!X;"]W;W)K&UL MC)3=CMHP$(7O*_4=+-]OG`2R"U&2U2)$NU(KK:K^7!O'22SB.+(-8=^^8QLH M$BN5&X+A^#LS9P:*YZ/LT8%K(]10XB2*,>(#4[48VA+_^KEY6&!D+!UJVJN! ME_B=&_QY14`83(D[:\><$,,Z+JF)U,@'^*916E(+1]T2,VI. M:W])]B2-XT6B[2Q,.X.&7%]Y_;[FAD&@@(G2 MS)&8ZJ$`>$52N,V`0.C1/R=1VZ[$LRQZ2N+E[`DH6V[L1C@D1FQOK))_@B@Y MH0(D/4'@>8(D:90NLB1[!-/_4$BHR#>XII96A583@J4!3S-2MX))#N2/.X)6 MG/;%B?T5*-;`%`[5/$D*&ULE)3;CMHP$(;O*_4=+-]OG`3"0D2R6H1H5VJE5=7# MM7&/N.8TC94K64"Q+#/]_\F9ISBX#0F@S7UG8I(8;57%(3 MJ(ZW\$^IM*06CKHBIM.<%D.0;$@7-TC M4ZO^@Q;%)]%R:#:,R0U@J]3.25\*]Q,$DYOHS3"`5XT*7M)]8[^H_B,756UA MV@D4Y.I*B].:&P8-!4P0)X[$5`,&X!M)X38#&D*/P[47A:TS/)D%R6,XB4". MMMS8C7!(C-C>6"5_>%%T1GE(?(;`]0R)XB">)U$R^S>%>$=#@6MJ:;[4JD>P M-)#3=-2M8)0"V54V@?[\N3(HR<4\NZ`A%-0&IG'(I^'CDAR@A>RL6=UJXE%! M(/GH`++^OP,7!$XQNG(P'_F#RY773*\TR:AXXP`PUP[^7KL39QC85YD7(]=G M]IKYT)DHF83N,TK>I`9W]Z=VXM]21[^X/K77^-3)='Z;V"^YWX&.5OPSU95H M#6IX"16%P2-LI/8K[@]6=<.LM\K":@ZW-;R)."Q"&("X5,I>#NXA&M]M^4\` M``#__P,`4$L#!!0`!@`(````(0#G'H?6O`(``/H&```9````>&PO=V]R:W-H M965TU-@LWKQ^<]QSZL;Y_J"CU2(1EO$NQ:#D:TR7C. MFF."?_V\O[K&2"K2Y*3B#4WP,Y7X=O/QP_K,Q8,L*54("(U,<*E4&]NVS$I: M$VGQEC;PIN"B)@J&XFC+5E"2=XOJRO8<)[1KPAIL"+%X#X,7!-T"XL`JIIX[*$9U%G\Y-ER00P6^G]R` M9#V[&RSP-4R@P2"AC+6VE2QBL(`'Y1S?3)@(20I^[_S')5)M@/ MK57D^"[(T8%*=<\T$J/L)!6O_QB1>T$9B'>!P(H+Q/4L[WKEKL*W*;:)J#.8 M$D4V:\'/"`X-["E;HH^@&P.Y=V;B&+S^SRIXU)`[34EPA!&XD%">QTW@K-;V M(^0TNVBV2TWD3R6[7J(SJ+EI/_'"=:=+]KU"EP\L#;X@6V-?_ZY4'[X6Z_#[ M?;=F`MB#'V^Z[VZIB(*I)%U*9I#]4C&"3.SX4SNZ3#X&^[&<3Z'U=?/VL`!:3TN.]!L11]9(5-$"MG*L".ZW M,,W+#!1ONP9PX`J:3O=8PC>&PLUS+!`7G*M^H._7\-7:_`4``/__`P!02P,$ M%``&``@````A`&R2ZQ:Z`@``,@<``!D```!X;"]W;W)K&ULE%7;;MP@$'VOU']`O,?XME>M-TJ:IHW42E75RS.+L8UBC`5L-OG[ M#F:7]>92;5YL`X=SYLS`>'7Y*%OTP+41JBMP$L48\8ZI4G1U@7__NKV88V0L M[4K:JHX7^(D;?+G^^&&U4_K>-)Q;!`R=*7!C;;\DQ+"&2VHBU?,.5BJE);4P MU#4QO>:T'#;)EJ1Q/"62B@Y[AJ4^AT-5E6#\1K&MY)WU))JWU$+\IA&].;!) M=@Z=I/I^VU\P)7N@V(A6V*>!%"/)EG=UIS3=M.#[,/X#LS^D:F4;LO6I3? M1,E>Z*=A,7NR^'0KP0Z.25W3;VI]J]Y6+NK%0[0D8B=(V!RL< M)49L:ZR2?STHV5-YDG1/`N\]23*)\G0RFY_!0GQ$@\$;:NEZI=4.P:$!3=-3 M=P23)3`?G/DX@M>WK()'1W+E6`H\PPA<&"C/PSK/9BOR`#EE>\RUQ\`S8)*` M(!!-"`G"&(?T>I(/R@[LE%W272C7?F(LD[XND[U'QH&A:J/@T_S(ZY4])A]A M)J\K`^1\@PY<8'`5TI8NIH'7*WO,+!XR#VWH#5TX:^?K.O"I;I[-G^EZS%XW M#HLGU9R^1]2!3T73Q2+P>K,>LQB\PGW+P_*)+)S%\[TZ\*EL%A_M>%F/&5@,:GD%6^-H!F76ONGY@57]T#@VRD*S M&CX;^#=QN'YQ!.!**7L8N+8:_G;K?P```/__`P!02P,$%``&``@````A`%R/ M:0>1`@``SP8``!D```!X;"]W;W)K&ULE)5=;YLP M%(;O)^T_6+XO!@))&H54K:INE39IFO9Q[1@3K&*,;.>C_W['=@))4VGT)N"< MU^]SSO$'R[N#;-".:R-46^`DBC'B+5.E:#<%_OWKZ6:.D;&T+6FC6E[@5V[P MW>KSI^5>Z1=3-X2B05+0X."SW&0U658/Q1L:WDK0TFFC?40OZF%ITYN4DVQDY2_;+M;IB2 M'5BL12/LJS?%2++%\Z95FJX;J/N09)2=O/W@REX*II51E8W`CH1$KVN^);<$ MG%;+4D`%KNU(\ZK`]\GB88[):NG[\T?PO3E[1Z96^R]:E-]$RZ'9L$QN`=9* MO3CI<^G^@LGD:O:37X`?&I6\HMO&_E3[KUQL:@NKG4-!KJY%^?K(#8.&@DV4 MYLZ)J082@%\DA=L9T!!Z\,^]*&U=X$D6Y;-XDH`[,30-8QZ,D!#>!J:D4Z'G"YJA:3&$YWXC#A8!F(( M!V*>9+,^H0LB[*OQ1"<^(TYZRT`,X1-Q,H0OB-./$)WXC)B](89PYKLZS^=] M]`(X^PC0B1UPV$"3>&A=J#-H`G78UA=,=Z&//BY.?,E,9].^EL`,FM#;),_B MM]QP)X4CV]$-_T[U1K0&-;SR]\T,%D>'&RF.W,"JSA_1M;)PD_C7&CX<',YO M'$&\4LJ>!N[.ZS]%JW\```#__P,`4$L#!!0`!@`(````(0#,[.11L0,``)D/ M```9````>&PO=V]R:W-H965T#P3@N M,:U"PS#C?3C8>DTS\LBR74DJ:4@X*;"$^,66UN+`5F9]Z$K,7W;U3<;*&BA6 MM*#R79.&09G-GC<5XWA50-YO*,79@5L?M.A+FG$FV%I&0!>;0-LY3^-I#$S+ M>4XA`U7V@)/U(KQ'LX=D',;+N2[07TKVXN1[(+9L_Y73_#NM"%0;^J0ZL&+L M14&?%?(7VS_C=#-5D*[1Y"12FR6OS\2D4%%@29* M1HHI8P4$`.]!2=5H0$7PF_[+`B0CY111D&V4Y(5OXS M(&2I#$EB2>#3DJ!1E":CR6T/EMA$I!-\Q!(OYYSM`Y@:T!0U5C.(9L!\R,S$ MT>3Z4:J0HR*Y5RR+H:68Q#P8#[PWFB(@AFB8D".,T MI,M%/B@KL%)615>A/)@3IS))$\B9S-!'1H&A:R?!I^F1UR@;3'J"&5U6!DC_ M!!5X$4)63=G2=-CP&F6#&>O"HX%Z-8"SE&'8^@LK\+GP,#EVS`@;3*J%/]`< M^V@JL*OIEME@.C5A$/OGJ<"NIEM@@^G45%Y_\D?JGEH%/M=,T[3IF:FMP5QO MZM1'6('=.3Y.J1$VF!YSC,!(^^>LT6[2;J$M:&HF*DJ.13D;9*3,I'>U-?I< MN3W*%G3;-=+:C3MI"7 M;VGTU9$VSM4MZ^5:R%C2E9$^^)9Z_/C@9I1X.99&GV?;MFD+ZNQMXF57&NV: M],299POJ,<^)EVEIM)NSZQX6U-GAQ,NT-/IOE6.JIW[G_MRW:@KIEO;P*5B17]L(\&]!E6;,AF06B)'Q#OI"B$$'&=FK[ M07#O;,XVF]E]HG>KY@=8C&J\(3\PW]!*!`59PZ6#:`(UX6:U,@>2U7H]63$) M*Y'^NH45F,!#_B`"\)HQ>3A0RUNS5"__`P``__\#`%!+`P04``8`"````"$` MAY"T7Y$%``!F%@``&````'AL+W=O:=T#<-^`C)FJZM:'JS)9FI-%H#M>4D`8UA`CHZ>UG^=`8FR0E<],V MY6/Y]UKV^AW??GMO=L%KU?5UNU^%:!&'0;4OVW6]?UJ%?__U<"/"H!^*_;K8 MM?MJ%7Y4??CM[N>?;M_:[KG?5M400(1]OPJWPW!81E%?;JNFZ!?MH=K#DTW; M-<4`'[NGJ#]T5;%6+S6[",/E30,&C*Y8^G?=L5CSN8]SNB M1?D96WV8A&_JLFO[=C,L(%RDA4[GG$9I!)'N;MBJS2K\CI8Y06%T M=ZL2]$]=O?6COX-^V[[]TM7KW^I]!=F&.LD*/+;MLT1_K.6_X.5H\O:#JL`? M7;"N-L7+;OBS??NUJI^V`Y2;P8SDQ);KC_NJ+R&C$&:!F8Q4MCL0`#^#II9+ M`S)2O*O?;_5ZV*Y"PA%\,Q=UMU[X%L&I@S/Y0R#6(EA!9SHQ`?D[/#*8DW_DN M7U*O`MU#.5[O<'H;O4(&2X-D)Q"7R*<$B8](!/*.&F'F8XV7M4D8YA`&1VT$ M'<,J^9E&Z`AA+I%?(AQI,,Y\:1)>A1#;2L/NP)E&A,HIPX2[C_/QXR1)R?&Q M(PIF-E^4A#U1-JS.ET:X$H6(2'ER'% M%'*/2,'1CA5P5AR277GVDE.T)\X&UMO`,%J<0)QYZG,'2&/*[>)PI5WE`VAJ M!*/%;*1IQN0MH=!$L+>+@YPGS.@G2C1VD'!V+>JTL,PR0 M1\;KAOE%Q)7I.<1,F5.KH#8/)I]C*TC`I/A$Y9C@A,3<+A=7Y%5N@:9V0;VA M,\.80G($W<_/<^XR%!.<)+86KD#/-K[8Q5._H-Y*RY!C"@03$=ODZ/9LD/$Z MH+;'N_JN\@XT-0]JMZ&I[M@HTN M0V.?H)C3:;MQB!C#8>MT*\17&8FBW5;H#YT9QBS!%%%$4K_$+L.$B)/$YMG) M(K[*2!3M"?0&SPRC!1*.*;=#ZQ([!$\9%[8"KKBKC`3K+P/C8_OH&*G7GV$^ ML\=B(B:G!)?A+.'T7(?!5]F)HKWLV&H=S'94(VYL##?0E44LO`GD)HZ6=X/AR@5Z\YG._+_L M`T_M@]GF982.S2'%+/6`W`31*CD3V*Y>)X?R?F?^[E6TVUVXM4XMS3"?^8E3 M#J>38WX4D[L,2E,B1M]47(&>>B>ZGT?[*H-;.AX(;=TI^\)]8>A/:@+L\=V@/L]]><6[G,K MN$V+%P!OVG;X_"!O(H\WQ'?_`0``__\#`%!+`P04``8`"````"$`)*V8?-H" M```H"0``&````'AL+W=OA^^?'# M8LOXLZ@(D0XXM")!E93=W/-$7I$&"Y=UI(61DO$&2[CE:T]TG.!"3VIJ+_3] MV&LP;9%QF/-K/%A9TIP\LGS3D%8:$TYJ+(%?5+03>[0;T-.:9-_/` M:;DH*$2@TNYP4B;H(9AG@8^\Y4(GZ`\E6W%T[8B*;3]S6GRC+8%LPSZI'5@Q M]JRD7POU%TSV3F8_Z1WXP9V"E'A3RY]L^X70=25ANR.(2`4V+]X>B<@AHV#C MAI%RRED-`/#M-%25!F0$O^K?+2UDE:!1[$83?Q2`W%D1(9^HLD1.OA&2-7^- M*-A9&9-P9S("^MUXZ(;3*(CB_[MXAD@'^(@E7BXXVSI0-;"FZ+"JP6`.SBJR M\<7(("0UYT%-TE-!+6`[7I9QN/!>((/Y3I*>2BQ%=JH8^0<3#_`.C!#Y,>/Y MK._9E!CRBYQWMM'!5N.G1C(^DD1]13:DZ*'!.M>C*7&"P/L=;=Q?.#62F@(++KH938@K*RD1I)K*'@Y-&?/GZ\?O='9^;$>3GP+CA);.!,+QTC.XYP?Z^%,;L%18@MG:N$8R<5ZNCC< M@U)M[.B,&'[^E-B"FEE01F+J*3I?3X.2'MSL%C@E[L--K)I)C<3`!=$T"(-9 MT.?/!B4].&A*-Z1.JRT\:^UTIQGD&]880-/K3"OH\)I\QWQ-6^'4I(33R7^"^*2,;F_4;WT\(ZS_`<``/__`P!0 M2P,$%``&``@````A`(&!4]5E3```O^,``!0```!X;"]S:&%R9613=')I;F=S M+GAM;+R=VVY;29:F[P>8=]@PG+`-4$I)/F9U5C9DFH.YF`$P#]2SU*/DD\_UK1<2.?9#D+DPU4`>9W#L.Z_BO M0P2__>=?;J;%IW*YFLQGOWVTN[WSJ"AGH_EX,KOZ[:./YX=;;QX5J_5P-AY. MY[/RMX]NR]6C?_[NO_Z7;U>K=<&[L]5O'UVOUXO??/WU:G1=W@Q7V_-%.>.; MR_GR9KCFG\NKKU>+93DQ1,9IO9FOFW7VU^ZC8 MS"9_VI0'_M&+5Z\>???M:O+=M^OOWLU'FYMRMBY81]&?K2?KV^)HYA.P[F^_ M7G_W[==ZU!__IO@PGZVO5SPZ+L?-;P?E8KMXOM,K]G9V7S2_/)Y_VBYVGW=_ MF9:Q_T7+>-(>G,]G5S]-BA_*X71]/1HNR^+[ MY7RSZ+'ET7;SZ3#F`=19#J<\,BY_*7Y7WC:?>[*SL[/[_,TW+W??-+]*VSJ_ M7;17L[NS]?L[WS@MEY.Y6#(NW@W7K9?W8=K8&'UO/=YLC'XGU)B7#X@_E=+KU\VS^>58,RN$* M(1X71ZO5IES^<_.U)\?SYD?Y2#_.IYO9>KB\96W3CM?3LT]6Q5FYF"_7*%$Q M6`_7FU41MM6>\X_EJCEI6+O-4AQ`UZOYLLW0P-!_UW!7X.3]T?O]L_YQ]O]]_O'!_UB\$._?SXHGGX\WO_X[HAO MGO'WX%WQ^%EK'>4(==\UC6XM33\&): M]HI9N6X^]VY3%I?+^0W/3>'[59+*8=WY\NR\5P,B[* M7["F*S@ETS=?7\/P4="0X6I5KENL.)^O&39JT7[G,_T_;28+Z67G%@[F,\S3 M9K3&M!:36;%8SJ^0E=9,[Y#QU:2]@B.49'8U@4*%+[%SEO.3\_WW13<#WA_M MOSUZ?W1^U!\4^\?OBL'YR<'O?CAY_ZY_-GA2O.L?'ATOX0LP;E>CTMS9"%P9OC//G;7__VU^:')\:N.]Z('#([ M`:'GE\5HN)B(>5/L5(G@V#::@];Y^WXRO)A,)UT2=O#EH]TW"IX4XP`FZ!#2 M+^(+DGQ98M/'X`A,SS\5CW>V\452C.+3<+I!C_9V>K@G_;=8N5T:;M;7\^7D MS[PEP9]AMHN)K+;_>WZWV0IF[LZY7CXTU^[+WIO=O=[N-[MQ,=T3(]QB&G!B M7=YI"QU:)$J3Z5TY:)WA^/X>%\!O--Z]&Z(`Q-]B/E MFYN-FY9Q>3D935HF*'\D6`P8?K^70,(D33NB=P MU?V[E/3O,.NG."K07+F6O;S3S.<++TKLV_KV-TW:-22Q5XG@@T]F\N@2^N`; M06B^\.E,H(/4-2?(Y?J>E=W#9])X?% MR6G_;/_\"!?_);[\^1<#^Y:G#Q,=?U^<]7_L'W_L-^E[--M:#+&C0,]5N?PT M&95H[*=RMFDA5##3ES[J2D5`M&1HP.!=(SH56%S_7T^%>EJ09']\,YE9U"`# M!=@<6=7 M;?6NR0;#J2"TAKI-='1\'K2/QN5&/HRX?I.W1KKD3++=[V#T_.^G$] MY_O_VF;YZ7+^::*PO"#0#4:[6`]_:1/LN']>:-3F3+YGB'1ZUO\!L3KZL=_Y MW.%\64ZN<#D&+$>WA8+3%3Y&DU\1IQ=/)18M:FG>AT<_+M/"!.]Q)W<8<[`]^*`[?G_SABVS,25+6H9RU0:N6 M)]&>WG=HRO[XI\UJ+:"X; M%7],9L^*2H7N60#8NU+TH"!-ZIE+9#ACXQW/D%(@,[,JOWXZ+OVO9X+\V1HL M@#`F32NLV2)(`M]5>-1Q`));-B1#[$_A@9LW M6!"V<-N699BBN*\PM1-3WMX6E2SL)UEHKN-H]@FC(.-^#[OV1R`28B44RD#C MY>07(=G.X*SY[*093C57T(S7V$%GO":AM2U^=%$C6127?O?V#B>S(2)\__9. MA[C];P*\G:>;Q?M>)\M$:06PV)ER:T%'<;"3`=J'Q%4-.AE,BXU5\F?C(0U$L M1;E4#&GS`-AZH+7E5;F\[157M[-R-)_.K_A[P3*&Z^5DM.H5,)LG9CC]ZJ7Y MXGI]/9S>A,?CJD?SU4VY#A\23GKFP82HQY:5[0]?SOD#D#>["O]&C%)\*U8@ M?=ETEB'AX1["[[&T7HTYFA+8A/M_]1OF'G5<](^\ESGILPK4/;AY-H3)L MD9XN2=2XP@2>F:H8T\I/P_%0_CY)B`M M]@"6P`UD/2R1O6W;:\HI+(LQ,>!\^HDW$?H/P^7HNMA[:D2&<@>_GP]87U2BXMR)-K=2ZA\5:?9*%K0_7-F)(Y9*+)$KU[N]5Z^?!VS M1*PQ1[?:C-XSJ!LR*B8M,A(S)'9TC3$C68R%RDES1[(IY,6:D_!OM@\S48AR M>"D.6F3%H!"*_*P+,`M!Y0!"P1'`CDMW["@3YC?:?"TXR:6-9':ZP,04&Z$& M-F7IO+B[`!0#K(E+06L3WHE[EJ4G&ZOBGF9G@?J`T51\A'/9&QN*6$LC'GN` M3&8MR`=8<9>]&A5D(]:WVX7PZU*N M?8KR:<1E2=TR.='X[OKS7$Q&;86E-YWO.\T'=S=E4B5)X8\)3M%.<+".7S2Q_E+*Q M4-QDS+C>3L@R`C8U3^3>-TBK3)GH&P4'YUQ0"%4F4U$FPV?USB,*$)/UQN`R M-CZX4,0%,<3X_004=$GT0JJ-8!06,8-+&%,_65HH%IDWGMB"(:8+ID708(N?S,09V.E[63@B6Y7D%81OV''@C78:O?YP M##_6!$>SJ[:#6:KZ+_M^LR'QPBK9*WNVI=D@:+BTG.DSS8GTLSJ<1,(YWQ(, M4(N7?_3,)4@7\@\IRC.?IT+6N%SU*6@*&2N>4;'EUA<@09+IQOF,D0V]!L=J M\OEI4GX6Y+QG$04SJN"SQN%BS60.]3PNL+BE]LW`1V;CF7PRM:S"#5T4&G&" MQE)I&P^7XY6A%T/"B;>1"C?#6U8(\3[-?RZ!MV&=U-XE_M/)E5DB=,&`)L)P MJ;E##A3X8YB`U"B>5K*3),*^\@"^O%E,Y[=E!4D-?$D^AF0[T`^9^R`.!+TP M4>#7EX+M!-*M>7>H/I3;8J6ZMI)%:.(ZB!E51C:P8OX1#Z:U2DQMM4G4+'&[ MVHY`!?G1?T[YGXNO:0_YLQ3JMX_>/.(?0L/F96YH:]G5)\M#[+`_<3ZY8:)C MN'=C'X^.'#_MD?E><>''U_?$39 M'Q^1+KWE,+V`57.II$/Z13M[Y303;6WA^*Q/>*QOW_"X'ST M)-+=P+!AE0P%``FJ]^0#M-3Y@FJ&N_UJ2VR151.FXH@5V[!LF5S,7%AH@@H5 MMZP#02.YT*PV4T\25;@4;,>2C+#9@FPJMT\F#N%]F7WQCU`26<'T*J*>J)G# M1[8%0JNX2!D$Y0DP8"K+,&!\T@!N<;EA;IEQ(^E=!+V@)"+;;_UQC,>[>&[; ME86?*5:-;2R&/,'(AD.2E\L4]LN899(O=APR(9YLZW=_#^=7*/04/9>+&=J0 M2,M/BMFU`U,6S1%75_$NBSN"6`1<:WYL?S93ZL4;J12,ID6:-]&0E]XB)OK2 MM#A&CGFL3:RG)(#2RTH"]7A387Y:6V5"JJ@WT/I%"\J>"Z*M-CCRH@DG$'F"^-`5] MEQE%W3#3;@5,X$S59%Q0>@-:LHCZY]58->WT*$%TB&(LN@B5 M=2>F<-+!>(X<4GA)$8B-37#_'20A=Y!X-,OBH1BH0[5>WB':$?:43F%Q#0)6 MWV-Y*<2#D]W MQ%V+J)0DE_`(DEY/KJ[1J"EMV42AX_("8EEOH%=[8G8F6-*AXDT/])Q MX,3%?_!-N(U__+*W]_R5LCWLJ=TP MMEU\CR=W9"0$`DT*TDHS,.((Q_9ILIQ[PB(:HTI+>#/V;L.W6*`5KY,(%:H:?B#:MBY*MCQ3I.OT,1R6Z MU#6&1!TV6<[%2]U1S.#3F#(768J1!`%;;]T&6JGQ;*'@UV/=II'\..@K>NH/ MSH\^T#;4$G39K[:!=^A:&;N*7#6CUM+C3(]5'OE$$"XZ*"\3K"`]C3=6H0]`?FB9&AL>QT7S#G3W.K')="Q@ M8^/(7J2H1MQ'%&37)#S=+P3YT\K'"@N"?DGEO3S(5)VDBF)7+<@4U+:L9H;0 MU>0[BMTZY%92`=1?E%@2UG-@0/G6M=!=]&B2P/&$K2,>RIP1),+$.JE,]/PA MZE70+R0V8I++A9%^)VQU!LGJ@T"91.]Z9!H"&((0;!9Y6*D--";K#8C'!"K4 M$B%8LA<%,5X;9WM>S>\I04#4)>P+@2>4V&=K.EG%K^3RJB8)*G1JBL60>8!] MHVYO>YO'F0TK//]L]@FUX2FWPL%QWV=G^\>#]P'OO/N7CX-S]?4U=5@Z&MP+2<3+$!C`?#=U MP9_KH5`9/"MGP("+2?'T[,-;BF,:H)*@^EN8LB#&'P?%.VID"K5BYW.B]Y=+ M.L(3FY_0!B#"O*'E8YN#?4A,69_2=X@*V)>P0(Q6CCD5=\"=B,AG.F]-HT-Q MH`Z&YG3TJCT:I>CLM3&8GBTJ6._&'.Y;6`E"DD>3TG1!,7`8(`6),OW$9VP0 MY#N&)HFS5.*M-D6DX%?E8)>'P&I@27EU;4&"TB[8^,2W(='("Z8LT ME^TT`D5+^ZZ5NUA,AR`J\J+SS=4UP61J#Q<@B;4",HJJ3RW8&B+M2L@*;\B$ M\&H@G#$M&##*40")%$CTY)_\LPO*S6$[21`&^#%)6.!YX=RUNIBT!QP1FN;( M/\:D8'4J36*<=IF]BHC%5^%06!CC&7E-`#G7(NT7<_.B'MLDLI%5U3>=EONS M7#^B<_\S_8/WG#BQ1*PU';>YE#*(E$0M4O\TF6]6 MR+9;(&3!JY/6AT'4WT5W]>Y[H),DB]='4VPIB0*&@*#(%CRUH%?<#C]8ZYN0KS#]9.*5H28D`)$[L`F`H M=+'4",R]O+32Z,:@1?&6=!9]^#-R12^*IXIL7NV\Q$(/Z@W3L@IA'AW@P!-J MB[)$)$[\48RB1!//`QZ7[?N#;"3I/J6^B`"6*%-(&5N!"^^I,8!E+([AW>6B M%..2*$Y1(R=^PBAZ,$RC1VU7/#6F89>*!]]2-\D`0JB!6&`:'$4@&^J*33>K M.4*!""*\Y<4B4'E6#FQ<""P#*FP3J0_.'3Q[ORAE`BV8"F-S+HQ^$1SNB#P) M:,CV#"&LU3R2S=@CK@@+K$QF/%E3%9LW,])>*F^'5SL%Y;R2@9!;$0_B9.;# MLC8GBCSJ?T<>Q![B/_Z?@N1R3+O[$JQ`LZ5A(H=*,CP*M;*"*J'6U7*(WLC, MIRA!$9CZ7`U.B=\A-!>?4HT51MG)%P="&W)+^<"`N-0B1D,`G2`$C6=.,UDW MPET^O<%%4#26!QXO-_0'$%ZZ<&?2:$-K:GODHM0VAJ&[7J(HY1RR%B-%)U%/ M_;M(QFH&ZP/P#;#\Q;+_6"8$6^>C3%L2[*?=I:4IE`1UOB!RN; M(2&):B)Q]7FZ2/1^ER)@()CEU2\D&"HO%>RFO7W^AD22BI M#601^V1%WK[OMPWBOM=GS#:%(YQF^20$$Z#*B0!*UJ5<><,>%KZ=!R M/BH)VU"N+@!SR"/*@B1^Q-')`18ZJH#ET$*33IL56!44H:;N]R3-@'+*9:*3 MF_3T]&?$!5^!/0VAF`VF$%BQ5()OJ[FE.BMJU_IT;!#L%&/8ZRD$<(OL;(0I M0HF)P\"%R>0+E3T-B)&`W>*FH(C;],6E@B:#\[*.=[&KK7KX;3]`[Z7:YW>I.>HL6C@0$KG5\MV3QQ- MK>329]2FLZ=BZ)+B#'EAY"6BRRRVPKR[!9?&2!+EXC$9BD+O$9B6B'30W55' M2B8=JOP.&*Y#';,/4<&DH#Q9.[@M\";LDC_C6"Y\`C,K^7>O@YM9WFIO+A)9 MLP\URR45[UJZ.J!@3';B%V6`H M7?(TJZKW73[8\@,R$I)"S1<:XF+@)1;G_00&S821S.]AQ[0:R]QCM.3\))8F M9KXL#>G>#DI58]NB^"0C@A>M[5!]<(_>9W:QG)-8)"PI09P( M1)R`=1>$#R::SW(++7N&>:79PD=?M63?%[/GBX%VS6@O+2^LZVD5SK27$VL] M%5T%].!\L@"DB8@:)M@#D!C:L!YM/[MC3<]M33FDWLPR?(5<-$UKSF/3XRPN5,J_%\03$MXE<11&Y'T@D+NH#=HQANNW%@B1>2;APOMGZ3.V'MN_=E--'F?P2$$(/N7UDE3.!DG_+A68V^1UI#08U/F%+TK4R#56W,?EKZM!A$M\M%+.IE#S6"&IU M.$1A:+JY[82"0!.92[?ZR;_%NNU=)/)82Q[(W4KEHF[=0;&!S]A>9;-B/Z/5 MQQS]V'KI8"=?!\Y)NS\_TC MNG7[@S9ZVE?$Z@XZAPM5KM"1*'Y('*="- MMLA"6IZ*`05U4'5(JK70*BX6?BH4"ATK1@?I4UKB-]ZCE1S2GD*E[ZP\`HV]8837./L3P5!M ME*#M9*>\E[?JN>`Q/+JBTCSMS'0W2EX1M:DV1*E68>A\QN'*=*9$-&45RJP[ MBLF'TC=D+W7GA80AZW'>+MYR@$U0-Z._C(H;+'-3SIO421%,7Q`_A,J7&J6F M3D:9.E$Q2QRE)8)96*3UFE06JRH10VYBPJHF;C@GT"47E$SHH\1F?#3\REJ% MF[!>1MLH;A:57F)3^=Z2@G0VQ'Z1T/$5J`;913[9/B["<$L6BQ@6B%MC255D MRR9SLY4V;5RJL2WG1A/?8B'4KM\GT=%E!@Y"UWG%:\3P-E8/+)P66U4`,?[R MW.J!C@L$V@\"9I(;1-+&=A64%.'%-RKFINLE<@FZ((AR%3&>6';M0F47YM<9 M)@-%ZFZ3QU&A(HQER(B%"QKI.YD3,S'ZH`8+3,LJI3.Z3LLK](!D!*<&T`=2 M+;1^6?L&.X\]*AED<-[8`_ZP%10G,^],P,H!8[5>Y%<')SD9,D%3D)9DULW8 MV#R2#5U64C<8['AJ-A@SZ:NS7"?:/+M2(HJ$BFR(P($&&.K2$T+\G)10@<"% M.:PEAV+>A#J'O2E>5_RP;62CU]32J%4G#\4@.64VI]GLV(NU=:N5B."570H) MM!?=N1Z2?57AIGLTS>*);(T-72;E)>:4JKHE(]0>8,UR4`I)\2\ZW2;'DFPL M(WLL`5N;J;-8C1W>&F][@\0$29@E:'/AOLS(CC@+&"$PQC8K'*BR`!2SM@B3 MJ/JB]:\H/KA`=Z+HNJ4^`5Y\[\8R?98][HZ0K84,$XZJM9'&NBD'D0M"U!JFK91MZG86E56<[\0,)XI@VGZ;- M;C3AX?F58U-+#DA5`DGB:U93U3_B0ISDD\L41:;T6]IF(E=,M%*KU`&TJ7A.B7V0Y^V3C+5@X^GI^\[+;F7-G1), MU#0-WT,#)"2T>+)NQ+1B-^HA[RF?IFP;A\&6GF,UGP+393A-*N<>G5A9(9);47:;%P0JK%I@2^R0B.R:X'PQ>9 M\8;X05HEG"'XY1,#ZSJJK.[&.ZJ+.BQ!_>A`S2Q;1\=;IV4A`R(;DVX^B_2#_=,C M;@8.-QNI^YOHNX\D=!B&HYB)M35+]?W.6TMQB]->>K8:4%`80[Q&K%#K#21( M25T?*H(/JN'1$O@`3\`-:)??Y17:F<7D6A\AMGV.-T0)+EWHG=M>WM'D83'> M+1]:+61D'5H'>)9O1D"?_V0G3,%,5);9<\P`,QT9&Q57;;^:)HW@H9+J4;+1 MM@("?S4$5%"0P9,AR$2TL>A<'&,S]WGW5*'T<<_2\76L.GA(KY99<3@53R_F MR^7\,QS`9E97_K;74#RUX^PK^IN/!3M>/.OT,0=1/$+HZ#2TY@AWE+#;OPI2 M83D]7!XJ&;)*AF_`64Y$\QC*O9&K0]P$V,TQB/=8;:7JPA5_9M7O(6O5*6C. M5@:D(9(TU%BS$F8F]`M7XE_?%\8!+ZV>!"R=2E7Z?\\.9QO2%)*$,)Y<&;NN M3QI'ZJ3FT8=3RHQRV=+2]R?'WV^]YXK)=QQYTJWJ;3\N.3FPWIA;#X1415-G MO7REU^/-Y^C6!#XSBH)B)N8869G)?_/@53IMQ>*MFNF]`VI.?/[*JYFG2R4G MUIR%T65"6&-M/8$**V+JDT8M=(]^4TYKG0*BP/Y)+*I$_2#FS%4'K07%!>$< MHM#8@%PD/$'I*VAZ^ M2>C(2YEV*Z825U-AIU)P?6QT!J1E!WZ\-RBU3]J4"CD-N$TJ^L<^3.Q0]JGY M_>@1L/%J+E7[A/9N$_I9+BR3H_?:VAP6JD#.#1KV>%4QZ!2Y\TJ"`HW;I-3, M6H@,G-V-CE&,5VP08]&,1$:!9SS?(;6&O'R4&@-#0WY0",517B=2FP>!Y4.4 M5]-8D_J8Z=HQ1!F*;*NI\Q_QOR+=R05M)J,Q-\"_G*N"SWAG*]5&$@N#6]'T MDLLMN6JTRL%"4=X3CJ/2<*7RC6 MX[17=>0!N87P)(("(HZ)I!B5PQ)/&J/&VGW86@`A57R=B58P4`Y8JE@F-G5T M"79P;JW)LTW*!L<$1\C:)'2+%D:RF**DW$"3G]$]F/V/\EM%&6D.P"C=$CK- M*)7P/%VU%L=;P2(26UBCA>M!M;F,("B1L%O5\W_OLJ!%4\RD/F&5@?"5$`I* M5+%YJF8R9]R"@%#:66LS440=9&1Z2D>N7U?(@J)`9PF5K$1=%[-(SEQ3U"\' M)0-BJ-V4\"D>6$3`N.U"B_V,^+L%#5)(&B&F##WN"L`78H10*H@V<\26##^Z MC@[I`C,J-1D_D()N\R,C=VY7^$B&CQ4Y?L`GSIB M?F`%J7='[S_J=U#Z^V?'9*0'!3>'\V,H^V<=_:Y]^L,-.J&;X6ZOI_U3KLHV MH#Q5_5%B>8=?;7K#X$O3H*<,.M"/-6SC_8JW=I6S3%\(]_S&:`'D,#63.O.2 MG6UE0BCVZ(I-R*KH`":O-'X-^A'M^U71UIO[X%Q!4%#FT#,13"(!#,=T2H^VTD([*6LN&V#V5&D"^49P@*BYEWD M=]A*!"&^8H2GK#;XC]C)JMJ"M^`2H4@,EER*H?F0<3[QUNQT@1YC+4OV8T0P MI,(*XN'OQ"O;5I@GYK9"-D@%:X+`*I;RE6USN5'(J^*;$D.J7AOM-,W#35OY M+X1D4F(SV^*44D0HE+(SP185Z"4R40\63Q_95#RA$Q0-#3&DK+Q6*(FF_"?` M<;*5UACAS7],RQ&5B@;>>R6BLX9P4CZR["XSX1ZCD[K!)47-<9JPFY!5!<9H MYU%HK(<@.;NZK&M)>O;`H;H9/HR$E-O07BP$ZQ2O\B%0,-Z:6!_(6%*GF\:N MM[X_P*Z[6=7*'(3+_>TR_7;PT;!GKU\0&SPZ\MS4N6[5EQD+09[[X(!F8Z*$ M?MU2YS15>I0J=O4/1[%HNDF](MAD8%.`'6X%6&\8K8K^FN2HZN^I1<="`8U( M*\5F.5N1UFD;D;1:!E3ZC>>95E:D`Z2WE@>[@X.W<_E:[EVG/_2N#'L&%\V2 MQ`*-8N<@46A5M1T_3RP:?"+#SM!-RV=EB/`E-N MG.GT+NL(]U=;?Y!4!1ZON!](11D(3MI>.;"V_/"MEAC07KX(##P.0\!IW`$) M[%[$HW9`K*C7XU_D>VO7PU]I*0A4I)9\?@2BVRUI=OJ;RJG)Q[G)QZ]_^=_% M_HS/\`@+Q*N*>N-5)FETU"4J67;+WN0?=LM>KV.V?\Q]?AZH)E-0*9#J9E;S MP3Y0Z=`UC/324#8GB<%9C]LM='FV)1^4FP[9>?K-.6?,2\;6%"0CDF)_I125 MCH.%D>EL0H5RL"0>1P6XV^&JL`X-T[F2:O;\GJ[V"I:$E;J#Q`'!(-/KQ:9F1II:&,W@&G!9Q!?O-'RR[=`^%GE&A(9_[]L(E_6 M.M,]I#R[WO%<:NNV)CH(;3'9IJR=1+`P:X7Q4KY,HKH.=0N&Y=R2NE4QBMG- MJA-'D:1,Z;#"D$)65 M@V0`''EPA*M`,TL4AY#O4;E2<0/(W.DV"3X)`W!>,<@3,XEN-7D&70MJU MI+'0;`!0%X`H-6$!. M,@U,J'.PJJ=`^JA6DBJK+G:\VC;@60MD\@DM6"))B5!*W0V>W[5`H3H;KQ5P MV2AD5FNH?.H3BB#<*F5)F M2D)PL0$1;#I94)/))N@Q1%SQHC@`I;?^' MNI_@Y8O7>WBMZK2O`T+]8H+>Y?^_,5U/.U8,K/H$:NR'5)#GQ'NFIIEC.:";#PQG_VCUYL,([D++YK`XA^POU ME2Q0Q[C.^HB)L"8-&H2Y/2S/8Q>XS72-A'3PQI!:!W31=<2;?QA82C^`I-$Q*(UC:TT];/AK$>H?TX$!G^P[)1Z]ZC_*4R908C8+>KS^R:))-=]YWF"S4,9A?/LU!S,+8G'`,U.=2WM6.A'9*P M_J[_X?3]R1_[?7[][9C?L#WGQ],&#]3)9!=IF*5!#('7AA5&D"Z0NPU?2&Y1 M6WYCPUID%I2X<'3VVP4BL2X3!QO><06]OC-SJKP]0EX5:0+_3$$$#,,/CJ#> M.'Z=$2.LJ6N^[A@V0YX6+$-3G?[&](5;PE-=@NY#_Z%@MD9>&YO'(0/JMT'= MM!?KR/`1V:D1P1:M;>8SGBF2L4]\]>BC@)#]>76X2RT4Z06N"PM(RL0GM\UJ[%\FJ M_4/V3G&V7__=(C=M/]+]03]<:7>!12L3$8*90)Q)[$^Q3$'L6I`F:5)UJ"O< MKIH&]&EDKF2<]7IZ:41>*MZ29H$[>14\`0C!1C)QONM(^KA'=[KZQA\3K.%'Z0^Q\4!%OB!`6^@4+\9SCE MIY>,<]&[A]SN>+@>&A&S8F!0$G6\V^\B139*MA*F%T,IIM!_/.9*UBD>0C^M MX/"IRH3HC"T/2AC"+QF&9%*5LF&1EZ6U4UD.B%N`]&,K>L./7@?A\0]"\:_Q M3@POV*'<`:NT(V=\[`>0>5=H():1!#(K@0W&ZBTWE/U<#$:$^DCQS9S#5-:; M2!Y+0I[*'E65HYXM#3!1>7BZ2<*!H^Q$3_TDCP=*:AUE M_09"&4N!E5!Q.H)0[)J`?CIBM;CB9JUD'-7#+(>(;N%&O8+?R1 MR*DY,<`,.84PAIA!'PCW\A")22;'8JH;2Z=": MS#I7HV<4Q>I+SI:H=T4+S')*E<`9:]"Z,"943RW)]F-H&',N]U*CH'2N>5XP MC=-]86^7*)BH9",X*V]:8YY2K(YE\IN+I9+O=FLHJ8,T#7 M:7&.E4N;OO>S:XI.Q2D9.3$99<62WKW_4)YE?'2QJY8ZW4!N,G/TD4&?ZI<< M;)8`T>VH:[KSD,3SFF"ZD]QA.N3(#9&#)-3=+H>W,2-A;3%L/:%\HE)MVGX_ MS`M0?/OX]5[OF[V7]LWC;_0[;)66>F&-^C%>(";_H1:R=4_=O1[J&][Y3]W/ M+K]`N/?-GF]H[\4WO6]>5#OZ>^Q.QX:^;;3:_N%:D?\]4H*62*`2GTR-0QK8 MM)SR8N@L&BL]PVE6&LM(B]?C9F6N@])@IE*3J2M0I[P@>59JU$\W[)\<'(%\ MGLD*Y=(3!E)6*$/;]PPJ`Q(2./FUEW8NSP]=U[1'\PJ@D]D!ZB@RU-<=LR9) M]6).4HY<:XQ:Z3I>ZTW#Y@3UAFA1AO7UQ]9`;OSIN;6A?Q?`&_=3G: M,5)`SRC+_Y\4PW[!@K%"M$F4H;.(#; M/SHXW3=A%M$&_0.Y[C&7R`.O[/B30C=!K0L=0%,'*$-DQPC7,&0)AO42[O(1"\1Z&FR16^%6QJ@<+JM_SPT(1LO(^-S?@D`F; M]3<&VY(M4=8#G21-_!:"73K&8Y0`B:Q_H)V0%'@]96F!)"4< M:$NNV$,%R3L%:,QOQZ,R)$'M3)H`>6YCS`Z)61!$.U-=`.Y&,HD)\0[:ZG*A M5/"P5%K*L;';F&[K?B\6-Q!WH^,NJF_&7!JPQ7\92&N)4N@JG^XRN(=O MG2F'#^ET/]K$Q&2ZS0GFI\"8$QMWIGEC4.7H"2V6IH^3?<&-<[`'+F,<%B5]O M?.;OHK1<2VM\3P6*X*#X5/KAK9CC`=ZBP45K75A)GY;=VJK\XPJACI7PG';*W/W MQGD1-E#;^&'=X):%&7=1O`%3[^-`%>]50='S[2(=%?RV`6A.ZXW^9G?Z<2\V+K[I&K41Q%W($D6UX9[A)Q<5Q=N4;J.78/-_QKW<3=#[F%3 M7VA`*E?-%W\L^;$WDB#-SQU0I^%:W[_7/0%U=[+`/OG)SN9@3W=[+U^]Z>WN MOFQ^TZ*6'MU[TWNUU[J^/`J,24I:&'<-ENOZJ);#K!TT#?D"Q8WTUENVH+(= M%JT\WMOKO=AY;F,_AEFO@/=1^+,8!81IX/A+<@GULZY?L(17KWNO7_#+,YB' MQZ]?]5[M[J8E5$'%?V0%$1-E>5"5LOXQ2]8*20'98E/.!W$/MAT7K M3..G8^DO-2=PF*[7&L0J5DO\CD_.^\4+K,"7CGZ>.3:@A1RX&W+LLW[X-+/A M%YO)U-*`I+?T:Z\(##Z$`LJ!9:C203T^K^(-#8ACL;`E9.W]4%$U$\-9C@N4 MD1U+U$<]FZ#XLE.H@B6U$ZB.6O)E69,*'K:&P[R`@46QOLCP,Y,/+%5^JE&7 M?MU[\]I+TQ)4X1IE;OV2@:IXKUW%ZH5V MUTW0"^&'Q">-E?$S[\]#WW%4W=HDP5^G2XPCG^M4@FP&0065P*C5E9?&NQH: MT`-P(_[$-7CJ\?.7JMKKOSZJ!,>%B#-0I,?-WY(*`XA8DEDNIWZ^MU,40P#Q MM[\BNE6^W5K4"$NTCIO)>$R"@#W2V/"R$Y"=\UC$=K8.4".9PC^35N`;X]A= M)*J.YW,[M,VB5[+-Z<7/(/7;^$/(Z?@F6A+%T?-""TA6W7S\4G''/5_KSKWZ9%,=4XX3WSOF?V_GF=O,+/]!P)9IS08S=A'TP)VGX?HTM4;:D M_ISE3?S'+KF9A62;[GX@/HL7W*31Z.$>FL(9<7+Z=EM./BE1*ENR2;$T7!/O=SHI3]]8 MDHY(9[V.^BD8'6(@&R-6>.XJJVCJET)0EY=N39XVM/F-J]&S_\?;N>[$<61Q M_%7F`Y&]$C@,P\5XI94F,':(P+`,=F1%^X%;8E8V("[Q.MJ'R;/DR?;W/Z>J MNOMT-S,XSGXRGJY[G?NMDK"?2@=X/7BF%3P>PRU6=L*EVC/# M6G;[S,F"P3C%J8HR-0$*8]E'-F(T=))=E/6*'K0 MP19&*XGJL:N]XQN`"L2`%*U49^(P)*I-L+1+8=KL#C81LH;/5"R7,V:J"LSX MR^XTV^\Y;Y3TKG.PC"\92##`WV"CLN,UT7L]KZ-[,K0SS`JR..L[`2<69]5U M"S:D!X\-?=!59TSM'N&;5Y)VZWL!-PD$70U^9M\C/D9SG#=;S="WB# MDX8-WMTE%$@-%XG0W'V2"/-O MC!^I0@XYKIGM5^)RDM<'?3Z%%X5X3^\O;Q7T,3A`2:B]3E*1;*%#)O4)EDWM M4B=:&5T'8!N6A60H//410LDVQI'E\H4EN0I:*AJH^:9OLZZLED82-,A MC8;?&/@-5[\Q7(:$"`-5+K&LPX]S_J-\4'PS=Y-;J1`"#<7FWB!G.OOD/>%M M8;B&'HSV#%\]@HHVKCI0GTA!54W2BM%5 MPEX>3V-LC98O7,2#OL&AUSD!'2S=3$C*14/HLQFP=P%S&25Z+G.U+));]44H MW.TTO[VC*S:RE`6U2E27!/[&1749#S=0N+V^T&"7 M=Q%XP>2[W9U7%K768BG;>IYA?NE^0X:#><>>(JS8TG?-)OL=D4/9UE%9.HO4 MHV=0N&O<+4*SS+"@_U+SP-P26H&D:?G"Z>4T-^XJEJFJ^F#O>2';Z3TOI#MR M1C[80LPH<:((IBP5PZ_$NR`TH@C%..:T3D[>4GW`RW@DN:&G&Y4D"?S132ZL MK.,:>@X1$.KT-5=+ZR+07!AM8,(;XDEB$J=;"Z/1ZN)H?T$2QYW&ZD@&I(JJ`IMJUF;!V:+'$_3J4ZHN(FEXZEF5F1%5B11S5MC?$]S873@/XH,B@Y M^!P@#UQH0Z?(.F&".EO^=\E]/GU/"IQS4FP(7IW(DQUQ6"#TXI+@&30/-R6N MTZ;2@@S6P,0TI?U7[>Q>#$2&:/`;RT.Y\]A;VWCCM^8=2\:`CI$3YUQSJ"#G M22+"^2=K?D-8,8?^@6+8I'CYF:/$*UE/WD"+B9/12<%U[J+&#F532*Y2J"*U MG%PWQ/9$'QGH.[-]?%TZ;*(?4P#CFALQ[-)+:B'1-1$@9ON,.HV21/5P+Z;M M9LJW:]S_H$;YPG6NIXPM-M)-!R,,__%[RXWW'!O#T?>4B3D8O]/#B"U!)\WO M#(E#N;&8P)_&)QB@X(G_BG.\EJ[]'''GX6'W.2]B_M/F^G9@AUTC4";IC$2> MB^M#Y][O.!V?\9HJ@&:29!:Y6[Z='WGB3V":EA.WE"_$$3F)!N"'/`(8`FM" M4^QII#+^2$J<)4=\O[^[C;'BB?F5C][%9G:0FQSD/(T/D%V\_L14NGY;7.S# MC.X3;N*+,,6-;48[,``B2@ODP(HTJX6JUA_>=NF2,ZH]N;>PC,8TS.Q6!PZK M[1_-2]S;`NOE'?M@I<5L$4I4)N@O.A`W(H<#0>K6E%]X&KB3GF.^'&X.\ZG\ MN2,PMW0&A?^+2U;N4Z^Y<4A*`5;1V]KT-2J4'/\LA9A45./T,$>$.;T)>J*J/;*(*Q7.^.89[@R+@DY]C'0B M*'G'(NJ6VM5-,M*E'5ZT`&S/"XEAS:_%?3('TJ+EP2(.6Z"J%2BW2OU_CTA^ MT1YUC,CF$5CFF];"D,"KDR76QHSFX*!.6%(XJ`BG$7FZX_%MT]WC@2&(-XK! MNKQMZ==5^";I^2"V&%PM?7\1Z4+)QW9"="NA7S#U-9],G^HJ0)4#F.67CHW/ MM7-NE<@DB7742\'NVMBZ51!WCEV),89[M3C"%#&):8IA+G]I72*@V,D\(PED MWPV)P$(9K>]"B65,I`VE%!=.[5``3HMM=?'"H%`*/HD\.L]L7L%)FY`G[+.T MJ,6%S#(S=]K-C10.]JV"6$;,RJ)@7[OR9%R/Y(BY\;\JYV4_.W%&V9K14-3F MKO,%E.>,>E9;NP/33;=>[KL(G;+%(%">?R+;/J(MXJ>>]L"4Z0Y=(&,T6AR- M1ID@RWF)1I]3R#X(XVH]DIIK?593'YXCDO==,BNLP;"(8O!WW/\E.N*-"@$) M`FW5AGNU0BM5&X^DQ)!@)!!LU@!XYM-S)\`44HZ$(ITE%Y#N2 MLB]*$S9X55H9*7GF:K/%M%#E2*)6[=$V%WISXAW%Z%`^,0FF<`;3[[7=QJ"U MXOD=*7%)4<"H3FQ4"FB0_T M=C+)93ZKU,)(F;^)/Y0^A;7$%HY>=A7Q4^EL.B>/2CJ':`6CC?SWV/V0UR.7 M>,B!L%UN*'[5O>@))6]1]'^KM2G3"YICN8PWSZ9@@((]Y23X?'&.\>+T'CZB MHTLQ])D@57$?'7F6@!C3YI*!#C!FL\O'DP8'LCREL"89R=*BJW.2`O/^C6>\ M>!9.DCHYE6<>R8PT#N$L;%RJGV+^99Y))22DEWH4K[S1%+DI]V_%5!W5&U4& MJ_L6"K06UH"P6LIJK9NOF=5MV@VRA5NE/\Q9E;'![^IY"*A_.7W2)4S)!14"> M^(#Q9Q:5Z%[\LA1_L/4WD1^IX:-2='Y#M#'A(-O_ZHE+`$^68*A)8/7M`11W_AIOU:K'S;VPS'F36@1 M#@P,:ZNQ]2NOCQ-_SEL\BQ^VI.\3,W3V+>"IR,/8($S?ML_$#@9^[A*L86!" M!M['2X<-B<5*'&>O!R#.[0)=[<3-(93F<+([5H7?@_'AT;L!KU)25<$>14D1 M$/M[>SM'*KK?LN,T;:-$/3B8?<2..:(.G)WW2IVRW7R MLFBQP-_KFW@CF;\6_``9\14EE;2?>L[A3NZRG0[74_3%D(C_.2=OH>(7SDW% M$-_[VC)Q9XV-=S&]A\&[[C?(X#(05*MRODW32)/39=U5^%(%$GQ=?$BC33Y0 MZ0S^`1(@J:#,)`1)_LWY,`2AH0"NEY$V@<'?1HEH45HZI"(S/@;$QX\"YD42 M%T>+JT39K3W'L2AHQJ.^ND+Y2A M,#&)20]H\?,"W\+&YN+R:#UA&XKIYOJ\DWXQP"\,";[?6$VYYT/2.Y*-00\YS@'2[S<,(D5QGE3%!$P0-EP?D^*J( MF22.I";@'WZ/*=&-_.@>%N=]`30 M,P?\X^I5E/WZ\O+2"1!3%D^/Q'86072R4.QJ!3"GV"6$W(W@?)`%#!*C\-". MA'0A$M^TL&J*['N7T\024%@`'?.1;>6?Y=N:Z/G<(\]O"]Y=D*C57;&)+[NUN M7(/X/1X[1*XS3#1<$JQ$*BPJ"/884YEY(YG_%S67#!&K8>H%A2ODGX(BNSMR^Z(;P#T8!3*:*8N/KJ\NENKSS.388+B6W?_RP3FWF;CO` M<+@T[.DT7%^BBHO9G>-X*SB#?=.?5ZYV7/'49DOWW=W?T@/'@ MZ0&E?Y2\T)+IJ1"PR^M-UED/\;5ES,G;R>LWDP$-]YE$;>):QEM;E!0XFJK- M9.>M7(ZQR4O>C1J\'>\R$,M]N?-ZS,O*XUTRN?0$8*=P6^NR1^36FT,O61!' MMLS]U[/?6,-[=BQI-AF5FF+V+Y1YR%^?"0V'4FT;N/2 MU(P22NP83"E%>H$[03::<>6,R6A(66>-$)=!*3$SKHC-F#8'*1()'U?5>&*7 M42TY>O"T9V&3'+DQQ[RE;9SIH4C*WIFSFWW7*/M^+:"GYP0L5]VIML4F]@?O MU`^K=YJXB59H1._*/9CAP(,9;N^EF+E.EAX7_4A, MWN;%@XL/;51.@5,6[[CGR57_'9#^Y'_'22=UR235LY05008921/%O8ILJ!PJ M%/HKZB]O%_4AO>-J\N6UE8J1M"99L:LL2)R^<[$,C\WT^*9[Q7(]6V3C_L_[ MV!#<3LUU&!!+!BXUXW9YPW#V"7SA>`\O\LON$NG[1AOZ]?QO@Z]:7''E?FM1ZTEQBIV0272FX'$$V:M/LN'$0;?SVU.U MPFZ756678NBOU7O,IH"S]/P5(C4*'^^B%H]?G,2PNLO$;4G'L77CEM%L$?G/ M[:'WV/#'9D6@^-EF38;UWF&,4S?N/K6'Z]('.LYH+J$':_"AZLD^T8!;% MN"ZBUBLI#)ZF>YECKH:"N8.!-CVFC1)N]+0:(FZ[T=."7A5RUVKE$;+VKFBV M?L8V5?KV8U9.()+E0\]<*%*;)3VB8LLT1NYW"W!FI2P^9EU9=9^9J!>/X8!H M`1EER#5&:FPG:\7V'O]-W-!]BTCE-?38U`<_.1]HA8@)T%+#,"M-V_VI@@ISRSCOO<( M9@P79W]`EBY`T\N]FL+N2W]C-`M)"*QFY,)#$R?UX/JMY&>O!.L<7.]UHBK9 MN]6_Q-?'EK5(_=CI@9UBELA82(6M'E8]:]&G]5CZ1TQ>S3U;7&@>>*7$S$'M MZJLKUF:/TXN'&!>_I>(GH+0DD&N[4^_7V'$+-<"H6FV^&D=@)+O:6BA[G+%# M.4H7U'L]3:4G'T@]`>NS6I9` M]ED-;STZWB.WYVQ\545$Q!Y2>;'JN!*>QA[?$W>A@)86)#1:]RZYB?<>R!KG M?:Q"/PL[FYI]GW2`S;P1(_"YEXE^X?HJ8;,7/YLK;01*1!O$3'AS`6I0^=CC M,0?G>/R<^B?+4OQ:.K6QE":8L> M4$<215F2S_(A4LPV0.H>+BY:H%<4M$39O/"AHZC$OJ+_>V>6KUE1))?2BGNV MD5BDN#/??//8!U_7WSW[GO;%B;9N&,STP=N^KCG!,ERYP>-,__N]=3'1M6UL M!RO;"P-GIK\X6_V[F]_^YGH;OWC.IR?'B340$6QG^E,<;ZYZO>WRR?'M[=MP MXP3PS3J,?#N&S>BQM]U$CKW:8B/?ZQG]_F7/M]U`3R1<^4L1(;X=?=YM+I:A MO[%C]\'UW/B%R=(U?WGUX3$((_O!`ZC/`]->9K+91DF\[RZCN MU^[2*:.<]J8]D'1S'>Q\RX^WVC+) MY%YJP6#:VA-99J&1>+9;^APJ$E MD\H&A=:[\?O.Z)2OK,JZM`QWE0&8<')9="%U:_)[;.%O%W'2<8=V%H^5^S*6 M>45IO'=]9ZO=.5^U'T+?#I!7VJ>QH[DNF<;=>:3O2`#(UT##2[[T+'")Y+1? M,M@/'[M MO>2XAJ,?(_ME8+!1B5B#;>BY*T3QN&"CP-3:Q>6MM;AE>@DR41050BUK,3Z# MT-OY="$?Z6(ZE2W4L.!7LM!W(_R5+-2"GX4T3M,Z;,H"FFD`D+XY8:HZ13`$ M`./1:#(:3`T3_K'*?WX$LCD=Z:J]2A`H\BI!H,BK;.+0DU#YTTR!-13%N4H0 M*/(J0:#(JV/)%7BLW*L$@2*O$@2*O,J&JA)S%=8F%>S6;5BUN;RVV^%$>F4D;'Z>Z;-<(\]2&,5G`2 M*3LS,L!3(\F^FVO/6<MRW0?C$FA$;IL-)QP&N9(T'(IUMQYZ(76?8`OF:N9IP080$UE("+:0 M86.Q!BUJ(VDA9B-I(&@C:2%J(Z3.H>3*F%R%.S@?NN]@RYKT^\EZGZB>>H$$ M^(&(.0R"M"GSV=CD`*.-;=K:"O6EE!MS`W_9Z/B`I0TMRG8V-#A@94,+41OY MN,F\RPG/ERZP/!]`LLL%4L+VX6EQLS5F776R_\]S'P'?8$IF>B/D^ M"F-G&;-+0]CYBBH\D;G$<0@)"BQ%JB$`'"40B"-@)48]!D4],(T&15TPA<#UP1WF!(T& MKH=4A`'P*,F*8IPPX'J,#FD@$%152!(-AJH223&HJI&%*PQ5)9)`4%4AJ2=4 ME4B*056-)*Y052()!&!$286DGE!5(BD&536R<,5058DD$%152.*)X9E+9(\N MFR:+J&3]=(QW(E4M/8*#LNG_OJ^>UXT+J8.J21/(RIHGLZ=DY@B^8',I,I5& M<':V=JH]A9'["TPR\7:I)2RF.I&.M]?%[I+N^1K9FWOG&::BR1F8Y_5)!C9@ M*O3#"KZNM5$NG9\3L`AXNH&(1LO9I+YQ87XO,OC%[<8(:02!BSNJ,2#7*0;I M(2`I13!S5=,$G:1R#-15B"==K!;&$Y3@I(?-T42K;EH:9$-8"LEIPP_W9"<\G#\YBZXE=\3;< MG[0H@%85ACRVX^*09[/KJ&RRH,[S76.%Q#J]WK6M0"2;\>-IY:]-L:VL'0"C M+@4JZYA2Y71$\--N&[OKEW;#5%S)$F.?#]E?/QW9'.)8_YRC=C=B84/&;/A( M.N8&,"(=,U\0*_U'(TJ80C+PIOFE!C6[3HS.'=O/W<29Y[/B"(XEHSU#K]X8 MM*26<]X_`Q:IT5F/[TPY]>OW-^58,MHS#(,+UO&($P@%J*AU'^5\J0H!;EW"50_:V*=4I6XVC M1[$$+W'S.A.<[XM+54M)9U;E@`:LK\.0YLC$(\.B09PKR0D&JR00O$Q'4/563JH M'B?V9D*U5GB(+82SG&HBT7%4R@D#%RK#<%#=Y("OPD+$GEK"^'AMA4^8S\:2 M4,5=%^".2:8JO'Q_<)Z)02.90-KZT,FG!G`B&<3'I[#_7QO%I^*5/56A>(ZI M1QBNA\[-E\NHL$L;HY"F2!4?9?U\]RB,YE2"\!:(@PR!%77UNK)"-]*#IF=9 M6N6>DO+#*=H*!+O2&*XM)D]JX)_3D%^)K.%3D^$E#_W?:Q?:NR7&75[0!N#1 MAYWKP9//\!)CO$I\"=UULG"QA/F#6PR!-94*;:R@()J2R\55?B1C]6A8*Q2684?^5A%D]OB M*OP(4@E?)GS15E;A1[Y.F()U@MI8^)'G?B3(_7Y%Y2/>$(SX1$KA._A$.,)5 M/Q&.$BF%U_@H'PI&>2*E\!![3<>?":IA!?\L1NQ\%5%V(0CCQ$#%H\.KI0+XO,! MNU$10;?/&\\.[#B,7C2\!2<7QSM])"CNSV&8<\1+,&!3!-!?X)58\+8M#7A) M&.)C&*^E:R,FSP6>GH&@QS(TT#I!P\XA MOI9BURTBXJ,;?'96?.3P#!L`4D32G;.+(SN//SZE#$%B[O"97+D,OD2P1VSM MCQGOX!%<&8FX-D1R!\?0(L#_MHL)C=B*"#$$Z]*]&\-#!+,DYD0@+!$<]R'< M%I>+V*LH@C+^84=@BPX2F`F1&] M;?X&P)O_`P``__\#`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P```'AL M+W1H96UE+W1H96UE,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$ M;H<>:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8 MRTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L; M'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3', M3;B(L()7$53&`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ M`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K> M3!`6#? M!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`; MU69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY M$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^ M%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0` M]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N M,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7 MZ0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X#0[TJ=?L>FT1.[P M:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1: M!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W M1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[ M6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ. M&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y M:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:< ME,7*DB):#QL,^NQXBM4*W%J:[!MP.XN3BNSJ*]AEWGL3+V41O/`24#N9CBPN M)B>+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N M_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H! MT0)7O#`-005WU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/9 M94FRE)")J(*X,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3S MS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD! MS`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4 M(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F> M,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;Q MT7UP]`Y\-I@Q)4TPP:&PO=V]R:W-H965T-"XE- MU^2%!-_CPSWGVKY>WK_4E?6,&2>T26QOXMH6;G):D&:?V+]_97&(?A&@7CL/S`ZX1G]`6-Q`I*:N1@%>V M=WC+,"JZ277E3%TW)QWU"&=A7H?O$"E/?(LLMIW5LO/G#\$G?O'?X@=Z^L)( M\8TT&,R&,LD"["A]DM#'0@[!9&DK)ON#@&J'($CJ M6A2O*>8Y&`HTDVDHF7):00+PM&HB5P88@EZZWQ,IQ"&Q_6@2QJ[O`=S:82XR M(BEM*S]R0>N_"N2]42F2Z1M)!-F_Q:>3Z2STPN@ZBZ,RZ@2F2*#5DM&3!8L& MOLE;))>@MP!FJ@];_206-DN1!LB1V;%LPG4-YGE=!Y"Z=9_`T?\.L MQYC8UR&;'B(=E+QI/W#F]?0IVQ[13\G40&>=`QH'H6#?I=#W2]?KD6"IIV== MJP'@'@1.]40V8T0Q61?830G(!4;Z^]!"NA& ML:%?Q>$Y9WWT/4\UQ7",W:Y8@DW%QKY=*TRD%/N!%X4S8TML M%.2C@E\GV5XER302+YAZ?G0NCV8"G,6WFR#!I@E&<=8*HY9\/'?]2"_MYC(> M^/[7<2]VX\"H[U8#>#,W-C*`!B^S?-]CI5TU<-7?:LSV>(.KBELY/\,;[V%M",QN.IMX".`^/.,`'Z?(OV^#MB>])PJ\(E?,J= MQ+!$;(;5`,``,H+```9````>&PO=V]R:W-H965T68!JE3EM%ZGYA_?C_> MQ*;!!:XS7+*:).8;X>;M]O.GS8&U3[P@1!C`4//$+(1HUK;-TX)4F%NL(37\ MDK.VP@(>V[W-FY;@3!VJ2MMUG-"N,*U-S;!NK^%@>4Y3\L#2YXK40I.TI,0" MXN<%;?B1K4JOH:MP^_3E9#W*_)Q>N16 M#Q/ZBJ8MXRP7%M#9.M!ISBM[90/3=I-1R$"6W6A)GIAW:'V/8M/>;E2!_E)R MX&?W!B_8X4M+L^^T)E!MZ)/LP(ZQ)PG]ELFOX+`].?VH.O"S-3*2X^=2_&*' MKX3N"P'M#B`CF=@Z>WL@/(6*`HWE!I(I924$`%>CHG(TH"+X57T>:":*Q/1" M*X@<#P'*;:!LK=$ M68+'RB=>K:PQH5+VT,I;.:B/;:#L+U&6X+%RW/-J98WIE(-X%89.CQ@HP[Q= M7VT)'BNO>EZMK#%:&?FQ&X2GV`;*X1)E"1XJN]&XSQK3*2,G=*+P!!E(1TND M)7@H[0>GE'32&@-%[\3K<&J.3CAWO'=G5$ED) M'LN.)UMC?#79[TP6`MNX/E>%'JN.R]R!YF5'#C9?8J1M:6@@XY'N0/.RTF6N M[BS2GG0N.YWG#O11;]$BVU+H89W]8)*P-JXKYAE)H[D^;6U+YVE/)UI1)J9. MVXUBL"[O\I])OG(7B%]RK_%<*\JC^*QEHT7^I=##LGO>9+S/'BP^Z;GVL,X^YXP;-JLE99^ZV(51UR#]CD;("=S(&Z\'>AO3RTJ#]^0';O>T MYD9)Q?2#8(U:2G9,P`ZE;@O8F0EL+(X%X)PQ<7R0VUZ_A6__ M`P``__\#`%!+`P04``8`"````"$`OG0QA&D#``!P"P``&0```'AL+W=O-!BX)D.*79 MOL:-T"8,5T@`/R])RSNW.KO&KD;L<=_>9+1NP6)+*B)>E*EMU=GR8==0AK85 MQ/WLA2CKO-7%F7U-,D8Y+<0$[!P->A[SPEDXX+1>Y00BD&FW&"YB^\Y;IIYG M.^N52M!?@@_\Y+_%2WKXRDC^G308L@WS)&=@2^FCE#[D\A8\[)P]?:]FX">S M2BS*V@^DDFKF!!W)KB[FX)]+2MK(]%[3^IT4JHM[$/YJ$0'\<]R?^//*B MZ?LNCB92`:9(H/6*T8,%50/OY"V2->@MP;F+3'/TL5X*%6*4)G?2);9GM@51 M<)B?IW48SE?.$^0T.VJ2UC?`#E7S,*A)#V7!&XO&<`&'X&58JB.$[8P7/2^*BN)UL!D]?S1 M4+%Y5Y&.*0;T\)KK4RW%L0VIZ).,4(LC^>3O6]\&Y%B MD]C8%!*MT;4=O5W;6C)6'Z,F@XPO/L(OQ2:_L:P2K;E8VWIXC/VBP8#;@P/X M^L0KM4D^'2Z[Y"B:ZVUE&L[=^6PHV1PE8_A#%SA97?]U^0]#D$?3U;4#O8F9 M_&!A+M"C2(<0S`-CV]^\,RX;(/F2M^/3\+K!T>=_C=D.;W!5<2NC>]F\^)"\ M_F[?6-WY\N0T[B?>$DYKN._T`]#OM&B'?R"V(PVW*ER`I3N9P7;'=,>D+P1M M5=>QI0(Z'?6WA,X6PWGO3D!<4"JZ"_F"OE=>_P<``/__`P!02P,$%``&``@` M```A`$P%[]*_`P``FPT``!@```!X;"]W;W)K(?#\$AU.#"*-.6CTSTHZTVCGLM4D,6)W$6=LTW6\_Y3@$ MVX'9<`,D^?/7Y[+++M8?W\HB>*5",E[%"(_&**!5QG-6[6/TX_OSAP<42$6J MG!2\HC%ZIQ)]W/SYQ_K$Q8L\4*H"<*ADC`Y*U:LPE-F!ED2.>$TK>++CHB0* M+L4^E+6@)&]>*HLP&H_G84E8A8S#2@SQX+L=R^@3SXXEK90Q$;0@"OCE@=7R M[%9F0^Q*(EZ.]8>,ES58;%G!U'MCBH(R6WW95UR0;0'C?L-3DIV]FXN>?C1[Q*\1R%FW63H)^,GJ3U.Y`' M?OHD6/X7JRAD&^9)D>TW6M!,T1QF#@5Z1K:SQ7B"01YLJ53/3%NB(#M*Q1XO1-)HM'NYQF;0N\-VZX&@H2FB&U63LB2BR60M^"F"]`KBL MB5[]>`7&U],"^=#:1RV.T0(F+D82YN9U,UZ'KY#]K%4D1@&?G0*[BO2LT!,( M#!T(Y&8XB!9K$#U?FBPQ-^RXD1>WKYAT"@<$LC`<1(MA25CCG7:NALPHII9B MYBK2WRD<,C`93J;%,8)1=S,Q=^,F1F&3+5Q%VE=\ATV*7#/L+W$AL-.RO\+[D!AL4TO"L:;''YBWQQ$AF36%. M\1)[SU/SW&:_`:9/S,&;@A9[8)?*,C5@)'9@[)5)VI?<8%O>PZ;%'MO%UK`9 MB_68M)K?\QD?6W.+3V_6P_G,UF[S17[98J.Q8T=^W5[1W.+3 M6_9P/K/!.WQ>:2:X?PA$7A6E5S2W^&"<-M_`=:C?KGKW-!MF\_G!4]:C5\17.QJX?SA$O3KN:WP^T_J:1JZD8D]36A0RR/A1M[(84M_=[7KSMFGN'D"76Y,] M_4K$GE4R*.@.7AV/%I!E8?ID]`N!^A_%$PZLD@ MPIYD-]ELSMF]1JQ*!JBA.,Y\^WU+U9F^78]M2JLJ(V M9<*\&9/!]OLBIS'+SQ6M6QG2T#)KX?[YL3CQ6UJ5CXFKLN;E?'K*676"B&U1 M%NU[%VH:53[_?JA9DVU+:/<;\;+\EMUM/,171=XPSO;M!.(L>:./;0ZMT(*D MU6)70`N$=J.A^Z7Y3.8I<4QKM>@$_5O0"__TV^!'=DF;8O=G45.P#?TD>F#+ MV(M`O^_$+CC9>C@[Z7K@[\;8T7UV+MM_V.4/6AR.+72W#RT2#9OOWF/* MLNH_29%KEDQQKBDNW/[UN#-Q`I_XTR^D>-<4^+ZE3"H6QD%^9Z)%Q5&+]2+BVBL02@<_[A5#(1DLD6B(=(BSP MGXLC\-4O%\# M$1LMD6B)=(A0_,"-C/. MM$2B)=(A0G$$C[SQC@2,':'V19*1C@CQ/1[40V-(/1Z&:`[%\OB0'RV1:(ETB%#\P.MFO!\! M8S^H_9%DI!_7]F%MB&>92@1N:*-1&$MBR)&62+1$.D0HCL3*>?1;7,#8$1H# MD62DHR=8,04PU=`P0H@33!T\TR0R9$E+)%HB'2(42^%7+`E8M>2B81))1+[. MB!>0T$=3<:T0ON\[#X]K20PITA*)EDB'"$41@<7^^)'4T4A2B"U=H8$FKO5( MK$D6O.S\LDST;+N.@*#1J3.0-( MW)/BX>?8I@="\SS1(^D@HMH2R\_QMN1B5;6%YE@$E:R8J0,JUGHD[D$\&[TY M-CW0@RWMW8C2^])][[VD?^XJ>K0_ M(G.H/Z`40?O79`YEB"CB[P>@`C]E!_I7UAR*FALEW<.E[(DH,];>-L0%[O_>K/X'``#__P,`4$L#!!0`!@`( M````(0`"Y%V#ZP(``.L)```9````>&PO=V]R:W-H965T#"$A3112-4'=K;255JO].#O&!*N`D>TT[;_?9YRD MP5302Q+RY@TS\VS,ZNZU*KT7)A47=8)"/T`>JZG(>+U/T)_?#S>WR%.:U!DI M14I8(>*E9K2R)9233H5P5OU)FMHI^A MJXA\/C0W5%0-4.QXR?5;2XJ\BBX?][609%>"[]=P2NB9N[WHT5><2J%$KGV@ MPU9HW_,"+S`PK5<9!PM?G\Y>RHKGY[JA#';Y)G/WC- M(&P8DQG`3HAG`WW,S%_0C'O=#^T`?DHO8SDYE/J7.'YG?%]HF/8,#!E?R^PM M98I"H$#C3V:&B8H2!,"G5W&S,B`0\MI^'WFFBP1%L3^;!U$(<&_'E'[@AA)Y M]*"TJ/Y94'BBLB23$\D4U)_J$W]R.PMG\3@+MHI:@RG19+V2XNC!HH%[JH:8 M)1@N@=DXBR"?CYV!)=-S;YK:5D`KF,;+.KH-5_@%(J0GS*:/F701VSXB"KJ0 MM`^93R\0#!8N/B"=:Q_#^@TX0?!YI=]1M[$8B.2"F5WNW*:P'46D0XB.^JBK MWDPA'IV":7)=1%V-&XN9MC.*_?`]/&NA6PX:R"^;=3;)URDX&J5-^[^Z( M-T>]\R"=POR&'T2FR14?=]5M+&9H!*.(=`C1<;'HNQ@?@6ER7;@CL)B/M\!` M#4YUP^WV6#RFK;^#P``__\#`%!+`P04``8`"````"$`RB^8 M4+$'``#8(```&0```'AL+W=OV/]MBTD*6)+V@9LP#!TV[-BR[%0VS(DI6G_^Y$ZGD3>J8Z3]:6J M/Y$4/_*.I'2Y_?CU>)A\*>JFK$YW4_?&F4Z*TZ;:EJ>GN^G?G[(/B^FD:?/3 M-C]4I^)N^JUHIA_O?_[I]J6J/S?[HF@G8.'4W$WW;7N.9[-FLR^.>7-3G8L3 MW-E5]3%OX6?]-&O.=9%O.Z7C8>8Y3C0[YN5IJBS$]34VJMVNW!1)M7D^%J=6 M&:F+0]Z"_\V^/#?:VG%SC;EC7G]^/G_85, M6=I9EX$_Z\FVV.7/A_:OZN77HGS:MY#N$!@AL7C[+2F:#404S-QX(5K:5`=P M`/Z='$M<&A"1_&MW?2FW[?YNZH/V8]&T68FFII/-<]-6QW_539=,*&6/E.&J ME:.;<.[X+CSKDJ)/BG`E10^87WA20`IP)87+#X"['2VXDKP;W'B+T`VC5UR+ M2!.N%UV;J4!V>4GR-K^_K:N7"2QV"%ESSG'KN#$8T0E1Y/H4?2]#D!HT\H!6 M[J;SZ022T,"R^G+OA<'M[`LLA0W)K&P95TJLM03F'!@*FMPX*=QSTLU<*">1NFDM6ZUY(JR46DEI(QA'A,FS]ZUU&8>FR0J`J M:F_6%I)82&HA&4>$?Q`,[A^6J?GB9@Y\WEBIT)#T72%8T=DB6ACA[H4TP<1" M4@O)."+HX#S#JN[E%8+"TF6%\'!;2&(AJ85D'!'^P6:YWC\4EOXIQ`CIT@AI M+]2'U$)2"\DX(EQV(8'7^]Q)2Z<)"M@BMJ'$AE(;R@0DW<2.Q5*O&FZWDMM] MN?F\JF`5@LS(DO"AL5*[56T/"I^.W0J+(&0A@(H[+./(,6).4NZB5TRT(N@S M1:,UIX.4?F(F;$F.V-$NJ)G):"O(6F939? MEW342*Q&(PM*2FH"%E1GM>0ZZZ M\L%3IB`8[77F4Y(*5.;]P'6M_'`[DAIVO0O4KER.JG>*Y:@@R!M;6I$G8[[& M]QNLCP.;Q(92@G3R(L\)C8*9"2W)$/OF!8;7%175?`5!ZL<06E8;C$6U=DF1 M9U!!(H,*H@RZOA]:&>1V)#]LI!?X79E!U8X%0>K0,H-652%%GD$+2ET%Z0P& MB[EC5-&,1-12D`RQ%5]@>%T&53\7!!4$VX]GT*HOI,@SJ""10051!I>NXQM+ M/8.^,NQER0_[MLD/WK[!+>QZ.H%O:(%J$!!<:38`)]AJM>H-*?)D*BA`;_KW M5[M%D)1J$>$\BJP-RDT+^C@*6?3#H>MK_I=;1V=%#BT$P467RK4-)3:4VE`F M(.D^#A=&]J(Y9N^-T[=G#RX$X64(?F2^[@Q2FF=B0ZD-90*2I(PIY978V].( M1],(C[T%);94:D.9@*2;V.A9[%]QD\8"UH$]!6%VAP";S64]2`T![A4UE-I2 MF8"DY]B1K_><^C?W7$'@N79@C84,FBF#$AM*;2@3D'03^S-S\UV3#WZF,UZ" M"'IE(M>*;"+7BG)'&+TD':1T<#)A2W+$UGJ!XY7UAQHT3Y&"(+K=1S][(O=X M4U=?]0:(+4BKW)(47-#R,@PB8^[(!CL0`4D76S&C^\J>H5[.:2GH^Q.Y1SJL MB]A02A"-!/["781&8-^ZI([,N2EH2)G9(7&>Q;7,I@&"^#1` M$$T#GC>?A\9+528,26[8*2]PNW(]4K_EY!2$3QZ*G362>[Q1TZ*TH)2D*'MS MQW'F%D.N)1B"UD6&5PUTG1'9\`G"&5-2#%23\)U@OC2V`AYG=DYUMA5_=3RICL&.1?U4K(O# MH9ELJF<\>H1CD/O;'E;GHBO/BW%&@T9CW?'A3G=D:MT)X$Z7/_/./(9/PR.V M%C%\DAW!ES%\]QS!72?&3XTC=SRXHX8D\]D>'/'"4&SKP)?`&+_SC=SQPACG M#?L.G!<_C$8%'C)F:85A'+&S@B".Q?`AB!\@@?:#5Q#;T="&,1QRC,A',1PN M`#[KXP'GRN?\J?@CKY_*4S,Y%#M(OM.]D]7J9%K]:.EKY6/5PLDRK`\X)86_ M("C@@-+!5Z!=5;7Z!SZ@_YN$^_\```#__P,`4$L#!!0`!@`(````(0!N%X&X MA`(``$X&```9````>&PO=V]R:W-H965TP%BINX(F44P)=$*7LJL+^N/[[<4'2JSC7*RHX$A-^=PZ*J2`FZTV"KH7"`QT'*'^=M&]O;`IL0Y=(J;S;:_$%KU2+&6 MK71/`RDE2N1W=:<-7[=8]V,RY>+`/1Q>T2LIC+:Z2K&66+^="?GQ)V]NB9V$;O/AE9?I$=8+-Q3'X`:ZTW'GI7 M^A!>9J]NWPX#^&I("17?MNZ;WGT&63<.IYUA0;ZNO'RZ`2NPH4@3I9EG$KK% M!/"7*.F=@0WACP5-45B6KBGHY#+*9O$D03A9@W6WTE-2(K;6:?4K@)(AJ<`U MI';#'5_,C=X1'#>B;<^]>9( MLPH8_!TQR8A@*#HJH]KYRA[LE7U7?"JK$#B62=^6F?R/C`=C6X^23Z?/O$$Y M8*9'F.QM982<7Z`'XPQ."LJ>.Q>D`^@,:?3#L;1W6CJ+H]D?W7:8L+\XI#$V M>A]!MX\#3;/GGIR,]/)4]N]F\N!3J7TD;-&Q5=!Q+\M)XG^ZU=\Z%=A'3FN9 MO)A>V-^P)`I,#1^A;2T1>NMW,T7;C]'QL[%,O3-?QJ?Y\AGMN M:ME9TD*%E&$N)GP0PL'I'C/'I=8.%WEX;/"[#>C\.,*)5%J[PP&%V?A/L/@- M``#__P,`4$L#!!0`!@`(````(0#.`_``90(``(H%```9````>&PO=V]R:W-H M965T/V[((2Z_C8\$&/4--GL/1J_?'#:J_-@^T!'$&&T=:T=VZJ&+.B!\5M MIB<8\4NKC>(.EZ9C=C+`FW!(#:R8SV!3XA0ZQ4K5>A/K\D[.W1 M.[&]WG\VLODJ1\!B8YM\`[9:/WCH7>.W\#![<_HV-.";(0VT?#>X[WK_!637 M.^SV`@/Y7%7S?`-68$&1)BN"#:$'-(!/HJ2?#"P(?ZII@<*R<7U-Y^?98CF; MYP@G6[#N5GI*2L3..JU^1U`>3$6N8.V&.[Y>&;TGV&Y$VXG[XUT90_VREC?8.4Z M;AS+%._+S%_+^*+/L77_#^H/(>XH1%$N$W]T$#'E$6:1$*^"(N3TH!Z,O7@5 MK+Q(Q%$Z@DZ0QKDXE@[A\T6V_.?4'3KM#P8;J>`O.UBZU-BBO$S&8N(X^W'` M%)@./L$P6"+TSL]U@2.3=M.5VQ2^JW_OE]4FW`&6/N!5F'@']]QTPEAOM<-+$%Y[_.W:[(7+Q_$YWYW5]8.LT3W71J@FPU$08L0;IG+1E!G^]?/V8HF1 ML;3)::T:GN%';O#U^N.'U5'IO:DXMP@8&I/ARMHV)<2PBDMJ`M7R!KX42DMJ MX567Q+2:T[P[)&L2A^$ED50TV#.D^AP.512"\1O%#I(WUI-H7E,+_IM*M.;$ M)MDY=)+J_:&]8$JV0+$3M;"/'2E&DJ5W9:,TW=40]T.44';B[EY>T$O!M#*J ML`'0$>_HRYBOR!4!IO4J%Q"!2SO2O,CP)DJW2TS6JRX_OP4_FM$S,I4Z?M8B M_RH:#LF&,KD"[)3:.^A=[DQPF+PX?=L5X+M&.2_HH;8_U/$+%V5EH=IS",C% ME>:/-]PP2"C0!/'<,3%5@P-P15*XSH"$T(?N?A2YK3(\FP>+*+R:+8!EQXV] M%8X2(W8P5LD_'A3U5)XD[DG@?B*Y#.:+`]AY/`_+P;C3LWE>@MTVC^43^WN\\>#0>>2O66 M431^O?CQDUR7_!.O:X.8.KC5$<-`#=9AJVUBU_//[4FZZ;8=&3[`MFEIR;]1 M78K&H)H70.DKKOV^\B]6M>`FK`ME8<]TCQ7\5CC,5!A`0@NE[.D%A,GPHUK_ M!0``__\#`%!+`P04``8`"````"$`V799-&D'```5'@``&````'AL+W=O>%5^>NYN+14I"Y.60OC;X[EM>%JY_P>N7-6O[Q>O^35 M^0H23^6I;']THMKDG+OQ\Z6JLZ<3S/N[OLARKMU]0?+G,J^KICJT4Y";T8'B M.:]FJQDH;1[V)]3=5%]IL\U#9]#?9?'>"/]/FF/U'M;E_K?R M4H#;<)W(%7BJJA<2&N\)@L8SU#KHKL`?]61?'++74_MG]1X5Y?.QA?[^6^/:XU&3SVVZ,"S;Z0RZT2.LL&Z$ M\/G)N:U82_B\:VXZ9`V]B"1]V`6Z;W9Z?_WAG[OF-Z,)U.6CE[79YJ&NWB>P MR$&@N69DR]!=(LLSD5K4Y^;/4A-RDJ@\$IFU!FY#UC6PGMXVAF$\S-Y@#>0L M9HMC=#EBQR-(PA-93P6^"@(5A"J(5!"K(%%!*H`9^-2;!2OF_S"+R!"S^#2W M'`CN*<[P"-[$4X&O@D`%H0HB%<0J2%20"D!R!O80Y(P)>3V^H?&L(:U@ZY*R MQI1GOJ4QL!D/YEARR*X/Z=U!Q$-T1\1`)$0D0B1&)$$D12D4B^@462;[>SBD1W M]O!I;2DQ(!\%P]0LZH-X,P\1'Y$`D1"1")$8D0215"22&W`S_(0;)%IV@Q)P M@T]TAXB'B(](@$B(2(1(C$B"2"H2:>IP@_G$U$FT/'5*Q*E3LI!38RFO)8\% M&;UC_F@S6VX6]$'D6<&?(>?D@*J/9;Y MR[:BE>+(HC+A3D[O[T1$MI(2T4I*%K3([&[?C`B^]3%=B3#7E5TKZ'_G\PJ1 M1H1(W+=BJLH]).E_YZJIJ"&Y!?OE3;>^55?PX:,;&U&1[:+$@"U.V()6\E7= ML2"K*Z`6NKU4`CRFNQ@2L2>"KCF7=0.FN^QT'=M>*@:%+&`H22)$XI[W)6CK++IC1`[V8@&4_*8D%VX;#%#!ES;P6,3U9BDG[5FK#HS ME.%Y7)8^=)$D]C$*&(("ITLX9ZY;WY0AEDRD+&DI'4N:*+]+'HDYNF M3JMEZ&8PER(E1Y5)[UC#G^4HDQ5SE*'!I8!IF&0/?]LL+'.I[+4ACQB&%V$4 MUQIF MZ&,4\(8TG\RY!2=F:,W341G#98AXLP'%&"4<<7''7,V5%9>RF+%L)86SZ.D' M:Y[5V:)W%$%:5;:HF=:0BP&+,@?Y$*,(HQBC!*.4H;'4 M(A6S:,-_6[2T[I86+2O%8:["C47)^1V,B.V;W$./(1@R1SY#IF@8;6A"U2O( M*S5H.&B)44K)&?%!B.G6R_-!)'P0`Q[4&Y#-D@J20B,I=,^!1#KWS+QQ]92DWL)#W-Z1AA%', ME:`F_'E_"8]B_5F69>!ZB!G3348VGE3ZMXR_,R_I`X/D/$7B$Y".D(>1CU&` M48A1A%&,48)1*B'9'E*/J_88QA3VC$\>2I$3.N69AR%P2+B^:A6V&Z*&W*1: M@K4^C@HP"C&*,(HQ2C`B[W^Z_9R^R>F.@>G[''I^?B[JYV)7G$[-)*]>R;L: M&.[FH";&6K'M MPCG!"'=<>"+&/+5=>"[&'%Z&/7:/\$J_6_*2;"1^:[AP3HQUMJ8+1Z.8/R[< M1S`;_[!=N'`F.,)M=SLVT)WM[L:X9[O>&/=M%\YHL+[ON'`0@7EHNW`<`7S6 M.P$OY:[9<_%[5C^7EV9R*@Z0"//N.:&FK_7HEY8=&SQ5+;R.ZTX0CO#ZM8`' MS#E9;(>J:OD7TD'_0G?S+P```/__`P!02P,$%``&``@````A`)K8Q7GI$P`` M)7(``!@```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`=^#;D\8"_`32=!0BG4_W*0/E4XP-PQR1I[0" M4`RQNC^!(1T%2:9D76E*GU),LQ)!,QVR[D-ZVA)1O)$"/X$W'04)A>4K^3`= M:5:?..@UXGU(3UPBBC@N0$>\&;\!7)G*=*".>S[GIX2,83?BTS3ZTZS[H#RM ME8BB.M=48_?)5Q8%:SH)`9U\IK5#6HFH<^,2M3)-0;12(SJ*)I60L5YQ>_7T M09EY*Q'%D_9<84NO:T3!FDY"I$8.:26BSHV,O/[<%*S/G9`QG$&DR\2D2Q_4 M2R$11:=!XEW/IXO6A!B2:GBH59`F0#8L%H/VB-F"M)\R90%W]>3ITD6CL/E0W]BR%SQUE5+5)[8*DAS(L>]GA/[L^24()-6 MSJ(O6=LZ0.-O:0ZV"-`%CYQ<( M>,LFKX9.VHIFIKQ;EZ@^BQ2D.559-IW9+!1#2I04):!616D"Y)(FBP99T3C9 MK*NA>6,/DP(J3-.5TU8T=U"I(ZT4N M>3V!Y*F*@+19)N"@EFH,2K5``7+)ZPDD3U4$>IN5JV)+UG$?559%0EH4LP?H(+2;>DC.DM;`5 M:QQ5:DC-KLJ2)]Z2,R2UX*@.TF<+_%=FR569._'>FZ$Y9^Y\8C?O'-$]!]*< MR!!?N9JNR]Q)LE5Y.65(KY;-W#BJ5+":*QFEX'HA@Y*M*DX,R=62D#X;6:`X MV]69FZQ3G9AC.4;7@V M+=F0MM`-+=Q'=;PY7)[&VX.S!<\,("AF9]QGJF53;<16L;9D@N MH(=:!:D%G!IG?OUJZJ(-@631ID2VUL,3$=47%PK2G*K\>.K]F"$E2HH24*NB M-('`HM-V57F?-?4VS1"(B+U\;F\I2E31*QTK?0)-EWQ7>-2%-:1HLX8)$N*L MIPYJ%:0)5%DR/86U!!*DDVAN[QMXHDJB?J(MQJ;&N"^(XNVZ.T`NR)/G>*A5 MD!;%>#/M'`,>0$^]:3-D4LC6J26JI%`Z5I1"QLYH@E4(.:E645BLP M[9=G2$E6(H24*NB-('`U0=>=M[89[T_R]K`5KXEJ@C63P2D^589 M^\P;.T-"G;6'6@5I`H&Q#ZJE9M[7&0(WJ5>Y5^($DR;>06V9:/6:5_EZ%ZVM MDR&IEX=:!2F]YL;77[>I+MH0B`KRN2W(>:*LI12D.55Y-]YKLO4=0TJ4%"6@ M5D5I`L:[R::&??,Q][[.D,ZBA:W(2U1_U2E(\ZWR];GW=8:$.FL/M0K2!,A! MK[XEF">_E0\K&-*;W<)6Y"6JB,+>W=WI:4Y5WCWWWLV0$L5[MXK2!`+O'F1% M95U=]'&"5P!ON8H(6&K(*U78-W#]KJY]VZ&C&"V M)B]113!IYXKOHLJ[NV@M&$-"G;6'6@5I`L:[137UNHTODF?+"S!#R_Z)R;I` M8KM;F*J\C:-*F:H9&V>_GK$W^05#DG$/O:J)7#V!BM1191^HA5E M6;4;=-%Z-V!(BN*A5D%*E&6P&ZQ`JO(9:A6D"9"E7D^`#5@22)"N6)>V`EOV47T**4ASJG+N MI7=NAI0HWKE5E"80./>@=W66WK@9`C>91+8`*U%%KW2L]*$TW2KC7GKC9DCI ME:($U*HH3>"G&??2&S=#1C!3?JU+5!'LK'$OJXR[BS9.X%QZS5%*,!FE!:LR M[J4W;H;,55>JS?0(ID054]A]3WVA5D&:0)5WK[QW,V2RJ-33+(KW M[C(1B:4Y57GWRGLW0TH4[]TJ2A,(O'O`]W\K[]P,@9ET;EMREZC^FE.0)EOE MW"OOW`PIM;QSJRA-P#CWZQ7DRKLS0R:%;%E=HHHH[,[^@=6JRIV[:'.M2]_E M''90RQ.3=%H4X\YTXS8DA;QMK]A]50JM;+U=HHI:_41[P36C*M].X5JOC,DL M"C`T\-"I\G?S2K)F9,S[]41*X98%6S2,LI37*UM>YZG(N%X=C1EB52[=C+Q- M9TS+D^($!GDD9E@8JQ[^+*`9>1_/&-A(Z6P1+L*$=.SN_@7H9E3EY2G22;PW"=2LS( M$UC_L$=0S3;!#L"8N2AM*=^4,"$/[P"^$FNZSLJ*S$HNKC-+.GN6QV'( M+(D9>8(=8&AF!3L`]W::S+)U?5/"A'3G=X"NR;)"NF`'4'V:63II[3FS)&:D MJ[-[;LS4"]A[MJPM;(7?1#V="C/$ZNR>NS,U,6GC61Z'(;,D9E@$=C_H05\3 MM7:6%LVB''Z1QW8(ES"16.?=GO+T^NI;,L4:Y9.*:F#-V*.

KNQ_@%E/Q0>`P_50G75V3:9/[ M1\67>AD39UP'6*LQ+5W7"WI][N?64<6B]W(ICZOY>:H@"V+]5"\/>7,%L63E M:MVX\U2<$?)(R^?,4IB1Q]3\?^*BS`VF2CHNZO5%Z>X'>*KX()"NG^JEJ]L) M48!EG'O+;KE7RK&'O@S=!2VO&8`-2.E?UYP[6 MQ>G,ZCI+!0N2;ECU&C2W-J5O52KGZOX2 M5I).889SG=MSHZI..NGB63F'8?TD9EC4N3W=2MGBGC%S3;KBOH0)>Z>)9'H=!'HD9>0*W'UBA!CVO36EGE9GEBOL2)J0[7]QW#:GB:KC@ ML]R_JJ63+IZE\$P4.,KC7U>NFX MDU5)I[I;63J/M8W"M'11&^R0AQA!$VQ3FEFE;J[J+V%%-X49QN37%;H%VX!J M5QE7\*$/%S9!P5&UZM:(4_R:YU6TL.S M/`Y#6DG,R&.\?O@NR4VPFB![N:I<&U?TY_[94EN"R*%&6+DOQ7R)+O6Q*2% M9WD$8S<,3TG",U@$/(L,Q6@<\ M,@S':!WPU"X7\F-8!7XV&\V@=TB-./X_6`5\7AO-H M'?"%7336T#R\;!*.T3R\[A&.T3K@38MPC-8![T2$8[0.>-T@'*-UP$L`T=B( MYN$EMW",YN%=L7",U@&O9$5C#:T#7K(*QV@=T@[MM&YH'?"64#1O1//PCFTX M1O/P[FDX1NN`-T;#,5H'O.,9CM$ZX'7)<(S6`6\L!F,K3,/;[M$()N$U]&@$ M2X#WPZ,1+`#>THY&(#_>D@Y&\(XRL0O57V(66F*"62M,0F-*-`+AT0(2C4!V M]&9$(Q`='1+1""1'ZT(PLL0<=,1%(YB#5K5H!&JC42P:@=IHUXI&H#9ZI:(1 MJ(TFIF!D@3EHC(U&,`?MJ=$(M$;?:#"RA-;HWHQ&H#5:):,1:(T>QF!D#@;X M*85H!`SP.P;!R`(,\&L"T0BT1D-W-`*MT3H=C4!K]#0'(W.P1H$8C6"U\3,F MT0@8X/=%HA$PP`]_1"-@@)_?B$:PNX M*J2B,*X)J>2-*UXJ".-Z<(8Y<34X@]9Q+3B#UG$E.(/6<1U(975<55,1&->` M4\R)*\`IM([KORFTCJN_*;2.:S\JI>-*>HRCQ;4(E8MQM4A%7USS3:%U7/%- MH75<[U'Y'%?/5(#$]<<81XNKCS&.%M<>8ZQ"7'E0(1?7<6.LPIDJ#G/.U!R8 M[Z$^-O]+ULOF[_W?XWEVP`2K@)'M M-.W?[PP&"H$TR4L4AO$Y>%*"YD'A(X\XO`\E)'(=P'Y\_OQ MYI8XVK`\8JG,>4#>N"9WZ\^?5@>IGG7"N7$`(=RU/4];^9F3.3$(BS5)1@RCD7('V2XSWAN+(CB*3,0 MOTY$H6NT++P$+F/J>5_2E#B9.'R:9=+Q;8IZ'ZE$Q;6V.5# M#SX3H9):QF8$<*X-M*]YX2Y<0%JO(@$*,.V.XG%`-G1Y3V^)NUZ5"?HK^$&W M_CLZD8>O2D3?1OG&Q M2PR4>PJ*4-@R>GO@.H2,`LS(GR)2*%,(`'Z=3&!K0$;8:T!\(!:120(RGHVF M!4(2)]QK([-_UHF605FL,K0'9MAZI>3!@7J#MRX8=@]=`O!P M+!`$^F[0.2!SX@"-A@2^K*E_NW)?0'18^=Q;'_A]]VD\7"!MF('M'2$@LOE0M$9 M:M$61L=>`VRIK=,%U""T38WBIU"^CZN,A\H0FF17%NCX]Z*.:1-41^VL2_DQ M%3IWJ2J+O4GM=H&PCZ50[VS'XJDN067I:CG1.SAY+[XV,<8V=ZK3QY1(-@ M8.J*FIP0==44H=74*$>BO4JU:4#4X.08S<]KLI,!I#47B%:FKJ83\X)>-3!* M[Z,,5D-D0!/>Y%9'8Z&H/SG?>OB=.NJ]VM35-#M1IZO&`NW/A=HTH&EH,ERD MJ3\>IMH)Y1X7`Q^^N8VU65HV M/C;:L7VRW-AEQFW>P#)1L!W_P=1.Y-I)>0R87MG1RJXC]L'(`MH"5@II8(TH M_R:P-G+X[GK8*K&4IGX`9K=91-?_`0``__\#`%!+`P04``8`"````"$`TY]W M(NX%``##%P``&````'AL+W=OWW;B=E[T"$0[=R=WU_?/"\KMS)NNB6S5$>X,JF:>NB MAX_MUNN.K2S6PTWUWN.^'WEU41UUOW.@J(\ MQ1X^G(6OJ[)MNF;3+R&WH< M$O1/)=\ZXV^GVS5OO[35^K?J("';4"=5@>>F^:ZDW];J*[C9.[O[ZU"!/UIG M+3?%R[[_LWG[55;;70_E#F%%:F$/ZQ]?9%="1B',DHI*M09D MI'@?_G^KUOUNY8IH&<:^8"!WGF77?ZU42-B+I\>V>7.@:^"9W;%0/<@>(+):F8#\(,>XUDM+A36J M()]5E)4;NP[%*@7@C8RP"">%'D<5&%!R:.1&C@K!!EYMLJLN"B_OG M5$EUDYV_*3[F#S7`,:[#SM\U!6&,*./U+E-B.W]3SR`;:J(A?U$!LJZO(]DE+&74!M9IDGZ`A_9N MX@6VCS#4:#KPZ61"T)DCBHA'[%+C*< MF12&T^L0J)(H4,CKN+)O"N:<'0ZZ%[QO')V!19PZ'HFB/K./,2 MRF?-C0\:$*V>%OAL>Z!(-V`2)%8'Y(P(N"_":8D4[JZ!P68F!COS9139SJ&W MK3DN%O#&'`83.R'C=PV,04T'!C,<`CH65P?2^64\$F$XQ:'55?9]L^MQ-'NZ:>UAJT7S.U(#8IQY">4#S1U\ M2FUGT#+=C*/HU'TI#R+[=<"21&%HU('RW34UU(]EBR^PMZW6(!Z'QD_BJ78Z M?>;88`$+XF!:),7[7X.#SPP.;@W^3(N0D\'L"FP'RJF$P6N7F#)-.>^:'1S' M`O%F/MF7WBBGV:&.!!;,YL]UD!._F-9'R>Z:&GQF:O!IS9J,#@5S;^KZ$D', M(^/W,86[:VKPF:G!+>_(M`C3$L?&L-=LYN!(8&1/_4O0U$G.[1MW4%L;E]NN MK$6(%G)C'"`:N9Z$8EH:);MK7`C\?4$LCT]KQHIJT;R?:3B,,R^A?'<-#8'S M@.Z%Z15<\Z%H_E5`1[`O4B9EV#>/"3@/M6V.<*M6RW,I?[?>>4S8LZ#^7P6V[\=CRK_@"/48[&5OQ?MMCITSEYN(*2_C,%Y6SR$Q0]]8F-6`X6:[O5KV]ZVAD'S*ZXRNB(W7$/D3)HJ:^&QN1CTUN#L MU'6J2L,R3=>HLJ+6N<*V>42#G,]%CB.2OU:X;KE(@\NLA?'3:W&C@UJ5/R)7 M9]WM,[R0;M[F,E71=X02L[M M"N0,/M!YSK[A&Z!TV)T*R(#9KC7XO->?T39%EFX<=IU!?Q?X3B>?-7HE][0I M3K\7-0:W89[8#!P)>6'H]Q-K@L[&K'?2S<"?C7;"Y^RU;/\B]]]P<;FV,-T. M9,02VYX^(DQSG-KK7K?=E;,Q;02X M=L2T30HFJ6OY*VU)]0^'4"_%1:Q>9`.C[^/6RO(0 MNP:K!MY);QE;@V@+RBPS&_SAXQAS_:]4(4$-W#KF$8Z:3`@Z3%S\'.:^==S M.23(8);@\)J`-X#VF+$ECBR<$YNUB$1S1!*)YX0LDLP1VQ3?DWZ!>-[("*[8 M_\<5!L-ZF9B`;'_4[:8PX,QZPC@B$2X2T2(1+Q+)(I&J",$C2.;QER?3\&;C2^+I-.PA9']. MGF`)'&./6\)@R1)?6K(!9UQ^EB#3E.(AC\/H1EL_1\;/C@6%>%$AF2JLU[,Q MI"H%P1U7=(<=LFOHK#YR6"?9)>GT"SC#76(FS6SB@,JF)8EX42)9)%(5(3@% M7R&/KR,&RPY)!VC`&84!X2(1<:)?BYY\PL7J<+*HGZH(P1UVGYQ\6:O7#X-E M=Z3='7"&9[:Q?$O:0^$T#E%'.KBB:1R9+BB(1U<\!:RU[Z\EA80#BOE)583@ MCB^Z,UQEU"ZQ3J)+7T,=+=IC^](M)N@A;M`3\CRT=CWII`I[2.72(SKQLDZRC*1*1/2+71\? MWG.(7S:GW_;.YT6+7XAZIK?+>*=^5PYY1NL5?I9*)EV42:31039B6-'>I M4D9TB]TT'W>+WTNG;MF^=`0%4->Q'ASI'V`ZM$V8B_'@VWBU>:O!"K<'/!(2Y+JN7DE561-MQZQM:QPGWN"ERI M/4!;J)J@*I':([2%T@C:C3$`!>DMN^`_LN92U%0K\1E>9:XV$G+'UIR MZ\K"(VFA%.T^7N&G!PRUE+D"^$Q(.SRP%XP_9AS^!0``__\#`%!+`P04``8` M"````"$`;'$[S9(%``"%%```&0```'AL+W=OY>4^(DJ"&.@+8S_WZ/ ML4W`)]-MI;DIY:=-6[+(RRJSY9CVW.K+JJ+*13"YB,:['"H2AJQ\J6F METZ(-/1<=/#^[:FZMDJM+C\B5Q?-\\OU2\GJ*T@\5>>J^]Z+FD9=AMGQPIKB MZ0QY?R->42KM_@;)UU79L)8=NAG(6>)%<5^4C" MG+BFM7[H#?JGHF_MZ'^C/;&WI*GVOU<7"FY#/_$>>&+LF8=F>XZ@L85:QWT/ M_-D8>WHH7L[=7^PMI=7QU$%W^Y`13RS`JTIG M<.0=%Y:R&5QELV`6$'OI\M?'[2S1$7V_1D57K!\:]F;`8`&OVVO!AQX)"=2# MZE$A,?3QC[H8^I:K/'*9E1F8!G1?"W7YNG;FRP?K%6JIE#$;'$.F$5L5P0N' MRT8ZV.D@UD&B@U0'F0[R$;#`EL$;J+"?X0V7X=ZHK#8*C,S2C%`1JDFD@YT. M8ATD.DAUD.D@'X&)$>[/,8++P(@?%TE@3S/?B!@"93U4DC\-V0XA@SN([!") M$4D021')$,G'9&(2S"0_HUJX#`Q&J,G!`"?0!LI&!KWGTA`RN(3(#I$8D021 M%)$,D7Q,)B[![#1QZ?[*H:85'MV;H9+8".+`3#6RQ]$J9`A2S2)$=HC$B"2( MI(ADB.1C,LE]_JG<>?0T=T$@=Y76%I$(D1TB,2()(BDB&2+YF$P2A77@$YW, MHZ>)"C).%)%($'_1+S8>61*M"'9#@'(K1B()(JD@WJ2^G,6TOK(A2$GG8Z&) M%7SGB]?7&5^ENU-5/F\8U#$,]COCP(74Q.K*1:8."3)V")%($'\YE,L.D1BU M2A!)!?&(6-9MXFIN#+\/;HPU)F[`A/6N&U_9]4=NP)9*V<%5IG8(XL"L,YH5 MM/?<#D'J/:.!C)JYVHJT$T&>*+0OKKUTO*D!L8RX&9T@D@[DG4=EDT?Y9*Z] M2BY^AS0A@XFO?.-+-0RW=ZB!@\QVDGDVWW%$-== M:F,S5A%B9\^W>@E&*4:90D+:):ZG]7(N(R`19!+?YXW'XO^8)+:%L!*K7#=\ M58;*T^I,WY_HTS82#0I,4*T&M_>HE3#2"+?&;1V"O$Y\G5- M?,?6=Y*Q"KF]08)1JE`_IOK9-E-(:#LD0-JY#+E79'Q_B-R#ST(YWZL9[N.3 M/WS/Z].=1%H=SJ==O+U%W9P46CY_F^%##IB)E/G%&(;]F:-D>ZI>=S:Y3LA9\_ M$"XV8'$XD@=AWL\*&H=#D\>^M#2^X8.%L%&^P_T0-I%W^#R$/=<='H2;>XEM@W![CT=!"%L!K!,'(6P(,$^"$+8% MF*=!"%NA.WP19GV\-3@'AT#7XDC_*)IC=6F-,SU`)]G]G-*(8R1QT\D-P!/K MX/RGWPN&PO=V]R:W-H965T7K]6ASRO1^3A7#V,#W5]64\FU>Z0 MG[+JKKSD9[KR4EY/64U?KZ^3ZG+-LWW3Z'2<6(8QGYRRXCSF'M;7C_@H7UZ* M7;XM=V^G_%QS)]?\F-5T_]6AN%32VVGW$7>G[/KU[?+'KCQ=R,5S<2SJ'XW3 M\>BT6P>OY_*:/1_IN;^;TVPG?3=?P/VIV%W+JGRI[\C=A-\H/O-JLIJ0I\?[ M?4%/P&0?7?.7A_$7-\(]-\B?Z]Z_X^J0_GN78M]7)QS4IOBQ"+P M7)9?F6FP9X@:3Z"UVT3@7]?1/G_)WH[UO\MW/R]>#S6%>T9/Q!YLO?^QS:L= M*4IN[JP9\[0KCW0#]'=T*EAJD"+9]^;SO=C7AX>Q/;^;+0S;)//1[MZHN3__C1J9PQ9U8PHE-=X].!AI.14/Z%`T7=PO36-D+ZGR@'5UM[IH^ M13N+GF\Y,V=S=ML#+>>BY:)MV7_>@88T8)HNZ?-3M[H2[>BSTV9JS1;+1N&! M'DU*!AX;4K]KVP9GJ*F,B$G_?.IV38HA[U0)YL=N6(;3[.(YK.Z$9V.3W-NL MSA[OK^7[B&8,>N+JDK'YQUPS;S*M^3.WB?ZS/*<$9UZ^,##HP-6!IP-?!X$.0AU$.HAU MD.@@[0%%3!HIOT-,YH:F7R59%ZIZ3]S&I,FDS>B9:K)I35J%@3A`7"`>$!]( M`"0$$@&)@21`TCY1Q*;)X'>(S=S0Y$+CHQ72MI:JE$_":$CMUJ15&X@#Q`7B M`?&!!$!"(!&0&$@").T316U:3!6U;Y<52$%Y'-^K,!L@7B`'&! M>$!\(`&0$$@$)`:2`$G[1!&,LD41C"W^EG5'`G]R^6>.5"TY(2U[P]XVM'QL MC=I\!.(`<8%X0'P@`9`02`0D!I(`2?M$D9=M_?JUU?"89M:JAIST\Q'(%H@# MQ`7B`?&!!$!"(!&0&$@").T313":_Q7!?CD?F2-52TZT?-3KS]:HS4<@#A`7 MB`?$!Q(`"8%$0&(@"9"T3Q1YV3Y'T70B\A#YB`)$ M(:((48PH090J2-6/%?D?']"LYM&R4"!UF;;URKVS:O,0D8/(1>0A\A$%B$)$ M$:(848(H59`J*2OU/R$IWQF0/ZG,$]MXD\I*2@+:HI6#R$7D(?(1!8A"1!&B M&%&"*%60JA\KW_OZ_?*4R('$0N(@^1CRA`%"** M$,6($D2I@E3]6.G>UX^?-MVQ0\CZ4.R^/I54@=*T>4-7FTZ5Q%D3WP`HDX!` MS1$N+]W9V2S+YPYM!9HJ>U%[JN:STUG).<85R++;:<=#Y'<-^S6O=FH0=%;2 M?8B^(D1QU[!S;RVT0[:DLY+N4X&X$FH\V,Y@*!Y_E9>?Q8..?]N`\`V&$A"Q MYZ#<[K;]MG:S&[.UDC>[[5#7T-(W#HZPFBZ;H\:E86LJN])@U8L8[VS:(;^S M&N@LD%:\,VNQG,\-;1(,I4WG/$(4=VB@OT1:R?Y6T[FM'4^EPL::LN=38\JV M(_V8WAA+_=CQW8L2.[&AH3*]%SOM#C9F:]7%#I`CK&;*D#.TXQ^WLY*^/$0^ MHD`B@Q\YFRM[96A%?2AMNEDX0A0C2B0:<)X*&VN)<6"[G$_$@6^*E#B(?9(Z MAC3M-F9K);7;(G($HN3OQ13CP'WUAHC7-93N?42!1#QE[=ER16-$G5=#:=,? M(M!?C%:)1`/.4V%S:SRP[5`_#K^VYO!-E1(>L<^B9^@-$_W(C9T@L]6]21#Q M4H.CF=7.38ZPFBFAQO"(AETF>[)AAWR)FJFAZ3&0B*VAWQ[-Z=*:S;4\"J5- MYRE"%$O4.4\D&G">"IL;PX05EQ@>>C-*JK**0*Y`'R\/&H_JME4@RHXN5+!T M;CHKF>I;@6;L;N2++5R-I-7\9ZN1,.B/*T2^=$.SZ,\["Z05[\PTC9FUT'>0 M(7J/$,72U6"'B;1J.YP;B[FVDK,W[TV:]]8C_B:=OVP\Y=?7?),?C]5H5[ZQ MM^24$8_W+>:O\&DOMV9['9(?KMATI2F_X,J4KC3=ZE?F:SKYO.%KL:8CNQM\ MN::3J1M\M:8CE1O<-*CGIKS4>S;IMPA\JM"N4`FZ9@4F>J/J<F/8E[2]LO4_)_\P%)\YN2S]9T.D\W.FF?FWX" M<\R2[OA;G:G3,7RCX1E/Q7_F/*/B76E2:SV5-/WYHBLX#_=@EI[?`!IL, M7LJREE]8!^W/9Q[_!@``__\#`%!+`P04``8`"````"$`Z_T\MX(%``"C%``` M&0```'AL+W=O(ON]',<&>U':2G-3RL?R[_A?7K;CWL^W M_&B\D*+,Z*EO.BW;-,@II=OLM.^;__R:_@A-HZR2TS8YTA/IF^^D-'\._ORC M]TJ+I_)`2&6`PJGLFX>J.D>65:8'DB=EBY[)"7[9T2)/*OA:[*WR7)!D6S?* MCY9KVX&5)]G)Y`I1\14-NMME*1G3]#DGIXJ+%.285/#\Y2$[ET(M3[\BER?% MT_/Y1TKS,T@\9L>L>J]%32-/H\7^1(OD\0CC?G/:22JTZR](/L_2@I9T5[5` MSN(/BL??6_41[HZZS( MMG%V(N`VY(EEX)'2)Q:ZV#($C2W4>EIGX*_"V))=\GRL_J:OY#127,1M1."S$0E;H>^W@[#S=9%V(P*?C8C;ZCAV MUV,:=SJ'7^L1P&?3KG,W'F9^'0^?LA\W]!T_8".^TU&W:0B?34/GOBV.\(7] M(YI\WQC':SIF_S0RX<6:^SFR>+[KZ3-.JF30*^BK`34)CUZ>$U;A3N2`YV+B M<`/D5/IH)L$48BH/3*9O@N,P24J8_B\#KQ/VK!>8LFD3,\0QCAHQ$A%L?C+9 ML0XF.ICJ8*:#N0X6.ECJ8*6#6`=K'6RN@`762G\AY?^'OTR&^2N<&0IP,=S5 MS!01HLE8!Q,=3'4PT\%N9,C>[JEE#'N-`3(V&'O#[1;;XZI#ECX-*=]M;\QL#Y97ON@RD=IKX=&P(?59 MH8X9(3+FI*UDR&NK&9K(("$]Y<3UY!(T0V0N6UTEW]/J:"&#A/02":T0B66K MB[3;"=2G7LL@(;WAA)^\E`0$GR3@%SW7F^.-!,#Y0&2`J:@9X,2%Q%_FOZ<] MYT@&B><<2W)IYGI:V4QX4#NL]]?0UIV=-K]W+RE"9"[)G8X62D=N)PP"VU.M M7DH=,805(K$D=_I::WUUVX'74?O:\!#P%/I2D@CG#:6*[B>+1:O)XL2%(^!5 MLK3>1S)(C'2,R(037ZDI6SO_3&60$)HA,D=DT1";'ZJUM6/3$C5:(1(C MLOY<>,-#P!_=>/;:>'UJO&\\BU:-YT2K$LVOD0P2?HT1F7#2OMY)/&2\#!)" M,T3FB"P:PJO-\\,N5($Z,9>HT0J1&)'UY\(;'G)CQL-`%>/YV3E_ALA<"HG.%@UAV]_+P&F' MKA]H,V:)9%:(Q$AX_;GPAH?<*`3866XD!%Z=FWU<;"-?W]1K134[#5+*!6U^ MHTN4L&S<()\]C7@OP]N*B`H^VE>:`*@RH3S#:"YD8-'XN+.%B.*=.8[MNQU/ M>W598O451K&0NMOA6D3)#@.[$V@;,KN:825Q77#\JH6_*^>DV),1.1Y+(Z7/ M[!JE"UY)RJ]XQGX$QR9P2.-S/X(S#^:Q'\&!!7.X*GJH*TK3&;(KI!OQ0S>" M%R:L,_0B..UC_M".'F"\^(=A.X(#*W!+]@Q71.=D3]9)L<].I7$D.QB[72\W M!;]DXE^JYK3T2"NX'(+9"Q<)&ULK)I;<^*X$L??MVJ_`\7[`K:!$%>2K6!L[C?7GG.>"7$2:@"G M,)G,?/MM69>VNAT/G)IY&,C/K;_4:EU:PG=__SCL:]^34[9+C_=UI]&JUY+C M-GW>'5_OZ__Y)_JK5Z]EY\WQ>;-/C\E]_6>2U?]^^/./N\_T]"U[2Y)S#12. MV7W][7Q^]YO-;/N6'#99(WU/CO#D)3T=-F?X\_3:S-Y/R>8Y+W38-]U6J]L\ M;';'NE3P3Y=HI"\ONVTR2+_#[A]/>;+5V_@>3/^RVIS1+7\X- MD&O*AG*?;YNW35!ZN'O>@0>BVVNGY.6^_NCXL=NK-Q_N\@[Z[R[YS`K?:]E; M^CD\[9YGNV,"O0UQ$A%X2M-OPG3\+!`4;K+241Z!U:GVG+QL/O;G./T<);O7 MMS.$NP,>"VZC<]/R'#"O/279.=H)R7IM^Y&=T\/_I)&CI*2(JT3@4XFX[<:-T[KU;BX7 M:2L1^%0B[4;;[=STKFD)5)>[`Y]*I'NU-S`U<@WXU-XTW%['Z71%EU1TPZTJ M")^J8`=[H:*^F$I-_*I*WNB2\$65="[MJZ8<1?F@ M'&S.FX>[4_I9@YD.XR1[WXAUP_$=Z$`]'&5#S`#]:GS"P!0JCT+FO@X-@Z&7 MP:3Z_N#=M.^:WV$B;)5-G]LXMD6@+<2H%[(#"D(*(@J&%(PH&%,PH6!*P8R" M.04+"I84K"A84Q`70!/"8V($@^QWQ$C(B!CIWNUK@$%S24"TA2XRH""D(*)@ M2,&(@C$%$PJF%,PHF%.PH&!)P8J"-05Q`5@!@:G[.P(B9&#Y+DP:Q[NU(]"7 M-@ZL4&9F=6R3P)B8*#$2,A(Q,F1DQ,B8D0DC4T9FC,P963"R9&3%R)J1N$BL MH,$V]3N")F1@L82Y:@("FZ8=DKXRJHJ:,3%18R1D)&)DR,B(D3$C$T:FC,P8 MF3.R8&3)R(J1-2-QD5A1@PWF-4+0^Z5WD@K&T/)(&4M%A7S]25;Y2!,3(>2-)Q M<@]:MGEHS(N:7[0?-O4K(B"L[?9+0B)`EKG`&)GV2Z(B`+DPR2;"8@FKOZ&C MKFBOL+;;*XG5WUZ+=&!@C$Q[)>G"><`,-*]%$IS0&$$QJ]&P4ES1:&%M-UH2 MJY.]%MW-C9%IM"1ZF#<\4B(T)=`I]_:+<>*`ZY8/_V\J*71R[[!2[X9,V7Y> M&UA!"TU_DUD:H(UQF*.0HXBC(4#45RW2<-JXF>9G( MDK%]$$G"%3ZHG*+H@T08&L_>%P/'&&!H&`J5E8I#Q_&(3&3)V#Z(S.$*'V2B M80TOE7N8.)"-,1"7230.#(7*2N4'O0Y)*")+Q79!)`]%%^0ZCS/GLN5!IB"6 M9RHK@0XO+`]D?`2.L<(02=3%2(?*J@MSL:#%G"QJV4Z*]((Y"5=3:@G4J\,5 MZZ%,6"R'50X#68%II$MWNL`Q5NBP1%V87EB0+Q?*2BY$3J=-LYC(DK;]%YD* M\Q]NQV@'_&(=D0D/.(T-]6Y(2/OBWDGL^)5[N;'!7F`H1"5M%7$TY&C$T9BC M"4=3CF8,$E1RM><,U1K%!9U,1AI3CU:%ZK<[[J+=259QYK MJ57'("NQ=\C1"!%&EATYQV@E M3GW\&FZ"!KK54XYFB"HJFY=9>2TRTQ=HI6M<7MM%B?! MX@#YQ4"0!T=K($ADWRVZ9,,(Q"T>I%=P--,.#C@*$55X$Z&5UAIR-.)HC*A" M?H)66G[*T8RC.:(*^05::?DE1RN.UH@JY&.T`GD[U.+`?$6HY?G:"K5$H@I< M.%V2L0;B_00(-5S`:@<''(6("EIT7D1HI;6&'(TX&B.JD)^@E9:?#K6X`RB&FB[[EVW6\B;!&@'JQA>P8B;N>JAA=-DO5C1$.L;[8 MBV$%)ELR.;P$RLJ:I;)@5[ZC)]Y6"I555UVXE>9FLE1!:,BU1UH(=@>S>93D M9J8%7^5FK+(IKVQV467S,BN6/"VX_)*C%6KI:;%&A!XS>?%>I@J66<7E>Y;R ME;9#_#*Z'Y MD"'V?1>$2G3ZGA][)?RQ[3_F.SW5:?MQOD00_NBT_$>XH^4M[<.36/Y"QLKT MP(G\-QCR!"ZK?'&4XFIP9^6+$Q5_`E=7OKB8*GGBMGQQM5'VQ($G9?T%1S1X M4E8/W-/YXLC(U>"ZSA:N;9HC"&\[OF]=DOCF][HY9;9^\P.QMY3\WG.0[TO*/L_I5]BD]P[O-^0^T M;_`N>P++;TO\./.2IF?]!U3=-&_'/_P+``#__P,`4$L#!!0`!@`(````(0`U M.O2\W!$``'1I```9````>&PO=V]R:W-H965TMVN_@\OO8NL=6)9F*Q?N=K-G=9\=6$E?;5LIR.MW??@](4"#P9Q2K MJN=AW/GQ``1Y"!(`)?O]O_]Z>CS[<_NR?]@]?SB?7DS.S[;/=[O[A^>O'\[_ MYS_!OZ[.S_:OM\_WMX^[Y^V'\[^W^_-_?_SO_WK_<_?RQ_[;=OMZ)C4\[S^< M?WM]_;Z^O-S??=L^W>XO=M^WS[+ER^[EZ?95_OGR]7+__65[>]\6>GJ\G$TF MJ\NGVX?G\ZZ&]ML^O724OV\?;5VG__MO#]WU?V]/= M6ZI[NGWYX\?W?]WMGKY+%9\?'A]>_VXK/3][NEO'7Y]W+[>?'^6X_YHN;N_Z MNMM_H/JGA[N7W7[WY?5"JKOL&LICOKZ\OI2:/KZ_?Y`C4*?][&7[Y'M2E(6?D]J_VY\^'^]=O'\[GDXO%;/GN:BKQ9Y^W^]?@0=5Y M?G;W8_^Z>_J_+FJJ6G6H9:9KD9]]+:N+Y;O)O*WD2,&Y+B@_1PJ^<>\+78G\ MU)5,I2%']BH'UAZT_.P+7%W,KI;3Y4H=])&2*UWRW:'D;#DX74=*2H=K]RD_ M]3X7%U?+Y6)U]>[X+J]U0?G9-_;XT4WE(NIR*DG31=[:2G7BNK(FE:NW'>"T MSZ7Z#[W;Y9LN@FF?P*F2/S_.WKU[?_FG=/\['7/#F*D=L>DC5/]4U7HN^"X$+H0N1"[$+B0N MI"YD+N0N%"Z4+E0NU"XT`[B4]!QR)-?S/Y$C58W*47]V;WH8),U)2!_1%_%< M\%T(7`A=B%R(74A<2%W(7,A=*%PH7:A20)8@/"2`A)(+$D`220C)(#BD@):2"U)!F*%;2 MY$[]3R1-52,W2^FKAX3,WEW9*;G10<>R=@@Y9`WB0P)("(D@,22!I)`,DD,* M2`FI(#6D&8J5-1E@6%D;'QSVCR$5W2:G/ZDWG2SL)Y/3R3:'H+Z8!_$A`22$ M1)`8DD!22`;)(06DA%20&M(,QD)YNSBGU]6?Y1BUL M2<:LK@+R&.63`E)(BD@Q*2&EI(R4DPI22:I(-:FQR,Z%FAR>D`L]EQSFHB-G M*#5WN\HAJD^BIU86[23ZI(`4DB)23$I(*2DCY:2"5)(J4DUJ+++3HV:!)Z1' M3QJ'Z>G(ZBH@3RW:NKD`!8P*21$I)B6DE)21R2?%)!"4D2*20DI)66DG%202E)%JDF- M178NU%SQA%QT4TLK%YID[C,8@+GKO-/1J-6A0]F-4O.H$QK53;NL1@UG8OH" M`7GJG9%]S?BD@!22(E),2D@I*2/EI()4DBI236HLLG.AYE'#7*B7;,N5>JO] MBY?=_7JF6O>7LVNE19.<]\&UXKQKV_0%[2BS3&VU3]VBK?8=GT&TX7:C>KHZ MC%HW%MF[_/1LS3EUZLH_37=\=C;HV"V!V\TX;L,\X8-]IS?7)G=('O876:' M@NUR[RSXFJL^81_))`2DD1:28E)!24D;*206I)%6DFM189*='C9I/2$\W MR+;2@W'W9@;R2#XI((6DB!23$E)*RD@YJ2"5I(I4DQJ+[%RH(?()N>A&U%8N M.E*]T3Q9KMUE(/704@_\V>'FYI%\4D`*21$I)B6DE)21%>9*60OMUBM-E.DJ75V+Z_9#ZM.)T[M\4V18L5E>LX]#357?/E*9=S/; MX9Q+DWH`#X[#K-/IX]!38K.\YNF"RVE['&8IJRW@CU?[JZ,X;>8XY\Q1DY,- M=Q7.1)EL='7I;,CW?)QQ@6^5L<_]:1.J.2=4FJQS/Y\XIW)CHDRKN[I6P]'_ M?.*L*?FZH$1)0;OII\T_YIQ_:+).^'SB3M5-E&EZ5U=_^5_,G3*^*3.\(']U MY:A!]0G7?S<&MZY_#,LW?!<1JWM2/73@F-[3>K'84P\=P?JF[Z@>J":PR]C&<-D-07VIPEL`UF3S@"=25&9QTSY3I M#\O7I*>95TMG9AI81>Q#<.<&;L]YV^V!4P8YG^T+2.D_@U[N7!\;$]4?BZ=I M93XOZO22?%)!"4D2*20DI)66DG%202E)%JDF-17:.3AO22E=W M[R6:K%QT40/R&.63`E)(BD@Q*2&EI(R4DPI22:I(-:FQR,[%:>/7)<>OFIR9 MN+O49J(.-P.23PI((2DBQ:2$E)(R4DXJ2"6I(M6DQB([/>Z0]C>W+8Y=EQT- M^L6&Y)%\4D`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`I)$2DF):24 ME)%R4D$J216I)C46V3ERUY3<'+VMEW*I22WKJR]BV8]D9_*RT5%6+^T*=K_: MN_N\H(Y:Z7<`8V,S5A22HKXBF3`?%E@X-C-1OQB;L>:4E)EJCNPL'XO"X*E@ M]26I,G7UW:(V9!J!ZAL=U;UMLZ\/=YW+O3[>V(>Y_B79;"\0LT"U(7DDGQ20 M0E)$BDD)*25EI)Q4D$I21:I)C45VCM3ZS]O'S]*S\$CM2"9O@ZMDYLQ&-[K@ M8);LD7Q20`I)$2DF):24E)%R4D$J216I)JD_16`NYRX]W9\6Z'Z?^=/VY>MV MLWU\W)_=[7ZH/QL@RP@?WQ^X^YL&-TOYHP;=S1!;9K*E_58KMLQERUP]"=TM MJX7\B83V&8DMR_Z/)[A;YI-U(]\B&:EM+FV3+S",;9&VRRI5T@P19I M=74:Z";>[MZGTB[YU69C9:1= M\ENUN$66X>7*':JW#T2WRD2UC;9,U=]DRUC99L94M M8RWPYJNU^CH%]R,?^5NK#_1QRXVT[6:T-GD)N%;O\UAF(ZU6;X3&MD@+1EN] MD5:K16J6N5E(5Y:/LHYMD=XD'ZP/VBSS<)NWG+%^ZOYK3_>-5?Q3Q\^Y5_MA-^ZG$;_+7C;;RAS0FZA-) M7W:[U_X?:@>'OY?T\?\%````__\#`%!+`P04``8`"````"$`>?](US,%``!< M$@``&0```'AL+W=OUM M.XL?K_7%>L9M5Y%F::.):UNX*><5UT$W+%#7QS)&U=]/"Q/3G=M<7% M@0VJ+X[GNI%3%U5CE:2^@L1#=:GZ7TS4MNHRSDX-:8N'"\3]BH*B%-KL@R%?5V5+.G+L M)R#G\(F:,<^=N0-*J\6A@@BH[5:+CTO['L4Y0K:S6C"#_JWP2S?ZW^K.Y&7? M5H<_J@:#VY`GFH$'0AXI-3M0"`8[QNB$9>"OUCK@8_%TZ?\F+RFN3N<>TAU" M1#2P^/!KB[L2'`69B1=2I9)<8`+PUZHK6AK@2/'*GB_5H3\O;2^:>+,0A1'P MK0?<]4E%-6VK?.IZ4O_'62PDJ>(-*O`4*K.OJP2#"CP'%329A6$0S::?GPHP M64#P'$2B23AU??2%<&!Q,`UXBG`F*'"9(Q^X,!^&P7,8-IU,D3OWZ?3-<0Y/ M!7WD@S9I2KW5&9I3VT+TM=! M93ZO_"E:.,]03>7`69L0U$`R`\G'B&(2=)+OJ!8J`XL1 M:E(:X$]]U8+U0/K()4F1+AG(SD`2`]D;2&H@F8'D8T1Q";J3XM+MO4.T%L3&0+8<"6>L#P5HCK0BVTF"D$T,D;V!I!P)H$G*S'C>3,U, M)DE".A\+*59$FA6\]4YH`^_/5?FX)O`>J(,;%OD0&F^\5$1UB"-CAPQDRY%P M+GO2SD`28]3>0%*.!(@Y[;E(J]-,?B_=&&LH;L#>H12&[L9/PX,I21'P;>7/,W&1BC,C*0U$`R37?N>5.U/'/.N%$U]"BH MF*,OQT\U)Z:BFC9`2CTAI%7SYHTE;1N@T'OK60*BW?!YA4+/G6I"B:",BLJ$ M4@&QU::H.J6_PUUX,QV539^W'<$0T\?L@OH<`S"_600RGI1MX&*]O M3703QIM;^#:,81,W=9(PAJW8&W@4PW8.N",=@KO]M3CA M/XOV5#6==<%',-UE!YB6_SK`/_3#UOU`>KC40U[@F@F_XF!H\2Y=$T=">O&! MOD#^+K3Z'P``__\#`%!+`P04``8`"````"$`(B<(_W$&``!Z&0``&0```'AL M+W=ORW; MKFJN:\V<&]JLO!;-H;J>UMI?7\)/GC;K^OQZR"_-M5QKW\I.^[SY]9>'MZ9] M[LYEV<^`X=JMM7/?WWQ=[XIS6>?=O+F55_CFV+1UWL/']J1WM[;,#T.C^J); MAK'0Z[RZ:IC!;^_A:(['JBB#IGBIRVN/2=KRDOT)OX*EIGE%H7K<+ M,T(3\P_?@K(K0%&@F5O#,(KF`@.`O[.Z0M8`1?*OP_.M.O3GM699VNRI[/JP M0E3:K'CI^J;^!W]IHL&PQA`Y-(8G;6S.3<=80%?WZSL);WL\" MD<-(X$E8S/F'21:$!)Z$Q)L[EKOTS`_,9TE(X,E&XBX-^R,<*\(!3\;QX=F8 MX"7\:I&I\.O[@?F8S"'P#QO-G3/2L=L&\P9YGV\>VN9M!AD!N+I;CO*+Z:,> MJ&VQV9B1O^=C\"!B>40T:PVD!JMVL/A>-_;">=!?8<$4)&:KQIABQ(Y&(&LC MVD`&]C(0RD`D`[$,)#*0RD#&`3KHQ,2"Y?4SQ$(T2"PZS2T%1O4L21D:09L$ M,K"7@5`&(AF(92"1@50&,@X0E(&D\3.4031K#?YR-G)%*;8XQH0ER8*DD!T+ M87(IR%Y!0@6)%"16D$1!4@7)>$20S?DYLB$:6,!@6R:)O5A(NI&@]W1C(4PW M!=DK2*@@D8+$"I(H2*H@&8\(NL'N(MAM>I.ER0E%#_+0:6TQ8@T[^I!I=AAQ M($,S"2U+DC`@019;N?O)9DM1^9`%T?XCA2A6D(2UXD?DB=0I"Z+4&4\D:`:; MJ:`9SO1SM+?WYZIXWC8P<[#0A)8V9'2"DQXN`*94CC!.%T8S%H MJ[`,4]HK0O8]G5>D<,0*DK!6A-66U&+?4]:,YQ#4@JWL7;6^-+?OJ04U"I4+ ML8AR8<0"9W,^6XGCW)$@Q/.Z<4K$G;^5)*3K#`>8P`T%X=![B"Y().W("HVA18(Q8\!@% MMN5"@P2M!B&DH06$$Q?IR+][!0DQ8AL#@>49IFM(2S,B(>,RB!4D49!4(K9- MSY-J@0R'X+.,(!VD]@](AZ)%Z3`B>M.6>M_A(-L:9FY*#@L(*6=,!0E)-]B% MINDZMFQ#$L'94$$2!4DEWJ7A2*/+<,2$Z5")+DCW0\EQ8!$E)9!D1VF^.QHU M[4=*RQF20J-"(8%LE*LA:;A*_1W1",Z1*I10:'R%*84H]6HE+9F,1$QX$A4E M[RI[7R(=:"1I<94NV57:2':D(431G!]0KA':JU!(&V*;VH8+URGR$J%^S=IB/$X>*S'H9LJ,4X(TJ;9DBX;`_O M^(YGKEQI`XMH?Z,-8Q5**!-LP]_O+Z51I#_7=2VE!"(QH#^L/>Q+?#&+[[;J MLCV5N_)RZ69%\X(N74V4:1F,;X1CUX.+Z<*Z:P!=^.A6?N3Z<(]1X MN'%^'(X\$O\6W41/Q&\M'^Y75)ZM[<,-@HH_.OXC"*%^L75\.#I/X*Z_G1KH MSO5W4WC@^L$4OG=].-.J_/N%#P\/577;G8I MC_"2C.$PVN*[<_RA)\>LIZ:'NV]XCW!#";]QE%"5&W.P[[%I>OH!=/EVLTZ1(WOS\^\OSZ+?M MX;C;O]Z.LZOI>+1]W>SO=Z^/M^/__/KEI\5X=#RM7^_7S_O7[>WXC^UQ_//= M7_]R\V-_^'9\VFY/(V1X/=Z.GTZGM^O)Y+AYVKZLCU?[M^TK/`_[P\OZA#\/ MCY/CVV&[OK>#7IXG^70ZF[RL=Z]CE^'Z\)$<^X>'W6;;[C??7[:O)Y?DL'U> MGX#_^+1[.W;97C8?2?>R/GS[_O;39O_RAA1?=\^[TQ\VZ7CTLKG^Y?%U?UA_ M?<:\?\_*]:;+;?](TK_L-H?][F?H<9&-I'A^W# M[7B57;=9EHTG=S>6H?_NMC^.Y/]'QZ?]C[\==O?_V+UN03<6RBS!U_W^FPG] MY=Z8,'B2C/YBE^!?A]']]F']_?GT[_V/OV]WCT\GK'>%*9F97=__T6Z/&U"* M-%=Y93)M]L\`@/^.7G:F-D#)^O?;<8X#[^Y/3[?C8G95S:=%AO#1U^WQ]&5G M4HY'F^_'T_[E?R[(SB@D*7P2_.N39+.K,J_F"YNE9V3I1^+?BP\_<5.QS+3K MT_KNYK#_,4*]`>SQ;6VJ-[M&XHX2!R.0]!Y'(,(3I'[&RO]T5 MY?1F\AL68^-CZC0FXQ%-%V&8-VE;8I@`;P"-!?@$T":+`=T=KNX,<1:Y0-A% M=$-:8F`(L;J?@-!D09$16O-20*I=3+8D095`'4(";&IAN%$"GX#;9$%!8?E" M/61EP5'5/J@/>`@)P*F%`<<)*(%7,W,:^W/QPZ5L$EGLW3%K9\GY;$H^FR8$ M=<-::F%09RE4TX4N/.5,EH3C&4=5^Z`^CD-(`$XM##C.;\GQ;'YU.723AU/L M+#DZ.BF8.9],$X("4FIA2(UD__FN9K(D%"\XJMH']5$<0@)P:F'`D48"GR^N MYI=S;!)QCIU%<+SDLVE"4(!*+0QJAM626`?4L4TC6:X2\3`'0Q30A`J1;:[+ MM`P=O64FCMYHBRB10<5LNIQ@VILXU56B=FX@H@+7<2!,'*X1&@)7W[($.7:R MA'1=ZCIS)G*T)C6US,0!&,GX.``O,!2`,S$`B:G-J(D#,*W_XP"\4%``SB16 M1+TM-M\ MJ_CLK86_""H4>D%5B6]%D:E24:X[5-&*"5>&)8O)MFQ+E3>YRP6Q:FXR: M^-%,+R5',ZN5YT9`SQS7]6#&A3=Q+I*.J$;%30)#9TX,BJX?DXWFQ=R9"!?, MQ(^F]-^LNK!RS9Y,G%&=:>8K=U9(B>LB[,:?8Q)-5IY-'ZO&JC-5@>W?3 M1:1M.%?:<%[8*R(K#1\LYK0-V\184[XTR0*J;?B]UB/:L#OQ+KXDRD-_C@)1 ME&+?57=1Z(U!1A+T/A/92L9A4O!RTV5)^<63X\)+.IM(G"VN@YL^&L!F,[$[ M;OQ`1(5-"S.Q8BU$GQ](MDUCP49D17IWX@/[]BX3(9N9.'I%-TJF(A4.;R(+VZ2FEIDX`*$29JV+8LCU9)$JB#<) MPJ2JQ:A(F,OE9L7Q&G$@I](9PDPT/U\*9V*$)::617$`INT3`'^","<@5&:* MH"GQE,EF<6OJ6GJ,BH2%@3!QO*KR7'XZ!.V)R(KDCEWAH_HZ9XR)Z,.P!+VB M40/+,]6IPIE$>48%\FR'J(B7FCC;0J?.E&>0HRYU73@3*\_$U+(H#D"1FH&$ M.6%AY:EJC=QQ%"&JFU7+3`QO*;2FGS`;S<]G;Z*$I::6F3@`12[<)=>%@E&F M@N%-HL#B'M456(P*?#$3AWN18)2I8'@3X\M%$5/+HC@`13`&W-0K@UK0?B(Z M7=U%H:+"YD;NQ&),I,\GM_L%CE[(A^G>PVZ?EJFT>!-?[KGK MJ,T0MH/41!Z+4C!9FUV24MD-,1$]-'+VB/')QQ(K<>'T^@SB5E\J;*.)@ZD6L1L6-#T5[_?D)KFB0B@@U6XC[:XT?R$HC#$RH-GI`:G,HU4Y6(#X162%OEM:5C^JE.L1$ MJJF)%!-9 MVB8UM,2@X9Q*$"3EO_$`RA9:9.%XA-0.K7G=1?=498^)R^^1I(Y@I.C7L9H'-),I3TZF%:&Z-'\C8#@-E+Y@)G1K* M=A`PRK80A-H>#%/J9=MG(C>FX[`$O2)R`VY,SU*%\R91V*)\FA@52^-=A9M] MCL+9-+8N"-7)LSM=5"_55,ZL,+9Q6$*UHG!#J':J1*]89D&HXH2RI;S&CU&1 MZC`P`6O40_2\`9N)F4F34"VTM^ZB>JGVF6A54Q/K@'-%X89U;)N)]Q!OXH6] ME!?Y,2JPS4P<[T42-T\ESIM(QVI24\M,'(`B<<.:[CR5.&\2A,D]08R*A`5M ME.4Y_QR)LVF2\A1+67=1?>498R+Z=R5NKDC

^;M; M0#$JXGU7XLR#G+09]._`;+0X99PDL?),3*T?Z*)X>2HJE67V&:0+KP_FJ5!Y MDRA/N2>(49&P=X5J+H3J#&%>1XF@U#J36&ZY+YF'J+C'Q./;\>H"-?E M4GK!0DA5_[EEHWDS\B:7VG7#U-0R$^=+T9YA?'F!(,6Y<";!E]@O-3$J\A4& MPL3A"K$YPUIKP'[WH43#"IUWB38$O+=Q*C(%A4? M#E8HS1FV4C594%'P;"6FED5Q`$(Z#%N#?IY:I*KB38(ON1&+49$OE\N=,ARN M$)HS?`4]Z5+7"V=RJ3U?B:EE41R`ZNO[,""RT_]MI\*CIRXP>2 M*;3,Q/":>YH4;S]A-IJW+V\B1VM24\M,'(#2[H<1MDS[O3^K:'@S5W8 M:-`-"0HKSFV,\6SZ:6KG4G'2.YM@76X02!@![=33+84`+22O?X^038.T==G! MI;.1A09UB0UOFE*;0*%(U[#3.YNFVM79!'7I>E.ILH(&T-0F0`O].D==T"E" MG;-QZA(;4%";0*'HT(!+GFR:JE!G$[P):<5B>]$A+U=PFT!LNKQH30-N8613 MKQ94)(M*B"3*,XA*WZD>@KK%`>G4)J:@R-&@[II-4SGJ;%S],]'#0+M7GWA- M#\S4)C`+21K<89TRX=HE\EG(%VY`NP_K[[`AB-!.;6(*1C]$Y0QM$TZ*Z!58 M-G4V7NZYO(-$P@CH,!0V#EI^!>!,F^A>R(^K6F?>QMI$:L.G@8R(=K=R!0I% MG(:T";/L8CM@ODCD#QLK(L_E_HF$1=[BT,";^SB1^P3/R_;PN&VVS\_'T6;_ MW7QX*,,[H'Z^BX1J*_%E)'1)9$E]E?'9MSB%;X5S_!K_L2^Z"I]I'&;< M3,\Y-SYM'-(MD-,55IIS8<;9Q_]2W]+X[,5'XLNF\&%YM?EE\:M08MQJB>EA M'Z:,@J?%+EWS8&K8ZVH>@,>.4_,`NGH-+'X%"X"D_'U$L<2!VS6I;(ILX8 MGA:7E%HV%*D^9@$/[BLJ8Q980]S=TSQ80]Q;TSQ80]SATCQ80]Q+4CQ++!-N M\BB>.8Z#7X92SVJ.DP`_;*0>_(2#,2J".1"H8U8+%)&Z8-T3#T':OQ$KWF`&K^= M:QZ@5H^SFA=`H*T"?D[&&'4^<\P'/\QJQT&]X>=1S8-ZPV^3J6+PF M]>`I(G"@9ILAFSIF-9LCFUHA\)BG7K3CH*K4,:L*ZX,'V)0Q\+1XXE'QS+`^ M>$I0\V!]\/B>YL'ZJ,=9S;`^>,Y+&X/UP1-KF@?KHX^IX,&CS,J8"ESC&6/- M`Z[Q@&_J657@&L^CIAX\=HLQ*M<5N%;'K$K,%._W*-G@:?&FDN;!?-0QJQ)5 MI:+&FSH8H\ZTQ$SQAHMV',P'KYYH'LP'[WUH'E0(WKY0/!7F@P?@4\^J@.;B M];'44\/3XNU/S0-L>!M3\P`;WG;4/,"&]PH53XGJQ0M_F@?5BW?K-`^J5T6] MRM')\:Z\,@:>%B_]:QY@4\>L"G1RO+^KC(&GQ5OMF@>H\0JYY@%JO-NM>;`^ M>+%:\Z#>\'JSYD%5J=BP@0$'ZOK8C9F*VFW+M.-D0(WO2"D(,J#&!YXT#U#C M@Q*:!ZAQ^:QX6OP*I:%6!@I#K0N4A1:/[YJN M=#XP-0T/"%3CS:(K\2MLR#0>:M-ZE/@:Q-GX2=A"XBNG;^O'[3_7A\?=ZW'T MO'W`QSWI^X/ M+,PD?"+W[O\"````__\#`%!+`P04``8`"````"$`38"O%10$```6#@``&0`` M`'AL+W=O'[XL74?(I,R2G)=TX[Y2X=YM__QC?>7U MDSA3*AU`*,7&/4M919XGTC,M$C'A%2WAS9'712+AL3YYHJIIDC6+BMSSI].Y M5R2L=!5"5-^"P8]'EM)[GEX*6DH%4M,\D6,_G:@+I.D49?3R6ODT,.^WXA89)VV,W#`+Y@:EQX^Y(%).EZVW738-^,'H5VO\=<>;7OVJ6_<-*"MT&G5"! M`^=/F/HUPQ`L]@:K'QH%OM=.1H_))9?_\NO?E)W.$N2>P8YP8U'V>D]%"AT% MF(D_0Z24YT``_G4*AM:`CB0O&]>'PBR3YXT;S">SQ30@D.X87+# MIA=-1?SFO#8RQGK$L,W^\5(S-+L7@T*>QE-?J& M7RUM)(ST!Z96UR!,-OFT$34'\:#%>L2H!`;2*V%'?'\"`GU<$Y>9-=N(V0/[ MY(PFS<=[0.`XZ]0^)M1DFXRZD-8&(V3T`8^;7LVVQDU6;4`L$FJBDGEKUGFP MZK>K#D^WJ!F+)J?1J?MV?&ZS*U$C%,KT)[@+F6+9AAW/6O3T3:XX%&^V+&E' MJ,ZI#>EJZ2&S&LXVK=JMMB6XSA*H#9F]L(W;+32SEN_T`N>AQNX7SE73T]!' MA?01B]\18*Y"9B\^8\B"/P>-L<;L+'R3OG7NNW.6C`Q:/\";F1K\-SIW.&D; M8!#0U&&@UNBL?6_._-:PA3ONH%$J9*BEAY1:ZF:K+GX%K4\TIGDNG)1?\-:Z M@O'01_L;]<[',VO%]WC3'HO[$=R61O*#*&Z^A!;.+HQVZL9NO=B'41R.`G1]C_M)EJM;K7JP?9?HP/ M7,)]'#2'JS'\_J+P.9OB!^K(N>P>H+37_Z+;_@\``/__`P!02P,$%``&``@` M```A`*2C%XDB!@``SA@``!D```!X;"]W;W)K&UL MK%G;CMLV$'TOT'\0]!Y+U,T7V`[6MM0&:(&B2-MGK4S;PEJF(6FSR=]W*`XE M7G85+;`O<7S$.>;A&0Y'W/7G[]75^4;KIF2WC4MFONO06\&.Y>V\VO:^\KRFN-`J;V;L M3F_PY,3J*F_A:WWVFGM-\V,75%V]P/<3K\K+FRL85O44#G8ZE04]L.*YHK=6 MD-3TFK*Q_):MC\Z4M>IBM67\XW5^>,5 M='\G45Y([NZ+15^51)B=J:E][2`Z;M^EB"`K[L3DU/&_>!K+(@ M=+WMNEN@?TOZTBC_=YH+>_FM+H]_E#<*JPT^<0<>&7OB0[\<.03!GA6==0[\ M53M'>LJ?K^W?[.5W6IXO+=@=@R(N;'7\<:!-`2L*-+,@YDP%N\($X%^G*GEJ MP(KDW[O/E_+87C9NF,SBN1\2&.X\TJ;-2D[I.L5ST[+J/S&(()4@"9`$/B6) M/R.1G[R#(T(.^$2.8!8L8A*_AP2FW*F!3R29+,83"].M\R%O\^VZ9B\.)"]( M;^XYWPIDE;B.7&"Q'/V2O[7BL-2%GCU`;(X"YB3%DJ0R*]2'[?D@OS$)2"\E41-,&^^`#_.$L MD+B0!$K>+?69[W#0F+A^2"_.0E(+R51$$P?[TQ8WFP/<7LKB:<=$R7FEB(6P M=\2.XAR=-#FEG4`B6-)>;)#XNM@]ABWZE#U@F+I&06+LO+0?)'\M4XDT<5`D MQL1]9?>NJ+PB#LJE5,=)='4"":*N>`0^B0QA&!$-PGI$68_06(\4:1-!&\<+ M(_6SG@64:SJAF*DZQ_7PP;H>@00+J)6=8Q;-!QL)!4(-*N)/!CHQ1E:HPFC4!G-*9M4LGH M2'1M"(%CJC@CB_8R4/$-(=4XA-`Y$H:QZ9S&H^OCY_1(/D[SCA=ZPSR$#/?, MXB$#%?ML*$5(&A@MYKY1)S,M2E?(3_$1A=,<%*T`_(JLPSLB(,-!LYK@**(Z M*`(U!P6$#BZ)'QIIGFD\NCY^E)OZH/W$,TT:./V`(]@;J%H%9)AI%AD9J)HI M`B,^&]F`!M99@(&1.`SB>9*8^U.CUN7SP]Z4'P\%5>H?/R;`'TS@89[AW#BS M=G(45(M>C66XVGQ@LVQ!Z<`D\RG3(%TB/_)')$[+8.P;5%<%])/&A;_5\;VM M="X(1>.MRS!JT*ARZ1KY<3^B<:*-V#2H(K'1>+-_(6JC@8;UT.#S*UF+S")K MEW&4&.4[TZAUN;P_4.3^)#NQFU!E">CM-H:H'0C*LJ`41V%E#1=D$1MOAYE& MI(O@#8$B0KRB#EMO6EYB5Z%J$]#;W0SD8I>2:E$5D%94!81%-0CF\]C8T)E& MI&OC'<&(MHGYB'V%*DY`1BDUROV>O_'Q3:>64@M*<12Z-_=]WRQ9F4:D*0P^ MHK/I2/3.!B'C7#2VQEX&*A8BI%J($%H8+Q=6XZ;QZ/H^I+,)[,X&(<-!L[.1 M@8J#-I0BA`XFD1\0L[/1HG2%O&L8R=%)^R\0K8?:V2!D.&@>=#)0==#N;'`4 M.@BM:62]5FA$NL"/;FW@1A2/>7DD[1`RW#1;&QFHNOE::Y,8G7>*@=C:A'XT M7QI;@5_3#GM=Z!?7KN(ZL*+UF>[I]=HX!7OF5ZK0S6_7/2SN>P_Q"NX*0)6) M$W@@RHCQ!&Z('X)7(G9P<]S5*V/\+H`;Y=?&ARNX3;)_^2%:/4#;9C_812NX MH;'Q!P(1L!CV$VB\8$Y=C-?/"FZ3[_F9_IG7Y_+6.%=Z@J7QN].G%O?1XDN+ M]QZ/K(5[9%@]N$N%OQM0N,;T>9=\8JR57^"GO?XO$=O_`0``__\#`%!+`P04 M``8`"````"$`;LD]^C0!``!``@``$0`(`61O8U!R;W!S+V-O&UL(*($ M`2B@``$````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````E)'12L,P%(;O M!=^AY+Y-LPT9H*=S$YVX)-&G*BW=[>K'9UHC=>AO_/E^^<5(N] M;;(/"&A:5Q-6E"0#IUIMW+8FC^ME/B<91NFT;%H'-3D`DH6XO*B4YZH-W`2BQ2PZ5PTP8K8SJ&+?52O* MGEK#?3$"[2#P+^+DC'@"B-[[YY^+3P```/__`P!02P,$%``&``@````A`$Q^ M=I@%`P``-@H``!``"`%D;V-0&UL(*($`2B@``$````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````G%9=;YLP%'V?M/\0\=Z2KW5M1:A< M0A,V`@R;5MF+Y1*G026`;#=*]^MG8$E)ZS`U;[;O/?<>G^MKV[C9KM/.AC*> MY-E(ZYUWM0[-XGR19$\C+4)W9Y=:APN2+4B:9W2DO5*NW9A?OQ@!RPO*1$)Y M1X;(^$A;"5%?QRYIF0N]WNQCBK-@'U.J(UQMQ:M!%'I?\^#UZ+21ATP!%D28Q$7*7YBR)6<[SI>C8 MVYBFAMXT&I(=I/$+2\2KV37TYM2`,4FI)0.;2Y)R:NAO"\:4DE*T@"2,F\9& M7&]H+'+6XKJYWD3>;[/5B^-[8]:(^Q'$'?=<8`RI_! M0"2SS3Z5YA]$G::'_7`"/.#T)^$-H1*]V_8!0\P+$X$D3^S0V7`[]@"@8.`BUT;0!O[MZXSJ110$[C$/IK:(0[` M'-RZMMKI"LN,UL^I[XY+$J4":*Y,W^OBT':K8Q.`$,TQ"H$'024&Q$I(>Q'4 MM6W'])5Y&I7#B#S*UE*ZM0@H84K(>PW;PBNE;`.T*WJ*/`/E)MHE'2HQ34G' M5)`D56NJ\,,>84S>]QMY2^\OH/*^K6^OXVV$92(E9-]*I4=)Y3\IVIM++>SQ MPW&4UG$(E!CE3HY#RBQJ9A_.8%L]U(?P9(2ZKUN38/4NVC'JOFYOD%,P!PUR M\$"_>Y+=)'OF48'R,1%T]^&```$P``````````````````````6T-O;G1E;G1?5'EP M97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+```````````` M`````"4$``!?&PO=V]R:W-H965T&UL4$L! M`BT`%``&``@````A``-FNQV[`@``9P<``!D`````````````````*!4``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`&[Q\G3-`@``[`<``!D`````````````````S!T``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`"Y'RY]``@``(`4` M`!D`````````````````."<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%R/:0>1`@``SP8``!D````````````` M````DR\``'AL+W=O&PO=V]R:W-H965T M&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`(&!4]5E3```O^,` M`!0`````````````````&C\``'AL+W-H87)E9%-T&UL4$L!`BT` M%``&``@````A`&=O=ET1#```1W````T`````````````````L8L``'AL+W-T M>6QE&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0"J M``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`%X1LAM4`P``R@L``!D````````` M````````/Z(``'AL+W=O&PO=V]R:W-H M965T_2OP,``)L-```8 M`````````````````&JI``!X;"]W;W)K&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,HOF%"Q!P``V"```!D````````````````` M_;0``'AL+W=O!N(0"``!.!@``&0````````````````#EO```>&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`(/@6;ZB`@``[08``!@`````````````````/,(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`+VV8`31!P``@R,``!D`````````````````T?0``'AL+W=O?](US,%``!<$@``&0````````````````!0 M'P$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$)0`EHK$```9U<``!D````````` M````````8BL!`'AL+W=O&PO=V]R:W-H M965T)(@8``,X8```9 M``````````````````]``0!X;"]W;W)K&UL4$L! M`BT`%``&``@````A`&[)/?HT`0``0`(``!$`````````````````:$8!`&1O M8U!R;W!S+V-O&UL4$L!`BT`%``&``@````A`$Q^=I@%`P``-@H``!`` M````````````````TT@!`&1O8U!R;W!S+V%P<"YX;6Q02P4&`````#``,``" )#0``#DT!```` ` end XML 14 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
8. OTHER PAYABLES (Details) (USD $)
Sep. 30, 2014
Dec. 31, 2013
Other Payables Details    
Advance from customers $ (30,924) $ 5,160
Welfare payable 13,392 31,343
Capital lease deposits paid by third party 354,294 359,227
Other payables 152,070 217,070
Total $ 488,832 $ 612,800

XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
3. EQUIPMENT (Details) (USD $)
9 Months Ended
Sep. 30, 2014
Dec. 31, 2013
Sep. 30, 2014
Office Equipment
Sep. 30, 2014
Medical equipment
Sep. 30, 2014
Fixtures
Sep. 30, 2014
Vehicles
Office equipment $ 87,763 $ 88,985        
Medical equipment 2,801,508 2,831,882        
Fixtures 115,433 117,040        
Vehicles 45,364 45,995        
Total equipments 3,050,068 3,083,902        
Less accumulated depreciation (1,568,115) (1,528,620)        
Equipment, net $ 1,481,953 $ 1,555,282        
Estimated Useful Lives       p5y p10y p5y
Estimated Useful Lives, minimum     5 years      
Estimated Useful Lives, maximum     10 years      
XML 17 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
9. STOCKHOLDERS' EQUITY (Details Narrative) (USD $)
9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Dec. 31, 2013
Stockholders Equity Details Narrative      
Preferred stock authorized 20,000,000   20,000,000
Preferred stock par value $ 0.001   $ 0.001
Preferred stock shares issued 0   0
Preferred stock shares outstanding 0   0
Common Stock shares Authorized 50,000,000   50,000,000
Common Stock par value $ 0.001   $ 0.001
Accumulated deficits $ 2,648,087   $ 2,515,021
Stock-based compensation costs $ 3,839 $ 3,839  
XML 18 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
4. CONSTRUCTION IN PROGRESS
9 Months Ended
Sep. 30, 2014
Notes to Financial Statements  
NOTE 4 - CONSTRUCTION IN PROGRESS

The Company is constructing a new hospital building on leased land. Costs capitalized primarily consists of payments for construction costs, acquisition cost, land rights cost, development expenditure, professional fees, and capitalized interest. The Company is required to make payments for construction costs of approximately $7,870,000 and any excess construction cost payments incurred during the construction phase. As of September 30, 2014, the Company had paid approximately $15,300,000 for the construction of the hospital building. The Company estimates the additional costs to complete the project to be $35,000,000. The land lease term will start upon completion of the new hospital building, which is expected to be in the middle of 2015.  

 

The Company will amortize the cost of the hospital building over the life of the land lease of twenty years. Capitalized interest was approximately $548,000 as of September 30, 2014.  

 

EXCEL 19 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\W-S'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/C)?4U5-34%265]/1E]324=.249)0T%.5%]!0T-/53PO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/C-?15%525!-14Y4/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I7;W)K#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/CE?4U1/0TM(3TQ$15)37T51 M54E465]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C)?4U5-34%265]/1E]324=.249)0T%.5%]!0T-/530\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I%>&-E M;%=O#I7;W)K#I7;W)K#I7;W)K#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/CE?4U1/0TM(3TQ$15)37T5154E465]$971A:6QS/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I!8W1I=F53:&5E M=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF M72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U M;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T M7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)U1O;F=J:2!(96%L=&AC87)E($=R;W5P+"!);F,N M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^ M)RTM,3(M,S$\2!A(%9O;'5N=&%R>2!&:6QE2=S(%)E<&]R=&EN9R!3=&%T M=7,@0W5R'0^)SQS<&%N M/CPO'0^)U$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO6%B;&4@86YD M(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^ M)R9N8G-P.R9N8G-P.SQS<&%N/CPO3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPO'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N(&5X M<&5N'!E;G-E'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D/@T* M("`@("`@("`\=&0@8VQA2!/<&5R871I;F<@06-T:79I=&EE M'0^)SQS M<&%N/CPO6UE;G1S(&]F(&-A<&ET86P@;&5A2!T'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0'0^)SQS<&%N/CPO&D@;V8@=&AE(%!E;W!L928C,30V.W,@ M4F5P=6)L:6,@;V8@0VAI;F$@*"8C,S0[4%)#)B,S-#L@;W(@)B,Q-#<[0VAI M;F$F(S$T.#LI(&)Y($YA;FYI;F<-"E1O;F=J:2!-961I8V%L($-O+B!,=&0N M(&%N9"!A;B!I;F1I=FED=6%L(&]N($]C=&]B97(@,S`L(#(P,#,N("8C,38P M.SPO<#X-"@T*/'`@'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE&D@<')O=FEN8V4N($Y4 M2"!S<&5C:6%L:7IE2!M961I8VEN92P-"F]P:'1H86QM;VQO9WDL(&UE9&EC86P@8V]S;65T;VQO M9WDL(')E:&%B:6QI=&%T:6]N+"!D97)M871O;&]G>2P@;W1O;&%R>6YG;VQO M9WDL('1R861I=&EO;F%L($-H:6YE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE2!O=VYE9"!S=6)S:61I87)Y(&]F(%1O;F=J:2!);F,N M(%!U&-H M86YG90T*9F]R(#$P,"4@;V8@=&AE(&ES6QE/3-$)V9O;G0Z(#AP="!4:6UE2!IF5D M('1O(&ES'0M:6YD96YT M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE7-I8VEA;G,@;W(@;W1H97(@96UP;&]Y965S(&EN('1H92!E M=F5N="!O9B!A#0IN965D(&9O3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\W-S'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!S=6-H(')U M;&5S(&%N9"!R96=U;&%T:6]N'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^5&AI28C,30V.W,@8V]N28C,30V.W,@;6%N86=E;65N="P@=VAI8V@@:7,@0T*86YD(&]B:F5C=&EV:71Y+B!4:&5S M92!A8V-O=6YT:6YG('!O;&EC:65S(&-O;F9O2!A<'!L:65D#0II;B!T:&4@<')E<&%R871I;VX@;V8@=&AE M(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@ M86YD('1H92!&;W)M(#$P+4LN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^5&AE2!O M<&5R871E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP M="!4:6UE2!C;VYS:61E2!O9B!T:')E92!M;VYT:',@;W(@;&5S2!S=6-H(&EN'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z M(#AP="!4:6UE2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D M(%-T871E6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!I2!E>&-H86YG92!T6QE/3-$)V9O;G0Z M(#AP="!4:6UE&-H86YG92!R871E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)W=I9'1H.B`V.24[(&)OF4Z(#AP="<^4V5P=&5M8F5R(#,P M+"`R,#$T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`S M,24[(&)O6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#AP="<^4DU"(#8N,3<@ M=&\@55,@)#$N,#`\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E M6QE/3-$)W9E6QE/3-$)V9O;G0M M6QE/3-$)W9EF4Z(#AP="<^0F%L86YC92!S:&5E M=#PO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I M>F4Z(#AP="<^4DU"(#8N,#4@=&\@55,@)#$N,#`\+V9O;G0^/"]T9#X\+W1R M/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)W9EF4Z(#AP="<^4W1A=&5M96YT(&]F M(&EN8V]M92!A;F0@;W1H97(@8V]M<')E:&5N6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)W9EF4Z(#AP="<^4W1A=&5M96YT(&]F(&EN8V]M92!A;F0@;W1H97(@8V]M M<')E:&5N6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2=S(')E=F5N=64@2!I6UE;G1S(')E8V5I=F5D(&)E9F]R92!A;&P@;V8@=&AE(')E;&5V M86YT(&-R:71E'0M:6YD96YT M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE65RF5D('5P;VX@=&AE(&1R=6<@8F5I;F<@861M:6YI6QE/3-$)V9O;G0Z(#AP M="!4:6UE2!B:6QL6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UEF%B;&4-"F%M;W5N M=',@9G)O;2!G;W9E6QE/3-$ M)V9O;G0Z(#AP="!4:6UE2!I;B!T:&4@86-C;W5N=',@2!P;W)T:6]N(&EN(&-A6QE/3-$)V9O;G0Z(#AP M="!4:6UE2!H87,@97-T:6UA=&5D(&$@8F%D(&1E8G0@86QL;W=A;F-E M(&]F(&%P<')O>&EM871E;'D@)#,Q+#`P,`T*87,@;V8@4V5P=&5M8F5R(#,P M+"`R,#$T(&%N9"`D-#0L,#`P(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$S+B8C M,38P.R8C,38P.SPO<#X-"@T*/'`@'0M:6YD M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M:6YD M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6%B;&4@86YD(&%C8W)U960@97AP96YS97,L(&YO M=&5S#0IP87EA8FQE(&%N9"!O=&AE2!D96)T(&]R(')E8V5I=F%B M;&5S(&9O6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)W9E6QE/3-$)W=I9'1H.B`S M)2<^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#AP="!4:6UE2!H860@;F\@ M9FEN86YC:6%L(&%S'0M:6YD96YT M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE2!O9B!I;G!U=',@;V)S97)V86)L92!I;B!T:&4@;6%R M:V5T('9A7!E(&]F(&EN2!O8G-E6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2!C;VYT:6YU92!T;R!O<&5R M871E(&%N9"!F86EL=7)E('1O(&1O('-O('=O=6QD(&AA=F4@82!M871E28C,30V.W,@;W!E&%T:6]N('!O;&EC:65S+"!F;W)E:6=N(&5X8VAA;F=E(')E6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!E>&ES="!A M2!R97-U M;'0@:6X@82!F=71U2!B=70@=VAI8V@@ M=VEL;"!O;FQY(&)E(')E2!I;G9O;'9E&5R8VES92!O9B!J=61G;65N M="X@26X@87-S97-S:6YG(&QO6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2!I M;F-L=61E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!C=7)R96YT M;'D@=6YD97(@9&5V96QO<&UE;G0@:7,@86-C;W5N=&5D(&9O<@T*87,@8V]N M'!E;F1I='5R92P@ M86YD('!R;V9EF5D(&1U'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6EN9R!A'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`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`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`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`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE`T*<&]S:71I;VYS(&EN(&%C8V]R9&%N8V4@=VET M:"!R96-O9VYI=&EO;B!S=&%N9&%R9',@97-T86)L:7-H960@8GD@05-#(#6QE/3-$)V9O;G0Z(#AP="!4:6UE2!B=7-I;F5S2!D97)I=F4@9G)O M;2!P2!C;VYS=')U8W1I;VX@=&%X97,@86YD(&5D=6-A=&EO;F%L('1A>&5S#0IW M:&EC:"!A"!B=7)E874N)B,Q-C`[)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2!H860@86-C2!D;V5S(&YO="!A8V-R=64@56YI=&5D(%-T871E'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(&IU28C,30V.W,@2!I2!T;R!R971I65E6]N9"!T:&4@86YN=6%L(&-O;G1R:6)U=&EO;BXF M(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)V9O;G0Z(#AP="!4:6UE'!E8W1E9"!T97)M(&]F('1H92!O<'1I;VX@86YD('1H M92!E>'!E8W1E9"!F;W)F96ET=7)E(')A=&4N(%=I=&@@=&AE(&5X8V5P=&EO M;B!O9B!T:&4@97AP96-T960@9F]R9F5I='5R90T*2!D:69F97)E;F-E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2P@=&]T86P@8V]M<')E:&5N2!F;W(@ M82!P97)I;V0@;F5T(&]F(')E;&%T960@=&%X#0IA;F0@=V%S(&$@;&]S2XF(S$V,#LF(S$V,#M4;W1A;`T*8V]M<')E:&5N2XF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4 M:6UE2!I;B!A('!E'0M:6YD96YT M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M:6YD96YT.B`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2<^4F5C96YT(&%C8V]U;G1I;F<@<')O;F]U;F-E;65N M=',@:7-S=65D(&)Y('1H90T*1D%30BP@=&AE($%)0U!!(&%N9"!T:&4@4T5# M)B,Q-C`[)B,Q-C`[9&ED(&YO="P@;W(@87)E(&YO="!B96QI979E9"!B>2!M M86YA9V5M96YT('1O+"!H879E(&$@;6%T97)I86P@969F96-T(&]N('1H92!# M;VUP86YY)B,Q-#8['0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE28C,30V.W,@86)I;&ET>2!T;R!C;VYT:6YU92!A2!I2!A;F0@8VQA6QE/3-$)V9O;G0Z M(#AP="!4:6UE2!T:&4@96YD(&]F('1H92!N97AT('EE87(L(#,I('!L M86X@=&\@:6YC2!C87!I=&%L(&9O<@T*=&AE($-O;7!A;GD@=&\@8V]N=&EN=64@:71S(&]P M97)A=&EO;G,N)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-S'0O:'1M M;#L@8VAA'0^)SQP('-T>6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI M9VXZ(&-E;G1EF4Z M(#AP="<^-2TQ,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CH@=&]P.R!W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W9E6QE/3-$)V9O;G0M MF4Z(#AP="<^365D:6-A;"!E<75I<&UE;G0\+V9O;G0^ M/"]T9#X-"B`@("`\=&0@F4Z(#AP="<^-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CH@=&]P)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=V97)T:6-A;"UA;&EG;CH@=&]P)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!T97AT+6%L:6=N.B!R:6=H M="<^/&9O;G0@6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!T97AT+6%L:6=N M.B!R:6=H="<^/&9O;G0@6QE/3-$)W9E M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!T97AT+6%L:6=N.B!R M:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E MF4Z M(#AP="<^-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@=&]P.R!P861D:6YG+6)O='1O;3H@,2XU<'0G/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E6QE/3-$)V9O;G0M'0M M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V M97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P M="!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)V9O M;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE M/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#AP="<^,RPP-3`L,#8X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W9E'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P M.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#AP="<^,RPP.#,L.3`R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E M'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!T M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V)A8VMG M6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9EF4Z M(#AP="<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@=&]P.R!P861D:6YG+6)O='1O;3H@,2XU<'0[('1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S M;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W9EF4Z M(#AP="<^*3PO9F]N=#X\+W1D/CPO='(^#0H\='(@6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W9EF4Z(#AP="<^)#PO9F]N=#X\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H M="<^/&9O;G0@6QE/3-$)W9E'!E;G-E(&-H87)G960@=&\@;W!E'!E;G-E(&-H87)G960@=&\@;W!E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPOF5D('!R:6UA2!C M;VYS:7-T6UE;G1S(&EN8W5R6QE/3-$)V9O;G0Z(#AP="!4:6UE2!W:6QL(&%M;W)T:7IE('1H92!C;W-T(&]F('1H92!H;W-P:71A;"!B=6EL M9&EN9R!O=F5R#0IT:&4@;&EF92!O9B!T:&4@;&%N9"!L96%S92!O9B!T=V5N M='D@>65AF5D(&EN=&5R97-T('=A6QE/3-$)V9O;G0Z(#AP="!4:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO&EA;F<@0V]M M;65R8VEA;"!#;RXL#0I,=&0N("@F(S$T-SM4:6YG>6]U>75X:6%N9R8C,30X M.RD@9FEL960@82!C:79I;"!S=6ET(&%G86EN6UE;G0-"F]F(%)-0B`U+#`U,"PP,#`@*&%P<')O>&EM871E M;'D@)#@P,"PP,#`I('5N9&5R(&-E6]U>75X:6%N M9R!A;F0@=&AE#0I%:6=H=&@@1W)O=7`@;V8@3&%N9V1O;F<@5FEL;&%G92!# M;VUM:71T964L($YA;FAU($-O;6UU;FET>2!/9F9I8V4L(%%I;F=X:74@1&ES M=')I8W0L($YA;FYI;F<@0VET>2`H=&AE("8C,30W.U9I;&QA9V4@0V]M;6ET M=&5E)B,Q-#@[*2X-"D]N($1E8V5M8F5R(#,P+"`R,#`Y+"!T:&4@4&5O<&QE M)B,Q-#8[2!T;R!4:6YG>6]U>75X:6%N9R!D86UA9V5S(&]F(%)-0B`U+#`U,"PP M,#`@*&%P<')O>&EM871E;'D-"B0X,#`L,#`P*2!P;'5S(&EN=&5R97-T(&%N M9"!T:&4@8V]U2`D,S(P M+#`P,"X@3VX@36%R8V@@.2P@,C`Q,BP@3F%N;FEN9R!4;VYG:FD@87!P96%L M960@=&\@=&AE($EN=&5R;65D:6%T90T*0V]U6%B;&4F(S$V,#MA7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^ M)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE2!H860@='=O(&UA:F]R M('-U<'!L:65R&D@4W5N&D@ M4W5N2!H860@='=O M(&UA:F]R('-U<'!L:65R&D@ M5&]N9VII($UE9&EC:6YE($-O+B!,=&0N+"!W:&EC:"!A8V-O=6YT960@9F]R M(#(P)2!A;F0@-#4E+"!R97-P96-T:79E;'DL(&]F(&%L;"!M961I8VEN92!P M=7)C:&%S97,@9F]R('1H90T*;FEN92!M;VYT:"!P97)I;V0@96YD960@4V5P M=&5M8F5R(#,P+"`R,#$S+B!!&D@5&]N9VII($UE9&EC M:6YE($-O+B!,=&0@=V5R92!A<'!R;WAI;6%T96QY("0Q.#4L,#`P(&%N9"`D M,2PP,#`N,#`P+"!R97-P96-T:79E;'DN/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2!H860@;VYE(&UA:F]R(&-U&EM871E;'D@)#(P-RPP,#`L(&%N9"`D M-#`U+#`P,"!R97-P96-T:79E;'DN)B,Q-C`[)B,Q-C`[/"]P/CQS<&%N/CPO M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0Z(#AP="!4:6UE M2!C;VUP;&5T960@82!F M:6YA;F-I;F<@87)R86YG96UE;G0-"G=I=&@@86X@:6YD97!E;F1E;G0@=&AI M0T*86YD(&5Q=6EP;65N="!S;VQD('=A2!A;F0@97%U:7!M96YT('=A6%B;&4@=V%S("0Q-#@L-S`Q(&%S(&]F(%-E<'1E;6)E2!L96%S96AO;&0@:6UP6QE/3-$)V9O;G0Z(#AP="!4:6UE65A6QE M/3-$)V9O;G0Z(#AP="!4:6UE'0M:6YD96YT.B`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0M M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#AP="<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T:#H@,C@E.R!T97AT+6%L:6=N M.B!R:6=H="<^/&9O;G0@6QE M/3-$)W9E6QE/3-$)V9O M;G0M6QE M/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,3`R M+#,U,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CH@=&]P)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W9E M'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT+7-I>F4Z(#AP="<^,S0L,3$X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W9E6QE/3-$)V)A8VMG6QE/3-$)V9O;G0M6QE/3-$ M)W9EF4Z(#AP="<^3&5S M'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^ M,3,L,S4X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E6QE/3-$)V)A8VMG6QE/3-$ M)V)A8VMG6QE/3-$)V9O;G0M'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT+7-I>F4Z(#AP="<^.3$L,#,R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W9E6QE/3-$)V)A8VMG6QE/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(&IU&EM871E;'D@)#$L-#,P+#`P,"!I2!S=&EL;"!H87,@;F]T(')E8V5I=F5D('1H92!A<'!R M;W9A;"X@06-C=6UU;&%T960@9&5P2`D-38U+#`P,"XF(S$V,#LF(S$V M,#M#87!I=&%L($QE87-E(%!A>6%B;&4@=V%S(&%P<')O>&EM871E;'D@)#8T M,"PP,#`@87,@;V8@4V5P=&5M8F5R(#,P+`T*,C`Q-"X\+W`^#0H-"CQP('-T M>6QE/3-$)V9O;G0Z(#AP="!4:6UE65A6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9EF4Z(#AP="<^665AF4Z(#AP="<^06UO=6YT M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E6QE/3-$)V)A8VMGF4Z(#AP="<^,C`Q-#PO M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M=&]P.R!W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W9E6QE/3-$)V9O;G0MF4Z(#AP="<^,C`Q-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!T97AT M+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$ M)V)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE M/3-$)W9EF4Z M(#AP="<^5&]T86P@;6EN:6UU;2!L96%S92!P87EM96YT6QE/3-$)V)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#AP="<^4%8@;V8@;6EN M:6UU;2!C87!I=&%L(&QE87-E('!A>6UE;G1S/"]F;VYT/CPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#AP="<^-C0P+#(Q,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V M97)T:6-A;"UA;&EG;CH@=&]P)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W9E6QE/3-$)W9E6QE M/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V)A M8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\W-S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6%B;&4@87,@;V8@ M4V5P=&5M8F5R(#,P+"`R,#$T(&%N9"!$96-E;6)E6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)W!A9&1I;FF4Z(#AP="<^4V5P M=&5M8F5R(#,P+"`R,#$T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W!A9&1I;F6QE/3-$)V9O;G0Z M(#AP="!4:6UE'0M86QI9VXZ(&-E;G1E6QE/3-$ M)V9O;G0M6QE M/3-$)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#AP="<^*#,P+#DR-"D\+V9O;G0^/"]T9#X-"B`@ M("`\=&0@6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0M6%B;&4\+V9O;G0^/"]T9#X-"B`@("`\=&0^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE M/3-$)V9O;G0M6QE/3-$)W9EF4Z(#AP="<^0V%P:71A;"!L M96%S92!D97!O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#AP="<^,S4T+#(Y-#PO9F]N=#X\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^ M/&9O;G0@6QE/3-$ M)W9EF4Z(#AP="<^3W1H97(@<&%Y86)L M97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I M>F4Z(#AP="<^,34R+#`W,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,2XU<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,2XU<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@ M=&5X="UA;&EG;CH@6QE M/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0MF4Z M(#AP="<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H M="<^/&9O;G0@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O M;G0@6QE/3-$)V9O;G0M M6QE M/3-$)W!A9&1I;F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\W-S'0O:'1M;#L@8VAA'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE2!H87,-"C(P+#`P,"PP,#`@F5D('=I=&@@82!P87(@=F%L=64@ M;V8@)#`N,#`Q+B!4:&5R92!A6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE&%T:6]N#0IC86X@;VYL>2!B92!D:7-T'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=W:61T:#H@ M,3`P)2<^#0H\='(@6QE/3-$)W=I9'1H.B`U)3L@9F]N=#H@.'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-EF4Z(#AP="<^:2X\+V9O;G0^/"]T9#X-"B`@("`\=&0@F4Z(#AP="<^36%K:6YG('5P M(&-U;75L871I=F4@<')I;W(@>65A6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0M M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M2!S=7)P;'5S M(')E'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2!H860@86-C=6UU;&%T960@9&5F:6-I M=',@;V8-"B0R+#8T."PP.#2!S M=7)P;'5S(')E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE28C,30V.W,@0T9/+B!4:&4@;W!T:6]N('9E'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE'0M:6YD96YT.B`P+C5I;B<^ M)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M M'!E8W1E9"!D:79I9&5N9',\+V9O;G0^/"]T9#X-"B`@ M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#AP="<^,"XR-#PO9F]N=#X\+W1D/@T*("`@(#QT9#XF M(S$V,#L\+W1D/CPO='(^#0H\='(@F4Z(#AP="<^17AP96-T960@=&5R;2`H M:6X@>65A6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,R!Y96%R6QE/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UEF5R;R!S:6YC92!W92!D;R!N;W0@<&%Y(&1I=FED96YD2!T:&5M(&EN('1H92!F=71U M2`Q,RP@,C`Q,"X@5&AE(&5X<&5C=&5D(&QI9F4@;V8@=&AE(&]P M=&EO;G,@:7,@8F%S960-"G5P;VX@;W5R(&%N=&EC:7!A=&5D(&5X<&5C=&%T M:6]N&5R8VES92!B96AA=FEO&5R8VES960@:6X@=&AE('!A'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9EF4Z(#AP="<^17AP96YS93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,2XU<'0G/B8C,38P.SPO=&0^/"]T6QE/3-$ M)V9O;G0M6QE M/3-$)W=I9'1H.B`R-"4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#AP="<^-"PR-C(\+V9O;G0^/"]T9#X-"B`@("`\ M=&0@F4Z(#AP="<^,C`Q,CPO9F]N=#X\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0MF4Z(#AP="<^,C`Q-#PO9F]N=#X\+W1D/@T*("`@(#QT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE M/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^+3PO9F]N=#X\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0G/B8C,38P M.SPO=&0^/"]T6QE M/3-$)W!A9&1I;F6QE/3-$)V9O;G0M MF4Z(#AP="<^)#PO9F]N=#X\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@ M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP M="!4:6UE2!I;B!T:&4@0V]M<&%N>2=S M('-T;V-K+6)A6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E M6QE/3-$)V9O;G0Z(#AP="!4 M:6UE&5R M8VES93PO8CX\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#AP="!4 M:6UE'0M86QI9VXZ M(&-E;G1E6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E M;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&-E;G1E&5R8VES86)L93PO8CX\+W`^/"]T9#X-"B`@("`\ M=&0@6QE/3-$ M)W=I9'1H.B`T,"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,3`P+#`P,#PO9F]N=#X\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(')I9VAT M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#AP="<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=W:61T:#H@,3(E.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$ M)V9O;G0M6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)3L@ M=&5X="UA;&EG;CH@6QE M/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#AP="<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^+3PO9F]N=#X\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^+3PO M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9EF4Z(#AP="<^17AE6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP M="<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M M6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)V9O;G0M'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P M="!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)V)O'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#AP="<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[('1E>'0M86QI9VXZ(')I9VAT M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,2XU<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI M9#L@=&5X="UA;&EG;CH@6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#AP="<^,3`P+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,W!T.R!T97AT+6%L:6=N.B!R:6=H="<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#AP="<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H M="<^/&9O;G0@6QE M/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@ M6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,W!T.R!T97AT M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V)O'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!4'0^)SQS<&%N/CPO'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2!H87,@96YT M97)E9"!I;G1O(&%G&D@5&]N9VII($UE9&EC:6YE M($-O+B!,=&0N+"!A;F0@3F%N;FEN9R!3=VET8V@@1F%C=&]R>2!W:&5R96)Y M('1H92!#;VUP86YY(&9R;VT@=&EM92!T;R!T:6UE('=I;&P@861V86YC90T* M9G5N9',@=&\@87-S:7-T('1H96T@=VET:"!T:&5I2`D,38Y(&%N9"`D,38X+"!R97-P96-T:79E;'DN($EN=&5R97-T M#0II;F-O;64@9F]R('1H92!N:6YE(&UO;G1H('!E2XF(S$V,#LF(S$V,#L\+W`^#0H- M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE2P@3F%N;FEN9R!4;VYG M:FD@0VAA:6X@4&AA&D@5&]N9VII($UE M9&EC:6YE($-O+B!,=&0N+"!A;F0@3F%N;FEN9R!4;VYG:FD@16QE8W1R:6,- M"D-O871I;F<@1F%C=&]R>2P@=VAE2!T:&4@0V]M<&%N>2!F6%B;&4-"G1O('1H97-E(')E M;&%T960@<&%R=&EE'!E;G-E M(&9O2X@26YT97)E6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE&D@5&]N9VII($UE9&EC:6YE($-O+B!,=&0@=&AA="!E M>'!I6UE;G0@:7,@87!P2`D,BPU,#`N(%1H92!#;VUP86YY#0II M2!I;F-R96%S92!E86-H#0IY96%R+B!"87-E9"!O;B!T:&4@ M97AC:&%N9V4@6UE;G1S(&%R92!A'0M:6YD96YT.B`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E M'0M86QI9VXZ M(&-E;G1E6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W9EF4Z(#AP="<^,2TU('EE M87)S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@F4Z(#AP="<^)#PO9F]N=#X\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=W:61T:#H@,38E.R!T97AT+6%L:6=N.B!R:6=H="<^ M/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q-B4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,BPW.#8L-C`S/"]F;VYT/CPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q-B4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,BPW.30L-C,W/"]F;VYT/CPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\ M+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$ M)V9O;G0M6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#AP="<^,RPQ.3,L.3`Q/"]F;VYT/CPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,RPQ.3,L.3`Q/"]F M;VYT/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#AP="<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,2PT.#(L-38X/"]F;VYT/CPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#AP="<^,2PT.#(L-38X/"]F;VYT/CPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W9EF4Z(#AP="<^5&]T86P\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M M6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP M="<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^ M/&9O;G0@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O M;G0@6QE/3-$)V9O;G0M M6QE/3-$)W!A9&1I;F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\W-S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0M86QI9VXZ M(&IU2!A;F0@:71S('=H;VQL>2!O=VYE M9"!S=6)S:61I87)I97,N($EN=&5R8V]M<&%N>2!T2!L:7%U:60@ M9&5B="!I;G-T2!&961E2!O=&AE2!H87,@:&%D(&YO(&QO65A'0^)SQP M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE2!A8V-E<'1E M9"!I;B!T:&4@56YI=&5D(%-T871E2!I;FAE2!I&-H86YG92!R871EF5D(&EN'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)W9EF4Z(#AP="<^0F%L86YC92!S:&5E=#PO9F]N=#X\+W1D/@T*("`@(#QT M9#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^4DU"(#8N,30@=&\@ M55,@)#$N,#`\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)W9EF4Z(#AP="<^4W1A=&5M96YT(&]F(&EN8V]M92!A;F0@;W1H97(@8V]M M<')E:&5N6QE/3-$)V)OF4Z(#AP="<^ M1&5C96UB97(@,S$L(#(P,3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T* M#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0M M6QE/3-$)V9O M;G0MF5D(&]N('1H92!D871E&ES=',L('1H92!P2!E>&ES=`T*86YD(&-O;&QE8W1A8FEL:71Y(&ES M(')E87-O;F%B;'D@87-S=7)E9"X@4&%Y;65N=',@6QE/3-$)V9O;G0Z(#AP="!4:6UE2!G96YE'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UEF%B;&4-"F%M;W5N=',@9G)O;2!G;W9E&%M:6YA=&EO;G,@86YD+V]R('!R;V-E9'5R97,N)B,Q-C`[)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M2!I;B!T:&4@86-C;W5N M=',@2!P;W)T M:6]N(&EN(&-A6QE/3-$)V9O;G0Z(#AP="!4:6UE2!H87,@ M97-T:6UA=&5D(&$@8F%D(&1E8G0@86QL;W=A;F-E(&]F(&%P<')O>&EM871E M;'D@)#,Q+#`P,`T*87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$T(&%N9"`D-#0L M,#`P(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$S+B8C,38P.R8C,38P.SPO<#X- M"@T*/'`@'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/CQS<&%N/CPO6%B;&4@86YD(&%C8W)U960@97AP96YS M97,L(&YO=&5S#0IP87EA8FQE(&%N9"!O=&AE2!D96)T(&]R(')E M8V5I=F%B;&5S(&9O6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0M6QE/3-$ M)W=I9'1H.B`Y-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#AP="<^)B,Y-CF4Z(#AP="<^3&5V96P@,R`F(S$U,#L@'0M:6YD96YT M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`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`R M,#4@)B,Q-#<[4')E6EN9R!A;6]U;G0@;V8@=&AE(&%S2!N;W0@8F4@2!S=6-H(&EM M<&%I2!W:&EC:"!T:&4@8V%R6QE/3-$)V9O;G0Z(#AP="!4:6UE2!A M="!L96%S="!A;FYU86QL>0T*;W(@;6]R92!F6EN9R!A;6]U;G0@:7,@9W)E M871E2!I;F1E M<&5N9&5N=`T*;V8@=&AE(&-A'!E8W1E9"!T;R!R M97-U;'0-"F9R;VT@=&AE('5S92!O9B!T:&4@87-S970N($EF('1H92!C87)R M>6EN9R!A;6]U;G0@;V8@=&AE(&%S2!M96%S=7)E9"!B>2!D:7-C;W5N=&EN9R!E>'!E8W1E M9"!F=71U2!U M=&EL:7IE2!E2X@5&AE'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`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`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE`T*<&]S:71I;VYS(&EN(&%C8V]R9&%N8V4@ M=VET:"!R96-O9VYI=&EO;B!S=&%N9&%R9',@97-T86)L:7-H960@8GD@05-# M(#F5D(&%N>2!M871E6QE/3-$)V9O;G0Z(#AP="!4:6UE2!B=7-I;F5S2!D97)I=F4@ M9G)O;2!P2!C;VYS=')U8W1I;VX@=&%X97,@86YD(&5D=6-A=&EO;F%L('1A>&5S M#0IW:&EC:"!A"!B=7)E874N)B,Q-C`[)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M2!H860@86-C2!D;V5S(&YO="!A8V-R=64@56YI=&5D(%-T871E M2=S(&]P97)A=&EO;G,@87)E(&-A;&-U;&%T960@8F%S960@=7!O;B!T:&4@ M;&]C86P@8W5R'0M86QI9VXZ(&IU28C,30V.W,@2!I2!T;R!R971I65E'!E;G-E('5N9&5R('1H92!P2!D871A('1O(&-A;&-U;&%T92!A;B!E&-E<'1I;VX@;V8@=&AE(&5X<&5C=&5D(&9O6QE/3-$)V9O;G0Z(#AP="!4:6UE6EN9R!C;VUP M6QE/3-$)V9O;G0Z M(#AP="!4:6UE2!D=7)I;F<@82!P M97)I;V0L(&]T:&5R('1H86X@=&AO2P@9F]R('1H92!#;VUP86YY+"!T;W1A;"!C;VUP M2!T M"!A;F0@=V%S(&$@;&]S'0M:6YD96YT.B`P+C5I;B<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2!D2P@04]#22!I2!B>2`D.3(L-34Y(&%N9"`D M-C4L.#(U(&%S(&]F(%-E<'1E;6)E2<^4F5C96YT(&%C8V]U;G1I;F<@<')O;F]U;F-E;65N=',@ M:7-S=65D(&)Y('1H90T*1D%30BP@=&AE($%)0U!!(&%N9"!T:&4@4T5#)B,Q M-C`[)B,Q-C`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`@'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE0T*8V%P M:71A;"!T;R!C;VYT:6YU92!I=',@;W!E&ES=&5D(')E;&%T960@ M<&%R=&EE2P-"C(I('1O(&-O;7!L M971E(&-O;G-T'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA2!/9B!3:6=N:69I M8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%1A8FQE'0^)SQS<&%N/CPO6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E M6QE/3-$)W9EF4Z(#AP="<^0F%L86YC92!S:&5E=#PO9F]N=#X\+W1D/@T*("`@ M(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^4DU"(#8N,30@ M=&\@55,@)#$N,#`\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E M6QE/3-$)W9EF4Z(#AP="<^4W1A=&5M96YT(&]F(&EN8V]M92!A;F0@;W1H97(@ M8V]M<')E:&5N6QE/3-$)V)OF4Z(#AP M="<^1&5C96UB97(@,S$L(#(P,3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P M/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0M6QE/3-$ M)V9O;G0M'0M M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@/'1D('-T>6QE/3-$)W9E6QE/3-$)V)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(')I9VAT M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG M;CH@=&]P.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)V9O;G0M6QE/3-$)V)A8VMG MF4Z M(#AP="<^1FEX='5R97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@F4Z(#AP="<^,3`\+V9O;G0^/"]T9#X- M"B`@("`\=&0@6QE/3-$)V9O;G0M M6QE M/3-$)W9E'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M=&]P.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT+7-I>F4Z(#AP="<^,3$W+#`T,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SXF(S$V,#L\+W1D/CPO='(^ M#0H\='(@6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^-#4L,S8T/"]F;VYT/CPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#AP="<^-#4L.3DU/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W9E6QE/3-$)V)A8VMGF4Z(#AP="<^ M5&]T86P@97%U:7!M96YT6QE M/3-$)W9E'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M=&]P.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$ M)W9E'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P M.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W9EF4Z(#AP="<^3&5S6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M8F]T=&]M.B!B M;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V)A8VMG6QE/3-$ M)W9E'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P M.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE/3-$)W9E6QE/3-$)V9O;G0M2!A;F0@97%U:7!M96YT+"!N970\+V9O;G0^/"]T9#X- M"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M=&]P.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT M+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O M;G0M6QE/3-$)W9E6QE/3-$)V9O M;G0M6QE M/3-$)W9EF4Z(#AP="<^)#PO9F]N M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P M.R!W:61T:#H@,C@E.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#AP="<^,3`R+#,U,SPO9F]N=#X\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SXF(S$V,#L\+W1D M/CPO='(^#0H\='(@6QE/3-$)W9E'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,S0L,3$X M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E6QE/3-$)V)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#AP="<^3&5S'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,3,L,S4X/"]F;VYT/CPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W9E6QE/3-$ M)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V9O M;G0M'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^.3$L,#,R M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E6QE/3-$)V)A8VMG6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E M6QE/3-$ M)V9O;G0M6QE/3-$)W9E6QE/3-$ M)V9O;G0M6QE/3-$)W9EF4Z(#AP="<^)#PO M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M=&]P.R!W:61T:#H@,C@E.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E M'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,S@Q+#@U-SPO9F]N=#X\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(@6QE/3-$)W9E'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,C(W M+#6QE/3-$)W9E6QE/3-$)V9O;G0M6UE;G1S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E M6QE M/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^-S`P+#`W,#PO M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M=&]P)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE M/3-$)W9E6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#AP="<^3&5S6QE M/3-$)W9E6QE/3-$)W9EF4Z M(#AP="<^3&]N9R!T97)M(&-A<&ET86P@;&5AF4Z M(#AP="<^)B,Q-C`[)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V M97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQT86)L92!C96QL6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)W9E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E M6QE/3-$ M)W!A9&1I;F6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H.B`V-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@F4Z(#AP="<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T M:#H@,34E.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H M.B`Q-24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#AP="<^-2PQ-C`\+V9O;G0^/"]T9#X-"B`@("`\=&0@F4Z(#AP="<^ M5V5L9F%R92!P87EA8FQE/"]F;VYT/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP M="<^,3,L,SDR/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#AP="<^,S$L,S0S/"]F;VYT/CPO=&0^#0H@("`@/'1D/B8C,38P M.SPO=&0^/"]T2!T:&ER9"!P87)T>3PO9F]N=#X\+W1D/@T*("`@(#QT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W9EF4Z(#AP="<^5&]T86P\+V9O;G0^/"]T9#X-"B`@ M("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,W!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE M/3-$)V9O;G0M6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP M="<^-C$R+#@P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,W!T)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/CQS M<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPO6QE/3-$)W=I9'1H.B`X,"4G/CQF;VYT('-T>6QE M/3-$)V9O;G0M'!E8W1E9"!V;VQA=&EL:71Y/"]F;VYT M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)V9O;G0MF4Z(#AP="<^17AP96-T960@9&EV:61E;F1S/"]F;VYT/CPO=&0^#0H@ M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,#PO M9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#AP="<^)3PO9F]N=#X\+W1D/CPO='(^#0H\='(@6QE/3-$)V9O;G0M6QE/3-$)W9E65A6QE/3-$)W9EF4Z(#AP="<^4FES:RUF6QE/3-$)V9O;G0M M6QE/3-$)V9O;G0M'0^)SQT86)L92!C96QL6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)W9EF4Z(#AP="<^17AP96YS93PO9F]N M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU M<'0G/B8C,38P.SPO=&0^/"]T6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`R-"4[('1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^ M-"PR-C(\+V9O;G0^/"]T9#X-"B`@("`\=&0@F4Z(#AP="<^,C`Q,CPO9F]N=#X\ M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@ M6QE/3-$)V9O;G0MF4Z(#AP="<^ M,C`Q-#PO9F]N=#X\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^/&9O;G0@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I M>F4Z(#AP="<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,2XU<'0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0MF4Z(#AP="<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R M:6=H="<^/&9O;G0@6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE&5R8VES93PO8CX\+W`^ M#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O'0M M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F'0M86QI9VXZ M(&-E;G1E&5R8VES86)L93PO8CX\+W`^/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`T,"4G M/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H M.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#AP="<^,3`P+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[ M('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#AP="<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@ M,3(E.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M6QE/3-$)W=I9'1H.B`Q M,B4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I M>F4Z(#AP="<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T M:#H@,24[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CPO='(^#0H\ M='(@F4Z(#AP="<^1W)A;G1E9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#AP="<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^+3PO9F]N=#X\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9EF4Z(#AP="<^17AE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^+3PO9F]N=#X\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)V9O;G0M'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X M="UA;&EG;CH@6QE/3-$ M)V)O'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#AP="<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,2XU<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[('1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG M;CH@6QE/3-$)V)O6QE M/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[ M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE M/3-$)V)O'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^ M,3`P+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,W!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)V)O M'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^)#PO9F]N M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@ M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=P861D:6YG+6)O='1O;3H@,W!T.R!T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V)O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F'0M86QI9VXZ M(&-E;G1E'0M M86QI9VXZ(&-E;G1E6QE M/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W9EF4Z(#AP="<^ M,2TU('EE87)S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H M.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@F4Z(#AP="<^)#PO9F]N=#X\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,38E.R!T97AT+6%L:6=N.B!R M:6=H="<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@6QE/3-$)W=I M9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q-B4[('1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,BPW.#8L-C`S/"]F M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@6QE/3-$)W=I M9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q-B4[('1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,BPW.30L-C,W/"]F M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[ M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,RPQ.3,L.3`Q/"]F;VYT/CPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,RPQ.3,L M.3`Q/"]F;VYT/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#AP="<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O M;G0@6QE/3-$)V9O;G0M6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)V)O'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,2PT.#(L-38X/"]F M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,2PT.#(L-38X/"]F;VYT/CPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W9EF4Z(#AP="<^5&]T86P\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$ M)V9O;G0M6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I M>F4Z(#AP="<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R M:6=H="<^/&9O;G0@6QE/3-$)W!A9&1I;F'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`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`U>3QS<&%N/CPO'0^)W`U>3QS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2P@4&QA;G0@86YD($5Q=6EP;65N="!; M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\W-S'0O:'1M;#L@8VAA7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\W-S'0O:'1M;#L@8VAA&D@4W5N'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&D@16%S="!$2!0:&%R;6%C975T M:6-A;"!#;RXL($QT9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\W-S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^ M)SQS<&%N/CPO6UE;G1S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#@L-S`Q/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G0@1'5E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6UE;G1S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#`L,C$Q/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\W-S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S65A3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-S'0O:'1M M;#L@8VAA'0^)SQS M<&%N/CPO3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-S'0O:'1M M;#L@8VAA65A'!I65A&5R8VES86)L93PO'0^)SQS<&%N/CPO M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-S'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA65A65A65A65A2!;365M8F5R73PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO65A65A65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC&UL/@T*+2TM M+2TM/5].97AT4&%R=%\W-S XML 20 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
6. MAJOR SUPPLIERS AND CUSTOMERS (Details Narrative) (USD $)
9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Guangxi Sunshine Pharmaceutical Co., Ltd.
   
Percentage of medicine purchases 31.00%  
Amounts due $ 152,449  
Guangxi Tongji Medicine Co. Ltd [Member]
   
Percentage of medicine purchases 14.00%  
Amounts due 996,999  
Percentage of Revenue from major customers   45.00%
Accounts receivable from major cutomers   1,000,000
Guangxi East Dragon Century Pharmaceutical Co., Ltd
   
Percentage of Revenue from major customers   20.00%
Accounts receivable from major cutomers   185,000
Nanning Social Insurance Center and China UMS Co., Ltd [Member]
   
Percentage of Revenue from major customers 9.00% 10.00%
Nanning Social Insurance Center
   
Accounts receivable from major cutomers $ 207,000 $ 405,000
XML 21 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
5. LAWSUIT (Details Narrative) (USD $)
Sep. 30, 2014
Lawsuit Details Narrative  
Accrued contingency $ 1,324,000
XML 22 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
7. CAPITAL LEASE OBLIGATION (Details) (USD $)
Sep. 30, 2014
Capital Lease Future Minimum Payment Due  
2014 $ 25,588
2015 102,353
2016 34,118
Total minimum lease payments 162,059
Less: interest payments 13,358
PV of minimum capital lease payments 148,701
Less: Current obligations under sales lease back 91,032
Long term sales lease back obligation $ 57,669
XML 23 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
7. CAPITAL LEASE OBLIGATIONS (Details 1) (USD $)
Sep. 30, 2014
Capital Lease Future Minimum Payment Due  
2014 $ 95,463
2015 381,857
2016 227,750
Total minimum lease payments 700,070
Less: interest payments 59,859
PV of minimum capital lease payments 640,211
Less: Current obligations under capital lease 335,418
Long term capital lease obligation $ 304,793
XML 24 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
3. EQUIPMENT
9 Months Ended
Sep. 30, 2014
Property, Plant and Equipment [Abstract]  
NOTE 3 - EQUIPMENT

Equipment as of September 30, 2014 and December 31, 2013 comprised the following:

 

  Estimated Useful Lives (Years)  

June 30,

2014

   

December 31,

2013

 
Office equipment 5-10   $ 87,763     $ 88,985  
Medical equipment 5     2,801,508       2,831,882  
Fixtures 10     115,433       117,040  
Vehicles 5     45,364       45,995  
Total equipments       3,050,068       3,083,902  
                   
Less accumulated depreciation       (1,568,115 )     (1,528,620 )
                   
Property and equipment, net     $ 1,481,953     $ 1,555,282  

 

Depreciation expense charged to operations was $22,403 and $30,692 for the three months periods ended September 30, 2014 and 2013. Depreciation expense charged to operations was $67,746 and $76,611 for the nine months periods ended September 30, 2014 and 2013.  

XML 25 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
7. CAPITAL LEASE OBLIGATION (Details Narrative) (USD $)
Sep. 30, 2014
Capital Lease Obligation Details Narrative  
Capital lease payable under sales lease back $ 148,701
Cost of equipment under capital leases 1,430,000
Accumulated depreciation of leased equipment 565,000
Capital lease payable $ 640,000
XML 26 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $)
Sep. 30, 2014
Dec. 31, 2013
ASSETS    
Cash $ 5,236 $ 7,793
Accounts receivable, net 138,967 351,221
Due from related parties 111,754 120,352
Medical supplies 70,753 148,286
Prepaid expenses and other current assets 0 10,690
Total Current Assets 326,710 638,342
Equipment, net 1,481,953 1,555,282
Construction in progress 15,331,474 13,376,281
Deposits 185,739 189,851
Intangible assets, net 81,650 90,468
TOTAL ASSETS 17,407,526 15,850,224
LIABILITIES AND STOCKHOLDERS' DEFICIT    
Accounts payable and accrued expenses 735,165 633,061
Due to related parties 16,167,143 14,232,773
Settlement payable 1,323,801   
Other payable 488,832 612,800
Current portion of capital lease payable 426,450 402,138
Total Current Liabilities 19,141,391 15,880,772
Capital lease payable 362,462 695,689
Total Liabilities 19,503,853 16,576,461
Contingencies    1,267,637
STOCKHOLDERS' DEFICIT    
Preferred stock; $0.001 par value, 20,000,000 shares authorized and none issued and outstanding 0 0
Common stock; $0.001 par value, 50,000,000 shares authorized and 15,812,191 shares issued and outstanding as of September 30, 2014 and December 31, 2013 respectively 15,812 15,812
Additional paid in capital 443,349 439,510
Accumulated deficit (2,648,087) (2,515,021)
Accumulated other comprehensive income 92,599 65,825
Total Stockholders' Deficit (2,096,327) (1,993,874)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 17,407,526 $ 15,850,224
XML 27 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
1. ORGANIZATION
9 Months Ended
Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NOTE 1 - ORGANIZATION

Nanning Tongji Hospital, Inc. ("NTH") was established in Nanning in the province of Guangxi of the People’s Republic of China ("PRC" or “China”) by Nanning Tongji Medical Co. Ltd. and an individual on October 30, 2003.  

 

NTH is a designated hospital for medical insurance in the city of Nanning and Guangxi province. NTH specializes in the areas of internal medicine, surgery, gynecology, pediatrics, emergency medicine, ophthalmology, medical cosmetology, rehabilitation, dermatology, otolaryngology, traditional Chinese medicine, medical imaging, anesthesia, acupuncture, physical therapy, health examination, and prevention.  

 

On December 19, 2006, NTH filed the Articles of Incorporation in the State of Nevada to establish Tongji Healthcare Group, Inc. (the "Company"). On the same day, Tongji, Inc., a wholly owned subsidiary of the Company, was incorporated in the State of Colorado. Tongji Inc. was later dissolved on March 25, 2011.  

 

On December 27, 2006, Tongji Inc. acquired 100% of the equity in NTH pursuant to an Agreement and Plan of Merger, pursuant to which NTH became a wholly owned subsidiary of Tongji Inc. Pursuant to the Agreement and Plan of Merger, the Company issued 15,652,557 shares of common stock to the stockholders of NTH in exchange for 100% of the issued and outstanding shares of common stock of NTH. Thereafter and for purposes of these consolidated financial statements the "Company" and "NTH" are used to refer to the operations of NTH. The acquisition of NTH was accounted for as a reverse acquisition under the purchase method of accounting since the stockholders of NTH obtained control of the consolidated entity. Accordingly, the reorganization of the two companies was recorded as a recapitalization of NTH, with NTH being treated as the continuing operating entity.

 

The Company is authorized to issue 50,000,000 shares of common stock, par value $0.001 per share and 20,000,000 shares of preferred stock, par value $0.001 per share.

 

According to the PRC Regulation of Healthcare Institutions, hospitals are subject to registration with the health department of the local government to obtain business license for hospital services. We received our renewed business license from Nanning municipal government in November 2007, and this license is valid until November, 2020. Other existing regulations having material effects on our business include regulations dealing with physician's licensing, usage of medicine and injection, and public security in health and medical advertising.  

 

NTH must register with and maintain an operating license from the local health department, due to the fact that NTH currently maintains a facility with over 100 beds. NTH is subject to review by the local health department at least once every three years. If NTH fails to meet their standards, NTH’s business license may be revoked. NTH is also obligated to provide free services or dispatch our physicians or other employees in the event of a need for public assistance. NTH dedicates a very small percentage of its resources to providing free public services.  

 

XML 28 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
9. STOCKHOLDERS' EQUITY (Details 1)
Sep. 30, 2014
Notes to Financial Statements  
2011 4,262
2012 5,147
2013 5,133
2014 858
Thereafter 0
Total 15,400
XML 29 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Tables)
9 Months Ended
Sep. 30, 2014
Related Party Transactions And Commitments Tables  
Minimum future lease payments
    Related Party     Non-Related Party     Total  
1-5 years   $ 8,035     $ 2,786,603     $ 2,794,637  
6-10 years     -       3,193,901       3,193,901  
11-15 years     -       3,589,660       3,589,660  
16-20 years     -       1,482,568       1,482,568  
Total   $ 8,035     $ 11,052,732     $ 11,060,766  
XML 30 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
9. STOCKHOLDERS' EQUITY (Details 2) (USD $)
9 Months Ended
Sep. 30, 2014
Number of Shares  
Outstanding at beginning of period 100,000
Granted 0
Exercised 0
Cancelled/expired 0
Outstanding at end of the year 100,000
Weighted Average Exercise Price  
Outstanding at beginning of period $ 0.24
Granted $ 0
Exercised $ 0
Cancelled/expired $ 0
Outstanding at end of the year $ 0.24
Aggregate Intrinsic Value  
Outstanding at beginning of period $ 0
Granted 0
Exercised 0
Cancelled/expired 0
Outstanding at end of the year $ 0
Number of Shares Exercisable  
Outstanding at beginning of period 0
Granted 0
Exercised 0
Cancelled/expired 0
Outstanding at end of the year 0
XML 31 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Dec. 31, 2013
Dec. 31, 2012
Accounting Policies [Abstract]            
Cash and cash equivalents $ 5,236 $ 8,533 $ 5,236 $ 8,533 $ 7,793 $ 81,135
Estimated bad debt allowance 31,000   31,000   44,000  
Dilutive securities not included in the calculation of the diluted earnings per share 100,000   100,000      
Stock-based compensation costs     3,839 3,839    
Comprehensive Income Loss 72,925 92,559 106,292 249,949    
Accumulated other comprehensive income 92,599   92,599   65,825  
Working capital (18,814,681)   (18,814,681)      
Accumulated deficit (2,648,087)   (2,648,087)   (2,515,021)  
Stockholders deficit $ (2,096,327)   $ (2,096,327)   $ (1,993,874)  
XML 32 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 33 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2014
Accounting Policies [Abstract]  
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements include all of the adjustments, which, in the opinion of management, are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. The condensed consolidated balance sheet information as of December 31, 2013 was derived from the audited consolidated financial statements included in the Form 10-K. These condensed consolidated financial statements should be read in conjunction with the audited financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended on December 31, 2013 (“Form 10-K”), filed with the Commission on March 31, 2014.

 

This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the condensed consolidated financial statements and the Form 10-K.

 

BASIS OF PRESENTATION AND CONSOLIDATION

 

These financial statements present the Company’s results of operations, financial position and cash flows on a consolidated basis. The consolidated financial statements include the Company and its wholly owned subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. Our policy is to consolidate all subsidiaries in which a greater than 50% voting interest is owned. The Company operates in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”.

  

CASH AND CASH EQUIVALENTS

 

For purposes of the statements of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. A substantial amount of the Company’s cash is held in bank accounts in the PRC and is not protected by Federal Deposit Insurance Corporation (FDIC) insurance or any other similar insurance. Cash held in China amounted to $5,236 as of September 30, 2014. Given the current economic environment and the financial condition of the banking industry, there is a risk that the deposits may not be readily available or covered by such insurance. The Company has had no loss of cash in domestic or foreign banks in past years.

 

USE OF ESTIMATES

 

The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of net revenues and expenses during the reporting period. Actual results may differ from those estimates and such differences may be material. The more significant estimates and assumptions by management include, among others, useful lives and residual values of fixed assets, valuation of inventories, accounts receivable, stock based compensation, and allowance for bad debt. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

 

TRANSLATION ADJUSTMENT

 

The Company's functional currency is the Chinese Renminbi (RMB). The reporting currency is that of the US Dollar. Capital accounts of the consolidated financial statements are translated into United States dollars from RMB at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rates as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the year. The RMB is not freely convertible into foreign currency and all foreign currency exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US dollar at the rates used in translation.  

 

 

The exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements were as follows:

 

September 30, 2014  
Balance sheet RMB 6.14 to US $1.00
   
Statement of income and other comprehensive income RMB 6.17 to US $1.00
   
December 31, 2013  
Balance sheet RMB 6.05 to US $1.00
   
Statement of income and other comprehensive income RMB 6.15 to US $1.00

 

September 30, 2013  
Statement of income and other comprehensive income RMB 6.17 to US $1.00

 

RECLASSIFICATIONS 

 

Certain items previously reported under specific financial statement captions have been reclassified to conform to the current year presentation.  

 

REVENUE RECOGNITION 

 

The Company's revenue recognition policies are in compliance with Staff Accounting Bulletin 104 (ASC 605). Service revenue is recognized on the dates services were rendered. When a formal arrangement exists, the price is fixed or determinable. When the service is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.  

 

The Company generates revenue from individual patients as well as third-party payers, including PRC government programs and insurance providers, under which the hospital is paid based upon government established charges. Revenues for pharmaceutical drug sales are recognized upon the drug being administered to a patient.  

 

Patient revenues are recorded based on pre-established rates set by the local government. The Company bills for services provided to Medicare patients through a medical card (the US equivalent of an insurance card). There have not been significant differences between the amounts the Company has billed the government Medicare funds and the amounts collected from the Medicare funds.  

 

ACCOUNTS RECEIVABLE 

 

Accounts receivable are recorded at the estimated net realizable amounts from government fund, insurance companies and patients. Collections have not been considered an area that exposes the Company to additional risk. Hospital staff verifies patient coverage prior to examinations and/or procedures.  

 

For any Medicare patient who visits the hospital and is qualified for acceptance, the hospital will only include the portion that the social insurance organization will pay in the accounts receivable and collects the self-pay portion in cash at the time of service. Management continues to estimate the likelihood of bad debt on an ongoing basis.  

 

The Company has estimated a bad debt allowance of approximately $31,000 as of September 30, 2014 and $44,000 as of December 31, 2013.  

 

FAIR VALUE OF FINANCIAL INSTRUMENTS 

 

The Company applies the provisions of FASB ASC Topic 825, which requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of September 30, 2014 and December 31, 2013 the fair value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, notes payable and other payables approximated the carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates except for related party debt or receivables for which it is not practicable to estimate fair value.

 

FAIR VALUE MEASUREMENTS 

 

FASB ASC Topic 820, “Fair Value Measurements and Disclosures”, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements.  

 

Various inputs are considered when determining the fair value of the Company’s investments, and long-term debt. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below.  

 

  Level 1 – observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets.
  Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.).
  Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments).

 

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or non-recurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. The Company had no financial assets and liabilities carried at fair value on a recurring basis.  

 

The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment.  

 

CONCENTRATIONS, RISKS, AND UNCERTAINTIES 

 

All of the Company’s operations are located in the PRC. There can be no assurance that the Company will be able to successfully continue to operate and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. In addition, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. These contingencies include general economic conditions, the price of medicine, competition, governmental and political conditions, and changes in regulations. Because the Company is dependent on the domestic market of the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company’s operations will be subject to risk of restrictions on the transfer of funds, domestic policy changes, changing taxation policies, foreign exchange restrictions, and political and governmental regulations.

 

CONTINGENCIES 

 

Certain conditions may exist as of the date the consolidated financial statements are issued. These conditions may result in a future loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.  

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.  

 

MEDICAL SUPPLIES 

 

Medical supplies include both western and traditional Chinese medicine, are valued on the lower of weighted average cost or market basis. Inventory includes product cost and inbound freight. Management compares the cost of medical supplies with the market value and allowance is made for writing down their inventories to market value, if such value is lower.  

 

EQUIPMENT 

 

Equipment is recorded at cost. Depreciation is computed over the estimated useful lives of the related asset type using the straight-line method. Maintenance and repairs are expensed as incurred and the costs of additions and betterments that increase the useful lives of the assets are capitalized. When equipment is disposed, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in other income or expenses.  

 

CONSTRUCTION-IN-PROGRESS 

 

A hospital facility currently under development is accounted for as construction-in-progress. Construction-in-progress is recorded at acquisition cost, including land rights cost, development expenditure, and professional fees capitalized during the course of construction for the purpose of financing the project. Upon completion of the project, the cost of construction-in-progress will be transferred to fixed assets, at which time depreciation will commence.

 

CAPITALIZATION OF INTEREST 

 

Interest cost is capitalized for qualifying assets when the portion of the interest cost incurred during the assets' acquisition periods could have been avoided if expenditures for the assets had not been made. The amount capitalized in an accounting period is determined by applying the capitalization rate to the average amount of accumulated expenditures for the asset during the period. The capitalization rates used in an accounting period is based on the rates applicable to borrowings outstanding during the period (also see Note 4).  

 

Capitalization period covers the duration of the activities required to get the asset ready for its intended use, provided that expenditures for the asset have been made and interest cost is being incurred. Interest capitalization continues as long as those activities and the incurrence of interest cost continue.  

  

IMPAIRMENT OF LONG-LIVED ASSETS 

 

The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of FASB Topic ASC 360, “Property, Plant, and Equipment”, and FASB ASC Topic 205 “Presentation of Financial Statements”. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value.  

 

The Company tests long-lived assets for recoverability at least annually or more frequently upon the occurrence of an event or when circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. The Company considers historical performance and future estimated results in its evaluation of potential impairment and then compares the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, the Company measures the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows at the rate the Company utilizes to evaluate potential investments. The Company estimates fair value based on the information available in making whatever estimates, judgments and projections are considered necessary. There was no impairment of long-lived assets for the Three and Nine Months ended September 30, 2014 and 2013.  

 

BASIC AND DILUTED EARNINGS PER SHARE 

 

Earnings per share (EPS) is calculated in accordance with the FASB ASC Topic 260, “Earnings Per Share.” Basic net income (loss) per share is based upon the weighted average number of common shares outstanding. Diluted net income (loss) per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Potentially dilutive securities to purchase 100,000 shares of common stock were not included in the calculation of the diluted earnings per share as their effect would be anti-dilutive for the Three and Nine Months ended September 30, 2014. During the three and nine month period ended September 30, 2014, the average market price of the common stock was less than the exercise price of the stock options and the Company was in net loss position. Accordingly, the stock options were anti-dilutive and have not been included in the calculation of diluted earnings per share.

 

INCOME TAXES 

 

FASB ASC Topic 740, "Income Taxes” requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.  

 

In accordance with ASC Topic 740-10, “Accounting for Uncertainty in Income Taxes — An Interpretation of FASB ASC Topic 740” which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.  

 

The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.

 

The Company has made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by ASC 740-10 and has not recognized any material uncertain tax positions.  

 

In addition, companies in the PRC are required to pay business taxes consisting of 5% of income they derive from providing medical treatment, as well as city construction taxes and educational taxes which are 7% and 3%, respectively, of the business taxes. In April 2010, the Company was granted an exemption from these taxes until further notice from the tax bureau.  

 

The Company had accrued approximately $40,000 for failure to file US tax returns and Form 5472 between the years 2006 to 2009. The Company is current with its required filings. In addition, the Company does not accrue United States income taxes on unremitted earnings from foreign operations, as it is the Company’s intention to invest these earnings in the foreign operations indefinitely.  

 

 STATEMENT OF CASH FLOWS 

 

In accordance with FASB ASC Topic 230, "Statement of Cash Flows," cash flows from the Company's operations are calculated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet.  

 

EMPLOYEE BENEFIT COSTS 

 

The Company contributes to a defined contribution retirement plan organized by the municipal government in the province in which the Company’s subsidiary is registered. The Company makes contributes for qualified employees that are eligible to participate in the plan. Contributions to the plan are calculated at 30% of the employees’ salaries above a fixed threshold amount; employees contribute 8% and the Company’s subsidiary contributes the balance of 22%. The Chinese government is responsible for the benefit liability to retired employees. The Company has no other material obligation for the payment of retirement beyond the annual contribution.  

 

STOCK-BASED COMPENSATION 

 

For purposes of determining the variables used in the calculation of stock compensation expense under the provisions of FASB ASC Topic 505, “Equity” and FASB ASC Topic 718, “Compensation — Stock Compensation,” we perform an analysis of current market data and historical Company data to calculate an estimate of implied volatility, the expected term of the option and the expected forfeiture rate. With the exception of the expected forfeiture rate, which is not an input, we use these estimates as variables in the Black Scholes model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. In addition, any differences between estimated forfeitures and actual forfeitures could also have a material impact on our financial statements.  

 

Stock-based compensation costs that have been included in operating expenses amounted to $3,839 for the nine month periods ended September 30, 2014 and 2013.  

 

COMPREHENSIVE INCOME 

 

The Company reports comprehensive income in accordance with FASB ASC Topic 220 “Comprehensive Income," which established standards for reporting and displaying comprehensive income and its components in a financial statement that is displayed with the same prominence as other financial statements.  

 

Total comprehensive income is defined as all changes in stockholders' equity during a period, other than those resulting from investments by and distributions to stockholders (i.e., issuance of equity securities and dividends). Generally, for the Company, total comprehensive income (loss) equals net income (loss) plus or minus adjustments for currency translation. Total comprehensive income (loss) represents the activity for a period net of related tax and was a loss of $72,925 and $92,559 for the three month periods ended September 30, 2014 and 2013, respectively.  Total comprehensive income (loss) represents the activity for a period net of related tax and was a loss of $106,292 and $249,949 for the nine month periods ended September 30, 2014 and 2013, respectively.  

 

While total comprehensive income is the activity in a period and is largely driven by net earnings in that period, accumulated other comprehensive income or loss (“AOCI”) represents the cumulative balance of other comprehensive income as of the balance sheet date. For the Company, AOCI is primarily the cumulative balance related to the currency adjustments and increased overall equity by $92,559 and $65,825 as of September 30, 2014 and December 31, 2013, respectively.  

 

RECENT ACCOUNTING PRONOUNCEMENTS 

 

Recent accounting pronouncements issued by the FASB, the AICPA and the SEC  did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.   

 

GOING CONCERN 

 

The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has negative working capital of $18,814,681, an accumulated deficit of $2,648,087, and a stockholders’ deficit of $2,096,327 as of September 30, 2014. The Company’s ability to continue as a going concern ultimately is dependent on the management’s ability to obtain equity or debt financing, attain further operating efficiencies, and achieve profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company not be able to continue as a going concern.  

 

Management has taken certain restructuring steps to provide the necessary capital to continue its operations. These steps included: 1) plan to convert existed related parties’ loans into equity, 2) to complete construction of the new hospital and begin generating revenue by the end of the next year, 3) plan to increase sales revenue with additional medical equipments. No assurances can be given that the steps taken will provide necessary capital for the Company to continue its operations.  

 

XML 34 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) (USD $)
Sep. 30, 2014
Dec. 31, 2013
Stockholders equity:    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, authorized shares 20,000,000 20,000,000
Preferred stock, issued shares 0 0
Preferred stock, outstanding shares 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, authorized shares 50,000,000 50,000,000
Common stock, issued shares 15,812,191 15,812,191
Common stock, outstanding shares 15,812,191 15,812,191
XML 35 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2014
Summary Of Significant Accounting Policies Tables  
Schedule of Translation Adjustments

 

September 30, 2014  
Balance sheet RMB 6.14 to US $1.00
   
Statement of income and other comprehensive income RMB 6.17 to US $1.00
   
December 31, 2013  
Balance sheet RMB 6.05 to US $1.00
   
Statement of income and other comprehensive income RMB 6.15 to US $1.00

 

September 30, 2013  
Statement of income and other comprehensive income RMB 6.17 to US $1.00

 

XML 36 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information
9 Months Ended
Sep. 30, 2014
Nov. 13, 2014
Document And Entity Information    
Entity Registrant Name Tongji Healthcare Group, Inc.  
Entity Central Index Key 0001389518  
Document Type 10-Q  
Document Period End Date Sep. 30, 2014  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   15,812,191
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2014  
XML 37 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
3. EQUIPMENT (Tables)
9 Months Ended
Sep. 30, 2014
Equipment Tables  
Schedule of Equipment
  Estimated Useful Lives (Years)  

June 30,

2014

   

December 31,

2013

 
Office equipment 5-10   $ 87,763     $ 88,985  
Medical equipment 5     2,801,508       2,831,882  
Fixtures 10     115,433       117,040  
Vehicles 5     45,364       45,995  
Total equipments       3,050,068       3,083,902  
                   
Less accumulated depreciation       (1,568,115 )     (1,528,620 )
                   
Property and equipment, net     $ 1,481,953     $ 1,555,282  
ZIP 38 0001199835-14-000562-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001199835-14-000562-xbrl.zip M4$L#!!0````(`&)I;D4:\]RHU8\``!ZV!``1`!P`=&]N:BTR,#$T,#DS,"YX M;6Q55`D``[A%9E2X1694=7@+``$$)0X```0Y`0``[%UK<^,VEOV^5?L?N)Z: MU&R591-\T^[N*;?=[GC3;3NVD\Q\2M$D)"&A2`T?MI5?OQ>D*(,2)0$D9,N/ MI-)1DP3.P<7!Q1OX\,^'4:C#CSB_7O:/KX[.S M'>6?G_[[OQ3XY\/_]'K**<%A<*"^1FYP_"TA#E0C#WD*;T>1YS7<9[X>!;AS<7Y_RFJJZN:B@P% MJ3_K>P]]P#OQ,GA+'_Y=.T&(_F'<(.M`-0Y,BQ,I\[(\G2&I#^KTGS+XAX?; M)"0']$\%3!:E!P\I^;@SS++QP?[^_?W]WKV^%R>#?4U5T?Z_OG^[]H=XY/5( ME&9>Y..=*E1(HC^;PB'7=?>+M]6G"U]2\`I#WZ>O;[WT,69*<,7W"TS@;9#- M`K`?F_OER]JGI/%3J_R45)\&>.Z[%/M[@_AN'U[LTPSJJ:BGH^KS!/>74K;V MX6WU(4EC0T/VJO257U0!\K0W\+SQ+$#?2V^+CZ7$CZ'@/V0*"3[NG";QJ&*FHBPN?[N]1_Q9,!QE))O,GLZ>DX"^Z1.< M*`5+7#-=);'CLY]V/D&)1;KCFLCYL#\?^!%NOQ%OBC8&L\?!(@LH/TE&7T*96 M,O(R>/AY3'5UD[\1ZA0%%]D0)\?Q:)S@(;7='?X6I^F[-VQCKW=_N0VB?>L>=2N5^Z9\KO[N9O'H]RL<0HX$EUZ235Z'*-D4W21> ME-)9'E#9YPG[AG5<"R9XY=7NG`3.X^A=!0>-5GCE0M!>^DBQ]G0CQ;^?>U%$ MHL%U3.NXLRC-$SH>>A?S+4^4/(,06PV#O'O*K1P( M>:.^M(N$W[JWW4H=OS%__,)7,FVT\;Y\C6=5@FL]GM=1C)=VXAK2^M2EX\6N M57W7R_/K9?O6W*[W+U]S+QH\D)LX&OQ!ON,`;!;AX_A;%KQR\:Q+^+OG$?0\ M[TK:1B5MLT^R7]>^%GM;2ZS]NO:UB-OYN>K8J>OX_:+?)S[^\I^49\+RPZ3WNO0U3KNHWK+?"N+8YEHN]ZVEH]/>_ZX?=AJ2T9EGHJ&7"/ M5'[QTNPD\09Q1-<)YLFDH6&4`_I+VP8Y- ML3*@)SB*1R1:![O>+O.X31%7[VM6X##H)<"LR;(Q_.3/L`"3@R^%^*_P@*19 M`NJEYUDJ4W%>T2/\5AW`5WHNY4?LA=G0!ZLH7Y,X'^\J9Y&_]V%_6?R+^+1" M3.B6E0`__(0GW`38F.(2H18!&W.Y4#,[)2FT2/Z-O40T+;UJ M->6JV!8%\!L.PY^B^#ZZ!M7&$0[.TC0'1\\+>QZS`E@2VR+LKW&81]"`GIR2 M$.KFEG!SL33(N[3#%1['248W:!7'Q7*C_9MZFW6Q+:(6;([!W(,XX2]2UR,O MA'#*+'J%KA#VH@E+H19U4T$HL[P4\"D\XT_LSWJ]$"S$M!R.*DP,C/YN@IO% M5(%5;;EOQ+LE(Z@+:0]$IF/M@TL MEW#$8"\3W,?@V(+N"684T1!K2V">)(L!4XN0C#H=6HZ.`1*\+8Y\*%>MLUJS M;$NWZU9?@M&1SA)[/*3D("+AQYTLR=F3G2N4DQS?Q,PA#A#[M#YKG69#TS7; MUA\3O1RC&QLNU5O(LI'1BLV1[\?0D$@OO8EW&]*9>7@"9@P8C]O16):NJQ9B MO!(_I&2V/,:T=1-9IARV:8JS]N5JH7HNX^-':5?5-J.<$H@#?R-WT+"%=FG(AZ_)H>O(L(U6?$K[=?:OCFYH\P5XI4_JZ"-UJ/)K;>!5B-`J&4/K\\O# M&$/]Q6A;P&>:Z0P!P^;L_'3:>40N M:NP_LB@=R"S:9>-D+O*,SA'1"[(V;1X&JBLMF89:0>LT3C`91-59`5\>_"&T M\?`5E-#B=,"P.+@`K6"X^A*,1_K%3,H\>6L/,0Z"D\S3I&'N`(LU"4';D(J. MQT6OSRO[Q:;R!>6FI,._MSPW99X6O=VY*7PZWMJ<4\T7D2+!7-I3U2U*EISC MN]87PFW*2HGG/3U%9E?+NXZ".ZK`%*)AAQ[:=A-,9#'[J`T0'=GP M#35J;=D4[R1.Z2#-83W8DN@[L.":[G8<1]>$6=2G2#>.$_-5Q"$&; M7L&\;$YV'JP[->Y^LEQJEUYRD13U95#,,U_BI(B`6U"72VBJ4#.B91R7H84SCT0X^.(E]`*`%%HC^2@OYC9.<)]N M'6G;NNAI)C)5=JIB/98<=EQ]$1:ZA"-2!8C%^,W?^ M6EM;.70EV'1(:"Y*43BN57"V;>FKX2J;?/=\>NI%,F'+3:/'HP!3TZWGXJ?QM%\0TLWG(JCSM'A,O6L&G\<9KB9CNO;@5>AV M,HZW(>J6Z%S5H&89["8(#G1YG!+X'P/I+A)!9\W3 M>D;-!0_N-IM<%(^K:K7S::JNZP7?P5>$Q= MN;C4XRSRXU&QX.,<9Q?]&^^A=1:;CM9<0_.@;H`TCR%=#=K0ZZK M.^RVF_6;PN5M4.]IJFOI[$J)]>C5Z'`UGO[92XG/>VH`UYA^CP[J,YP:$5O3 M:CC6CY\6LC9%J^DVB^VPUL+E#_RT1*W54`P;"SZOPA8*FVII;GUC_3*\CM36 MJFRA)!JNRYYYL#EJ:Y4V3\T&FYE/9+358IMG!KS,=C9;YO7GUC`6ZQ8]?]K3 M9%8Q?O5(1&N(HX2D(.N3/($_RY-69"I6LVRV;G@"UEMB*.'RH]NZ9;U%2PD7 M9PTYIOD6+27L7FR7W2S^#(:"YX^-43DU(#W$@BDG-01A>/%:#FFFH\N"%Y:^ MB6H+3SLG7DQ.CE$;Q%V)7KX!24PW6W_&$>[/+?9HJ0&&PA*4#F1$%;%1,J+Z MV+1EA.32E@Q5$X4\+DXARL''/&X"^8S[X*QFT>'T.XGB!#IY9T`76O%TR+P> M2]D'_(ZS81S0C?!I>@S M+LI/RM"0X1K.7.]T$:D#(5$M(<0X3HN39Z>.2(I" MD&,Z:FW[\AQ(&Q+B/L4RU/H0?W<2PL(P-,=0I1M"2!26HR.V4ES'X=H+O:0\ M9?PW;R!'$:9CFZP=YC':ER.8CJ04.F:]K2[2"D!^08!ML;6,>A MJ&V^X@A<22BQKZ09FFW/5_IUF)9,1(6AV4[M^%]Y3$3EX>@:FI]?D642,8UH MFF//GRNPFDEY'#9ER%#]W0I#%/!\\#*HBI*\-U6GKAWX5C$A47*R7D3N9TP?(L"WV4/DUD!(8"G>JZ1X]^RD9BHK2<'7; M>F(3"DG1A-ZXV9I@<\OC"M_A*)>C0<=2$;OZ=B5B9WK"`K0UM;:/?[/TQ,=[ M7)W=);=QXXF-!*FVQFZIDL"NZ!C*E)\*74]W;1>(A95#5%2(+M(=M#:GY?,4 M520]]<)96YPW8D^Q&AK,:6\@WR_A3VAZ7N/DCOA8HE(=PW;4M?W;1GC)S(6[ M4=`8V%K7-VBVP*P$[ MLQ/?::8A51JYZ95Z)].#9AL+CW"/3=[91[(24QU/:B< M84%WI8^HL+JQZK;]IC4EGLN%I1@1J9JSDC,/D\VE1W@@S-(LQ.6.NZ6'O5)! M]MZ9]%/R13[0NWVUW'U670KN:>;^(C_S\Y23#?T8.M1P79$ZCY ML>6R%EX!I^JULZ#ET9Z_,5[R*I:U>%((BL^2JJ:Q2@:\+.QI&7\ M2',<=I'V.E`9)(4MB5S38GN=HB0;FJ9-=U!+:7RUNX6K-,$]DR>!?>!0?I7&F8T%CD.&/D.NST MYRK`KN2$G;"!#)L]8$R$W!*-GY+(@S:U;.^`H!EOL$OH^>'E$A>OZ`Q78V_R M:T_\2[^/_>RBSUZB>A$U'^?-7Y0E-\]6JG%JP M5I&(P,NF+CZ/H%GL*?]=N#/G0UQZ))#Q_R>OY3[]$&:'8R7-)B'^N-.'0`>*,\Z4&S("]W^.[Y6K>.1% MN^6#7>4:U-L_5$9>,B#1@:+N_##(#L^]B!YCJMS$T>`/HOP8IT738U>!K-Y3 M_O&#-QH?_DTW#L]O?IS]_E_EWDL5L(8';9-TB`.%1#_\#>FSR$BD9$.LC&DU M$?E8B?O*UQR\UP.A/^FK2QR/0US&B`SK,%6@&91#=#[]XG@(AF+`+Z^.9[^5 M.%&J8W4Z4*8N"T319TTTPRG&\IWS+@CW%BP+X#X@&4%\%.;R* M(^7"S^);G"BZNJMHJJKO54"6>DAMO3^F%BOB+?_H9O]#A>9R#SA@&E3=,TE4 MY,E&493,HAH6TD93K->Z8.%1U.#D0BD22]6JO+4IZ0C'2,9WX#\E?0&T:@4=])LUD0HM4!!@%%HGPK@)8`YQ,=I7! M),)^',8#^#V&UUZ6$!\2`V4FH;LW)H^!"B;Q>)@-O7`T#5*Q]^-TA+/IPP0/ MRS'OHC#N0M*3D5>]C.&'ETRBP?3O6>(%A'Y'14.O%8)JYI'GS#HC#XPZ*#EX M\!$D,"7>KN+Y^3B/?'KU#B1@.$F+S^GXNS>&V(?%.BL%/W@CD&])AQIQG-#% M5?3OKU=Z%Y$"%2>FZV@4Y!8%S=HMQ-(G($H6/[JDF3LK#.W3BSF_)G$^KMP:#3_S*/0(3"^:/+JW M/>6BU&KJC;`2>)!C97QE<,@KY7X8A^&DU-Y]!+33_#8E(-1D4KFX:;2[A;,D MLU04WE*I)>`81`=Z`]\TI5V0I,%H+R91`I)"I7('(<$"W[W$'RJ:22V'T%Z9 M+V]`*YI=:84UDE<.708*4M6_5Y;'Y1GR5:4$TAKG20H.*J,B`;=_-$AP4?T6 MI8Z.'].@WZEO279K']\/"5B;1G&+?:J&*NN5IFQGF5U.8RGU&I>Z7HG+B`:< MSUJ2YI2!HI&&PU,C29(O^O\UN]\AK;?* MILHL8?1&ZMY=,XJB>IFM`@Y0W7?O/VN),H'LDC(U^8!B/OWQ5SPRE8(4DI`` M[3DS0X$4X1'AX>'/G\LNQ!JIS2:7F20E<:[V!B^7QZ'HP->[@[]T4`8G:?%; M.3!_PCI-#M?/H]<`,=UP/!F']H[4G5D'$E]R/UI2\))XI`["WBVB):`>2[L. M!LL3/)31/;-'$L26LJF^G]W%>%:P?6CWX]*2`+^(A\LK&K)#R?H>T`.2*43=GT&`2_@+Q=*MJE$DBF3TRD#-[D%>V[YK'U24&91^,@>M\ MI'G5>L6/HA1X+Z<[[FJ5-666A;^#//XK&&8L&:ZE;@U&(4['T47U\@/88`JE MJTL$EA>H:-6\^)2?XC_QDF*F M(;[6>0+_B(([^'EZ###LE*GBC,$2'8:3(@$P\S'\BU^_1F./=<3L)C2#P(_` M)&#QHOP9Z8\S'[8:K0:H,JAUPD,0DO,>=T5V-G5NO%N:')4,$,].0+ZF%+4, M)%V3#$)ME/M!X;L^["-^F3:6-=S0B_ZF2--:<9YZUZ3D*.V9%A%&>$I&[V7+ M+PV&><(OMSHG_*O2MCT?MB8CK/'7JQZC-![G:2;L"T='.TS[`+Q(_(AJ@Q;& M!7Z"LR9*F)FG>!V,'A`HR8"61,U M"'@N_)0-/&#`PI6[#6&9E_=:29]!B`.SCL`.A-N'#R:^N/=`"VA'SGW@)3#X M$3^95UXX2G'H<1`@M4$(4A`U%2_Q4S(;;!]"^9(1&6/O'@A&VN(?@:_)!JF! M%YR"*RSD)^S5AIT$,M2M1G<#Z-\3+P,]$&^%YG7Z4\RW:SP9Q?>!,7+)C"/= M@$B(@D!I2L3H7IJ&N`IE)OO$X5F`6TY;D8Z]T0A%_A"=1WR!,$,27@N@`-]9.67?#]H4@Q[W<#S/6$7WD87^&,NT819K.#(1Y`'P>1*A+P#W#-P7D;SUDPA_()%8M`?6D,JA'Z*XB& M`Y#/**#"")A]S"\O?L'7AY,Z$?X%#2AY5<@*/-(2R!%%HNB:"]1A M&/A+,,&=,6HX:V$)3!!.<%5F:\RFXMT=AUDF.C+V#^<=2W.XZ)6[X8H4UCMZ M&8Q"N.DI2U'<*&NA6B7Q?+!'T=)'*>;]8//`WJ$)\S9,'\69`QL*DM&G1^Y" M&5-U.4$_U2@^Q$M'3C>3.>BR3>LJ415/PDCT++,TEVRL*,#D%;1MT6Q&69PH M8K5N9JB@W&IUXO"I?(2JQ)7XYY1A!D8-D$:;;!%%TZ&X%/:0,?!1PEL1>>A) M@T*4)#8BN2I:"`X8#R26/A.5.CSM(/H"D\)[N_/?3^&$ M%"[[R.>7SZ,AX3M_H5,25D$T:)U843F#*-LQ8;^V^U&$CO.S8!(G^)`;>NFM M(QT#[H/'VPU6H\\>+'OO1%&%_?M@G/IZ',NQ[XI[4!-M9(_QBLEA=%Z/B22S M@JY]#?_$^Q)>W"R^I]2\;K9'8B+O&U_#@F<2M2`C>_"*DUJ")T[^ M#NT1FG'^C_*@OF$U>!\O?!23"I0@R]IR1K]#%438,HN==2&I21/X&J8R*E8$ MT84!AVNT+\1=#\Q(FBMF+-RK*U:Q=;@"O/^X10^^.X[UYN#PA7<'MY85;(^0 MV'@O=*0,G[J"4V>>N\YVH2TP7LT%^$7IJ%I9S?&'3_OG1^?.R1?G].SP_/#X M8O_BZ.38V3_^[!R<')^??#WZ3+\A@G*MYFZ$POLLL@%9>992E9)WH_(Z$5GF M[;8IE--;&KG.2)ZQ"H@`@,9G%-OVD7=D$X!@L M?#SGFIRH*'/`3.\VWCNW<<8Q<8V[HH1$6?_- M;@JBZCH/^8]?]L\_.?OG!T#Q!(S!5K_A6M'RB/_:\@0\Y?M;2@&;Y,1VOL&XCN;'V=BP$I>L%0*>#'$R[` M37A]`]=Q%/X3F`]4WTO4'##W702-!$I$9?/0S/9H7/19C6,0-N5%&Z+2! M2P;:*A$0F)PK,!CHKH$RDJ'`\,;(]!7J3$$UP4'@HMT$([K@EU[TPX@!>731 MT4RR)24C8I*`^C',V`K\$OCXSCM2,HI^9\F#.+"BT1^^?#XZ^"AW5'T`K0R\ MT.092D',C+S$Y%'L.IA3I@GC3!=>$RMA[[INJ]T3,^,<58RQR4D!U=;Y'4P, MR<5@GYV#E6!@S`XE=J0Q+[5>8,0M:A6AK6;@SK!X\N$!23C.E`2<'9*$Z0_+ MN%5UNNA1PQT3VP*M+N_6@W6"OL4'D\!$MT%B6=36!MAB#S@$_H.JGS/"=@.* M`V%K_'B,">=#W-`K;DE)U-+Y3=!WR*["UW5#I\75]_-#5'0.SR^.ONU?'+X! M*751J1'/#"N7K%7S5!HKMUI'KU#F131\C\@@)O7^&`@=8BB5\@ULNT/[ M=9!;Q^S%1:4C!>.,,#U2T6C@&GD489%0+K[!Y'ZB"B_\SLA4Y;J6+XG#C()< MF\WX@D@,NJB25U(96W[0@#!$C5E4PBA1D%%,/,IE98%J`^%3QU?KB[2_E".+ ML>L,O0-*F429X8>P?%:MQ$,"[U!IVTA8\`>#:!CP%T'0J"`5BX]QC+$^R^*= MN?U1'>%[_IZ;CZ]W/G,]AMZ&^5LB9S.RIDU`P'!USW3#I/DY3.8B*A**=]FB=E M]RO0Z7@J9'@3IG@UT1>I4J(<-K?N;I0R)<05K,=X2,M"<58I=+63WR).M*72 M/$8Z%UW+N.A=1WIR:>D*.AH%2ZJ']AB,K)C=E5A"W[BW<1=$O\4@X8@4>0JC MHV\,]U'K5OH`11)-_T$OJ;!'%*W.X`%DFWGD4094$N?7-W8636AE;NPZQW') MQX=4CCT_,.HF':`\0T/R96OSW75(PV3_MJN65&",<^$&M6=\"I0UAK+/=#'? M?29C=*T^HG7)F-(E4$E[FJ7U`<.9$*LB0WX__XR\I_U`ML'*:J'2.BIEQ1V: M+W#=KF)\3=-?-VM7,T8^"T:C=.)AR1Q6F]"_)Y[OJW_/2]E=Z&,CC] MF-3?)Y@,!K\&D1;Y.UB6D/SJ_-O!P>'AER]56UAS-S[9[T#-C:@Y-%ZEWFZS MX]!M03_3NI1X5? M;=6TM:MI\\J\5Z6F;O++OS%7:OG>N[/#@Z_[Y^='7XX.R(5W7B+B5;OP M=*XM<">E==R&<9Z.[HT/GXO6J`3[*AQ6&@-\6'1E2R!(BI`O(XX MTJSSZ-";2=DVX\DHU+DL1`E(V:LKQZ3E.Y_R$3;`B^"Q[#@?,*.EU^A^W'6D M"XF>*$S57/_B[%(5`$M-"0=YA!+,/R57[I_H\O6<*\DT3A+T4.GK0)52DOPP M27`JF(+C/E@*$F1!@IE#(%-E),JA$*K"E%<'G_)=#&JK+``3J8HM-+%2/B9- MK>,P\(*-@F'&ON9[7JB7QCCU/05I:#&ZCZ:N.KL,T'$K&>`2G!L%MSCW,`DI MBD;AI:JCHA(Z("Z]4@F*G(UIJDGS""X])F#)U]_`E;?S%3ADC-REMH^"#1:. MR,2C;CGD\;\#?1'^5SR98>+O8`'4/7SFGD*.'(U$=L=<%*OT;Y+$UXDW3J58 M3J662(4212M)N'/2&=4UJG)$3.I%#!R.,^83.%4S,'.X!=PRO(&E8@;=F8KP M4ID2_';L#8.<5"S'3_)K8(N13L[5]XV&IQN''^$J8D\Z!E+Z!Q4.R):\`5:1 M5DE6O-R^/GPD7/&Q8Y]"(O**S^?ROK(@M9@X`U)AQ(>EQ9QP!VTZ`][`Y)H= M=4C&H*-XB<]0&*!7FHPKE5I%\#B*\_"S'Z7XGQ4%3@`"^6<+-SMP?QED=X'( M1^7FMZ4=QJQQ%1*PMKA?$<^9`L#I)D'!!(1(.-JU%GK)](TWP&S3JLC^P<') M]^.+<]1%#H_^V/_T]?`MJ2+[TUD7Q0NH0K.2\^!+;@L!(ZC<-<5AQ%<64R)7 MN?:-T(`+5,$LUVP7P5Q&P=#2J/5%42F4A+E!.$@<[`Q^`7U82H8V,2I4P+ MS$Z9`?)0[#K?3#Z4X'MP0;&Z%_S\A#^"47@3,\:)RD5RI'8,2]"CZQC?>\[Q M?_U\5$Y;-5+$,]MC,KCP!9W`1?M)'P+6>-=N(N@';]^,[%[BO7>=#J&#S*@T M?`-;/?VR?=D_.G/^V/_ZG7)AOQP=[Q\?'.U_=8Z.SR_.OG^C[/TW]-+9O,CE M9*E!7$R5;:F+02ZH&*2/H&%L,:@T5F9&D#L$Z1.R&)#$TT!0(D(%1%.H]K52 M_5WG,L85$NJ;92T)=QI2(F'`WI4;=EE2&0Z[/] MX`I3UDJ$>Y6D.XQR9+W[*#.-465]4F4;Z906+DO7OC`K)4IKOBC1*266(>HQ MB6SVM2I?3KCEDBJ)PJ9+.I?7Y>)+3N&R/L?^ M"_E-:DLT7[+FDH2`"Y@\"UXDO<&JX&+11U!DFW_F,8X#K/TCR-C9@M4@1(0N MEU)I>G@F5Z,ER;&SSLY58>Y).,1?7?]@,IBSE M,I.]^I182])^.]P__WYV^.:DZY3<+!31?4%>^(/8_5O@H1O.Y-!_MO`?=&F= M6_*Z$+!.XHV#NSCY(6BK.`XAN9BKSBGH4FY@&0(VF(9WB8@>>+'RE`6T^?[8 M(NX-Z`Q_>`D&0$#"3'+)&+8,+DKS5)T("()!NJI$<\99R)0`(M-)5I``NE7BL<"U.J1=58\,JB%9&I MNKI0M>4P*?UF?%74;NT)(P9(1BZ;!U2+=YG$H,..@MM`T-1&Z,+#%P\4VA?` M/B\L8-]^_T#@N]8W'X\<\^"#WM[@MZ<%\`>=VG-]1<9QFDI,=N$HXTLT..E8 MY*$6-N1**,3PC!@"!MA,5`'1`?"VA,@#C/O&BB66B5IZ)55Z$(Z1?W,=88@94&70AGE M.D$VW/VX/0]S'FW[/.R3R*,'SV+&>Q3?184:M_"1M\U^P.8[EU>3/7(Q;:P4 M[-D'K%=Q';,;T&PK%JRPBN4S\H7!JX([$\71COF%X&!\>6RZXH`58^B8+-=. M:E&J!2D6]!@:[SC47:B49&A"+&Q*R[785(<]M2$XUV1#R.(2(0Z5V]OE.%>L4'H2K!O807U+T"O6@K"(8,# ML(M@ZI(9%TY#%1,Q';?D+\'Z^4$?(:^R9,@O&FH5U$9\)2Y/M97C1\<5F1U]JZ@E9.1='L=2&:0V!R9=L41_/C(!6G'9FBMBPA6JSB:K1,D\`LEG>I_FH) M!60F5S#XXKTFQ$Q,=/R5^P1N\P;NU+33YN#D^.#P^.*,TR!=Y^SH_+_A?Q#D MYCO\Y>QB_^CXXNCP37EQ]DT"5)4*95H%$.O%0[LUQ^G9@20[2(HD.G7Q`:"\ M*X]!_KT"BA;'[^!3RD.=YD,TZA%O\E['V0A5G*&>N'T"2$9$>$"W.WPE=NY, MI:NG00]8[OCQP5PU1+0(+9+L%`PS6`B#SGJ*H`> M!B-!P]T4$OHL-'*7D1@R6;.)]TL<&',7,^DE9(:B?:,H0*JZC%@XL;O.IV#H MY1)`L<`6^:DB]4NRIA3$C8@XU1SK[*#<#<3>U5OQ=%D^04VF^!K5^LU;95`@ M.!)AH"_(9BNB/:N^G5\@<=74MNBDHMB9T2T>%_[)/@JWP.+HZ.?S\\/GAC M,E\EQ9O+2BH#)=:6`7)F(T\0.27T"6Z68P/Q6N.S=.6`X%6.T`V,9B5:H,[9 MRU5PT22,$(:6='BH;%8% MUR3)\B@-V(1)4T;"%;!`BK?`R8#-]07!T&$B&4EYND7Q\36"C@V08`QVO@^4PA1-NY0N?8&^AMO((&@-S3*^Q04'Q_8U1R.$\ M5/PP''GA6'R-Q2.BI5@SS)1\Q=T*6"<.4BW;")Z?4JX1'(H?5R1D>@V5I)G\ M8&?6:";CD67L*`RNX/',KV\D2S.A`.Y0-@]%,_WQ#>C`1[([AB4IRF\82R.! M!\(%*HT@OM1V%+L+3`,4XDW*2\7P/6@5!/Y22C[5#6-"9=**>J@3@HBCHE*J MH?GXG:02,%=S()X:7I065*+?@Q<.$821T"+%A45K,$-:)LF<8ND`*(6$C.SJ M4'M:_#@L1]#]JE;$6.P6=$]9;B"$8'S-)K7T+C'9&BJ416\XXGD(,>Q$P<6$ M5X4B"S'[9+EJZW2."FS?GUC MNHCJ.9OFDJ"EK!3*EKH+L$*"(90?;#:JWSYR(^H2)^Q705KU'>C%-Y2%*)F_ MPSBE?!>Q*<3U?"3P=#I%E2Z]GP\S_@(7FEQB[2PB1>&8=J(HF\'X1B:!Z@R7 M9MJ2LI>I\8FU-T]E,YCD2`7V1'DX&%*"-]W'J$8F2.T:2X_1%7$@(D$2O4!( MT#.N/?&T'6_RBB%^\2FAUKVANX4]V2?*2VNG]R-7[B)J;X*-AQ6P&#)NCG>$ M.E@I3X9YFPO0CZ9HSM/PG.PWSE/E1L:^4JP8V!N'?:WP:7*U2JM%@5X]F!?CG'_V[5UE[_0X+K8[4:F&W%[[WD$U MG>)']+(7.YRP\T$JZD454>F(;_(F8^>"B[/O!^C#W3DZWCD]._G][/#\33V: M^U8;\%G:UYHBN"`J`5/YFT608F5$<56OO^"J@=C6XM(#"A/IRVB%26$R2 M*LA?3:GNJ"-@>%;P6KX'$Z!3;M?Y/A'_FU0B6QED\AFW\(#/VBKM[E,^/%&G MBQBX)E\:HZJVB"`::`QLD8HU@:_?[[9_>G2Q__7H_V=$V9,OSM'QQ2',"EAQ3C2QHD`6D576_A*`;CU]G7;R'ZJITDV8O@+TH[LEI@XS3[.SS9UN6 M@ZY8JW&O;WJQ*7,B/>(R@_#*TDQ['>S'>#;Q]LXH,.Z+ZND,(.HL\JEDF4\C MLG!4J>9$UV)^8/BMLM.4)TF M&U*P384T7X\[4K%CE+O;J]2'ZR"SSAF3`^XY5Y(05#/NL`9'ZEJUX%)A.HM9 MS,T@@XS-P-+]I;I^%6@3/&1SR8OK,P6%7DIITNS?C-/"PI32*^-)O5QQ8C72 M)O'(&MZ4HV^G^T=G:.#A>_+UY/CWG:]'?QQ^=O;/SP_?5EW&C"`')>./R'5N MV3[G'",EMAC#95T%R55.\?U'U@)TNX5:D!.$PR+HJOS%'3!C%4\;91: MI1_TAU(]2:O1+0QE\)/4LV=RXDR#6S-H,3,-Q'&6EA9)]E9`.5'3FZ-$OAW8 MA><7>S!+E$G%%DR(VQF&";P]W+,XU9YIDP2A4RN+/G*6,85^,5RAKN%S:%I< M!W>)*9Z3PN+!MZC_$3 M`C.4>0I>(KNY&M_DS*[T-##]Z-I/XGPBT1L5O-,0$.@O3#.N=[%;1%+1P57( MQ22FLYW.*QTA7`YWF57)'+:N:C?#NQ(/!]'!GATBKGA]=5\MNTG!B=4/-E'J>/,*@BK+YF;(9;DS+;79A0G^J+K/^J8FPFU*0SFB_O';44G$RO<&I1=A>#0M`[ST(T01B^ M09CQEM8A"`B^H=@TG.D9'[+>8&LJQ M'CP#7>'-0BA@R]0#2@G]?/3U^P5HD(?[9\='Q[^?.Z>'9\[Y?^V?O2FTH$,O MB=S^$H M5WA'C\XGLWFZP$B>OQ'6'L,X6'-G=Y'A"4VJ$+6YBJ4TB;`738,6RECA'"%? MR"K':,INDBPA<7DO`ZM@RW?R!6 M!L`:5#VE?*7BLHB3,HX.IH(Q"%`(L@GUD8^NM!W#WU":([_#EYB,QD@)28#Z M*&Z&:H*B&F0ZZMQH>:46/S8V0I5CYU2)^M&].1Q3IZ<U2V6^%+1?Y7G@Z=)>ZI ME&6ZC&3+J#3M70)`3?#*CN[=BL&XM4UA_W2?<>VI?.3HY-C8OIHZNE?OHC\Z M/CCY=NA<[/]_;RL;I>2#V.OHMZK=^4W:CUUX/VW<"H,^P?%P#1.KC`P_4%$A M[^>LZCUUO\NZ+7X%%4&R'(XO?Q1;5LO^FFG2P>0KM,RA1)*BQ" M=.%BY:(1:N:I#B(L01,7,0% M9>*I%J;>3S$&<"-W"1#%6*`ZTT>^;[!.7;;_M>+OLMGHY_B^5?"3"HBP'5;* M=F7HQC>16WA@Q45Q[B,2ZI?V@7Q:1QZP;J-^_5.$NC;$SHD?.I1W"(;S?P4=WQP(/ M$[T41KJ)1X8?]"4N"PM3Y(L.F.*D*&\L`'U,K3PL)ZQ0Z9O&KM6A;7%OU2:5Z+ZXG4)7F6->:DX@K#>RU7A4%RN29_GAM`L)R0O M?'2OGZR,L]%@2-LI)7G:Q-JF$H0=S:L3-M:PMA/A.4FEZ M6KR/E$)4\?7I]\TJM-9/YBM3P6V/(Y96<)BYU#B'@W5D7"-0(0B1*^"J6"X) M[[&6;!4>&?M1(*^'E[#O6$.L@_6-[Q>_E&(UI64T2J11UQKH.S1-PAL05X52 M8(-U;>JC16OF!`7R9^"]Q!19LI')E-#>7D8H@]/LOK?:*%%E!3PSY`?`6\M9 M"_A1E56.SI^,81JL>JDAI07:Z7&BR&.H!U1)SUQAH<)4&N^]IX^UWU-1-*J3 M!/'@ZO;,A250\=H^V/>@ST%$2,A;`M/#R-\!<19E@T$A+@,D=]E5=2;FCU,E?A5(N]/WIE)O<'I^%TJ%\<3#6H( M#9/!2W&*C@C_*?'5]K;U`P4RP0=+L1-?]W,5W/6HL?H_&+_XE#EWQSLG_^7\^7KR9]O MRGE487R6&JOQ"*8TD]*R)V.=XV.:-H>2QEF M1W*"CTW,B9&"=)W.1+]^W;=P5B'3M].O)_]S>.A\.CP^_')TX1RBL)""6\S#,.^'L"=NZ;/R@'',(P,?:O,QEALP;N-,&*,+D! M\HA@G^P.0XI;20VC,CW;*5B1>8=.`-#7O$3:DUU+VR=Z7@OOX]C[$:0%^DTB M.&*E@>8TBN^#P$JU"6`O0O%4:I2J3*-"X;*HFD,O7#L+:<5%H<&7/7/:C?=* MT=-3FA5ADRO&'O,NXUL&B?M)\3OEN&!I\IM%KUF3TW]?#O=4;Y;2B\U96@(` MJ&NUWHN"(L6@]A&E#DL2*IO6ONK+(`)6L(JPV:;-2(71Q!9Q(I`*-H(D4TF; M/J9'G:D[X3YS;+]KWA+8'K+3*3.LP(EO4HR=7YP<_/?.I_WSP\\@P;Z='AZ? M[[^UGI`(_B:%2A3\*(.3(H(1`_&K9-12H%)%F#C\21!-40E`%:?::O9?^WJOSX@5>,&OLF^3+TQ MO?M86$E)\ND4V.R;DEP7<4:Z=Q5;I-I*Q'`>EF,;WP0]B&C8!$GZ-Y9=I""I M5$-/A),KVRNI;UC-QZ\<)1@P3K/.-*<,3N:'HFUFS^9\"'>#75V$LE(2=. M8T5_%F4*PB?>[;7<0:O+G0('+;?;-8\*9T+.^:H4XR"5EX76J'*,E[U.IV*- MS4;/;0U:O,A69^`..@,-[_#4Y[/&0E^75/CS)B3WR4.RH7!2)(KEH%2^`8(K M2=&3CY&Z"*\WGF(QLH`I-"(J[#)U`4JOFES!PGRPLI9.#HZ,M61SE#YX&1K' ML3PF#TQC4#\++E;"`&68\H($01(8)S`W."L1HD:R?,K\*1$0MN3@BFK& M[&$`(NJWR&(6ME+=86+U7M?MX]U^J#VHZA'(NJ[_6;'[?6;KJ"]6,!N M5^$P)+WL7V6WLS'Z^9(-56Q$*W23!K M=V3=#EH;DAEB8^FS.T]U"JEJ'V"-SQ59ZO6EE+S+S`!I(9P5?4!EZ6B_#LHF MA**7!@;L9+M!P4;(7F&F,85M-][%30WIA(T?K)(K0YCW4AAEV: M'Q&B=)I24Q;;>6[0S"C54`7"43:/#4Q?\;M4;FO%PQD_&\L.J0&&RMI7:<(V M!PK"@]T_]X'C?`,JBD%/I=N9>3^P]%YR"JE_`;J;RS*L=6V)55@W==DRFB\"3D` M.B+*[5`'85A>'8!MAFHHC=F'LHE\_N]_S].=:\^;_'INNCF9DI%3:;MQ`2-^ M&H'X_\__]__!QH?_KKZEX&\(_&8_\C7RC>E_K+_+S]W/["RX^H]?OB3Q&-^" MG483_G\6\\^#G7;CE_]<2DVWAC>M94*9-NMD.H8*ZXP3Y3`A&W;CUW6?5G'6 M9V]TJ_\YW2>VW*OS,LZR>/R;(Y3L\+]AV-UNH<]FO8:WLT:_Q%U\?_(HP!O8(FG5STMWG=KRK6'AER^_/$$LB@CO]&HW M[3Y!FR8PNM*"XJU$2+/W?A%)W-UI-I8A;Q4U\S=4,*CK M4@(V_5ZOO=0]G4G-TK9YC3.\J+/MNX-^][GNRYQ"[>XFS(+Y15K=M7\KVWQ+ MDF,+R*[%#V(93+ZKO$@]MQ&9[5,^3PZPH,& MV>,;\4=P$PY'2Y,0E;2L69%8J0>CGE]AU;,L- MC;*!%G*-+!Q+VY0+]A(9;COL*H_]N=[(!>V'KP@4-:M'ZBJ-BHT(0+YJR^!# MT^WV^FZSN6H=\7%25I=WL'F*^X9S1*OO]EI+B4NNB".V^L=6_]@.^X+UCW9] M*:#2,!GW4MGO+E;GK4CW:*]*\UC:P)7RO[7;P@?`C_/+4?"LP?W'R5G$C>]V M^DUWT%U*1*7B1)[->[G*N59Z`B^!1[K=KMM:1N1WWEM;(4/_SG4R]J\6KG=; M>1W'9\NFT_!3PQLLBJ;27[N1JIGKO7Z3$9>SVWUVP6R#`5]/-04=SMRXH#N-1G7RHUF*=H0!4<7)P<_^/7 M`ZO(Y"B"8:X3,+O74V!0A@W6I!%81J'TY3(/1P1$A5UXN?H;5NYS'\8#0A2R M>\B;@G-!S*8"!H'=$P`*N]J&,(G<0L][_)5+D[",2.4W/G8YC;DNPFH%SA4] M6+X&V\GE,U>!JFXKMK?GOMQ3J,DV_#F=*;Y-W[2[2@/_AD>FV.$//I7((R09C,9@,`>]&F.PBO=(LXZ.OS-':SJGE'*=YV#BHO'\"A% MMNQBF2[PY,QRVTT\FW__>QV)7BXW@_T?AUP-"^_&`17:77,I[KH+SHXB:^L1 M6=YU?L^]Z/IGZ!Q[W$_R`O[K/L[O\Y\A_`&9:8QM`PF]<9=E\-?,W[5Q4(I? ML1%1$/P>J[*'X6T(MST/,\>[]D+83C-?'%W_%>I.#4$,4L`NAS[`=BL$,<@< MC)7H(9J-I5E)%*8I]^WTG,N$6I!1Q\@H2Q`M<`A?'-OS9V9^%Z&FL/#SFHLL M2]2AP.4^2_KM`/F(C$T0$Q21%EE/A,"T9]\^.5T.IP+;?RA=ASZ+QH^""ZK* M;,_S"2R?7KY]1.=6[9[IH0'MY[I$6'D7%.(%$7&(C^J-\SLV],:-^`H?\'&, M/T`P8`])9M0L"%P<]B:G7^01EFESK87K_)\0F2-W/A,XUC!S-0$'^+$/>":& M$:8&MGB!%8F3R*IFI*N///C`R6.C'8(TGCZ4]`:A:;"/!YQ):1]\;^Q=,YKK M0P=!-)G#(%`M+<44>@@W_+D)N-\VZ!P5>D&[)4\=+/";EP#G#4BNM=PRU?#% MP!L9%![J7H9UP`KZE)9M^-&5@U>(9HAAY%;N!S6CIO[6<`MN$=8:B*%:MIZB MI3RAVN,`)(R95J)F=/)HNNU6A]@EM(=C M!=2[)Z-0/Q=/?-&,I3'?>U&P-;YY?\4)"8TP2.C;>0JF+OR\?GL#]S>[0VD) M-(+L%R)G0XJR/4>;/+V;O^J'ZCR/4@0:=T[!F!Q[PR#/!%QXUW7H:4(>4I^6 MNT%%%_@E^!1]R*6>"P9.0,!1N(4NT2!T6W@BNV88U:'89SC!Y=*F\%AD,W## MVDT&:V]V"!`>!=^X3`MO[:--A2V$DP>L#7K2&'B#B/!S$@BU%^K662EW"`:3 MI>5V.H(I-ACTW,%@4$8(0QJ6P%W3BVT;SCKT0.I_3KQK$"(':DSI1(;#7X/#O=JL9.#QRODM#UUS?SF-NJVXA3.MQ5[(,T@R[)V7Z7 MC0(\^"8]H&@SEH[^U1IHR,,Q'B/Q\%!$M]$8SF/2NX\B00.APQ`;;6X^MWUS MCTQ0XM6!B![N12%0)@\34$M8$LBL)'1E%?Q@S%A) MA27::NR19X*YKM-@%IP#CU"LPAIO;]DR_!QJM+W-TLI($,8FU3LBP/A&U M)A.<+]34$Z5:()@P]0)4?A0,R6JC;XS07%&0E`*C[#9#Z-(AS$>`<-A^4WME M]->T*U)_%7-'?/'N]UINK]_FP6;,1)^DK^"%?M?>:[K=YAZ]1/QVO6NW.VZ[ MUZ4/\E44;#EL,:6@5^&++CSE]*&;8$0`SDEP!18NW]N`&E(R)81)[+%'$M&F M"+6N*'8(A*MRSZDI=Q*8]C_DJ"<:T)()HW0V**-S&<<_&$J,_&,:!XG]ACHA M#LVG?6MZJ\>,S"MO)Z+)Z1W3"+!*+@F!PR#P4]>L5&.=L?EO+&@1#7(%3PNV M!O;_"&>NZY.`O)XC7"P+MQ!G8P0K;%C.IZ0[L6O?M&E-0KRI?7KB\A.#A]D) MB'#W&LU'4//XB[K)(.XQ,CHV=IIHR#?J^!,%=])"%ZFE?@^1`J>Z1M9,!#R3 M<-C([Y\R7B=<3IJ&&S2/$0`KD*Y06+2$.#BO4'7@G;VANZ'ZGW2E8R3W2Y9^ MY=B^9IR/59\CW$91V^R8Q"CW+=!',;^-`R056*ETA:!2A4*S5PXT52_+]/$H M.<([.8?<-\9"J%EQGM\S@_PL4HBXSX;K&O;C^3*QA#5[@]K8+AI@:HM1HV=M M]1?!,0&EL=M?2K'4R\,QP8CJXBO?^'S8&CE+C9;;7D96VT:(E842O8$G>AOP M"KWJ2@\PQ9K-IL]%QMJRRC)OB5R"4P_1O=P58N<>';K\:P M61Z;;$75@QS8AH=Q*ZI^._T#[70EJH9E]\I69&F&8??25F0ID:6:ZAKWH_+7 M%;AH*\A6*\@&3;?17DE-PF8(LH7JNKYB>A(Y(XN2S?#L*C9N6X+U!#[N[KF] MWA(TPHVKK=FTYF5'D7,RS&).LRT'%-Q-,33Z9[P.[X_C\0'.0<0 M^Y:IGCC<,[5P"757'T[\-E^N>$12E;HZE0W7:7/R9&CZM.BNYG;8":=7X3B7 M^J%(),K,"R171XVP2:L%ZD1[DJBP'`PUY#DQM1%1P*EF($\QVY3(O<5R$,P* MH(W&_8+QKC&E/>)YJ1,]97!B2U7>+2`TC:,(&[%7)",0#=/%%W#(HQ$WL(HS M$PVED*!0`L/-`-G@``L,A`F.0)9J(:JC;\6]FI$,5YE@WZ-$ALK\#R=CW%C$26+EF:NZLZ(YFI.-BVKWJ%O'Q(C:MF^.6\BLMWJZ_2 M?3[-Z:45&4&.]\=;<2U589D:#GJ)WJQ!(IW;H8-^_I8`_!=L59L&\ MIM?3XQ\K#W6H";J+1#4^P*T?M#KS=D)8:AOI9QYL0T^BZ\("5\"=2[JB,VV- MFLO[,QA=89J,0J6JM]"ZIS\OERR4*#Z8-[]R<:[>X!%J6!]-M]VI:WRL\ZVI MN9XBZH"@1:2$QDOE\G:WX[8&\VJ"&\RDS[-I`[?5JAL;7I_`KJ'K M/;[8@ODZKU*U')-AZ8[&5=87=5M/",^MK+74R@9^CO94JXRW8__NY1S31AA- M"_AY*>*^X$8\Q6N[OB*'E7I@._V^VY^[,&=%_5Q6-.Q&=819*3&]9LOM-Q:5 M$TMQG2_7!5YVL)];H++85R2[/P41.[Q?,P#@:1)!_#R)03L4' MRO#1'"=@X&^JFDAOO(0QQR=Z)PD_V/'R["9.J$D"8P6B(6/@_-XA[FE3`:&A M/1_%#XP6IBF!5@ON7IQG:>9Q+OML7+;*/5SJ;KXNWM"WXH`@H=_*E:@_[M^; MS>[[VH/#_VLV\$%4:E:+_J_R:7C(ZMK7T;DG7UNG6W5E&?E[KOM*E)@[V^RZ M?7C!FH.F&M9<5*?6)9U^^;87=HFSTG4]S[PLS^+DWCD+J$]"^OHO-;QS:19. MI!Z1G&GF1GSU[G1?A;,#:L>)16SQ&+CZ"C&4,^^GIU$[APCB&8WN"2R5FH)< MYAD7GOKA;0AK\U/Y'M463A(I?-38IV//#S1,NQ5>W\#^/PN$W)\02=5/E?$D^M,HVC+O/5YJD%F*IV*!IDQU`R.J59C4%2-G(>+#)J M[).PO+?0E+'6/:.`0Z;@[&,J@0P3%(?S0)U`&HWD$!!1.UT^I M'.DLP>!4M+RMTYIH(UL7KL@8QA]R5J/13CIA./?B_+EFZ%>H2M.Z=QA$'YM# M!%$JP!YCZ5T`(N1=V^VW![-[$;$-.U?[XM?'6+/!U&$J0+P8!WM&>J,18WS` M+.VVVVZWE:&/O289(871[[G.M0`5[HNDZ(0)M1Y,`*U M-TGQ\8&Y:`'$%6E^F0(]#&BC/A-RE]XD(*6%R4!D(&R[C:T[4U*@APRO<^N- M!&2(6AN"#BU0)?#W";8.1,*FME&H\U&@*H)>(0[,E1G9=0/PW5 M%]FOW!(B)D]5@^=/%!TY'X):@-@QL1^,5'?D9M?MJ,[(."'+$.16W9^#`(72 M-!]/6#6!A\VH&]IN=DA)V+"SV!BK9AFYL?U&;8/D4!I1.[<.N[F1:P7;K5N!'D35]&XI M7T'5V2/L)SG2J#/[33#6.FN>Y4F@.A$F/X),)#K28#0FI-X0:-EQ>NMN0OAE M0OV&K:\QI=]@TB;;C:)>ZTT;A5&'9`#4H[0K$N]6&MMT_0*L2]26+<0VQ!'=RB=6?61*2`6>&] M;O/_<:-+V>W4I_&2#S+"O43/>T*1]"PF4HPUE`YO`C\?!:\MG+AZ(^DA2VB9 MJ)MSVAK+-VUIU,6BKLXA1W7%; MO7E3E.OLR888#7#BJ(7*[2YTU.1YM9*YU*K-J.':>1DZS=SEF=O:K85F7JAX$T-@ M*]W/E3N:-CK=^5E=7J6`I)/F8_@F''BJ0L@3G4/L#;/P%ETVXA21B/S?Y*-5 MV17L5'HL0:-2;M)Q3LP27]%*JM*5GHV4<\H( MJ:3C:8_M["F76](^[\@;#2JFC^//`-^RP%\_8^S#W?6N@_43&Y1\TQ[NZ0W9]'PT.^@?,];=3>)Y9'M_II\5EMUTO-C,/_@G!W>U1;N91 M+JJTOMISW!1N6<(!S?=(OX9R$YJ!VQS?X>0+; M2,14`F+.+-]X!`/#-.QYM*5.N0?/64`PLZ?84/("EI%B50JLR73QT5]=3S>> MSSDW6?Y[%CM"K(/4AF^A8\%%J64')2P2C`KLAG>=!`$C<1+1%' MUW^%SL&-%W*AT>F-EXR]X3T,M>M\S?Q=U_D]]Z+KGZ'Z[+?`#X?(C>83B&FC M1CR'\87P@Y8W$[?T?F,RCC'K6L MT@!$1`BB@C(247R%'I+W!/D):\W',@I]V4F"81#>4JW2K%XEU;U6"*?G7:?K M-GI[]`G\N3?HNHBQC#@ZX6TPNN?&*4<*&DD@UV<7=Z4SQ8.&RJ6)"?;Y)^%S MCNZ==\W>@&EH]OHE`IPC>UM*!$S#]3YM_FZCR_-W&ZWR!FP\.LUJ+W!D[K"^ M"'1OX;I&M&D>46+Q>0DOWZV\]<["-UX^=3B"LTK"(5%Q$'N$T2MBP)U'#EQ: M5U/+`>0T0C8O7?P9EUB85*[+@Y=XWHYF[^"_.LV>V^TWY:XTW4ZKZ;9[;7[L M56-Q>KH)-#@EU"IZCB;\',VZ7`JQ:0E7^]W>P&VT>RS%2*Y@Q_!>W8F??*7? M-?<:[EZGI3:G[S;VND1%<>;*"_U*K[;64,Y@:F^$-V`<9O0>OW7%1)J7&^$F M#`B/_$V<4BL/HH1DWB."";[G$2>'U$HL,M>7&_H1C!ZR-+PU/"W<59HTG'J* M6FY7H4TK^'.2*?#!41IK<+HD'@8I29#+/!RQ)\^)8&-ZC<;.):Q2+0*_(1+3 M!0VR,#.D<[.]4S"X_5<[([V.W['<0?)41&$>(@B74;>SF2E,<#<\F' MOXVP\GV8T`<0.9Z(P%%VG4\V^G?P69`>YL0W1>;//77L>XR+X>Q]'.=F]7L[?+P.W9O&+& M=NUBQN9.]Q&,[`=G6KQN?#5!;Y&:(]#EVT]L=[#!95CK**M;Z!A:[EZ_ MY_8:=<'_MD>QRJ,8=-Q>NRXDYCR28DD25.(-7O0F;MLZ5:.Z>E!SISF?)K2]^YL\0ATF[O8';J\W M;ZK4!B]Z$[=M?8]^#7.MAESH[;3FTPF6ZP%ZWM0K^&@-L(SM876WI0\U*=XMMY,+NH+.\MFTVUT6^Y>[?9\VP/=_`/M-=R] M7F^E`J]"[IMD9),W.T<:;#F#%H/O^`A2E+V4;?M<*;,/@M)C`E`8>=$P]$8P M!:R3@^*3!/X493.ZP:OLGGS$G=Y-DI9K#3>)TY#[+D:^,_32&^<*(^P8NOA?#ZSCI+SZ89#3BFSFA..PC'0(%W%A_9I[CHG>4)$3.A<,1$CBVWZ M'6\T*A"`8X"=-KR!]5\G`7P$,U^\R.DVWCNW,270Z1PV&(Z64$A)D9WFH>(H M<-+@&G=%TM^D[9]'_2A5SJ`L"P>_SD/^XY?]\T_._OD!4#P)ATZKWW!5?E9G M[[=S'M0Y"R9Q@E]4?^K_9G51-Q?D(2Z?NA'`!_N1C_^#.>BWW@@/=4U7@V[! MESAQ)GD"W!JD*H/28C?XC>%=MY#B@F<=8GXQY]S!:=^`E,-2$-/*_,OQ1*!$>892580$A"8[=IU]HFQ,NS" M";>#1#@JAOL<`J\8FC_[SK M(#MHPB19BM;$G5;?==U6NS&[Z(/TA*S63,J[&7[4Y[U(X23O:<?%<"!LC1\# M'X,Y@AMZ%22CZ;ZEM:Y>>7K^CT-3JX.8IJ&*(DQQI&B0*L>8!;ELO*)'\XE<(EZXNTOY1"#')JF&&FG](5QM0:&9;/ M+R= ME:@0+LOM,28^DFB"_<[3X"H?P9;>RBA`>H@9B=Q_E_;B*ORI3\REWVL.#2/8 M(NQ2C&>GA:LI%G&Y+L69[M_CZL1M#Q,126QB#N6EQP^)J$;8H@T%A\J: M]$4\89HM$I;#>$GF@7J!F94HSF@?Y$KIC3-$F,VKE"9%P5`6&U]8-AT0M<." MU@PBB/XY8H5QG2^_)73_EF+I`5&(+X+033H=E5V$$6[361"!.G@9.A_.OGWZ MR#4Z%P6^+WX3[KIT/+Q,AQ!64XWA(R\+K7"ETF&F*Q,G[6)K' M2*=+;T0LGMX$(%EPT:B>4Y&1EB[P*N`#8)P!RF6HXXOX9W M)P<9AXV^?-(&8552T'(<(^NPJ<4B)$11YP=&P:`#%#$,_#+RC77B4B$I_>X2 M!(LLJ<`8Y\(-:L_X%'+5;=WTV:N;:*P6J1>W4I9095)=EK[1NWJQJ2P@_U;(Y.T-WC_F[.L#N\+H[X( M4>UF;:(6CWK`/JTFX^23_0[,$TQ_?&B\2KW=9L>AV^2\:^X^``BSC-UX./%N MH229S3BLGY/$\"X8C+TW)(8E?W?C>>'F!43`J,PF&2':5.4G;./3$EVK"HXE>+5NTL"XP6<<.HV!H9R55 M?]MNCMJ05?/N[#2"%7FLX;OQ=12N,0A?X6\4;SINHB+.H5!R*"XOBCB/)Z-0 MQW/I'.`J7ETY^R:6\2D?C0+X"21JQ_F`4=U>H_MQ%VFX#8>!GBA,U5S_,@7T M/KDD4OZHN`T2!/X@?]^?Z!?TT`\Q1H]EDJ`;0W-$\#-,,XF)3K#?,$[!SO$X M#BR4@46A6JPM2Q0`40,$V"@\:='U^"5//$!UF(:SHTM796@YA# M,!IV2-[S0KTTQJGOR9--BSE5%?_LCL=`7(#>/7+SR?A),`IN<6[@*`HUD`^^ MZJCPA-!SGR+S:P\H?B+Q*3H`]PKX'I,0Y.NOV\=6YG")JR%WJ>TCCS20%=YR M1&4"V\>.;60\1`130;(P\7<0.><>81HH+L,A&V1W#%%?8R25@QZ3)+Y.O#$[ MI4W$&7Y]2[%Y5^0;)UYD)>B,B1?Z$HS))W"J9F#F\!3?C1"T?F"R&U@J9I&< MJ3`8LL:$T92"G-YAQT_R:V"+D5QAZ[[1\'3C\",,V>'Y"$V1,CP*@:/(EKP! M5CGEE5I!1?OZ7"J0#W@V=NQ32$1>\?D(Y@A(#I(A1$?EA9SPAVT MZ00JXQ&.D["C]ML[8_K;R(&_^\X'">281`R5<>%%%N?A9S\2!3`FO96<%P#R MSQ9N=G3S,LCN`I&/RA=L2SL,[.$J)*IG<;\BGL.I!)ZEHK@F:D#"$8-*'&X- MS)+I&[5?XT=?T^GG5\4]UQKGVY^.PQ:Y306K))SI2[0;E.I_Z?P-M9VTB=8) MX!:Z]O%K3$(\",53NW"6=`Q&@])PG,A>5'_A*OEO\!B$:Q1&# M&6'&`:M*&"NFQT#X+HU)W;;3I:Z!A?[%(4$:!)Y!E952D5505H12T;1&5SOX M134A*I282"33$@(?2"^1BKO.-Y,AP8DF*):15>1>L*P-?P2C\":.?0+!DNP$ M6*40`3]=Q_BX<5+GZ^>C*;@S+44\LSTFIP.?BR+R6+M)4/6T?0]A$[[K=/"# M$D2?LMV`J><0+DS\PV>;DZHNR18],%B5_>UV&&Q[>*!2I3&I$ MJNP3G51[04FU_5;7%:U3Y8OI/%%8!Z=KP>V2#"^^75>P=LXTXD0C98I;6:0N MEB#=S,K_LC1._!,^,@6C3\>3"PD8+JE'3&Q(N<>3!%TA0WHK;1%@"&104#^X MPMR8$N%>)>G(N0K33F!TOA+>DZ2W.,:F3P_#Y2O);T!(5_*)PZ*;////,9Q@+5_!!D;[)AH+*FZDG:N M\H'P3*Y&.:;O99),+E_D3\"YP+Z*=6R@3N_E-4BL/4FGF(M3BVT&4]96F](4]9.)GOCRWB M-O(96NZ+_X>7H`\5;MG7#KE_-(Y.K9,*9>NV%GZF$#*;LV4!>P( M]*D=',S*`I6)Z3BSF]B/1_%UJ#*+\)1Q)IPZ#88H#Y1'$>]=%""`*:Q@=*\T M-G3)#.TD:TYRAQ<&%=-,E2LP:9P8+WFC9GPB+`WL/4GS,>R;I+U9X,:720QJ MT0B,R1%+P!&Z0%#:@X[T`MCGA47%VD\&IZN/G\>##WI[@]^>%B4;=&K/]149 MQVDJ,=F%HXPOT8:A8Y%'2MB0T^V!%_/(HW@!L)D\@_+^$42IPNH; M2Z>B<@*$L9;1)2-Z&?'YA@3**-<)LN'NQ^UYF/-HV^=AGT0>/7@6,]ZC^"XJ%%*$C[QM M]@,VW[EL3-;#,JS%DJ)>L.4>L-S$&\F>);.MF!7.*I;/U;,)7@_2XN#.1'&T M8WXAM;1?'INN.&#%&":K_X:M4Q&E6I!BUKRA\8Y#A85RG%M*&,#J@;154A=;:Q,8V[7.([:V^4 MT5JQ06A&V[>P@OH7H%G3"UGR=F!AJ?3)0,\&"`%3 M#289-C<>VLNP;"S_3-G',]L4O!GKXUZ*2A#%WP_L6DJJO&./`]$<`I,KVZ8XFA\'J3BLR!2U M90G18E7PH66:!&:QO$OU5TO%U3.Y@F2-=Z\),1,3'7_E/A7(UPZ@<)S0+H/_O2\$323(5&E(VCX!][;>.A95;2G9P<2#94T(O38H82C MQ`SR0>I(B)*!NB^0N!_3?(A6ZU4^XMHMBDW@'P0/@4X,).`(ZV31IPI?B9T[ M4R_EZ=)1OE@^Z'Y8]\B5N!*9KUC:-)J%ZU0"7Y1`+K"837M2^-K(&F0?B8R' M]Q(N4YI?_D6EPK$3`3FDQQIJGU&V%L:FG9S6P*B,DH*:)$S#A$6+>1T`;+1UH&]E;PG MX[$G"7_%;;XH<.^:10L&B6RDRS_02^3]]`JI9:ZN:#1E:=:$;NFH\%_V24X= M4)6\>T!L34LXW1D)P0EL=ERG7U9E31I.I0>!TL[*-?:SBW=ILTH%O"%(/5'Y M^/[9X[-HX5"'ZE83,PR(S<.7N0J;F`@S`4\`#;?*!8GP,.+=IT)Y&8^4,\2@-64-.4B_8MA`(;QT"K,_0A_H*4 MXG,M.L7(;Y%\%*6Z62INM'YN2:;25Y&S:6,*\DM'(F`Y3"$E-`2HDK$O2.OP M5%V,&5C7'JH*A=V-\8;C/)0=.QQYX5@\2<4CHJ58,\R\]L7="ECC"5)]L4$J M2$(BXDOPRX*$3*^ADC23/>?,&LWD`[&`&87!%;P<^?6-Y#`ETIB*-P_E$OWQ M#5@-1[([AB4I?FD8ZU[YQP/A`A4@C2]-VS\R!K6.P;Q)65L8F(0GE>KG2ZE9 MZF#4/;EW1#?2&03$45$I-\E\_$Z"I,S5'&*$2S*UH!+]'HCW+&#DH"+%A45K M!"!:)LF<8F(M:$1I2#%/%41,BQ^'Y0@D3M6*(B\35!,1H&6Y@;@[\34;3(S? M$IDXM`I4T`.&)=%"#)O(N)CPJI""+$J]+%=MG8Z^P\9]G18H5EB'KP7H[K!W M)3@1%"@&10:63$3HD>'*,I;33:"%G'.=>]08FAV<(LV'GB@Z^J]5A-:U.NH_ MK>5'^4A03-8:&OTFN9=I+AD72C.E](>[`--F&5L.36:EO2FH#JV4:I%/OA&= M]PY*.FM2=P$B$^+EE`RY89Q2`%OT2/&GZ2U19!"O^_DPXR]P]O$E5MT@Q@2. M:2=4L>F#3T,BN2,\S95.,=7+U,!MVD6A0K0FB4C!1%!@'?WD\)3YZ*IEH`\+ MA89QB7`@(D$R-^!NT.NEW8NT';4Y:Q9_3!?&H,:;W9^.@)F!!Q%W:F*,W_7P ME29"%42H%%`\D5U$-X-?AAJ.`P\M1_Y`)5A;;D8<%P"#3!6!IT&=V!&4I\HO M!+JVA^RQ,Z*.J^1"05;!,$=$I\OA^(D7)JPR2M8(%16HMT0K5(J76&OPE3:) M?[H,,I1_DM/L9::EHH3QIPA7KL9$(\%@^%:J-P)[XT`<87:J.*HT0S/ILGK0 M*,_`AM;4H=TYQ-7[>;JOY'<^6L"7Q,GOJ6CROA\9DG5YY0U$G.%D*WB0N@?`Q0!1/ MC,MQ*!!["F?$2TT745@7Z&,[5%X!K]=NH9&H_9?R-?*&L(^"_(D\8==N4-]0 M@H)-Y6\63>84&?A'3-$DOD*-GZ3[54!.;\V9ML,?%I.D"B7-M#Q5_8T%/\4* MQ=[Y.XT.S4RH>0S[@%R3UKJ[1MKPQV41^*L&$F\PUC!/;](!IH M#&QHCQ4"E49V73:>W%X5F?E1`):39V;W%FBL[T#'G]%[S>>''!G0C;4"]-A0&KL*4UH+1* M?^K?X;=<:EY7!2G\HI<6V&MW"4*:27$E\$]K72`56 M6FPQP`Z2*$M+BR0M,Z#0[O3F*&EGN^_AY0G0(&!WJG*BF4"&,PP3$+LIE06E MV@5C0ETZ0Z3H#.+K54`3YMHM745-T^(Z&$.X>$ZJ)!NS.HN+TUJ)50Z@[S23 M`"^-2<8O9;!@OG?@IZ6$GS<@B*SHEU;SAE[#.?2:][2;9%MP+Y MXE%$BVJNZH(%95/5"$4J?29A->;Y)F=VL8:!]$0?5A+G M$W%3*B^U+HY$#T&:<=JN8IQ0Y4Y>A9P3:T#^=7K,"*NFR;NO0W:VFF;W!;@2 MNX[H8'N6B"M>7XVZ;N.9PLTDD`)E/JM@AS;35="6D#!2M3Q+@AB?J'5QY,%A M(`;CNGGHZHHJ-D6`M5#;UE-GNPOBT18DQ?U7.9.-3U8E9E_>. M6@I.IEJ$U:%W98;6J7OWZL*\SL/'?7V MV5HLH)/""4O!QHF-T/WV+J=T`JX`SZ@Y?0''A4Q2QLC)WZ"68TIJ>!LGY M#>S\6GV40@O*-2=%:IP/AZ?G']DL'@USA0!=J96A]D2'86E016U,CP^+=6BU MNT9;QE8.7._D[LMNZ&\7?R5J^;4E-P1F(X\O+0<'6/21"@9 M=AD`:U"ZM7)'B5T<)^5:;LPNX$+T$*0`OOP?70'#Q]]0V@B_>)>8W\!EA4F` MFA]NAH(F5HU*''5NM+P2\+9=2%CE/3A50G5T;P[')/8KZU3/U6PTJ+Y9,?ORJ.K[2`$2)&L2=O=,Z8&KO#5K-'&/T)%ZL$B@*7RKROS*G==:= MIU+`Z#*2U:#2WG8)<2K!*SNZ=RL&8\#IPO[A^$6HBT>.3HZ-+9FIHZOT@CXB MM:>=GRA@+KR?&U3TN=?1LKG=^4U`\(%$N[#3E&=R?$DCL"CUU0^4H]G[.2N] M7?%S66O"KZ"*03;)D*^>I`F1=#7.GO+YSX MXC)JDB)YBD0@0*BGCC?JG9F%JH/?QQ?$LBJF6Z?P=0CM/&)31:#P7]`OAJG] MYA*;IRF(,$=;_&XPX\B[DWXFL#,Y18]I5RJ5",9 M[Z>HF;B1NU0Q;&P;'366[QLP)9L)K<`D<3:M=A=N\TRPH6Q94'[+S=].)14E;^\[K\JWF;\Y^Q`[3"=PC+22G MI8<1$\6UATBL6]H/^F41EL*Z@5K>IZHH?XS].3QR6^P0]LO]#CXR.Q:RA.AA M,-)-/#+\H"]Q65A8?0IV<='VI"AO+)!*S$XTCFRBA5(CJJ@Q%,!_RX->1462 M9M0]C5TPE9==13+,193<03,'2S+0/)BG,)";-+>0LX?Q>-8_&JMT1;75GYS*5^<4S)5*186_N3D-+`OJ;'H:3"K M\Q)S>^4T<)KC-.#TUZ20%BY)VAXUG^/D4U2-V=.LF.$J3(>2NSZ\=VT_-%`< M"HXMJVW!;2R6#:6"&A(80"I/X%[G"*22BHL!\\5=%6/"Y9H,1&[+)<4YG%HW MNM=/5L;9'3"D[>Z05#=B;9-,RRY,Y1-#X6KGY-/I6$\U8I59U@5B"":IM-XI MWD?*2JCX^O3[9E4BZ2=S]_7QO0U5Q;&[$GPSAX'(F$04&Q`B5\!5L5P2WF,M MV2H\$/:C0%:^E[!74F,X@K6)[Q>_E&(EI&6H(J11IVOJ.S1-PAL05X52(H,O M:+?L)*V9H[YDO^.]Q)0SL@G)E-!^1(;P@-/LOK?`O"DY%9X9LGOQUG(H&#^J M,A31V9%Q':.50PB@"KIF2LL5)A*I;WW]+'V>RJJ0G62:B!= MW22LL`3*_]\'>W:$)G*C6-:#%O`UYB'.9O MVXZ00LL!:A!,-+OZ`U).JB,^^OX:C/529:KE.B^YKQE!6`*P"CQ.Z5NN-OZM M`B.VB;4_MXCD(,CZ,GAJK\0BF"+R)4PFQZ..G;0]EA;''K\$I63,:5*"WY?. MQ/1[E'UFLD5%C9YN4WK&.W"`&<>;V-#>#A-G27B99QSJ\P2IT#=_4`X2K"/G MFFQG,D(`4T9?946%S+0\HKIU&V):'0H]DY22;SMM*G)N="-XP:>_%MQO$G\% M^85MA-,"_2;[$<$>X&4;Q?=!8`79`]B+4#Q)NLP^TV7MN"Q*X-4+U\X<6G'Q M;C!/9TZ[\5X]Q'I*LR)$.6?P!.\ROF64BY\43U"&)5^:WRQZS9J<_ONR^[EZ MLY3>8L[2XG.@KM5Z+P^(%'[81Y0Z?&&H,DC[$B^#"%C!JC-BFR.C)T836RR% M1"I8294X@J7G/'P$='G1+'] M'7>61T^\=X'*=Z$$7-"N[Q'\!A\749TD8.1[FV^5U M:C-#;#\"VWT;XR9+39X=02!@0A$2'`G2U]I$&>+D*J`L4O)\[SI_JD`U@XA: M<;N*[["(AN\ISX$4)A)NX21'4!7.F,F*G:Q15S-,(_SRB1HOG0]!/B'<3^P' M(ZKXD6I@K0[HX#6S$V^'!+K$RG#)0E40JE%1B.N"*4(C)#3(;+!4W[-JQ?\V$4^YU%88&9ISP"I#0 M2N?NZ[>>Z.[N3'=SEY*L!\)GMV.> ME2>\#U5JHG8CL4VR_JH26R5DO3RM;%=6YE.W^"+.2!VK8HM4&P[H@<>B+&.5T>.`NFZ0I'_C>TS*@LJ& M\>2BNK*]DIV!50TL\2DFR-AC.NV0DHR8'XKJNCV;\R'<#79=G>]#(7M65.B5 ML'!_:2BLZHC\]..N\[M*JG2U8)'[@>'?F?L@*5D!FB%I5:[6*&=`XC#*Q2K6 M#=J8V\6XOB^TG7<>V'H9.0GD54Q5#`++0;B"16TP$<3(%FR?BY>8,ZW0DJ=D M%OC$N[V6.VAUN:'"H.5VNT;`/=_NA+BJJYP.GVTG?A[EXNVB+U]%XRIH2,*!)"CE-XBC& M`)?5O&#C/&O8O27*"L6>!;(%UDH\9K2WJ#VQM;A_='"ZK^W"\\.#JOWU0^I6 M@F`R&JO^$H&*;@._A+>2Q>XC]M0,U[QNE*(;9UGEDW^B`^+:CY:.@;AW&5$/?!2$8H49J MRCPT:&B!S^#ZAY.1G3H`6S">D,]"JCT+R;^Z4P^^B=2+2CD1AT$28:^T.\P7 M*,8/R;D77+-HQ&X9M%XN">4WM>_VFQVWUV^Z4O9L@5MT-L./G*Q8^%YCT'/;K;V9TFLF-IOEQ=30F&;MCJS;0753HGDV?J)= MI5T-&6F-SUGC2OQ2&L5E9O`4$-6`/J`BJ]K(Q?N)\(,"6LD>AQN\W`3P$&8: M2LOV:5SB5(3=BK)-G[4*]B(#4K,["ROEE]7+%]!`5 M`T+Y-#90)<7O4O&-%0IBV#@LC2#04Y5IJ5*[;`Z4>D^[( MSLS[@85XD@="F)7H>R-#*\V""=E(4L`NZ42RVQ(HY+MLWQ)"QROR&S8UH<&4 MK^97I_F1HR3\32P681S(P$#=2,LI*SHRBCWR"&*5&=T6!LII?>1AN/%Q,6]" MQ%<$NU/H.4CE'ZJ=+JY6]=.5\!2F(.OO_N1VVZ[3-E1KV!]J3"LQ+QZ"<=5, MHI7*]=!8/[`KQQ94;ZHPZJY)ES4M#/D`Z(BX8:$_X9H'_`$[ES&61:/?W4N MR1/?W.T"723?Z[9_F7X8:W;1*#>W:=8FJK+WQ[R=16`R&!Q+FR-_9QB/XN17 MY]\.#@X/OWR9V73D\=WX9!MERVTG8^I& M=\O4KTQ,/?E$-Z:1U%9-L]2T>67>JU+3-N1*/?GE7^.54GFJCUAMM:&'G^9* M??:K_,#-*',M7XO?'*%$7Q.Z('/W_IPU^F-WL!@[P&A!D-05%HD[@Q)_ M)5#B#_^#Q0(?YQ05CVM-LDGZSNO+2L4S\0V0)Z?'=K/S@X/OOIS/?"/G;&(\$ZO=O_B$XR$ M!,;#NJ!X*Q'2[+U?1!)W=YJS%8,Y#DQ1,W_OZ3K#/;Z.=\M<1'E+"<"\+B7] M/7>O-Z_R^_`FS*1F:=N\QAE>U-GVW4&_^USW94ZA]JAWJUJ2U%W[MW*D:$ER M;`'9M?A!+(/)EW-1GLR3+;??:+K=1G\9;+DB*?`JAJUU%*!O]?NME3+F<^DZ M=5?])?Q)]2-KEP?+T&1>@4!H-KMNI[T4#>15W-LU'L2>V^BLEBF?1T=XT"![ M?"/^"&["X6AI$J*2EC4K$BOU8"S@#E_B+`OR`7MAZ\("3BKN^PJC8J-"$"^:LO@ M0]/M]OINL[EJ'?%Q4E:7=[!YBON&S7NYRKE6>@(O@4>ZW:[;6D;D=]Y;6R%#3?:V*9=]/#]Z M"D%49V"?>Z/@*Q84HTBF=&R/&U:^WMSJ995%8$:S<\AHDU92YHI5VV?.:UTD M]K9/T`KKV(_G4SY,O4WM3)+YRYQ??5IFJ[](ZEZKZW;[2XD/O+S4/>"F;:X< M/=.-EMM>AB*W$6)E(=\&\$1O`UZA5^W<;'?<9G,I,F?%;]N*Y0^'OA'6RR%54/8PF&[&L16:H5A^D/DTH#D@(7;079:@79H.DV MVBMQPVV&(%LHE/$U1EA,;.%2E&R&9U>Q<=NHPQ/XN+OG]GI+T`A7Y$Z>QSD\ MV['\A4"9O_%K2X._U^_Z?:[>UL;:>MN?@[3I]7:<_>ZJTZ;?`$":.MO?F2#]AH- MM[&W497)6W_SFY)5W0&\C"LQ;U^6J-KZFVMN5*_3<%O-K;_Y>NMOWBA!UFZ# MI?>:@_Q;A_,R',Z&E,UW/;<;'7=OL*IT]V7ZGI_J/Y[1'^@$T;EA!&XAO]$^ MYCK:1_4Y+4>8+]\;O$JO[\(]A%[JIA4908WUQA&'E_K.S@QB/$5=5)[[3FV/ M][Y_2XU6J*GX,$]A;NP[.1]W/]UMOW(/O9J@NX@S_@/<^D&K,V^!]U+1<9]Y ML`T]B:X+"UP!=R[IBC[;O; M<5N#>37!#6;2Y]FT@=MJU0UIKD]@U]#U'E\LV8-*F,^K5"W'9%BZ?VR5.>3= MUA.B2BM#S%G9P,^!NK/*,#'"$B_GF#;":%K`/4F!X@4WXBG.QO4ELJ[4<=CI M]]W^W,G7*X*I6-&P&P5TL5)B>DUL+;&HG%C(X_N0?_8!N(H;L,$^@=KJBS=X M_\Y+_/,L'OXXF5"@[`]OE'-#P33-Q_R[EY1AO$KG4[]1VYES^',2#!&/\3;& M_HRCL+8Q4)JS\W3/4VL1=T2S,6^B8HG@QZ=X/W."#?%9Z$/TP]O0#R*_KJ+[ M;#9'71&T*2>RC/:Q*((F23AL+TJZ[\J M^]?727"M7-MK98RC*$O"*`V'#JD"ZR<(0RG939RG7N1+.&7+LNMGV9?Q[J]# MNNML_>6PZ29YOSOUO=\G>99F'J/'>9GS#R_*O>3>:3ZI9&YI147/GQ32K6^YB*5NVHK9E_F8K?;M=VN31[A58C9U98-'R`B MRV@4^'\/?D["9&Y1O"U<76$2Q[:R>'M`VP/:'M#V@)[7\?;Z:@YI]1,^"*/-&%A#\R21(8(KH^N6U$GU8UWFB!W-1 M.[W^*,];+K*OQW&TL]W;U>SM,LKR-B_GM%T[ MY[2YTWT$T6;%Z:7+5[;4!+U%4L/Z;J/]1'"R#W=W^01ZC!QMS]P>W/WP]G@16_BMJWO MT:]AKM60"[V=UGPZP7(]0&\.Y6>;WK+"#B%NI]]RN[UYV^5N#^HE']1&>*:V MR%F;$BY\BF?KS80,7]A9-IMNH]MR][9-7U[1@?8:[EZOMU*!5R'WY^CT/5^$ MMQPVWH^RT`]'>1;>!N?!,$_"+`S2PY_#4>X'/H:`,2R=9Q25/KDZ])((1DY/ M@X0"U_MC>'FRNF%C)X]"_A`CGOSB^,$P''NC]#]^.3K^\LM_-AOX?V;)2Z'N M.9>\MUE+)E3$/^/D!WQ$];"T"=]/3ZXJB?U^_MFFM`%T]OO-3J_?%*C%XJ"% M^0[3#+Z6!?[W-+C*1U]A(:GP:DU&^5_9C/\]N;H*A\'A/_-P@MS]C9()?_G/ MT^[_"!D/S/4X3=[/9=+4;#Q(%$]6YL73)(;;FMV?CKPHVX]\/6S5&/-2.D7C MI'MO&&VNJ9^5[B\Y\#1*.!CX2_@3?TKU$IJ-%[&&/X*;<#BRZ%[:UG\.)@E< M3+K_\PO>Z8O=V]OK]`QM]O#S3MVVIF[7F!H>UF9S.5,_+'NGIVZU.HWVTE:] M-\^JVXW>H%5OZH,X2K,D'^+?I-7;09XD`7'-<1P-^1]/ENG==NGUJ3GAU),Z M'.;CG')BY$4`/P#9QD$UAKML+C!&\WILEXUZ#:?0O\ M#&]0?:LK>(9Y"JKF__Z>>]'US_`BCJ[_"M5@!_'7S!=)9-8"4P13ZLANLR.O MV(-4K9K^\SQ*;W`8T&G&WC#(R?=!Z]BMN9!V<^Z%L/*4?LZ#;]Y?<7*>3R:C M,$A2X/T#(@]^?H!/%EE#U>5L=3H#64,=RE:XE#KL-+V"P:`W&#QE!98TPI-+ M2#9B"RUSE,TY^8HF51/5Y*#&H"`89Y*R*-D5S^8B9#<;:R=[82G4Z6[*&@Z] M-/N<>-=Q=`#CY,E]Q76NN:C6$P_F+!@&X2WU>27[K\[]/?8BM`O/8]`L1D=1 MFB>(PW!`V9@UKFZKL5=XU&:1L`BI[>60VFETGXW4);!&E66]K@4\3:RSQV(. M@DG^?X6Y+H)D?.[!Q\@S]AIK,Z: M3Z3?(S](BM]_*F6#9J/=4I35G6S:2`U2^))TM2@X_N@[RN^'H]`O,!YT`3W>ST]QI-VV9=D)#RRI3*?AHG[,IZGF6UV]V^6=5B1)27]#PKZ+4: M74LS>3Z*_PPST&_V-D(`=-&.,OFS\$E^A+$=J=Q+(EXL)A#H]WH[`W: MMBT^QZ13NN1J2&QW.S;W/YVFM""$U>D4Y?1QD)7^_E2Z>YU&RW;6+4[)_&M3 MTOHHXFC(4;3HJKJ#OBU+%R%A_N5\?KK7";7SO<8\A'\V3J>YOG2T!('?:NWM M=>>E]N@!*5]W@`4E>[L/NOG>_'3/D.:UOKZ@>!ET.[WVG!37D#7^?IH&6?I[ M$J<+:)3MDK-YQ@0/[AMJT@&HRB,T$L]O@B#C;WZZ9U_)R$M3RT?,WO7%+(Q> M=R;9"Y`S'69XZ(U:0&P7B']XEJFB\LKB]/T$'OWK`-GGTWUU>W;=B6_?M&3' MAMI#V(,_8MB*P)?.'L"J=*\W=AN4R>@:ZGV6K/H>WH1]$_A(WJK'B M7;))KMPC:MQ5FYU/9Z1-[+8ZI870N)4S7CZ^Q,MYEH@:95W_\R__>=K^GQ*E M*Z%GI?R(#LHO\!@K[6>9_+C;:+9;*V+**KH+3J!9'4-Q:R.8@+)=ZS'KK/R> M;@?E;_W9YJ-/=SU>B,C:!.KIYJ+R*/H2Y\D;.VTF_/G_2V=NK4L_\EICQN_?.(Q,/]/@R2,_6E#:)&TUR7N M0P694SN!V%)'\$B"LI8GL&'\6:;-!I[2W3-6LM"YJ5CVB7Z)DZN`\@PQ">$0 MT>G9"E*[MXGG^RC1*[SVJA^R="-6!S-3H9^6A7,I]*LG>H/V:D'C9P/W*IU+ M4M7>K[I9KK/V;IZ[N+PE+'WWU.@O>P/G6L6SR_^-W-)5+FJ%\E!WY9Z9;%OY M6I2\F:M1&(NTK743ZKATGW,3R-Y:BDY*.=JS5O_$T@7EME@)@ MS*!PJ7R@6T$IR;3!^_$XLAQ63NMH=T2)).NEM_L:4*2Y+CE*I^K*S9)K-1J^QU[.J M&VM.N'PZ5>:U($<3<'2-7.M^H]W=(.J/XVC.!<`1=%M[=H!OSD408];\SE%T M'O[,@B"ZB"_NX'?WB^5U=OJM;D]%G!8BX5D6\T06:[RX!3Z!"]=]E(>CX!8' M^A)>X8B+9.BVN_U!KS?WJ550\!Q+>2ZF7//RYF?)=1\C\#;P]8*LV!RT!XWF M$ZZ5GGJEQ#^C1'S>!3V!W=9U5"=1@-QZNV`&\=Z@TVOOS4M^\% MK&M^IFOM]4'$M9>SNG+)UE$TC,?!2793\A<\T6_4M?-'*^9X(AGS0J)T&ZU5 MD#$O/$JS-UC1;LP%E=+L5=3JU2!#,H%L=ET&CS3W&GN=BO.IF&Y!RN9EFV:S MW]BK8.#E4S8O)^T-&NW>,VW97+S5:;<'M0G[][__O$Q&X:_XW_#/_PM02P,$ M%`````@`8FEN1<<$U&%9#@``CK$``!4`'`!T;VYJ+3(P,30P.3,P7V-A;"YX M;6Q55`D``[A%9E2X1694=7@+``$$)0X```0Y`0``[5U;=^(X$G[?<_8_>#-G MS_0\<$WZDDSWSG&`I#U+@`%G>WI?YBBV()HQ$B.;7/;7KV1,&GR19,!(V;-Y M2,!1E:OJ*U65+I8__O0T#ZP'2$-$\*>35KUY8D'L$1_AV:>3VTG-GG0#4'3\F/U@#,X85U#3&D M("+T1^M?(%BR*[_\ZN"(7?,B]`#9U=5=+ZRS>@M8M9H"SPE94@^^,'2'@Y^M MYOEIL]ULG5FMYB^G]:`K1IY/[*%I<-!J/CX_UQ],ZH;-& MN]EL-7Z]Z4^\>S@'-82Y,3UXLJ;B7/+H6N?GYXWXO^NFF99/=S18W^.TL1;G MA3/[+Q*TWY`D1!=A+%Z?>""*?4%Z&ZNP!?]66S>K\4NU5KMVVJH_A?[)VOBQ M!2D)X!A.+?[W=NR\W#4B^/>Z1^8-_H\&`V.5)T'@O*A(\Y MW5,X_73"Z6H<>.X5_';?J=!&SPOFUR&:+P)FC,8.$G8(]B$.H<\^A"1`/O-` M_Q($W+R3>PBC4":G.H=C2#L"E-GL'D;(`\'^HN>RJT@/WG,A1SP<3H<+'H(8 MTKN97\SJ"/)W0'A_%9#'_<7/<-I?^B&=`8S^H]0+\]KN+\%D.9\#^CR<3M`, MHRES+M;//8\L64?'LQ&S@X>@U';EN.PO=>_/)5IP6&2"91H>Q./"B"X]CH.# M1Y3,*`Q5O$M`M;]4??`8+I'4'JEF^]_W!OQ.Z&2Y6`2(U2(L0W26843F[+-, M%#GE`;`""Q2!H`]9$AW>!6BF&,G$9`?H]RR0TQ%X!G>!O'/E-CY`SX^(]\<] M"7QF<=Y-HF=I+R^DV%^:,0QXO&59+GIV*<`AB+M*[!=D/D=1'(1E$I;C=@H>OAHJG9?5\E9=^%UP'R@)F1!\\KBC9I42L0'CCUJD@E(JHA#BIXFH3M6 M3%*3=A=>Q^K971@!%!RH:Z>8'5F'`:!\B/$`#ZI,ANL!(Y:B\8O:'UX291-* M":NJM6_Y/[M':L`-+D%=M2 MO5^5XG+@RD41>!%-%;6+:BZ5$58HF]0-Y9052M?>6;KV$:13KR^4.1RK3E7T MS)V8'5D'913VXRK2R@.!MPSB@-=GW[X,!]W>8-+K\D^38=_IVB[[ M@!!-S9[:C#_/R9#7+B==EB113)TPIN>)A- M/8M0%@$_G;2:S?6=`/6V/"N[]IFT:(1\C,89U1#SF#7]E)*YR.*)='6UHR;BN;&P=5=PBNF M[$;R05`>.,14:G"=:H9+17/CX'+P`Q./T&?F6L7P;+=2@^-,,QQYFAEG_A&% M"X#\WM."5Q0L2,=#-L5LJT2L!M9;S6"5L(-Q&*ZDE!5%YA0+1=GF51A[1,D" ML@'-*`"K@<-Z'E88O\14IE0#A7U#KK)Q..5/.U]3$@IZBI#(E"*@J,B6*VP< M2%VX("%B0X%8L0'!GK1.*Z0PI2@H*LXDJAJ'S17"3-L^>H"^@R.`9XC5_XGT MHE`GHS.E'BC`24UMX]#J(W"'`J0TULEK:\#X.EDG8`F&7:%+Z)?1J103_850 ML6H%0_`2QC'.-]FXU"7EQ^.%-/K+)67XY*H;A]:`1'#M;E*8$]Q"%Z@`[VR!SV2<@G&(=3%SP)I[G* M,=(_A%#OI;L9R3BP-^I`&_ME2BTYI?[:156[%+BRIU>-+OC+*)HW3C#-0S=V MW\9[<>.GKB#VA(-A(9'^8F!'N!1,(8;O8R.M<)]]U[/M-_^4DJT]P*?[[@&V MWFS=Y8=C[G&6'&>RI>B9FJ(3E_VYZ0V8DL,K:SCJC6W780T,V?;\&8(@NN\P MBV\>0#*&#Q"+1E@2,HVA)U^R$?O-8)I`^H`\N*-Z!4STITPE$%-Q:0<[&9=F M\G6(:[L=(=ZFU5\C'`[9/*L8!VB'A'&:3'9)"HN%=$OC_/`&^CR!)<_1J:,F_XH5`2>DGNJ&\C`\$5H3W\@"C!?*`$`C[%MC4,'H'GK7.[1F!5-4BCF M$>CO3U)0\JK&8MV-BWGQT?DPC+9TDSST6T2A/RR414NFO8%PK<,=?Z9\5>PL MF;+?YMTOX9309&'6!4\PO$&8T/@4E96N+!9NE`Y>YODF[^$1/H[IX).Z<"9"ZUIG:EH,]H5 M"R)HAE=[_;W-$^Y8_(B_K4GW$,*2*^'/.CW%Q_)R_O M.T=$Q>@-0.)WY&QMB7F[RY:8CCWY;%WUAU],V1+#CR!C>HXH>4#,;I?/MR%_ M5/^E9&#:7?W9:`MMQY:OB:FL_Z!2,8AR0 M\6[1X2+>814`+)T,+6JO?\5Y;_C$IC`..18E*#\`O0M7?QVORS7*F/(59/K5#,#JI(4=G:&0A1K^ M'UX7_A*#&0>Y[?^^3&;:^2%:'L$>BH\@_S8V=,G>GTM$ M8>&QS,6JEN%A[#2B`-ST\3FE369>1;S6X8K0S`G/'A1-"\LIC9UN+`^QS#SF M`9L3;?/>WU$J'>4S,'9:4AWFDL8R#^U,*$H?+ETB:&=)C9VBW"-6%QG(/&P+ M=+]"&+#2>:\B))>'UN.H%@E.PVD7WD7Q6[UR7YM:K&H9'L86(0)P,\=6E369 M>1X>)U/HAZF(^\SU$00N(96QQ8'XVAXX_X[/1*GHI!>U=\'GB_P^+7*[;DUN;V[L\5>^=V7B7`^<*Z=C M#US+[G2&MP/7&5Q;HV'?Z3B]244*90<56S)_2,M\6K=ZO]PZ([[EIKK3='+> M#9,OWWE:OK-ZO#_('=]VN!M8SL`:C8?7X]ZD*@LF[V+/E:_53,OWMF[U[2^3 M6Z3AFOCD:]9W>>&+9@Z[5N9VXPQOVK2K4)6EF M2^AV6NCW#'9[Y+AVW^KW[$G/&E[VG>O5Z4@5";SUNO!\,4_38GY@0`Y"TGNL///S\-^EV']?=S9W:\5B:GVSN5\T=]F M$D"S;HU[_7A7X,@>NU\M=VP/)G9G=416[,/#FQO'C7<+:LT/PCS1RJ2V4GG" M>K/F7M5I9VHZNH)^L5\FM-ZL>%>EWTM*%*D@3(Q52U@0*T7R9A*E*&)6+?]6 MZ!1(W,0@ES(S0<`+HZ*2E?U4R>WTU5Z^4VE<=>(7*9W+\=?"L&)BVCQ/:9 M=)XK;/6FS1]6J>F02=B"8=8154J&7FHZ9#+VMZ'8$44N'IZI:9')X[+AFG5, M%\NM2T1=^323X05U2>4]NZ"N2N[:RM<@D_+%E=4:C)86$,3>=5IF7'U$O]JJ M%X7N)!]Q6QM>]+_XVK5C/A>J>7M8N5D1+J7TF1O2*.E%-(97J] M%(*\@\2X-,]/FS$J[G#P\V]?8#`%%!:_?HVW2C?2O[BA:.T\X0]NV0/UC;(+ MC7NN*E:Y(:)D7RB]7JCY>3H8L0PRW]YF+(W'8BK]6QS*8:9B`^.`2STAL+EA MO!@W(9'^IZS*P:9@`5-6=+/3:,(Z3G5AHOI9F"*Y"T8#F:D)F>#5#00*16_G MBYZ9J)"*WCZZZ)+Q2V:>0JI"Y6,7M9E886?(S%R4G8JMN(^44E&"8&9^8T== M,\`FH8[_NF.5";OR7U!+`P04````"`!B:6Y%!1JSB3T-``"8G```%0`<`'1O M;FHM,C`Q-#`Y,S!?9&5F+GAM;%54"0`#N$5F5+A%9E1U>`L``00E#@``!#D! M``#M75MSVD@6?M^J_0]:IK8F\\#5=A)[XIV2`3N:Y18$,Y-]H=JB`252-ZN+ M#?OKMUL@@I!::@G=['(>')#ZG/[.^4Y?C]1\^FVC:\(3-$P5H]M*L]:H"!`I M>*ZBY6UE*E=%N2U)%<&T`)H##2-X6T&X\MN__OXW@?S[](]J5;A7H3:_$3I8 MJ4IH@7\5!D"'-\(#1-``%C9^%?X`FDVN?/E+0A:YIECJ$R17=[7>")>U)A"J M50Z=,K8-!1X43H:#WX7&]46CU6A>"LW&EXO:9D'JZP"+W*47_]GJ-)OTS^6D M^?ZF<7ES]9ZS)@M8MGFHJ;%I[/_MQ#]I*OI^0_\\`A,*Q(G(O-F8ZFUE95GK MFWK]^?FY]GQ1P\:RWFHTFO6_^CU964$=5%5$G:G`BBM%M03)-:^OK^O.7;>H MK^3FT=#<.B[J+IR#9G)W;AT$C@M?U7E8TL,*L)RPB40D M,$O0;U6W6)5>JC9;U8MF;6/.*RY/CK,-K,$Q7`CT_^E8.M1J8?2MIF"]3F_4 M"8^V#I$EHGD76:JUI:0:N@.4@'&2M[9HT`5/5 MUQIQ1CT!PC9&'B^&:]E:$Z63N#U>5`_XV,%?W&GX^'[Y/T_GHA\82 M(/5_7*TPJ.SY"&1;UX&Q'2YD=8G4!0DNTLX5!=NDH:/EB/A!46&D[^)I.1]U M][^VNJ:T1`'S%4PEXDS+L!7*@X1&!EX:T.2)KA"I\U'UP+-IJY'^."EV?KU] M\`T;LKU>:RJ9MI`1HFV;%M;)YR@HT9(I<`76J@6T'B2#Z/!14Y>8JC$^K2GV6)S.9Y5/'PFW"R,%LYIKQP4:3TMJ<_&X,"/$LIRKQX4:7U-6 M8RMG\^$2SFS\W]?33#@#.!7/V)?\[2J6EI1G+IS$A\ED,7?A'4NC!#/$%AF& MT9(9HFLE1M?*`1W__();0U[S5,[(3*0L9QNX63A/:YA5P%!Y#9=4Y MUH$:$[1?.@?$3DU5'>J/T(@)URN:/5:@:?$0.@+9XT+8$N-"$&OG<'@XZW8'<[=!/\K`G=<0)^7(G]L1!NRO( MG[O=B2R\FP[$:4>6K)T]:('*W'SDL^.^4)^:_? M'1`;A_?"<-0=BQ.)%"B(S?`TKL?`JR0&MD7YLW#?&_Z9@X&!>6"/">]IQZ": MBH9-VX#D2[,F#,,*(_(1'LPMTXQ M?R"4N\+PKB<]['KBC#JGP%RU!^7%*:?.Z.A9'X5;SK M9=6>0[+7'GR7I_BN25\T&;;__7G8ZQ"B?W::^>1K-BAC9K`]R*]\_7ZC)HR[ M/6?`&HGCR5=A,A8'LMC>C<5._`[[?6GB#&1%#@NAPT/3-Z#%&A[(S&JO/:,1 M.5'.VV/@>>.?\&ZG.R/S6-ERCP6APV'&`/D2YQZXON$QK*O,&'Y8=OT8=,LW M:/IZ3B%CJ)$Y=P]>WQC*Z$DS!ITH]>XQQ#>PQNM8LR8E45[>8Z!O3([9_^R5 M_^(^F>X:J&'%8Y5&'XW'1N">CK,7LP#FH[,A8YO5)0#K.MW.K4/-,MTKS@9O MM='5K9<`NA,F'+#WY4XA_P@G MT7#![S>T.'<-=[MH-PI&%@G`KN;4=ELQX?)X(;0PL![IS[WO<*@%QPXF0"H" M-DC7ZV]RH"2%&!YC-=W*@AD1=+2:K\ M!N8&HOCTTH23F\(DNE!*V:C-/U5KU5$7"VA`I$!30F.XQ@891D2==JQD[-A= M(#ULVS9HH6T'(JP3C8="9F>?T&!%0U[UIQI(_GP-(XJ2!`@NQ#^LZ&PUWL(S M\_IGS0`OIQ6A;O(FX<#V4D+8\2$KBB^21K$_GTY?+)T=IT;Z^S2H+X1H27_! M6>I4>[.Q#!IS[D=PE`O2'@T91!VL/4[K$(N%BIFS M!?H'LU&F/G-*SX5EGE?$:1C9_J)R82`-^+WK;V/YOKV;_VY6R3[5\+AVJR M3J6%[L;[\KC>7-K;9OO;9OMKWVP?&9C,_*WM2`.[IV/=AG.WG9"ZPQ%&[?W$:&^8THZ3;<]P$G=I4T)(F.35!!C#;3L$Y9=L@ M;B3S=F+@O;JAG]A;Z^X2CBDSNWQI5$78PF+MLEC6_H`K5=&BF?*6FUV]-'8" M\+,8N4HY&W72O3*VR4Y*S3Z4=?>%!99CAZ6`^.X#944L,;;'T?)@8#-D&<66 M*2\K?-#+N7!R>\L8%#%%2L]0./*<-N[=WI#1%[FWR^M,'TKFI*BBX%M%G(0QK_Q8JTTXVLVG5 M4/H82-50YE2MG*U[`$,B($RJ]*Q&@FZ'=&OQG<0+ M]/@1<);'K_-_4"#ZG%%/]MSWLG!@]CSS5'_,0T<])OA>!PXYO"$_BZ+.)_68 MX'L?^,!A!U]?\/:]:\%OI,-[=\0>^]13<4 MG-"8M'O!<((F&"V_J7TX5Q6"S,'"PPM3+/>G[\_@(]P()@_9$-$%IM4QP!*C M-ND&;&,;$"4\S/#K*>H!B"14Q;2*N?>?,G<>(T+9"2@Y^_@"_,_"S=PV2MG# M`X"0BI8RIF^=2H@L%NE+OS0((AP>+4A:^0L@@-<.]M(F94;:9`@#4]V,[I$" M2A;VSD\LGS.!,YV<^,DXAI-'9+5%*`9+"GH_0(UL0UD!DYE3#Y69-:_+O&?* M@3VG>9'[)KH-H\\U/2&`1[3D//";P%P.%OM:/48TCG;G`XQ5\_N/P`IY83%, MJL2$<:-G+OH*Y6H,%:@^."O_ MPG=V9LB!GT>O6.9Y7JGO1Y8\!O@.TPP_L=1-0S1SM8$KK7(1YYSJ_))%H;\4 MYL$??8*UD'4(1?]^F`@HW)G%.\>OCGF0^[+0D2./ M:*6^)'2D!5FWT&0_3>8QRI>6CGN2[]O+]V])W=>>U&6UL[OM\9WP9&\<'>5. M`L?W1MF2P\3-F_0L#<,DZHK:C4+>>[NV<8E5,SX88HJYL)GD!$$9[+ MX;&N5\*@SZ2TTP+G\D=&TR>(:)0M+)@.C0$J7PF;+,O2SA^DT"@I/A)YS^3: M-I4.-DCG*Z&5:1I'WJ&((Y+X[&)/XSD5E)?=!':PJ+S*/X44:R\Q8J?4]YI( MPDU%WP;JWAGTSR-Q+KGR?U!+`P04````"`!B:6Y%EYB*D^<_``#>Q0,`%0`< M`'1O;FHM,C`Q-#`Y,S!?;&%B+GAM;%54"0`#N$5F5+A%9E1U>`L``00E#@`` M!#D!``#M?6USXS:VYO>MVO^`S=VM2:KL=+L[R=[TS-Q;LBQW-)$EC21W)IN: M2M$2)#&A2`U)N:WY]0N`+^(+7BD)//+,5NV=CG4.^!S@`7!P`!S\Z;]?-AYZ MQF'D!OZ?O[CY^NT7"/OS8.'ZJS]_\3B][DR[_?X7*(H=?^%X@8___(4??/'? M__4__P^'Y._S6/W&9._)E_]@+[Y^L9!U]<:94Z#73C'>8&ST?`OZ.WW[]^^ M>WOS#;IY^]?W7[\LR??NG)C\2O_X?][=W=S0__/-[.:[#V^_^?#M=YI?BIUX M%^5?>OOR-OU_B?J?/-?__0/]/T].A!&I1#_Z\!*Y?_YB'?/[\^>O/ M[[\.PM6;=V_?WKSYV\-@.E_CC7/M^K0RY_B+3(N6PM.[^?[[[]^P7S/1FN3+ M4^AEWWC_)H.3ETQ^=27R!221^R%B\`;!W(D9%Y2?04()^E_7F=@U_=/US;OK M]S=?OT2++[+*9S48!AZ>X"5B9GZ(]UO"K\C=;#T*BOUM'>(E'XP7AF^H_AL? MKTB#+^B'OJ,U`E_4M`Y[B)O5^$'/?DV3\1\WJ^F"9AFV M1_\X(/\J`<)%!IV5)!CCV*3;NIF7GI0?S4KD>'2R#L%PC<>#_=DWG M'CHQ,7OI-/7KK>/1L7:ZQCA^P)LGG*LQS'_^0BCUIHJ"RG?"#(H3SA7VI!)O MY@$I>AM?>TG-)>K+,-A(/IZ:&PA%?O6>\K*26B&?$X`NB84X8K.Y4:,4D*_ZH)_>G,HK4E[IX@9VJ43/3'(N^AZY3C;-Y0';[`7 M1]E?&#.NW]ZDL^%_I'_^E?H>X89-O;?[>]QO5((-3AUA&N5;`_76N=@<LF),U88M"YVI7?.I8+0<;6F@ MA*EO0LY"M0H,SFGCK#(L M542))LI54:(+P]5Y<'X+PNXNBH,-#B.)P\,3M.GVB($6G9^Z5.LD4D*K\J8L M>%YWZ...?/G%'8?!LTOC`&9#D(FVM:'(W*1\2-)7;9U5S?!6J986@'I.%*.[ MT%D%/AN==N$>C=<.67'/\2YVYXYWKB4U]EB@VPGCO61MS9&RM\@60CRLMFLB M,/@AQ%5;?R>"B$FB7Q+9H\>-U$W&,0+,0FX8M8H(`&9$X`C`Z/YQH/J#8&4_<6>"O?G,?\,*=NSY6S"UJ'=MK M;B7\ZDI;J`"#59HH1:--HHTRPQAU_D<.[W<_(MR4+%<8UI!UOPM]-]Z%F'2`>_>%_HM_%$!'P29AU,"+W!%+@Z&1$F*5 M49D0#")]PFMW[BG(4Q6R21@^P"))RA)@B,&%525#)G3>Q=ATYT=D(8C+&V', M_?]:N2K34;:]/-,WJ+I.4VNV3J!&<$4KMZR`RB;H(;YX7N;1[=AD-S;=C.48 MHF2@22&VF6AN8)61^B6`8J8Q[.8[]CE9S\35NV"^HZX=74SXL1OO"V?T.T]1 M3"^V\FI"3\\:(TW,R$FHHP2#=P9(JU3+5%&'KOB8,BIHG](3B_#\ZU7P_&:! MW<0)(_^H^E[D3[\F*"9XY5+D?DPO)U>L%HO9H)0*)&602*9UPBB`5?F14N(@ MR^Z*MT<+.@R&]/S3`K_\B/="XVIR=HDA@%EF1D4($#7XR`3<2(41DT9$O`UV M9.,8C51QS"K_;(L+/%`9!8J_@6AY#B#A9$%EVFSE_-(_S7HAL:4B9[O=N3"K M!"@)@6("#YF0$HDP<2$6+!5)&^SH$"`+"N;>A*" M,'E$%5H='!)GY2?L>3_ZP6=_BITH\/&B'T6[6H1%0]ZN.ZF`778K!<(@2*2# ML)86(,H6I@ZBFM>_4U64Z:)$^;_;(]6GP-OYL1/N[UT/A]4-<8F<71()8);) M4Q$"1!H^,AE9<@W$5%ID2#H83O`V"&-ZSY!E6A,OOP3BEM>P4M"5I2Q7%A![ MI`"%)/I#A'*--#T>2DMJD4V,S5TRCZZ"4!P!J4C9Y0X78IDR)1%`3.'A$D0^ MF"C*9%L<7H+-)O"G<3#_?;IV2)6,=C'+7DEH*^X14B7+0XV&`94!1Z(!B$P: M,$51-::)F.H52I110;O-\$OBTR[`CN"9YC8L.3AXUA=/97(5$,D4!%.=3![0F*0$6=NL.^1(`.-V=P,_BL,=RYK8 M]XE1*U)1T<3Z:)OJP'=[2 M>'R4#*5#TJ;R!9U0W.IB3@&ZM)`3R()AE`)@;0&7BL.@S[WKNS$>N,]XT?=C M@M-]\G!JB7#>4RE9S=*A94`I4X=4`PRMMG^S*)%.G&]`\F&"7^HYM^-IB M)QNB=RURJT>SS@!!VH$;N,Z3Z[DT-$5<-W9L:AUX"QQ&U$>+]XI-.7UUFXPQ M-:K(*5U=,`.0(>`J)0?]SFU_T)_U>U/4&=ZAZ6S4_?&'T>"N-YG^`=WU[OO= M_@P<5_6VC&4*+?%18_-8+`V11/X2[O"B;J)B M_TFKA#9V^PQ,XVW^::B#X:4Y9N'6X#8I@H5)G:20/'8*@[IW.SP+#'<)A0J6 M]P@5P"L[A`)I,+130N3M#L8!S+W!`>DE*Y;%9H(C'#YC.:G$XG9G6#GH\OS* MEP5#)P7`VOE/',=><@`T';1@$(EM36E/HT)IJPFTY9!+*;3YHF!(),=72Z/- M-@)!T6<8Q#B;R.74X4K:I(T$:I$R'#$P=!%C$[GR['YGX--#YW-GZ]+]0@\[ M$8;%(NWQI^VA1V_4:7G`44:_M`><\@8SN&5AL3MH])CVAAO5.`-R@!&>\KV$ M843-_-8&#L6(`7:HD(X1X,8&>L78C3?L]+J_Z`8^37.`_;F8&U(-NP<%E-#+ M!P6$XF#&%35&SD&!@PP,2AGONT#9:3';6[F`W13C_1/`^R5C4A8F#E:R*22[ M%<65M'QT5P2UJ=X5>O?V MZNU;]O]1E.2P<';Q.@C=?Q(M&I+V`Q\CEZ;P2OX[.$^*B^-FR32%A_0^7DW, M]GS(`UF=!(LR8`@G`%:?[EA&%"'5OE51[>;;J_^\>7=U\_U-)L#G'7(B&@R8 MDCIG6?K1^[>4R#??,,$[/$__>L/^^AZ1DK9X'KO/V#MI$J`C-@,7"W9EWO'& MCKOH^^F"I%#1HGTG#46K6W_:AI1V_)1:8+BO#;6VOY(W]B(S1?7\>;/`@B.BQQM%RYKR(]^#-2K%\)J*) MB95S$29%@.%K,]PR\J:WQXKED/&4%@2#S_6UG/:BK^U5M-[J&59`3XB/']=>+R&J]LYJ@SWC\"F( ML-D84<-:3V]V4&&/YL;[#S"&B7+$9^R$HY#E8ENPY?@8ARS]J%:X2*S<7A1. M99`X,"?2!.,+&<%5A.^N#L$4B+1,4N!V\I".5HW4E=JCH<@`,?VJ&D!I)X"I MI%LA/)?$X^#2CKTQ84*Y3*%MNI6!JZB62(.F60FBDF)I@!ONX3=HW#E^.X_T\N8S]C?806U-'5M$LW( MG"+MM!3!D-`$;>W^X[@WZK`"2K#7!\YK[>).(H2>10F"I#YRHZ;-*%I6;%]=O(,49.R MJ`6I$?1F1&J6P'BEEDU::9I09)="!0S)]'#6KQH49:$E#\/;$,]=-@"3?WN8 M/31)#-S0M![)P"RH#3U5RWFJM8VIY*Q6ZH$AH0%83B[K7#5):%?0`49,EK#/ M\>Z#L.<_NV'@TP@1<2N"*"I=W!X[>W;I6U!;YL58OH;0R,C*/02C,L`0N2%P M\37^/?("*'G^^2YN^O33-'WYB?3:NW"WBN2S>[.BVE^KZ!FK7L+(RP%#YR/` MR.'GKHR\%H.OT*W4]&#RB-M8V&0&)LP\`/RO9DSVC*H[8:>G:S/VJ:44X) MJ5`",Z'I(JTY0K,?>A.4T3"-[GX%@WG,2:L;)G/^>-+6G6@QY)HC71<%PR@Y M/KY##2F-0=^/,:F3N-0;9`]WB\3M'FZ3@RZ?;N/+@F&0`B#G=3\]BP?64>AV][]:-++G-I9YV]0CBOD=J<#T2WV\5*8FDXH;;\K M"2'7:5\3M4/1[Q.*^GA%+RVJ22J"6;]K&SR[$=WO)<1-_5L44^;"H!1QIY1Q MG8J,50^$!Z_D=10%8(UF/&A5>@Q[,T3''!ADT$E0-T[>G^G$<>@^[6+Z5L0L M&#L:SX*>K'3K"_+354EM`7]\T6"6:Z>UAQ]H(C/R>-+[H3><]C_U+J#GW!-O MQ5WYR8,[\_TL=/R(V)@<(6+_Y3''YJ/C^K2>.B&9+/S5W8[N%HUQZ`8+1=Y/ M*U^&T./.4)4ZO?&$GP7?4T]O:[47IU]`\_03*#Z4BE:D6/0E/50$)(#,J2)% M;Y1J6+Y&K8)>N44M$H?E5*F!\EPLJ--&EL0ZRX]RZT3N7&"Y0-8FJ:1PBW3B M"H(9_F3H:NS!,3OFB+9)SN7\3OXUTTK>6'"]'5DTPJ#43V1\71,TG6<<.BL\ MW-'7'T;+6MH!!E_AL3O#$R M_135!YC@1Q/[,@DM(#+0$3I/P#%:=IUH?>\%GU4W&.4J=G/FJ\&7LV2+Y<&0 M30-D/3UVED4E6"*JA)@6N)PJQ'^AZ%@8>H$7M_O'""_Z?G["K$-?@DIRN2N. M8S4HR'*DN*&AE7"R82E@2-P8>BW2EA]$=7(5:>IW./%_NXGW%:W!P<5;70S` M7*+J+'[;I=NCLV"":?.X'BY9,@M.,YJ_ M%IY_"L4!"K./T4-BR0J?_)7^>TXG\VWZ/?2T1U_NR">1ZW]5.**O.3*V<['< M_#XYF&ODAK?'+^'2>(.[XAC2.3.6M7*T93FS"&3YP461L/5GO82`:T_XU"3! ML$@*C_M>#QFAX!&(C.4A=B)\AY/_+8S>Z?NAZK2AV@58/MMD:%CEN).F-AA" M&D/FI"!EBF^^7*1%?$6?@BW,JU&$R01-8S;>X9DQ('-LW?S.?![LB$=!7!?L M/M/3#-HUQU-ME[QB8^2TK>L!/+*GBYGS\"83I`YC*@F5C/1TJT^^Y@KO\RIT MVJ4?![Z<=P4%^(2K@^5FH7`\8`DHZI:,0TR?\+Y+WY#)K@GZR?.V'3:`:U>+ M7F'M$M/$8#EC=4J"3V4#*S@O#['GWU/_E,WSZ7/&[$!0G#H`4+E/5FE!Y!KP M^Z#0+H>KP.4\S:0!.YX5B)SE-/T9*H\RKV+L[*E'04,$-#L7Z8D'I]?8EY$7 M!L.WU#%8S]N4E03M^=VCK!!ZI-M$-\DLF&@#2QW"62^RDZ?)6-^$ZT+]EM?] MTL+3"\Y@U&U$"^.8R\Y M=/+E/$O#&>>!LCV04_/Z!Q&./LD`]8C)<4=+8)VX-\;-.^3`3DAE1:#;/3H< M,CGH@Z9OFI`4!H+.&H1JTEI0"9LAN#+V^K9%JP#L7D&5SG@6=^3]V M;HB)M:3KQ7NZHTBS)=#\"%LJ(J@DDP*LONIM;%CI@6]M;6CQ.&/D]?4C$8A< MEDZ#'EY=NB_TK#^@N%O-Q+X?$PMA2! M2*\(0B#LX\2]=YAF-9I@CU;(V`F-PF<"[9;W)F0F*38J>*K0F&D&N[:3L<.( MUB`*$VFT3<1A$%3?A3[:!X>Z.#IN4701:WTQ;N%:_S$Y,XT.2Z,+6>??N[[C MST^PSI<6!(#*&H9J4%I2"O1UOAIZ+7M)I@%OG3_!V]0!&BWO\!-="*9',@=T MSAD]>>XJ2:$HJ"23`FRRU]RP(FOUM:%Y#<;(:V=M4G6ZN)HGFLBCJC`(R]QR MO(@JCM">VBIR\:4J5A=4&N!+BRF)/+3#"AI8>3XJNU-U.1XJ9_`_>O:`.JT? M-YU?A(C7K:H\/$#LU+[2V7>!Z/EKV7^9J8@2>DAXU\:@";$*(U#?<^ M.YXD3;=9$5;S234PKI1FRD`?C#?:`'25PTD12?1>DE`/!H/YEB79`JNA$4&5 MF15A-`^-*>?<,],$PN`%HWBB<70&C80):5DLI)OC6=,@T$X9[,B5\G=)YP\3)UE8NK[9([;)%?I%5FR=+6MWD8W,ZET M/5U/%#DGS"*%YC]#-V0NKC`(FR%1X>H4C%&SYEJ58>W"A# MY#ZTD8B`X0\?%^<..;`W-+*W9Z24*(JT\2*C MPD/T]%Q!X+F++`7,F&"E`R/]S]$RC3%LJ]0J71V;:Q8/O4%\R^@PR?`I;0\JL+NW&CN!=$NQ#/\$M\2 MF+^?HUVXG[F8SB>II)/U0\XW7D>7%!M6"X*,9CUT@Z[1:/*Q,^S_/_9J-XP^ MEEXRI<]Z$./G&@D=)0I6[ZXI@9=NH@FEP7!1"5%P/YBNH#(-<$/XU%WY[M*= MTQ/K-?M4`[.NLM55OI%!I46^EB88.AK!Y0YX[\B`-WU\>.A,?D:C>S3M?QSV M[_O=SG"&.MWNZ'$XZP\_HO%HT._VH3R\*;QCH1@5-?0L'UO0,Z-R=D&N!(:; MND@Y;W0RO2O$-)EGG.N"&SN%5NJ[MF9%@&"HIDMJH@^?MX:NY'LRLO;^^M@? M/_2&LV/)&@?^;XR";[]__Y81<#8:_N7781"3<3[0#V!H:]F@F:$)E%F:*JV3 MR0QGC3]4D9[AXD4`SD2EVC4==O%&-';IJ5@CD2;XG$$*>1CTT0/)'7N^(6-/ M=S2@-0OH'6^'H.Z?@#SH]R93U!G>H>[C=#9Z(/\%8S"D]Q.T M)W*1L-UW3V2`RT^>\"1;)Y<6O'IFUJ<8\IS*N6M5&'*5P6E]==M4,S&J2CX= M75!T-`#,'?/^+UW.=,;]66>`!KW.M(=&MX/^1[9#!V2\2U/'1EGN6,=3[=%) M-2SG(U%!KZ0B$8F#(9T:(^=^)M-@2XY,!]QP6$U47,M2G.5]+_SIT-G2'+&J M0?/4'VEAP_G$%<39I#[1%\#TF+.8Q1W,_Y,>L9C]T)N@<>?GSNT`RJXB>[)K M'7@+XHG3F'^\9QNI>^4&N%K/^GMK.F;4GEZ3*8'AJ2Y2+O6^IYO=LU'WQQ]& M@SNR5/H#VZ"9_0R#@,7KW3-Z;]!AH5^5'Z%6LYL@0L^(/FI#?HS'IW9-*>S'Y& MLTEG..VPO:4T_#1Z>.C/Z%8WD.F\=%)4;R:7J]B-M*O!E^/J8GDP;-0`6:7? M;6?:G])S:>-);TJXQ5;\*=^&T]&@?P?HE*[@(K8>]?1T`5RFUR"CCB(<5AJ@ MK6U5=J8_)&RD_Z"^Y*?.`,X0^!CAT;(7Q>Z&S`*B?"15(9L4XP,LS(/+M! ME#\3=(>C>>BR]]I%,67C8NP>U6UF9/FXKED98-C<$'AMG=[K#CK3*;O_`&AK M:8*?L;_#]!6KE>_J+V&%NY`-V:&24FI98IKD.TM=OA:*Z9G%IJE*&1U5-Q!*Z M/O0ZT\=)#Q!%N[2Y_3ADCNW$C7[OAGCAQO1?XI"K6,-R0%L%O1+/%HF#H9H: M8RU<.!IV"9LFR>+B"DWZTQ_)_]``XB/Y93+K](L)8?>=;=3]`L`VK_O#:UBW MMK,TG^EMCC0IF\DRV:B$-C*S&IC&2]RJH0Z&JN:8ZP<@V*6<-%D>C?"0%4R/ M\!7(<-K?;!TWI+/!*+QSHVT0.=YH.0C\U']$PH/34D5P'#1CV2N2LY9B0P@G(/-7 M-]ALL1\E0?3DND(WB+2/3>MJ6XXOFYA4"2[KJ+9.P69X:[&7A_%@]'.OAVY[ MP]Y]?X:ZHRD4OXI-U[=.1`TZV#C:IGG'^VSOAWB4=+DO/[?0J"2K-T:;FUJZ M0VI>#!@>-\=>'VQ'W1^OB0?78W>BQKWA%-(5%6)=B-?$0&),XCJ8!&_TU6V/ MMR9&50=<'5TP3#4$7`\O/HPGO1\(*\E*%B7>(`QJ#O'G0@KS,/#)/^>X<,!( MCZ+FQ=A]);J9D>6WHLW*`$/=AL`YI[1[E>STD]%P1$]0`#JK,W#_L7,7;KS7 MOSDM5[%)4QWP14K*Y,'03P-DE6H?1Y1>[-C.Y.@97+15O.23I MC"1)O9N58V^Y?829A^5X@T):Y]^QR&L>9E(4&BU1H3#$>V@F*>]R1JI4C3X[5U!$! MXH2BUDBC`)MS12`'@R)R<+4@3?[TRFE&DS.?VVI\8@O:6:UFI[3@N5W:4&5# M4JYTKLNTKN/JN')$U%>P]AF!AR>`Y#1ZMU1AE#K;]ISG014T8% M;5!#VV$&GSH>9EB?G/GOQ2OZRI2$1D58C34W,*X49#;0;YVP1X"N#88.S4WK M,>)2713D[(7&VOM=3);6#Z[O;G8;9NS8V3,/\CX(2VF@6:_3YW+S@MMA^+$5 MP>=]TU(!]H8C39$Y#,*A_DP.!$N-F^605KL-4G%KSH(&Z-Q%D,BVSBQ-@+7G MV*D&RA-_6PJ6E'#*5_`5T19"(URPG(A(20X&'^3@9&-'F1?0IM?#5G4Z6'8^ M.^&"I45.]JLC>O\Y"?M$T6ZS/?C'!F[C23[2DF-YP@H2N)XG^$+KG>2L9M6N MU3MNB)[IO7S:P4C_0@'31@[]Q)G&W$+:B@3_1^)PQW@A[0M&FM9&9#-3\@%: M3ZUU*IICU>;7*BD$[B!>/&]4[&H=LBY\=N-]XX';M."V!^MF%:$:H,U*;;TG MG-R4FI]#%?/!-]4\T_@KS)9/!@69L"V%-"8$*".5XAHC+:8)HOQ5\='OTS+!A``:U8=&C$PLX); M[S3GL*:6:R,I"RU9R6G8>)N6":339/=7F$&B.JH(V7U'B0>P_&A240(.L7BP MZGY`*H1^86)`GI_)80U<'_?)/T59ZWF"K;"C!I3+D%P*'DNJT"1,H:*(R4KI MBK-G2>7&Y[6&@_NL[JTWUC,.G(,(#28LU`5^[_GDH M`SWM45X*.K1RWLCH%UH4D(&ADJ^^]S)?$[OPA*`N'%>[$52=MG:++Q*H3)*\ M/R!2!3/8F.&MG4!+Q5%(']M`.[(61G&`XE03(V?#GJY$KH\F#[?D?\BOC],[ M1+C.8D';7;@EG2NBL:%MB+=.2$_)TE^6>0>(L@X@]8_.2`?^.S2=N.N$X9[@ M9;$Q'AFT%'_]!MIP9@:[?I0G6K.G>N?T'_A0`(SAJN-YP6?"+$R8?Q?LGN+E MSLM>6#UD\Q;4C*ZRU7=UC0PJO9>KI0EFJ#*"6QNITA>!%NC)6:`%?HJ1DY4' MA)A^["Y<;TRAWS)".OM%GAQ3]JSP,$I'`Z??0%H?>"PW8"V('/$EXBPX%3N[VPO43W:Y` M\\)^!?F/J#W/JGYE>HCCT7+FO'#]*;&XK?;Y/FD?'Z_H9"+UHC3`UGRGH@Y* ME-`@B,YU]NFG(/R==,_T2!YO#Z$J86WOA@\MWY4I_PRE[<70JBV="I&QDTFU M.2J6GFP7CH@E*("+MVY>ZY;*Z,E*1WG=V-X-*F)V#M< MR@=W.%!:_KWUII:`JAT<95)LU7F22TFG<>T?G/G:]7&X+UZR^AB2<5U`:IF" M32=<#;PX3HBEH?E.2J2U;3N\<(F;"XU8]^X+W4:,='DED;<:7U7!+D541<+0 M2*4"6CL9E\J?:0KZA-?N7'"0_?";M4FG"B>?;;(?H#0G#U2UZ;*?88P"PGN\ MLJ%`I03BIK5P4)!KM.ZQ&,&L/=@NE%*<\D1E@^D,)S:HVFT&.(J0<_@& M6>$=/@*C#PE-RGG$EG$ MA,^5UX>#*SV7R/.%I.+V\ONH01]R_(AE6V>-)D`]@ERA3:)EDRG.BQ%3,O%V MF5(&+6=*(@N8*26`VDQ)M&#,A$4'0#"LED5LSF,\<,5IJOA[ZRR1@*KMYQ9$ M$$[V"\\UQQ2?6>M37VY%#([N<.RX7C1T0GIP_AE+\S<9EF`OD5,CTPX9G8S4 M6^=7<\SUS28)'7RAH0DR7\(MW\UM2V_ M]6UB4N7=;QW5UOG:#*^4J_2$!-HZ+I"[RH5U=/X\(%[D+P;2XQSJ%;A8LZ7X MB-YRD=11MSLWZAA2G9+56ZXPR MAEJ+D#F?HYT;0YUOZ3FG@WE[TG'"G>,)CME7>IFFKM5,_2;FE%+VZRBVSL8F M:*N$9,+L/&*NW])!J`?GMR#L[J(XV.`P$EU2JTO!.Q8JP5B;8%*I$UTG$\PM M8QS2)YJ<%1XMV3$*U\=C8OB:WIGF#7$*!6MSB1;P?`Z12K?>6[4A5CERT*%' MNS>I%KVWE:B=B33)N?3H;H<9GZ>[[=9S*9_]1M8H9&)&SB0=)1B$ M,D!:&_K3BX&+'1#OHQNPE^3"Y,%$-_K]P'S1W56YBN5UO1)\93$OE&^=6@8@ MY:/5!#]C?X<1K2NTH0Q%\XR6,$AWN+86L:LZ@J%-+6Z3;"K01:*)9,&03`&0 MX[$FXU:8ZY7I=1IV&;V%D"[GWID_AE#7;/DU!)$IBN<0JFJML\L?`VJ:\)K2,24"IWG5]"-YGA5WR42OV,!A^K>7RW3R?7QJKA?*A,[V MFOG'\CTO\*(97[6"P_GO+I#SIZ@AP)P^FL.7R5GI?:+TH##(C+/9:8@QO?U! MT]2<@LS'%FJ3W:>I@'(^S6-*!,/_DYC!NRGT(3]2`ZPOC`DF@B9];T/\#IMI M=SA!N7;O$IVH&LKWBXXL%$R_.)4EM0V43VR;-YTKTN0T)YXS!,%MVBO3$YJ% M1P$?_04.V1.;S(Q;A_\LD(&RM1"WL4%YE%M;LW4^-H++'X_3$@K/IT9H1\M` M4>6%U7,1,/!7,QQNRI@/%G%-5^K8HYLF_`/+%`I`R*6'LL:I@.81)GHU]ISP M?5ZS)\O3G9L&;Y;7--M^M%Q@BNK5\HH:#((98=5_MSP[9'L#PZW4VM/IRF^T M&!4!;I^N*[G;8J`/[;QG`^QPMRBTC.FKMB6,2P''U;J)QG3MM[/E<"K&UN## MW6W0M4>UP]"@'(C$E>XD&!=RJ>2]G(T#+8N.J0V`-&U,S8NDX\7N"ZBMR^+# M_30E?=_/?FE<8;(B81%9;;P9O\7E71[ME;9.AN;8S:]::27)N1?[R@(N,P/IS-)1)'4;7U@T@183[A&%MUD99&GO>>Y=0!7%A'U M2S&^=3SZDNATC7&<&'N[3S*Q>$X4U3*?R_*>GJSTUM;EQU>)<''>O&B0'>-X M>S@7U+D)\&G?8GUH`>T-([D?+:A$E9+==,$Z!I03",LTH/D56FBU7(9S/;87 MKW&8YOC4.64EE[?W#)\&[,.;?!+AUHU0W$3K5='/6?0BSV#B(G0>#+8?62:.' M3^ZU$/\YB-PX8KF_T=,>Q6LW7)#_"F-IGE)[W)KB./8P]>4'KO/D>F[L8L6& M@ES%)LMTP)>>H9;(@^&;!DA16N8H5X4U@&4YS]*QESEM-@[=[@\BZ>Y!Y[,3+NX=-V3;#)THVFVV;$;MO6SQ M/,:+3X%'BB%UL9\XL>C_&=EU>-9^^ZQ8^^[H[+L538;3-9()%%9NPX=.?2[I4* M6.\')6`UPK)?83&K"*E*@6D MM>)J7#_+UV#UG7.:*!R.V;G'+UT?[>G]N*\`=#97BO=16)W6@J75ODM%KY=$%H5$Z$P;9CG&T7+$$'XD9I$!HY>\ M5+S@QQS-5*UML1D:D^^]:>JUSL@&8#E7H(].CM*02L(4$L;:8`C%3QEAJ'H9 MM-+)#?&N/6:)\CPTT(?$+FY>!V/EBV&81@*']ZUQ[)Y4Q1$4*Z@#8EC-*`." MY;I0]ND:XCY':J:&+)NMB5?H+(EOV,2THC88CM5-TJ;80?4R1K`:WMH^9"[0 M%K_H1F@CTQ)%.*PJ&J)/**IU(5PJ0'V-V]F)T=%H%T>QXR]X\5\ZH];KC;/.&0WN=A94+:U#I-%20&GK^J ML^]<:)EOR$:L=;8M#-UA,8R>,9>>NSF5D[=C<00XY,7K"*]?WZ7^0 M#IA`?1T=D,WY4=\?,YMDEZ7/\J5+ZH22JCIE-^1\YM7,>&+;JOTO]46!=#)Z MGJ`?13N\N-N%9!1(\"<3,?MQE&V(XG#N$MM%]=>@(*M=I+&AI1Y@7`H<@C>% M7M_V3G\'PN`C.R[Q39?8I:E%HHY/5XANF-RHR?KRF08,C>]>TA2B78VGG%"4 M'X73^RQ96K__15K>\_#B#:8Z\DX+F%XM+1/L7LU(O.^>O["[3!!=[*@L%+"_ MH$N$>(W9.:?7,?H7;/P)NZLU<5/B0!4MS]]U1IU_=-]'LI)F_9,AQVJ/+8Z,HM;[>:&("ZJIS>J MX)-V=B,$KZZ_-['^7SVZVX)W?R0F4$."C>JW&C%^50.&A/G1OO^RPI*','6*:FV=KQT]KKK%8A7CDQO0`9NG[DSI,; MDOS,P0#P7,1]^U-5^TFNXQ\+!E8XN\4:J&72S;10KH:8'J!!XS0#:[E:SC^0 M5[]W2?ZKLMK.-.^7/_;*X])<8^U'H@6W?DYR,)#>C)/TNG-^R-JMHK-65'X+ MZ2Q?@;*P.[N%9PKPGJ?KY*&HL_<=X90FGBU:>J;) M)X_&9/$=&Q.1QD]E[7QI*UD98;0/R$5*IT7J0R@BFZCHS*JB^CF!2P:"S M7FWF?.>2@D?":CKEF%[[R&L,%HF,?#5!HIJ!Z<+\'"Z7^%L7XY6KJNMDSKCH M0Z_*!U<8>5$QH[HQHHO+9__:Y?8F[A7H,W_J=?J;?6J?/V=+K^MU&+] MHY?;QT05>+ZN5OWBZ^YQ`FM?:QRII;7&*XP;B8T$$2]BF3K6@;?`890__I`6@I(3LE7F4E]'2F MO,4A&4,9R"3XU=G%ZR!T_\E/IR/7L#RZ:!RXUL1;;;1<#47L^28G5P'14F,G M'(73V*&O!](`^1B'S#1UBXDTH;><$K>J!;=.B)Y5IP,M=[4DMY-N-TNDH3<4 M%ZNJ<:(D[.XR+4`-5/`7=%NIH'(93<4#K-E>P4&UI48C#N,F\+5G+XDXO,;2 M`5M;'#$=-"VV4J?MN:M@B,G$I:$&NM&,IZQ2X[4]7TVHB^KC1<\)Z7Y,U)G/ M=YN=1ZVYPTMW[G)O2:BU;#79]TF3^>R&@'3Y:8"Y=@7A((H6B6Q;K]I/,(-! M2!?O9V3E')$5"5T7&Z>6'UM>%VN`?;:VW*)(&*2Z!IGSP?7=S6Z3QC:BNQWN^R,?SX)[LC84/K+3N"AK<8(C MCAY^Q3_O1,L8G8">W/'@DE9AMSE5.81=&6;$%M?'T MYOH&SHA*P9*^]IG\;7_\O,\O$!YY988W&FEKI5T8?24FU/C[':'<:?A[FJ.J MFD8*G'EM;9O'2@U-*BZL-%6AK:G,8)_E03;!:"I:[75\NGN\<>,$F\$.Z[$E M6AM/3V-Z/J`>5QR,$?4D-LBC`<5B$2D7%0HVV\BU-P9WYO-@1_!-\!R[S_1@ M1*&B7!SQG[$WUK8Y!AN:5!R#-55;9W0SO+68Y(8JHS!7AD')OA]C4E%QWY\' M&\PRP`C,YTK:I)H$:I%6'#$P%!)CJ](EDT0N$X5!%N):S`(NZDJOA;%P:ZE]54=>#5YC(H`6:KSL@Z0G`JQ43YTMJUAIS3 M#]\#;;'/0>/V2E4OKK7*N#EM]0YB6\W69%7F+&..TZ>O>EEM5<-=VSO+!4"V M&-W9,V\LJG5A[52`;+R]:;MU9C12)G;A]=0NHWVXF`$NLS[N"*`7L@)Y=NE: M/)B[CB=8WXI%836)$B?89G#+H/M^M`MIB*2+:5Q0VBPZJA";R0`WW&:;!?[J M-_SNC)B+%M-*HA(E0@%8$^JAK;4<44-DK-S4VJC0C&TT%]M6R;92!.,A1P96HX@!`ASUQ!M9 M8J=;0P=@BV@!AA<_'SHL::B)>Z=6@=4\VG@!]I]AX!3&/M/5\\ML8JX1E]RZ9[B\?9DMRS'APMOUW%=&+[:=1:8`;.\Q<;NHV2L\ M6F:!T#&IO#4ULM:>4FE8[:4#%6![3!YN!:NS_!=8]5R%!;%.U4M?Z.O>2UKT M3N=KO-AY=..87GM*[Y'4!Q.!'*R*EX,$7?OLWJR7I/)>_$:0L3E*T@Q\!:CM M(44+L6$N^KE:6"0XIXVU].%G^=@%,A#DPZZOB9?:YIZ8HNKO7B);(3X?\ZK8 MJFONJ=FJ_.ZK8&LK#XJ];GY6[3P[,;6>*+L81EI_,/)UL[%LY=FYJ/$$)50F MIM#/[&MRO_*Z."@S\=0$Y'ZK%?;1!P`HNM&RZT3K>R_XS`F"<(2`M;T8(<1@ MQP%MNG&2Y(1C031*J!"O":?<9SP(HD@0E&U2"-A&,[4`8*,^3N\"SW-$!_K* M/\-J""XV@%7\":_=.2]8GOT`JUHKJ`!6Z$_86Y)9*HW;UZJU_#.LRN5B@UC% M0?B[ZZ^ZSM;EW4TM_PRLBGG88%5QGI,RBG`L3;)9%+#\2$P)=UK!$VC<.7X M[C_9S#^AIZ;YKP-(%0`UCQ[.:MLD6HBJH:+>%4HU6WN/,HJC9*^1)0/EM4Q5 M!E!C"*'5WY,D@DFO:"?M:>TUB20=-0TV\.J<(P:HVF7HJC6?RZ)$&'U)Q;]J MJ?J'@1^4P:=\X#6"4!A04Z@QUBY\%33R-DF5VFJ6`X_NR=^[@4_`[0B^0ZCN M%B^#$"=R,^<%1P^N'X1D?LOR&9-1H%Q*,OT]X'@=D%^>,>?470N?!T2=-JRN M9Z,NC`F(D@(=@*`#$O3$H*0^#4H^@`I?N,JHS'!>D6$^#IT@7+B^$^Y1/\8; M\D>:<)V43FK&2\B?6-$JZ0G>M//=8A\O^6\)"T3!D4F,4-#P1"&;D=&7J4Y; M@U!I%R#!-\3Q:$DP\MTBH?BO[\&TBPY*SN/;!YWRM$WZ$([I96&B?X4Z<1RZ M3[N81D51'-!7@MI;<1.<(;T0=(>3_^W[]<=C!'U+J0>KH^G#Y?0ZIH2^S-2_ M0JZ/LA+01.NE'*N-2,=X/R:S#G]Q(E4`W6P\G)KM55`%TT[C$&\=ESX3C\,P M3QZ9[;"*P[G-2@+=LD8&:#9Y6F8^6=*E+"L.M1I?%H]&Z689L9K\)=SAA2(B MVJPDT#PP,L!TJ$X+941(BT7MQV:)=T#/Q+",BPN\N-T_LOL6>1"@,X_=9R$' M]+4!M7L#T+4E.?&I:!DH*P0][=&7M!S2Y%^A0PCE4%9+[9O=KYX%G3E9BH68 M(";HXOV8&$27@]S$+>;:@-JW`>AJ^V9%4!\Y+01EI5PA5LY5'K+?MI`Y3&@K M62(30UPZ>@EG<*42Y,848M5IPX-RN[-PANT^"&O/OLPQ/\*LT@'8:$JHPC9; M!B$JJB8>%5,&XSC=[3"-H)4?"]3SE+BJ@!K0%+&F+T0*24*&Q5>*P?D^29"R MJ>_#T0;4L`U`&_H^>5'M^SX3L@)+QI/1\@X_T:D_/:[&$M$4!%51J4]!\J/;&UP9'E]O?7Y&AJC9! M6:REWO/@S->NC\-]<<7Z,12.CLO1@.J_O>V=MD+ M_J,P=Z/DK+J)/J`NT0AV;6.^Z#1'5R@I!Z4%H3S<08JB&_4O,9I]QMXSD0C\ M>-W6\*9E.O^MRH9%7%J[;D&7IMDOS=I77-Y%-;N&&0W9<)4?6D59 MX6PO(_T9+%'&!#+YW_09TR&.*[\WHXNJU(LBC;8QC:F3?@&Q3]!H+(T-5<5: MHI!Y0/UB@N@-`^=@0^658TU)!A7);7BQ.*!&TD%9N]E=.8MUE9S(:^OJL=9C MWGW_GM0;_XT(`UTHT8\FD&NQ)_TR6NIQQV8`&^WB*"9#B>NODA1TO'YZ\H\` MX,CY;>,F:[M^HN6@XK=0X6-T!Z8HEWX0L2^2023Y)OG'X:M7*/GNY1/P)^RN MUJ1W=9YQZ*QPEIAS'+IS[J+0TJ=?)UFU++9&X0P-2N%D3PW2PY`$$%1N1SKY M%H*'K<49HE?+]LR*]@AOA.`U<;Z9 MX6>E?0[I%3!?4?OW0;C$;KZO31/<)\OPLW6$?3Y]]'%/D[39DK[]CEIP;C7F\[^HI^1>QW< M4UGW[R?D+ND)N=?!20-#7_OS<:=R>6IOZ)S#=ZQ]!``?SV_;.7W%PE=;VL!X M)>]OM4]$._;]^^TMZ.\2OE8FUBW\]YN$E_:FZVOEIM#0U_Z>:RW?M/F93-YEZF:`J2.*%(+?\XUG[Z`TC*IB0":)"$&M)D'V8=&PVB^]<` M&HWNQE_^^K3RK$<21F[@__3JZO+-*XOX3C!S_<5/K^XG%ZU)N]=[946Q[<]L M+_#)3Z_\X-5?__<__\.B__O+?UU<6+?!G:V"OR`?K(_%) M:,=!^&?K'[:7T-_\_9\]/Z:_O/^[9OK-U?OK*LW?W][^32GW^O8,?TK^^5_7W>NKMA_WDVO?OCPYMV' M[W\`?BFVXR1Z_M*;IS?Y_S+ROWBN_^4#^\^#'1&+"M&//CQ%[D^OEG&\_O#Z M]=>O7R^_OKT,PL7KZS=OKE[_\ZX_<99D95^X/A.F0UYMJ5@O9717[]^_?YW^ M==OTH.730^AMO_'V]78XSSW3O[J"]H611.Z'*!U>/W#L.-4%Z6S55OBI!,/`(V,RM]C_WX][SU^-`_^W2R=8O69_>$W! M25;$CUO^K.O';KQA2(6K=*!T\&E/RY#,?WK%Z"X8\$PKV.?^`*&--VNJUY&[ M6GM4&*\KC+`=^#/B1V1&?X@"SYU1#9S=V!X3[V1)2!S)Q@GOX1BC'=DAE=F2 MQ*YC>_6'7MJ=)C[8S"4,\6@X'Z[9$D21KB9^<5='&'_;CI:W7O"U_O`/>JH_ M^F&XL'WWWZ!96-:V_@@FR6IEAYOA?.(N?'=.E8O.<\<)$CK1_<6(RL%QB51V M:KW4'W7W7XF[9K#(!G;0L!&-B^(P<1@./7\4!HN01!#M$E#5'U7?_AHEKE0> M>\WJ?_?._BT()\EZ[;G4%J$[1#N)XF!%?Y8-14[9`%;VVHUMKT_H)CI\\-P% M<"43DS4P[^E"'H[LC?W@R2=7:>,&9GX<.%^6@3>C$F?3)-Y(9SF7HOYHQL1C MZRW=Y>+--+3]R$ZG2JH7P6KEQNDB+!NA6B_'6CV;746;7TUAWYV"E+5*7PWN M![!!0U-[ MK[,C\S"P0W;$>"2-,G/0:X,K%E#XO/;-CP0L0BFA+EM;=:!JO31FBZL.4T*F MTU97':IZ3[KV5N#T`1%KV__S[UQ5M`#VR37+$CZOE'IIV'(!`B^BT6&[0/=2 M&:'&L4G54$ZI<737E4=W?831P>T+<`_'LE.!FEFILR/S`$:A7J\BKM;4A*"T MZ8K7I[_8(2%/,?%G9+;MB'%8XUZ&_IK1Y[=G5]:%M:4J_FC[,ROKPBKVD8]Z M.VXO<':&ZK'+JB"4"9)=$_XJ&FOK@9I85+K;CCS[@7AI][\R6ACIZRJ#S<6: M7I]%Q+E_8'^ZM=L#&.R<-FG_9A=6):,G#8M M;[D_T*(VM$+'"D(Z[REBVS[MT-G1@/X1>`F58+BY=;W"C7@9 M+`=-@7#\R3PX.%PCFJ?9_!V3=1"R>X$LI%%HI7(H@*#\:!XH8AG@89/J2)LN MIHL@%!X<]AH"D7AO'A*E'"-.CF"U"OS4T3594LZC81*G0SP6_H[SD(F:`X%QZ@SMY1]?$R8:0A&I-`8BH>1QW$.ZR5H M_.5UJ<]5BT-6(8A\QRU[;5U8S]'"].?V<-#I#B;=#OMI,NSW.JTI_<=-J]\: MM+O6Y.=N=SJQOKL?M.X[/?J7_ZGDJ2VJWMR.'E(8D^AB8=OK3/^(%T?;W^PK M8O[K7Y_'/9S?NC[EU*7S)(AG M%X>3YM>YNFCD5B44E(/F:,Y?L83+8."P:@8:+*F!W8;1_V/7E(^VQV[$6G'; M#L,-M5O2Y"T^.D!R-*^Q"EI*HC`#O3QB+1H3A]`!/WAD0.)$_K'63]CESNT=%QQP"(C64OD>1:L21AO1IZ=G=.W,=O" MI4Y,A>>A4YM:D?PR`JEO-M!D`=LF;'[BCC M:A#XCM1\XU)`H4&VW20N[,>F[CV36HR+T%RX]!^1#%BUO,CHH1KBV M`XQ[,Y#*AB6S%^"2-\%2.!<3H>_:#Z[GLM,9W28/X];E+CIX#V`_D($^554Y MF3'S"J,&NUQ%-%`$M9D6RC!P433:+[MU<.6I2Y15^ILPH4O+`0-R1Q^H$RBR MVAQ_-9&M(#$SH.XD9!JH^P>Y-%`@M9F8-8&4R\,,W/J4PRSE<4P%'#X2*6I\ M"BAFVOR)M9=5L2S,0"SUKJDLH%P"*%[:C@@U\9)(P@RX!D%,MLNY%*K2QE"8 MFH^%;08F@03,@$AE,M691\U'8^HR)\_E6%A4/=BL@U\=:XO*:'"Z&3O/0!,, MCH6IYGP)QZ<^I0HIYVD">EIJB/B.$%0A$11D4\U&@$3,F']5W&(-.,+>:C-, M:CC"3L7U-=JN$>F`)8%LI8VA*&ES1RM/*`'/9H!2R)&0A18>M(3"HYP/K6?A+Y^M8Z@V&J[R:GBX:\B*S.`YA?/AEB.<+BT>?65 MX9*5"S_=@YSLU%/]JAR.LS;/,L._F!;^OF!UK?[7SE M6[[@N1WV3_VHKS:I'TGX$$0$?S'?/3+3.38,4XG-TA/;B(1I+C_4<\"GQ\Y8 MK.E+D`G&#"MK=\Q9%896$B^#T/WWRUHO`_&0#CN!L29X/$&8"UI:B$D1L"T- M=@9C(V#M"L!W1!H:49\IB9\0.4M`NE6$=U=6FQW2O.@ELG&9"PKPJB*H#8? M2_,(\L$[R3O*=A"E095Y;1E`^4,^!7:Q([5M5<:Y&=/R(_&I[>JQ-,79RO73 M5WG8XU/YJ/DP20FQ?3%2^0=J_)B$6H=0:3IN_M#AVB.I4.G05ZPX^K]WGNTJ M+0L"H,;VRRCBIR(2,T!,\X)M[S8(N_ZC&P8^6U3HFAU$T4X(^LC>[+P77QIT MI=@3MD-'$=RJHC(#Z/*-_H[,6`!%_GPM$T8G3!:1=.&MUANV7T@1\#HB,P/T MU!+/-Q4IIJ6-T0N<*6(FX-@,2":V9X>9WGRR%Z)LI\.6>$\.5`.#QZL92.PS M`S\-&%!53A$)'J^G?K++G=[^XB7D6;#`E35&+T*GNL#Q.3YU,`>!'^QRMRT& M*SVO`TC1*]FIG=S!PC!C,4WWW<,Q2ZR-,@(H3MK.?'#)EY@>?!&8@5//CPD5 M:+S#F*36-X\"O4)A5:1D0C`#*BYW%99!.%C:#E]5P9**X=2WO9>-G+T1D+D2 M$LKLRX7^#9D'89[5-;6?2'3G^D&8/C*5*3(U'W9[R:(>[DB\#&:L\GT42[PW M1QT$],I+VSFF^L)Q=*C.0[NI*'()W]"S^5R4B\LE0"_*6$]KN")01_A]AK!/ M%BP("!]CNG5"SE][S=#K_%7>DB&[6@>$YD1LAI7*8^J6;H/NPL\JP3F;:6C[D>WD]V'IO[P4L8^V MZS,!M$(WHO+L)"'];_8PJ3S1_R@?A^J;MF-.TWH#TTH-`)JAL26\RC5-2`0. M`#+#M000P*GO9MN2)]O\E1L[?G5B#A<'X0=)\.76Y35.P.BJLVG[\:KK6$=H*X-X2W`24A->(LP->H MM!3VA.RM%WSE9*5\7R4KI=V:_&S=]H>?3,E**925>.97J?A'"17N>9X-:!0& MCRY5@YO-?<0>5GJ^>FQ1,_`Q*W(COYFKT):TSQ(_B@D:]ME1;Q3=K:W MCWY6"EKVP'#5_K#3M33HBXH@SU&1MF^;JRC+"PUV.I<&A=@7B.DF@>B!URI& M@K@_]&0PC78#1)*G7^"W1(#I]7_V7E]%Y>%V@9ZOID%?)/(R8\%H\K1\'&>A M`2EUM95%A]3-T">XH[V)BR`#DO)JZX*ZQ$X]Y(;#<1;2WLREH;`O]/R^YJX- M`3(S8UW8EKJ8!BWG7XD;$LH)U?!XPQRG+-6!)3>L61,^UBI]X.<&5@C\A"GMU8';/\=857)G?X>DUI69!;M M[:,;QK_`*!52035"FX>B,8V`2.?T+TO@XFIBSS`@T;0Y#Y9`1J=N473G<^)0 M"76?G"4]E9,QE=G09T)(U\5HR3PWC[8GKK>BU@MZ@FD%S:@B)S,LA?(Q9BG- M^XR,-S052M]^TX5V@-R]#33QC#E2*;R4KY. M=80.+XSQ%_1C*,.OUW!U,.F""LQ<(PK1]0VP_-/"WB2K[;X54\^?!^'*!K[I M#NT`JA`FV7N*TC%CN2^48QO9KN#MR8.&4(CT/66H*&].Y;%=QDU!):N()X.D MV`J![23HK^#]:%U7$CQPNB)"3T'U>7UG#\L37H_5_Z M-"1BWGUQ\"\%"+*_CH'?;:[<&4ZO5;@_O!]/>X*,U&O9[ M[5YW@K@&'3((2+,7T&":OB+8`&L`E!YY9LL1VS=ZE>2"/`D/`\=VYMF/^_/L M[:75_?M];\2JZR!.(V[\FWPV`4AQ;Y+*1Z>TO:KU@CS!P%@>7BLIBPJ__M5N M/-8B+`9D[4R]]_M3[]UE6N5J.KYO,T/:Z@VLT7CX<=R=5-O0V-!2-7SS_NV; M5`FGP\$OOPZ"F"Y3@9H)S"@AA)5F%F>@Y<(4S0Y&)J7"F@U0$>[.!1!+1NA^ MW_X:)6[Y/G/U9E_9O[^T^JU/D_L>YB[3#E8K-TO186[-XK.-+X.%/`^LU`UN ML5OY2`'[CVH_R#M0)9P/R^16$!WRG+RS?PO"_&W*,!UW$L7!BOYN7X9@>OD:C?J\[GEBM0<=JWT^FPSOZK]_EQL27JFQS`E&>W@:E(!!L M`TT2J;8S&Z[W9\.?J(76&O6FK;[5[[8F76MXT^]]3-V>F#X'%F>ELE_QVJ.6 MGSL()"PLJQ!O`[P'Y,U(C-9!93DUN6!?'[!T^+QV`F=2O=V?5#]>6L/IS]VQ M-6I];MWT4;UWVZ%OZS[8'L!])R3"?D,F+&@!F7M/? MP797R'7@\"EX#8+&]MZSNH?+P*.RCK)'R5='@;B#M>3GIRGGBH-)#G4C$HOO!R3G:0?#Y6EL^O M[P_NV]]<6N-N/RV$/VJ-IY^MZ;@UF+12IV%^/!O>W?6F:8%\Q&G'Y5HZ^>24 MJ)E#Y8-3\L#75@++ZZO#L)CE"ZNK>^VO5=[O^)D M/"M-N3,+P1+@C5!,=5K>%Q!+W,EE3'@U'#L8.=I3%/505)&-&7#>1V0X[T:Q MNZ(\"A*<]MNAO0%1"Z!R;LU`@O]`8[3[0B-\LM7H$NWQAUKXUI:A&:HP"MT@ MS!*OQL3Q["A*C9E4]L]%"3LDU6)5L(0(KVV$,M1,$R,07"[3L%\.591(/VI$--T&12,`.M6]L-TURW0D1V M+XW16;U8;()]%4:.]B)#O3U413:&P7E';'9J9P/-Q@DWE>!=H#VA@X!/A/;,05T'@4P.I@#&#;-2[9,\\)653X'WGD`MZ&0B,`,H;O`]&#AX#WBU_FL>&M5$9`BP M;+3%B/+[B"X=:2KRBFX)]E8O!<"">X`":Y@;2%5$9@"[S2;/8\7R?%)%.U:I M$[QW&6HNP,J",@3AU9I:X6F%CK#C1NL@LKWAO!_XB[[[2&99-7`XU)5Z@V)N MF#NHCNC,`+]KASY=A5A!KL^E5Q168AX%WK,7 M-9==L0CJ`L6)?2BK:L2)=BAOBO>21/6$#!'39DP(>H!EKVMF_H@L4J@=1"J1 M`-`.\!Y^J'O"5Q&0&:BF"_&-';&QO@P_>SV=GI!ZJ1.*;KC,PI:ZR2MUAO>0 M0RVT:PC.#.39L$.RI".GH\R6>L6C![P'*,:&.7Y4160&L`/RM1`#&08^_=$A MA;L<,,#J/>$]M5$+Z*HB,P/POONOQ)VY\48IH%E,!072,$<01!0G$;,\%23D MU2NU97V7]=UHO+(*4Y((YFI=-7H`<99DEGAD."\$D!4>A^4-7$J&&:E0E1F&^RK]XV:=-.,2M05K$GE M-P0+\O5!.;:#(AR6EF6X9("2Q5=(H<=,+RUBPK7.]UIC+HL`Z9;;WN5E6TRK M/R%2Z(/"99PJ%/6T^ELY"K[A\>S`SE?,UE<[G*4@9E[LB$4/9],@BI+5^F5Y M5C--&OG.R16ZT")G33>NA0R`;$@?J6T5DYD4;$8-)48S-I0A5.'*3'.S_'*J MJ'/YNXZ;.O-9M6^T%.(F)W$U@9Y$.1O1=GU065&MJ(T6VU2%*XG16JTK(^;Z MS@EHS+3%*QR!AFO"4DC\12.G2]7N,6WK.MH!.VY6$S:VE0ZZ!^B0V'8]SEIP M4!!2\?XI[_R;1=]0@;G\;C15-\&4WFLGFYL'VFK(GKS'1C'=RP04Z-PD/?JC MH+1*65LST"C7)1X"A>$7@[10@W:?7_*[V1Q&#VP'W'IR!?`H=7)"N"GQ53B- M8>9Y=SPDK_$*BGC\FZR"D&WYKQ184NLMGOZ`KR[8Z3(?XP8KV M^-PHZ@0KVQ544SG6]\W0H@JS9S_G_$CR>K$;FW2#W-@>'3V9+`F)[\CJ@82< MTT)90VSWQG&G2M%5PA>;_@2!W.+.S/K4*;X3L]D/HDB(9+6NT&IEH6-=1_1F M.,FV7(MM@-U69BS/H$U^=^`%CUJC[WQM-8>W?:;WNWN-S!!B&?P[+W?MC5K/ M3C.^NQ$N2X6_X][1EP)=E-S*>3)CF=PK MK-A]5>22F&64KZHU1R2 M63^3%'?XZ=@?2?@01"1MB_MFD.<%7]GYBZY/G2!YB.>)MWW>YJ4ZHT"W@?38 MYUME/5`3C!F[;HLR.'.]A"V2$^(D8?KR$-UJO(0N^[=4)NR,E612'\[W"RID MQSL/R#[A,+2A#>_I2WQW9E5'M!B,OXZ:_G)3G' M`Q(/YU/[2;"5BXC0"GQ7WL'E(E#'^7V<\6S-&%CS.52K)*TA"%0^=9QC1S MH6[FJ@T>2(^!>$7YCW-<@LXGHC]1FC5O2L%/Y:S>/IS;LP. MHCZ9;3?X@F)U"#TCN\(7SN2T:/6_J\XLN$`,LGI*G[B$O)Z(6,F[EK53_J:G M(?G5PDBQ@Z<0=Q.L:P6"R3*L\\ZA*=8'S4T()CJMD"ZQ/#GZ_2V:ZULTEVJI M@9O-E'Y;?(,+(CXAG$#\F!&UQ2^,0+\L"[D"$9N!FX)^@DM'%)BL>?7<#);# M.34#R?/XN->O>7M.A;6^7!338#IOJ,,DE809B_R!+U_'D*.VWPW;K5$>FG&--+K.] M191S%#MH97QD2.FH3=+K.YNRZ)-P4]2-CV$0"0QG$0WV)3`X6$?.^.G?%&T7 M5`5L!238E[KP."P9VYC(_HQM*,/6O'UV3G\N<3=2R822T6%; MV.!9!1.`&;O:SBT%E:CCIO*D/WLD+[_>6K$XP!T0`OY@*V^BO/Z<+S!L.4S>*W173R?N(S!.//?U4934N[P;[NK8^ MD"+Q:#K+E7TRKX?!NV(346#?R,(,'@#3QQ2W_:0J[BT%4-S-OZQ37]R[3!MV M_2W)H/@!=`]N1H($=[&1YTD`2!$WF:)9P^=AMQ6R"PJ,Q=Z&4<8J=A'RPNNL M/68^+FC'P`2D@P%@,AW?I^7&K-[`&HV''\?=27/I1KS<5Q`?L@+E MBIV@QB._##4O.)NEP#%]'`2^D_V#/Z'`':#6)Z^$ZD'^Y^=U MR>SYQ5WV@!WHG,PGQLU@;@)8!1DAK[)]^VN4N$"KY.#YD^\OK7[KT^2^UYQ- MPE]%610D\1KFAZA,FM@=.S`22(Z^7>RX)T]*1210'*_HS;(H=O*/RPZ5UU_IE.+8F]Z-1O]<=YZ52 M[R?3X1W[E^Z9!^=(,@VK=&1"2.?IQ=16A^Q;M*UA49P&1]NF6O:L6>+@VK*V M)X1"V?#-")T=V"LRG.^,3Q8P*R`Q`Q*^8NV_PLKG1$\9IH^)[2^>W$GB1RQ: M9+2TPY7MD"1V'=MK!_UX=BFL-Z1`CQTY(U6LHO]562Z:G-_Y.*:!O_C-O2,S MUZ&C2;\/@45`AAWL4@4-J13T@M"UH[@3VHO`;U/^DG!3HA405%3ZP;X\KP*3 MNIPTX;8S;"$RI2VQ;XJ49"_@59-T![;/,F8G`2O#V?/IZ8Z5FF&02X0-(81N M%F;L%G!1:,*B33@TI90:6L+TE*2MH!93>(=D=!A\EBP0>;;SR@) MG25[XX(C:`D-MC4$NX8&,:Y)Z-M*O`GAG_XYLH>18IM`,`A4Q&#&?4H[\)G2 M9*61QV[TY46+!-4RQ53F1P6#V#`)II<*<%%:_TLPIW(2/L7)!/G*F,8.$2A] M$5A48.+MP;.X@G?*]=2;$`[ZNM)#Y8?$J$5&"V\H[SQ_M7WXBB[.\M`@Q6Y0 M[[:4$#VH/EI!7&8LB66/:'-?7&?O#+C^T">?B2U(F*S3)[:16`W*H#'^3UPW MIE\#QH?H%J%.I]CV*Y)V[$OU=-6#?I]H4)!"M]AF,Y:*'$CV!)6D(:7`-\Z/ MK@1F@;X-DANQU#%67+DA+:C;+_;50A-JT8QLS="342;__,GU'8'4594&NL9. M^6M"6QJ3L":/9Y]$41XN_7+JBNY]*EDVI"@=TXU=^FHUZT"!'COQKQ:EJ99*?5R#KZU*G([_4HU(*Y[`.^;FPIR'ITY)4K\'Q=CZJ'I^]MA:S]_^ MI8Z^B'H]!\]>$W+]/6C7KD]K0.*]O]?1,7G?Y^`5;$[&YZ5OA0.HTM&KC.ZD MW8U`'DTZ4&]];QWR$*#5;&;DW995F/98!2NLY\"C0O6&.*(9.&&9OXSG;& M[CL)N;$]EEDV61(29^.^V6194YX=10<%C"6%_AK[`)IS2XM&-"!K,Q1(;,/P M]4)&A^:F:@QNF&0:7O:/:1*FKT3G%?@B8?[(VWT#\,=+:SC]N3NV1JW/K9M^ MMU"0J5%KKVR($MM.3(*Y5.=Y1*W9(ULSHENZ2A3*[@F68!DAJA4&@6A_(85) M0E,TSB?BS2E7^9`Y6K3?"-6>41%QV>!-VF^4-YJZ.XP>@Z**UH,W$LPB8R2F M"W^6)6D_N)X;NT3N`Q)3H9H"%8""R,`,M/*'TJ.Z==K!:$S_*IT%H^XMTF#>;ER:Y'[#UU0YGM[8;I@Y#>N1/5NMT M&^\^K8E##_K_".AYGVGK9DR9%6R9Q_@X9IPJ7&OVM]_CP6+&+JZ%X8[[Z,[H M;\D^C.AO,V&Y$F"!'H7#/ M/9P4`3Z-7T!4!.[O%5\0_NI;B%XU!U#04E?^=^08BI=.FIKG2Y""PR^^RUE4 MK=*VM)?#B^W'XH31-A(%P8*[)2K-/J;I6U!=UGN[:X(N:Q0RON&N1X&?PS&. MH<'/4WD1_(C+@NM'\U:(:U,TN$ER9G^EQ_(#?_#BGR0#D?PZ< M2F*&NND5!KY-=BQU$Z62:)&Q>K[)M:9R)$:HG"B[Y&R5[OE41+(CT;%T[_"[ M4!745&3%"!7DH?'M2(II`"H<0:\U594QQ034>#XTHGR&Y(W%/RF7T=#SOJ)\ M_)(#L4H'N.\J9IJ5CC?3_E82+X/0_;^>NXPHBEB&T:!G*C:@"7#KJFO`^ MTP0_O:0V(23^I1[0R+/]O#BGP!O$:8^68]L(XF(IG/!SQV.2JBU=T>+--+3] MR':R.`F?N;!6;IQ&40C?8?MQWTES]>;2&G?[K6FW8XU:X^EG:SIN#2:M]K0W M'$RLUJ!CM8=W=[WI77AYGDV)+XGSIF)?J),V+\`[Y;SF^ZS6N^UDD_1` MW9N?JK6`.YBUN^P54R=-0(=.7-*C/XIJ)Y:T14:)(UPQ`H7A%Z_344V<BH]'%"J*FP57#=&@)F)UA1ZPP&VK:M&>"HJZ0`N"UK+X6BF[P8 M+W[ICG`N"/?7\VU#[$K$?&TIWC;S6=3T3,`@\,%BY;3%KHH+DZR044W"':X) ML_3]1?K4?'2;L+H`=Z[OKI)5?A,;=1+2\X<^84\9/`J?LZG<&[;J\VV/(D`U MA84-X<1]F@93XK-!U05PMR_L^=4P?&6"P@:OZY%'XC.MFL>D&0Q+NT0O^=PL ME`*Q82-*M8P-B6K:5_J[32/K:GF?Z+63&Y^>7,&9D6<`9(5OC(,[0"\]+(56 ME:/?E^]0$NGUOB$GHJ8`L&JL-NE7-"M0+$^>BL;$(>XC\P<8M/+6JMQ5),PU6V# MT-EE;:+6VVI'EFO2SS_]X^\2_+GX9[TN71-L&N=2U];K,IW:/TI#9.%SZ093 MS)!KLQ^EWY#I0KU`FZKM,1VO&M24X2_2 MT=G)T?%1ZU1J'?UZTEA.H;\N>'H#:]$M#MRV? MCL\FF/,FMC!UKVUF=?$4>2:8[9N'3#(EV*A)+F(S[/*1[BR0C@4M15,%46K# MC(+I'I;PLL6"P)2!@K]=\+%USK'40&*)/TS&9QZ=K4Z%&7N(]\ MXC'+;[TF$>.R)J3@_4'O?H\&GA)*?+'"Z=V2ZE+$'G]$U)""MJ188Q?-=#.Q MQCT'&PK]R7]>,.Q`,SY3'PI"QI!D`Y..3-TSR_&L1[ M;0U^7+7[[6&G)ZFWO9ZF2F\FP_:D*T/-?UY-DX%\A!@H.L*T@=9:HL>%`%W8LFV@8&L?%.BQE/U>"?06\(AE.N)674 M&[YY[("AWDS*]-^Z&HU=;T8J.]W<5HG;9Z*UWWE0^';32%S1`E?\3B MAD2)&/AW/#B`(-^T'8]A^-%J2,KXICV4/_OSX>#05#W+0NQ1F:ID1B%.U!'$ M7[IN>Q`TT=D(!KE.<#C\"]**+?!#V@+'#4F=#`;M\2<^R%7Y9BA?RYWV4)/: MG8XR&6KR\$8:P9SHR#WUX.S3^^:1!?<2@0G6/\4HOT^C?-*0>K].Y!'W)@<' M(G?7+O-TWH%,1\R>@6)KGYY7)X;W+`WO:7>6)7:0PA!)JJF#.#7P4'?00OB(K./ MD8.5.Y/,$B'[ADHQZ,=IT'\`3]$>R5J[+_5[;;4G*5=]^28(Q@\.<`521C9" MC^C.C(*,9)$8W),TN.\AFM-N>V-IU/[4ONH?8+R@NK;^=6Z;!O@#'BRXCV'L MEBT78WN:QO8,XC1-Z?SO5NEWP3G\VX\GM$\'A_`8FSSM&R'F/FH,40?YL8/O MB6W+(JZ?"P:H%Z056^)M)FA-UT54X:MTNZ4`R],%T]7&0WA)QQG,4D8M0S6:PH-CU<*R0B4FU3J%H$\>-, MGIL)6*7#Q3D;HB8<_:9:,>*9I'=#&'NXL!>+4>.F*,4A-D\F/2X7VQZNU8K% M/5WL(F*6"I4B%K'=,IEWR5@I[.75;D(C#!'C+X'O\0X&7/.*+9G)\W>SI+3J M[_!LNHIU$],M4RJV0R;+3X;`!SMATC"FYL3F:C'*GV:J'UB[9\DVRJ%-L@DXBO7\2]0BY\.9=OA1+T8L-D+>%.UHI(;(E,GB_>RXJF1NO5 M&(GQGE[7B]&*35/F%?BKTTIO."9\56Z-&/WM[\BE`_9,V5W%Y);)QFHQZ$5? MGK\BGX6VM07Z;2M!)I'>AOTA+@(;T3W>@O[Q%O0S>?56](]?T5^AF][PVTXG MMD8FI=YJC0->=HN]UDBL#^58Q+;*I-YE7X4<[%)2R@JI*;8CK]B4F61]1U/^ M)62?8S_GQYTO:PZQ%B8_=>Z7S1F>7M:XG>O1J>3?0;7&TC(C M$MZTX!R[/S32:(0=1TT@IF=:R9RSAT;L!68NP4XS$CYJP"4N9Q_%NI%X/^`? MFL^ALHGNRJH,+-A\05W[O/UG51)&7UDE4P/VA53MK'MY5H5AZI15.#G;7DC? M[JJ3N+KAN?_F^N!_^#M].<`%*&XS5Z*9&P9$MTP$]V/T;=UO2L#"?]4COCHO MJK>.ZR>MQM(QUI*6$6(-0SDA(KX=A!#>=;%!BEP>_E!?,Q?M7WAQAJC_7,8F M-ETG*GFB--E++W87QV]K!WD*W/=19*3$.8(2"&>&J.J0,1:=]VG*0V._+N M7>H4TWB[RI^Y'8!F%BI%60:E8M!^[)2N3"<3K*B%V MB?.BZ9FT&V_EYA:_:-;P3*Q,_1<>P?YFV_@"(RT\NAZJNYVN"A9-G31-&VUC M=>7L(CS*F5:K(''EE,PY,YE634A2.876LR1UF4EZ$J6KJS!WKA%A_FW7?,LF MX`:?A@T?]O+FLX@!763H%LVQ2XL[L^Y((5O\3>N M2)GZRHT@90I1#H[=01AZZ$SQSK8P\-T+FN(W/"=ZS!O'?E=4XAZP6=SY3!P\ M]=9J_`A)=APR4>E+J8"66U58D>Q?A6+GV3(Q64FNRDUW4(!G M,K`ZY)PCSM&V"''EE"Q^)"NM\2ZK*CR$&IBI"!9L7Z,KM,Y%RC!4=*GOVW2F868EY5UKLU)U.]WW-7J=#8%Q M4>K*C=YBQ^1*3=;O82G).XTFW,RIOB4_8'.*&`X%7J6>Z=*JSK=-.S2]Y2+X M?RL"C[EM0R=+7ESAA%GF@)KS)^@E4^W!_H31>MDOQ5%][>8,X[+ZQ7DJK^&U M[;&2"L99*JZ?!DX0HZF[?J]>BJ/JVMFQ;;JBQ'O62>4-72'NY&R+2Q:\W8)% M%U):3GKUN"8!Q^]_(O"`F!$HY81:R92O/`[1?957F_XOU'B)U?%/C62?J&]O M"9DA<5X(S>_\]\HE2"HW)>J]19[-W>V5=_!R(\.D-G_KZ0<^VY'L/A MZ[UP&//-;)DJ%/.O.N^3>>'N[%7=TRBLD4J6FJUARA4J#4>*^;L'HV?B>TRY MA2&'W!&3_#:^>VC`U%P=,/<#E#WN-GTV-%)5<':[YN))/K9:*\Y%,S@O"X__ M!U!+`0(>`Q0````(`&)I;D4:\]RHU8\``!ZV!``1`!@```````$```"D@0`` M``!T;VYJ+3(P,30P.3,P+GAM;%54!0`#N$5F5'5X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`&)I;D7'!-1A60X``(ZQ```5`!@```````$```"D@2"0``!T M;VYJ+3(P,30P.3,P7V-A;"YX;6Q55`4``[A%9E1U>`L``00E#@``!#D!``!0 M2P$"'@,4````"`!B:6Y%!1JSB3T-``"8G```%0`8```````!````I('(G@`` M=&]N:BTR,#$T,#DS,%]D968N>&UL550%``.X1694=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`8FEN19>8BI/G/P``WL4#`!4`&````````0```*2!5*P` M`'1O;FHM,C`Q-#`Y,S!?;&%B+GAM;%54!0`#N$5F5'5X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`&)I;D4=JGQRE2@```F)`@`5`!@```````$```"D@8KL M``!T;VYJ+3(P,30P.3,P7W!R92YX;6Q55`4``[A%9E1U>`L``00E#@``!#D! M``!02P$"'@,4````"`!B:6Y%;$*\1:P,```N@P``$0`8```````!````I(%N M%0$`=&]N:BTR,#$T,#DS,"YX`L``00E#@``!#D!``!0 52P4&``````8`!@`:`@``92(!```` ` end XML 39 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
OPERATING REVENUE        
In-patient service revenue $ 269,207 $ 269,061 $ 847,809 $ 806,988
Out-patient service revenue 380,186 338,177 1,012,297 913,813
Total operating revenue 649,393 607,238 1,860,106 1,720,801
OPERATING EXPENSES        
Administrative expenses 49,376 53,145 147,610 108,397
Depreciation and amortization expenses 22,403 30,692 67,746 76,611
Contingency loss 0 25,500 0 83,955
Medicine and supplies 271,889 266,512 812,421 775,357
Other operating expenses 83,215 122,872 242,777 278,526
Salary and fringes 215,957 184,425 587,540 541,213
Total operating expenses 642,840 683,146 1,858,094 1,864,059
INCOME (LOSS) FROM OPERATIONS 6,553 (75,908) 2,012 (143,258)
OTHER INCOME (EXPENSE)        
Other income 7,023 4,333 24,948 18,947
Interest expense, net (64,646) (13,045) (160,026) (88,272)
Total Other Expense (51,070) (8,712) (135,078) (69,325)
LOSS BEFORE INCOME TAXES (51,070) (84,620) (133,066) (212,583)
Provision for income taxes 0 0 0 0
NET LOSS (51,070) (84,620) (133,066) (212,583)
OTHER COMPREHENSIVE LOSS        
Foreign currency translation gain (loss) (21,855) (7,939) 26,774 (37,366)
NET COMPREHENSIVE LOSS $ (72,925) $ (92,559) $ (106,292) $ (249,949)
Net loss per common stock-Basic and Diluted $ (0.007) $ (0.006) $ (0.007) $ (0.016)
Basic and Diluted 15,812,191 15,812,191 15,812,191 15,812,191
XML 40 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
7. CAPITAL LEASE OBLIGATIONS
9 Months Ended
Sep. 30, 2014
Debt Disclosure [Abstract]  
NOTE 7 - CAPITAL LEASE OBLIGATIONS

Sale and Lease Back 

 

On March 25, 2011, the Company completed a financing arrangement with an independent third party to sell and leaseback certain machinery and equipment. The net carrying value of the machinery and equipment sold was $262,683. The machinery and equipment was sold for $371,517, of which $334,365 was received in cash and $37,152 was held as refundable deposit. The transaction has been accounted for as a financing arrangement, wherein the property remains on the Company’s books and will continue to be depreciated. A financing obligation in the amount of $371,517, representing the proceeds, has been recorded under “Capital Lease Payable” in the Company’s Balance Sheet, and is being reduced based on payments under the lease. Capital lease payable was $148,701 as of September 30, 2014. The lease does not contain an option to renew. There is also no contingent rent or concessions, or any leasehold improvement incentives.

 

The lease has a term of 5 years and requires minimum annual rental payments including principal and interest as follows:

 

Year Ending December 31   Amount  
2014   $ 25,588  
2015     102,353  
2016     34,118  
Total minimum lease payments     162,059  
Less: interest payments     13,358  
PV of minimum capital lease payments     148,701  
Less: current obligations under capital lease     91,032  
Long term capital lease obligation   $ 57,669  

 

In October 2011, the Company entered into an agreement to lease certain machinery and equipment that are classified as capital leases. The cost of equipment under capital leases of approximately $1,430,000 is included in the Balance Sheet as property, plant, and equipment at September 30, 2014. Those equipments are to be placed in service upon usage approval from the Chinese government and hiring qualified personnel. As of September 30, 2014, the Company still has not received the approval. Accumulated depreciation and impairment loss of the leased equipment at September 30, 2014 was approximately $565,000.  Capital Lease Payable was approximately $640,000 as of September 30, 2014.

 

The lease has a term of 5 years and requires minimum annual rental payments including principal and interest as follows:

 

Year Ending December 31   Amount  
2014   $ 95,463  
2015     381,857  
2016     227,750  
Total minimum lease payments     700,070  
Less: interest payments     59,859  
PV of minimum capital lease payments     640,211  
Less: current obligations under capital lease     335,418  
Long term capital lease obligation    $ 304,793  
XML 41 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
6. MAJOR SUPPLIERS AND CUSTOMERS
9 Months Ended
Sep. 30, 2014
Notes to Financial Statements  
NOTE 6 - MAJOR SUPPLIERS AND CUSTOMERS

The Company had two major suppliers for the nine month period ended September 30, 2014: Guangxi Sunshine Pharmaceutical Co., Ltd. and Guangxi Tongji Medicine Co. Ltd., a related party with common major stockholders. Medicine purchased from Guangxi Sunshine Pharmaceutical Co., Ltd. and Guangxi Tongji Medicine Co. Ltd. accounted for 31% and 14% of all medicine purchases for nine month period ended September 30, 2014. As of September 30, 2014, total amount due to Guangxi Sunshine Pharmaceutical Co., Ltd., and Guangxi Tongji Medicine Co. Ltd were $152,449 and $996,999, respectively. The Company had two major suppliers for the nine month period ended September 30, 2013: Guangxi East Dragon Century Pharmaceutical Co., Ltd. and Guangxi Tongji Medicine Co. Ltd., which accounted for 20% and 45%, respectively, of all medicine purchases for the nine month period ended September 30, 2013. As of September 30, 2013, amount due to Guangxi East Dragon Century Pharmaceutical Co., Ltd. and Guangxi Tongji Medicine Co. Ltd were approximately $185,000 and $1,000.000, respectively.

 

The Company had one major customer, Nanning Social Insurance Center for the nine month period ended September 30, 2014 and 2013. Nanning Social Insurance Center accounted for 9% and 10% of revenue for the nine month periods ended September 30, 2014 and 2013. As of September 30, 2014 and 2013, accounts receivable due from Nanning Social Insurance Center was approximately $207,000, and $405,000 respectively.  

XML 42 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
Sep. 30, 2014
Dec. 31, 2013
Sep. 30, 2013
BalanceSheetMember | RMBMember
     
Exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements 6.14 6.05  
BalanceSheetMember | USDollarMember
     
Exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements 1 1.00  
StatementOfOperationsAndOtherComprehensiveLossMember | RMBMember
     
Exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements 6.17 6.15 6.17
StatementOfOperationsAndOtherComprehensiveLossMember | USDollarMember
     
Exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements 1 1.00 1
XML 43 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
7. CAPITAL LEASE OBLIGATIONS (Tables)
9 Months Ended
Sep. 30, 2014
Capital Lease Obligations Tables  
Sales lease back obligation
Year Ending December 31   Amount  
2014   $ 25,588  
2015     102,353  
2016     34,118  
Total minimum lease payments     162,059  
Less: interest payments     13,358  
PV of minimum capital lease payments     148,701  
Less: current obligations under capital lease     91,032  
Long term capital lease obligation   $ 57,669  
Schedule of Capital Lease Obligations
Year Ending December 31   Amount  
2014   $ 95,463  
2015     381,857  
2016     227,750  
Total minimum lease payments     700,070  
Less: interest payments     59,859  
PV of minimum capital lease payments     640,211  
Less: current obligations under capital lease     335,418  
Long term capital lease obligation    $ 304,793  
XML 44 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
10. RELATED PARTY TRANSACTIONS AND COMMITMENTS
9 Months Ended
Sep. 30, 2014
Related Party Transactions [Abstract]  
NOTE 10 - RELATED PARTY TRANSACTIONS AND COMMITMENTS

Due from/to Related Parties 

 

The Company has entered into agreements with Nanning Tongji Chain Pharmacy Co. Ltd., Guangxi Tongji Medicine Co. Ltd., and Nanning Switch Factory whereby the Company from time to time will advance funds to assist them with their operations. The three companies have common major stockholders. The advanced amounts accrue interest at a rate of 1.5% per annum. The amount receivable as of September 30, 2014 and December 31, 2013 was $45,067 and $45,695, respectively. Interest income for the three month periods ended September 30, 2014 and 2013 was approximately $169 and $168, respectively. Interest income for the nine month periods ended September 30, 2014 and 2013 was approximately $505 and $502, respectively.  

 

The Company has entered into an agreement with the Chairman and a stockholder of the Company, Nanning Tongji Chain Pharmacy Co. Ltd., Guangxi Tongji Medicine Co. Ltd., and Nanning Tongji Electric Coating Factory, whereby the Company from time to time will be advanced funds to for its operations. The advanced amounts accrue interest at a rate of 1.5% per annum. As of September 30, 2014 and December 31, 2013, $13,416,581 and $11,421,363 were payable to these related parties, respectively. Interest expense for the three month periods ended September 30, 2014 and 2013 was $79,036 and $43,396 respectively. Interest expense for the nine month periods ended September 30, 2014 and 2013 was $170,742 and $118,075 respectively.    

 

Rental Commitments 

 

The Company has entered into a lease agreement for their hospital with Guangxi Tongji Medicine Co. Ltd that expires in December 2014. The monthly lease payment is approximately $2,500. The Company is also in the process of building a new 600-bed hospital in Nanning, China and expects the new hospital to be completed by the middle of 2015. The hospital is being constructed by Guangxi Construction Engineering Corporation Langdong 8th Group and, when completed, the land will be leased by the Company for a twenty-year term. The annual lease payments will gradually increase each year. Based on the exchange rate at September 30, 2014, minimum future lease payments are as follows:  

 

    Related Party     Non-Related Party     Total  
1-5 years   $ 8,035     $ 2,786,603     $ 2,794,637  
6-10 years     -       3,193,901       3,193,901  
11-15 years     -       3,589,660       3,589,660  
16-20 years     -       1,482,568       1,482,568  
Total   $ 8,035     $ 11,052,732     $ 11,060,766  
XML 45 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
8. OTHER PAYABLES
9 Months Ended
Sep. 30, 2014
Payables and Accruals [Abstract]  
NOTE 8 - OTHER PAYABLES

Other payable as of September 30, 2014 and December 31, 2013 consists of the following:

 

    September 30, 2014    

December 31,

2013

 
Advance from customers   $ (30,924)     $ 5,160  
Welfare payable     13,392       31,343  
Capital lease deposits paid by third party     354,294       359,227  
Other payables     152,070       217,070  
Total   $ 488,832     $ 612,800  
XML 46 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
9. STOCKHOLDERS' EQUITY
9 Months Ended
Sep. 30, 2014
Accounting Policies [Abstract]  
NOTE 9 - STOCKHOLDERS' EQUITY

Preferred Stock 

 

As of September 30, 2014 and December 31, 2013, the Company has 20,000,000 shares of preferred stock authorized with a par value of $0.001. There are no shares of preferred stock issued and outstanding as of September 30, 2014.

 

Common Stock 

 

As of September 30, 2014 and December 31, 2013, the Company has 50,000,000 shares of common stock authorized with a par value of $0.001. There are 15,812,191 shares issued and outstanding as of September 30, 2014.

 

 Statutory Reserves 

 

As stipulated by the Company Law of the PRC, net income after taxation can only be distributed as dividends after appropriation has been made for the following:  

 

i. Making up cumulative prior years’ losses, if any;

 

ii. Allocations to the “Statutory surplus reserve” of at least 10% of income after tax, as determined under PRC accounting rules and regulations, until the fund amounts to 50% of the Company’s registered capital;
   
iii. Allocations to the discretionary surplus reserve, if approved in the stockholders’ general meeting.

 

As of September 30, 2014, the Company had accumulated deficits of $2,648,087. Therefore, the Company did not appropriate any fund for the statutory surplus reserve for the three month period ended September 30, 2014.  

 

Stock Option 

 

Stock-based compensation amounted to $3,839 for the nine month periods ended September 30, 2014 and 2013.  

 

On March 3, 2011, an option to purchase 100,000 shares of common stock was granted to the Company’s CFO. The option vests in two equal installments of 33,333 shares each, with the last installment being 33,334 shares, starting on the first anniversary of grant and subsequent anniversaries thereafter, at an exercise price equivalent to the closing price per share of common stock on the date of grant.

 

The fair value of the option award is estimated on the date of grant using the Black Scholes model to be $15,400. The valuation was based on the assumptions noted in the following table.

 

Expected volatility   105 %
Expected dividends   0 %
Stock price   0.24  
Expected term (in years)   3 years
Risk-free rate   1.32 %

 

The risk-free interest rate is based on the U.S. Treasury yield curve in effect for the expected term of the option at the time of grant. The dividend yield on our common stock is assumed to be zero since we do not pay dividends and have no current plans to pay them in the future. The market price volatility of our common stock was based on historical volatility since May 13, 2010. The expected life of the options is based upon our anticipated expectations of exercise behavior since no options have been exercised in the past to provide relevant historical data.  

 

The fair value of the option granted will be expensed according to following schedule:  

 

Year   Expense  
2011   $ 4,262  
2012     5,147  
2013     5,133  
2014     858  
Thereafter     -  
Total   $ 15,400  

 

 

The following table summarizes stock option activity in the Company's stock-based compensation plans for the three month period ended September 30, 2014

 

 

Number of

Shares

   

Weighted

Average

Exercise

Price

   

Aggregate

Intrinsic Value

(in thousands)

   

Number of

Shares

Exercisable

 
Outstanding at January 1, 2014     100,000     $ 0.24     $ -       -  
Granted     -       -       -       -  
Exercised     -       -       -       -  
Cancelled/expired     -       -       -       -  
                                 
Outstanding at September 30, 2014     100,000     $ 0.24     $ -       -  

 

There were no options granted, exercised or cancelled/expired during the nine month period ended September 30, 2014.  

XML 47 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Sep. 30, 2014
Notes to Financial Statements  
BASIS OF PRESENTATION AND CONSOLIDATION

These financial statements present the Company’s results of operations, financial position and cash flows on a consolidated basis. The consolidated financial statements include the Company and its wholly owned subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. Our policy is to consolidate all subsidiaries in which a greater than 50% voting interest is owned. The Company operates in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”.

CASH AND CASH EQUIVALENTS

For purposes of the statements of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. A substantial amount of the Company’s cash is held in bank accounts in the PRC and is not protected by Federal Deposit Insurance Corporation (FDIC) insurance or any other similar insurance. Cash held in China amounted to $5,236 as of September 30, 2014. Given the current economic environment and the financial condition of the banking industry, there is a risk that the deposits may not be readily available or covered by such insurance. The Company has had no loss of cash in domestic or foreign banks in past years.

USE OF ESTIMATES

The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of net revenues and expenses during the reporting period. Actual results may differ from those estimates and such differences may be material. The more significant estimates and assumptions by management include, among others, useful lives and residual values of fixed assets, valuation of inventories, accounts receivable, stock based compensation, and allowance for bad debt. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

TRANSLATION ADJUSTMENT

The Company's functional currency is the Chinese Renminbi (RMB). The reporting currency is that of the US Dollar. Capital accounts of the consolidated financial statements are translated into United States dollars from RMB at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rates as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the year. The RMB is not freely convertible into foreign currency and all foreign currency exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US dollar at the rates used in translation.  

 

 

The exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements were as follows:

 

September 30, 2014  
Balance sheet RMB 6.14 to US $1.00
   
Statement of income and other comprehensive income RMB 6.17 to US $1.00
   
December 31, 2013  
Balance sheet RMB 6.05 to US $1.00
   
Statement of income and other comprehensive income RMB 6.15 to US $1.00

 

September 30, 2013  
Statement of income and other comprehensive income RMB 6.17 to US $1.00
RECLASSIFICATIONS

Certain items previously reported under specific financial statement captions have been reclassified to conform to the current year presentation.  

REVENUE RECOGNITION

The Company's revenue recognition policies are in compliance with Staff Accounting Bulletin 104 (ASC 605). Service revenue is recognized on the dates services were rendered. When a formal arrangement exists, the price is fixed or determinable. When the service is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.  

 

The Company generates revenue from individual patients as well as third-party payers, including PRC government programs and insurance providers, under which the hospital is paid based upon government established charges. Revenues for pharmaceutical drug sales are recognized upon the drug being administered to a patient.  

 

Patient revenues are recorded based on pre-established rates set by the local government. The Company bills for services provided to Medicare patients through a medical card (the US equivalent of an insurance card). There have not been significant differences between the amounts the Company has billed the government Medicare funds and the amounts collected from the Medicare funds.  

ACCOUNTS RECEIVABLE

Accounts receivable are recorded at the estimated net realizable amounts from government fund, insurance companies and patients. Collections have not been considered an area that exposes the Company to additional risk. Hospital staff verifies patient coverage prior to examinations and/or procedures.  

 

For any Medicare patient who visits the hospital and is qualified for acceptance, the hospital will only include the portion that the social insurance organization will pay in the accounts receivable and collects the self-pay portion in cash at the time of service. Management continues to estimate the likelihood of bad debt on an ongoing basis.  

 

The Company has estimated a bad debt allowance of approximately $31,000 as of September 30, 2014 and $44,000 as of December 31, 2013.  

 

FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company applies the provisions of FASB ASC Topic 825, which requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of September 30, 2014 and December 31, 2013 the fair value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, notes payable and other payables approximated the carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates except for related party debt or receivables for which it is not practicable to estimate fair value.

FAIR VALUE MEASUREMENTS

FASB ASC Topic 820, “Fair Value Measurements and Disclosures”, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements.  

 

Various inputs are considered when determining the fair value of the Company’s investments, and long-term debt. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below.  

 

  Level 1 – observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets.
  Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.).
  Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments).

 

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or non-recurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. The Company had no financial assets and liabilities carried at fair value on a recurring basis.  

 

The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment.  

CONCENTRATIONS, RISKS, AND UNCERTAINTIES

All of the Company’s operations are located in the PRC. There can be no assurance that the Company will be able to successfully continue to operate and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. In addition, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. These contingencies include general economic conditions, the price of medicine, competition, governmental and political conditions, and changes in regulations. Because the Company is dependent on the domestic market of the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company’s operations will be subject to risk of restrictions on the transfer of funds, domestic policy changes, changing taxation policies, foreign exchange restrictions, and political and governmental regulations.

CONTINGENCIES

Certain conditions may exist as of the date the consolidated financial statements are issued. These conditions may result in a future loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.  

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.  

MEDICAL SUPPLIES

Medical supplies include both western and traditional Chinese medicine, are valued on the lower of weighted average cost or market basis. Inventory includes product cost and inbound freight. Management compares the cost of medical supplies with the market value and allowance is made for writing down their inventories to market value, if such value is lower.  

EQUIPMENT

Equipment is recorded at cost. Depreciation is computed over the estimated useful lives of the related asset type using the straight-line method. Maintenance and repairs are expensed as incurred and the costs of additions and betterments that increase the useful lives of the assets are capitalized. When equipment is disposed, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in other income or expenses.  

CONSTRUCTION-IN-PROGRESS

A hospital facility currently under development is accounted for as construction-in-progress. Construction-in-progress is recorded at acquisition cost, including land rights cost, development expenditure, and professional fees capitalized during the course of construction for the purpose of financing the project. Upon completion of the project, the cost of construction-in-progress will be transferred to fixed assets, at which time depreciation will commence.

CAPITALIZATION OF INTEREST

Interest cost is capitalized for qualifying assets when the portion of the interest cost incurred during the assets' acquisition periods could have been avoided if expenditures for the assets had not been made. The amount capitalized in an accounting period is determined by applying the capitalization rate to the average amount of accumulated expenditures for the asset during the period. The capitalization rates used in an accounting period is based on the rates applicable to borrowings outstanding during the period (also see Note 4).  

 

Capitalization period covers the duration of the activities required to get the asset ready for its intended use, provided that expenditures for the asset have been made and interest cost is being incurred. Interest capitalization continues as long as those activities and the incurrence of interest cost continue.  

IMPAIRMENT OF LONG-LIVED ASSETS

The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of FASB Topic ASC 360, “Property, Plant, and Equipment”, and FASB ASC Topic 205 “Presentation of Financial Statements”. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value.  

 

The Company tests long-lived assets for recoverability at least annually or more frequently upon the occurrence of an event or when circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. The Company considers historical performance and future estimated results in its evaluation of potential impairment and then compares the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, the Company measures the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows at the rate the Company utilizes to evaluate potential investments. The Company estimates fair value based on the information available in making whatever estimates, judgments and projections are considered necessary. There was no impairment of long-lived assets for the Three and Nine Months ended September 30, 2014 and 2013.  

 

BASIC AND DILUTED EARNINGS PER SHARE

Earnings per share (EPS) is calculated in accordance with the FASB ASC Topic 260, “Earnings Per Share.” Basic net income (loss) per share is based upon the weighted average number of common shares outstanding. Diluted net income (loss) per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Potentially dilutive securities to purchase 100,000 shares of common stock were not included in the calculation of the diluted earnings per share as their effect would be anti-dilutive for the Three and Nine Months ended September 30, 2014. During the three and nine month period ended September 30, 2014, the average market price of the common stock was less than the exercise price of the stock options and the Company was in net loss position. Accordingly, the stock options were anti-dilutive and have not been included in the calculation of diluted earnings per share.

INCOME TAXES

FASB ASC Topic 740, "Income Taxes” requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.  

 

In accordance with ASC Topic 740-10, “Accounting for Uncertainty in Income Taxes — An Interpretation of FASB ASC Topic 740” which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.  

 

The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.

 

The Company has made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by ASC 740-10 and has not recognized any material uncertain tax positions.  

 

In addition, companies in the PRC are required to pay business taxes consisting of 5% of income they derive from providing medical treatment, as well as city construction taxes and educational taxes which are 7% and 3%, respectively, of the business taxes. In April 2010, the Company was granted an exemption from these taxes until further notice from the tax bureau.  

 

The Company had accrued approximately $40,000 for failure to file US tax returns and Form 5472 between the years 2006 to 2009. The Company is current with its required filings. In addition, the Company does not accrue United States income taxes on unremitted earnings from foreign operations, as it is the Company’s intention to invest these earnings in the foreign operations indefinitely.  

STATEMENT OF CASH FLOWS

In accordance with FASB ASC Topic 230, "Statement of Cash Flows," cash flows from the Company's operations are calculated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet.  

EMPLOYEE BENEFIT COSTS

The Company contributes to a defined contribution retirement plan organized by the municipal government in the province in which the Company’s subsidiary is registered. The Company makes contributes for qualified employees that are eligible to participate in the plan. Contributions to the plan are calculated at 30% of the employees’ salaries above a fixed threshold amount; employees contribute 8% and the Company’s subsidiary contributes the balance of 22%. The Chinese government is responsible for the benefit liability to retired employees. The Company has no other material obligation for the payment of retirement beyond the annual contribution.  

STOCK-BASED COMPENSATION

For purposes of determining the variables used in the calculation of stock compensation expense under the provisions of FASB ASC Topic 505, “Equity” and FASB ASC Topic 718, “Compensation — Stock Compensation,” we perform an analysis of current market data and historical Company data to calculate an estimate of implied volatility, the expected term of the option and the expected forfeiture rate. With the exception of the expected forfeiture rate, which is not an input, we use these estimates as variables in the Black Scholes model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. In addition, any differences between estimated forfeitures and actual forfeitures could also have a material impact on our financial statements.  

 

Stock-based compensation costs that have been included in operating expenses amounted to $3,839 for the nine month periods ended September 30, 2014 and 2013.  

COMPREHENSIVE INCOME

The Company reports comprehensive income in accordance with FASB ASC Topic 220 “Comprehensive Income," which established standards for reporting and displaying comprehensive income and its components in a financial statement that is displayed with the same prominence as other financial statements.  

 

Total comprehensive income is defined as all changes in stockholders' equity during a period, other than those resulting from investments by and distributions to stockholders (i.e., issuance of equity securities and dividends). Generally, for the Company, total comprehensive income (loss) equals net income (loss) plus or minus adjustments for currency translation. Total comprehensive income (loss) represents the activity for a period net of related tax and was a loss of $72,925 and $92,559 for the three month periods ended September 30, 2014 and 2013, respectively.  Total comprehensive income (loss) represents the activity for a period net of related tax and was a loss of $106,292 and $249,949 for the nine month periods ended September 30, 2014 and 2013, respectively.  

 

While total comprehensive income is the activity in a period and is largely driven by net earnings in that period, accumulated other comprehensive income or loss (“AOCI”) represents the cumulative balance of other comprehensive income as of the balance sheet date. For the Company, AOCI is primarily the cumulative balance related to the currency adjustments and increased overall equity by $92,559 and $65,825 as of September 30, 2014 and December 31, 2013, respectively.  

RECENT ACCOUNTING PRONOUNCEMENTS

Recent accounting pronouncements issued by the FASB, the AICPA and the SEC  did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.   

GOING CONCERN

The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has negative working capital of $18,814,681, an accumulated deficit of $2,648,087, and a stockholders’ deficit of $2,096,327 as of September 30, 2014. The Company’s ability to continue as a going concern ultimately is dependent on the management’s ability to obtain equity or debt financing, attain further operating efficiencies, and achieve profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company not be able to continue as a going concern.  

 

Management has taken certain restructuring steps to provide the necessary capital to continue its operations. These steps included: 1) plan to convert existed related parties’ loans into equity, 2) to complete construction of the new hospital and begin generating revenue by the end of the next year, 3) plan to increase sales revenue with additional medical equipments. No assurances can be given that the steps taken will provide necessary capital for the Company to continue its operations.  

XML 48 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
9. STOCKHOLDERS' EQUITY (Details) (USD $)
9 Months Ended
Sep. 30, 2014
Notes to Financial Statements  
Expected volatility 105.00%
Expected Dividends 0.00%
Stock price $ 0.24
Expected term (in years) 3 years
Risk-free rate 1.32%
XML 49 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
9. STOCKHOLDERS' EQUITY (Tables)
9 Months Ended
Sep. 30, 2014
Accounting Policies [Abstract]  
Fair value of the option award
Expected volatility   105 %
Expected dividends   0 %
Stock price   0.24  
Expected term (in years)   3 years
Risk-free rate   1.32 %
Fair value of the option granted
Year   Expense  
2011   $ 4,262  
2012     5,147  
2013     5,133  
2014     858  
Thereafter     -  
Total   $ 15,400  
Stock option activity
 

Number of

Shares

   

Weighted

Average

Exercise

Price

   

Aggregate

Intrinsic Value

(in thousands)

   

Number of

Shares

Exercisable

 
Outstanding at January 1, 2014     100,000     $ 0.24     $ -       -  
Granted     -       -       -       -  
Exercised     -       -       -       -  
Cancelled/expired     -       -       -       -  
                                 
Outstanding at September 30, 2014     100,000     $ 0.24     $ -       -  
XML 50 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
3. EQUIPMENT (Details Narrative) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Property, Plant and Equipment [Abstract]        
Depreciation expenses $ 22,403 $ 30,692 $ 67,746 $ 76,611
XML 51 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)
9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Operating activities:    
Net Loss $ (133,066) $ (212,583)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation expense 67,747 76,612
Stock option expense 3,839 3,839
Increase/(decrease) in operating assets and liabilities:    
Accounts receivable 206,459 77,836
Medical supplies 75,143 3,210
Prepaid expense and other current assets 10,492 (970)
Deposit 1,499 0
Accounts payable and accrued expenses 110,280 162,616
Other payables (115,011) (168,937)
Settlement (contingent liability) 73,229 98,270
Net Cash Provided By Operating Activities 300,611 39,893
Investing activities:    
Acquisitions of fixed assets (8,481) (20,353)
Acquisitions of intangible assets 0 (100,541)
Construction in Progress (2,128,894) (1,195,636)
Due from related parties 6,912 52,973
Net Cash Used in Investing Activities (2,130,463) (1,263,557)
Financing activities:    
Payments of capital lease (292,462) (265,517)
Due to related parties 2,119,877 1,414,749
Net Cash Provided by Financing Activities 1,827,415 1,149,232
Effects of foreign currency translation (120) 1,830
Net decrease in Cash (2,557) (72,602)
Cash-Beginning of Period 7,793 81,135
Cash-Ending of Period 5,236 8,533
Cash Paid During the Year for:    
Income taxes 0 0
Interest paid $ 69,158 $ 65,300
XML 52 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
5. LAWSUIT
9 Months Ended
Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]  
NOTE 5- LAWSUIT

In September 2009, Guangxi Nanning Tingyouyuxiang Commercial Co., Ltd. (“Tingyouyuxiang”) filed a civil suit against Nanning Tongji in the People’s Court. In the complaint, Tingyouyuxiang asserted a breach of contract claim against Nanting Tongji, alleging that Nanning Tongji had failed to make timely and total payment of RMB 5,050,000 (approximately $800,000) under certain Supplement Agreement by and among Nanning Tongji, Tingyouyuxiang and the Eighth Group of Langdong Village Committee, Nanhu Community Office, Qingxiu District, Nanning City (the “Village Committee”). On December 30, 2009, the People’s Court ruled that Nanning Tongji shall pay to Tingyouyuxiang damages of RMB 5,050,000 (approximately $800,000) plus interest and the court hearing fee of approximately $320,000. On March 9, 2012, Nanning Tongji appealed to the Intermediate Court, alleging, among other things, that Nanning Tongji was never served. On June 6, 2012, the Intermediate Court remanded the case to the People’s Court. On April 16, 2014, the Intermediate Court dismissed Tingyouyuxiang’s appeal and affirmed the decision of the People’s Court. Upon settlement of the lawsuit, the Company had accrued approximately $1,324,000 in settlement payable as of September 30, 2014.  

XML 53 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
4. CONSTRUCTION IN PROGRESS (Details Narrative) (USD $)
Sep. 30, 2014
Construction In Progress Details Narrative  
Construction cost paid $ 15,300,000
Capitalized interest $ 548,000
XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 37 214 1 false 15 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://tonj.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://tonj.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://tonj.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://tonj.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://tonj.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) false false R6.htm 00000006 - Disclosure - 1. ORGANIZATION Sheet http://tonj.com/role/Organization 1. ORGANIZATION false false R7.htm 00000007 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://tonj.com/role/SummaryOfSignificantAccountingPolicies 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R8.htm 00000008 - Disclosure - 3. EQUIPMENT Sheet http://tonj.com/role/Equipment 3. EQUIPMENT false false R9.htm 00000009 - Disclosure - 4. CONSTRUCTION IN PROGRESS Sheet http://tonj.com/role/ConstructionInProgress 4. CONSTRUCTION IN PROGRESS false false R10.htm 00000010 - Disclosure - 5. LAWSUIT Sheet http://tonj.com/role/Lawsuit 5. LAWSUIT false false R11.htm 00000011 - Disclosure - 6. MAJOR SUPPLIERS AND CUSTOMERS Sheet http://tonj.com/role/MajorSuppliersAndCustomers 6. MAJOR SUPPLIERS AND CUSTOMERS false false R12.htm 00000012 - Disclosure - 7. CAPITAL LEASE OBLIGATIONS Sheet http://tonj.com/role/CapitalLeaseObligations 7. CAPITAL LEASE OBLIGATIONS false false R13.htm 00000013 - Disclosure - 8. OTHER PAYABLES Sheet http://tonj.com/role/OtherPayables 8. OTHER PAYABLES false false R14.htm 00000014 - Disclosure - 9. STOCKHOLDERS' EQUITY Sheet http://tonj.com/role/StockholdersEquity 9. STOCKHOLDERS' EQUITY false false R15.htm 00000015 - Disclosure - 10. RELATED PARTY TRANSACTIONS AND COMMITMENTS Sheet http://tonj.com/role/RelatedPartyTransactionsAndCommitments 10. RELATED PARTY TRANSACTIONS AND COMMITMENTS false false R16.htm 00000016 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://tonj.com/role/SummaryOfSignificantAccountingPoliciesPolicies 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) false false R17.htm 00000017 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://tonj.com/role/SummaryOfSignificantAccountingPoliciesTables 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) false false R18.htm 00000018 - Disclosure - 3. EQUIPMENT (Tables) Sheet http://tonj.com/role/EquipmentTables 3. EQUIPMENT (Tables) false false R19.htm 00000019 - Disclosure - 7. CAPITAL LEASE OBLIGATIONS (Tables) Sheet http://tonj.com/role/CapitalLeaseObligationsTables 7. CAPITAL LEASE OBLIGATIONS (Tables) false false R20.htm 00000020 - Disclosure - 8. OTHER PAYABLES (Tables) Sheet http://tonj.com/role/OtherPayablesTables 8. OTHER PAYABLES (Tables) false false R21.htm 00000021 - Disclosure - 9. STOCKHOLDERS' EQUITY (Tables) Sheet http://tonj.com/role/StockholdersEquityTables 9. STOCKHOLDERS' EQUITY (Tables) false false R22.htm 00000022 - Disclosure - 10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Tables) Sheet http://tonj.com/role/RelatedPartyTransactionsAndCommitmentsTables 10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Tables) false false R23.htm 00000023 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://tonj.com/role/SummaryOfSignificantAccountingPoliciesDetails 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) false false R24.htm 00000024 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://tonj.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) false false R25.htm 00000025 - Disclosure - 3. EQUIPMENT (Details) Sheet http://tonj.com/role/EquipmentDetails 3. EQUIPMENT (Details) false false R26.htm 00000026 - Disclosure - 3. EQUIPMENT (Details Narrative) Sheet http://tonj.com/role/EquipmentDetailsNarrative 3. EQUIPMENT (Details Narrative) false false R27.htm 00000027 - Disclosure - 4. CONSTRUCTION IN PROGRESS (Details Narrative) Sheet http://tonj.com/role/ConstructionInProgressDetailsNarrative 4. CONSTRUCTION IN PROGRESS (Details Narrative) false false R28.htm 00000028 - Disclosure - 5. LAWSUIT (Details Narrative) Sheet http://tonj.com/role/LawsuitDetailsNarrative 5. LAWSUIT (Details Narrative) false false R29.htm 00000029 - Disclosure - 6. MAJOR SUPPLIERS AND CUSTOMERS (Details Narrative) Sheet http://tonj.com/role/MajorSuppliersAndCustomersDetailsNarrative 6. MAJOR SUPPLIERS AND CUSTOMERS (Details Narrative) false false R30.htm 00000030 - Disclosure - 7. CAPITAL LEASE OBLIGATION (Details) Sheet http://tonj.com/role/CapitalLeaseObligationDetails 7. CAPITAL LEASE OBLIGATION (Details) false false R31.htm 00000031 - Disclosure - 7. CAPITAL LEASE OBLIGATIONS (Details 1) Sheet http://tonj.com/role/CapitalLeaseObligationsDetails1 7. CAPITAL LEASE OBLIGATIONS (Details 1) false false R32.htm 00000032 - Disclosure - 7. CAPITAL LEASE OBLIGATION (Details Narrative) Sheet http://tonj.com/role/CapitalLeaseObligationDetailsNarrative 7. CAPITAL LEASE OBLIGATION (Details Narrative) false false R33.htm 00000033 - Disclosure - 8. OTHER PAYABLES (Details) Sheet http://tonj.com/role/OtherPayablesDetails 8. OTHER PAYABLES (Details) false false R34.htm 00000034 - Disclosure - 9. STOCKHOLDERS' EQUITY (Details) Sheet http://tonj.com/role/StockholdersEquityDetails 9. STOCKHOLDERS' EQUITY (Details) false false R35.htm 00000035 - Disclosure - 9. STOCKHOLDERS' EQUITY (Details 1) Sheet http://tonj.com/role/StockholdersEquityDetails1 9. STOCKHOLDERS' EQUITY (Details 1) false false R36.htm 00000036 - Disclosure - 9. STOCKHOLDERS' EQUITY (Details 2) Sheet http://tonj.com/role/StockholdersEquityDetails2 9. STOCKHOLDERS' EQUITY (Details 2) false false R37.htm 00000037 - Disclosure - 9. STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://tonj.com/role/StockholdersEquityDetailsNarrative 9. STOCKHOLDERS' EQUITY (Details Narrative) false false R38.htm 00000038 - Disclosure - 10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Details) Sheet http://tonj.com/role/RelatedPartyTransactionsAndCommitmentsDetails 10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Details) false false R39.htm 00000039 - Disclosure - 10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Details Narrative) Sheet http://tonj.com/role/RelatedPartyTransactionsAndCommitmentsDetailsNarrative 10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Details Narrative) false false All Reports Book All Reports Process Flow-Through: 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Process Flow-Through: Removing column 'Sep. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Process Flow-Through: 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Process Flow-Through: 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) tonj-20140930.xml tonj-20140930.xsd tonj-20140930_cal.xml tonj-20140930_def.xml tonj-20140930_lab.xml tonj-20140930_pre.xml true true XML 55 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Details) (USD $)
Sep. 30, 2014
1-5 years $ 2,794,637
6-10 years 3,193,901
11-15 years 3,589,660
16-20 years 1,482,568
Total 11,060,766
Related Party [Member]
 
1-5 years 8,035
6-10 years 0
11-15 years 0
16-20 years 0
Total 8,035
Non Related Party [Member]
 
1-5 years 2,786,603
6-10 years 3,193,901
11-15 years 3,589,660
16-20 years 1,482,568
Total $ 11,052,732
XML 56 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
8. OTHER PAYABLES (Tables)
9 Months Ended
Sep. 30, 2014
Other Payables Tables  
Schedule of Other Payables
    September 30, 2014    

December 31,

2013

 
Advance from customers   $ (30,924)     $ 5,160  
Welfare payable     13,392       31,343  
Capital lease deposits paid by third party     354,294       359,227  
Other payables     152,070       217,070  
Total   $ 488,832     $ 612,800